Case/Application number: **10/569,873** PALM
Priority App. Filing Date: **08/29/2003**
Format for Search Results: **EMAIL**

Meaning of unusual acronyms or initialisms:

Identify the novelty:

Additional Comments:
Please search compounds of claim 1. Need ASAP please (after final). Thank you!

Follow-up search with limitations on R3.

```
=> d que stat l9
L5                STR
```



```
VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  43

STEREO ATTRIBUTES: NONE
L6  (    402314)SEA FILE=REGISTRY SSS FUL L5
L7                STR
```



Cy @44

```
VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VPA 44-1/2/3/4/5/6 U
NODE ATTRIBUTES:
```

DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L8 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VPA 44-9/10/11/12/13/8 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L9 33651 SEA FILE=REGISTRY SUB=L6 SSS FUL (L7 OR L8)

100.0% PROCESSED 402314 ITERATIONS 33651 ANSWERS
SEARCH TIME: 00.00.43

=> d que stat l21
L5 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE
L6 (402314)SEA FILE=REGISTRY SSS FUL L5
L7 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VPA 44-1/2/3/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L8 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VPA 44-9/10/11/12/13/8 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L9 33651 SEA FILE=REGISTRY SUB=L6 SSS FUL (L7 OR L8)
L18 STR



Page 1-A

@45

Page 1-B
VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VAR G3=X/46
VPA 44-1/2/3/4/5/6 U
VPA 45-8/9/10/11/12/13 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 49

STEREO ATTRIBUTES: NONE
L19 STR



Page 1-A

@45

Page 1-B
VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VAR G3=X/46
VPA 44-8/9/10/11/12/13 U
VPA 45-1/2/3/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 49

STEREO ATTRIBUTES: NONE
L21 9722 SEA FILE=REGISTRY SUB=L9 SSS FUL (L18 OR L19)

100.0% PROCESSED 33651 ITERATIONS 9722 ANSWERS
SEARCH TIME: 00.00.03

=> d que stat l36
L5 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE
L6 (402314)SEA FILE=REGISTRY SSS FUL L5
L7 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VPA 44-1/2/3/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L8 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VPA 44-9/10/11/12/13/8 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L9 33651 SEA FILE=REGISTRY SUB=L6 SSS FUL (L7 OR L8)
L18 STR



Page 1-A

Page 1-B
VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VAR G3=X/46
VPA 44-1/2/3/4/5/6 U
VPA 45-8/9/10/11/12/13 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 49

STEREO ATTRIBUTES: NONE
L19 STR



Page 1-A

Page 1-B
VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VAR G3=X/46
VPA 44-8/9/10/11/12/13 U
VPA 45-1/2/3/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 49

STEREO ATTRIBUTES: NONE
L21 9722 SEA FILE=REGISTRY SUB=L9 SSS FUL (L18 OR L19)
L22 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE
L23 (402314)SEA FILE=REGISTRY SSS FUL L22
L24 STR



Cy @44

VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VPA 44-1/2/3/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L25 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VPA 44-9/10/11/12/13/8 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L26 (33651)SEA FILE=REGISTRY SUB=L23 SSS FUL (L24 OR L25)
L27 QUE SPE=ON ABB=ON PLU=ON 1-2 5/SZS
L28 (21400)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L26 AND L27
L29 QUE SPE=ON ABB=ON PLU=ON 2 6/SZS
L30 (3263)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L26 AND L29
L31 (113)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L26 AND NCNCNC/ESS
L32 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VPA 46-1/2/3/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 49

STEREO ATTRIBUTES: NONE
L33 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VPA 46-8/9/10/11/12/13 U

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 49

STEREO ATTRIBUTES: NONE
L34 (7261)SEA FILE=REGISTRY SUB=L26 SSS FUL (L32 OR L33)
L35 29198 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L28 OR L30 OR L31 OR L34
L36 8396 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L21 AND L35

=> d que stat l117
L5 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE
L6 (402314)SEA FILE=REGISTRY SSS FUL L5
L7 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VPA 44-1/2/3/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L8 STR



VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VPA 44-9/10/11/12/13/8 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L9 33651 SEA FILE=REGISTRY SUB=L6 SSS FUL (L7 OR L8)
L18 STR



Page 1-A

Page 1-B
VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VAR G3=X/46
VPA 44-1/2/3/4/5/6 U
VPA 45-8/9/10/11/12/13 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 49

STEREO ATTRIBUTES: NONE
L19 STR



Page 1-A

@45

Page 1-B
VAR G2=14-3 17-8/18-3 21-8/22-3 25-8/26-3 29-8/30-3 33-8/34-3 37-8
VAR G3=X/46
VPA 44-8/9/10/11/12/13 U
VPA 45-1/2/3/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 44
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 49

STEREO ATTRIBUTES: NONE
L21 9722 SEA FILE=REGISTRY SUB=L9 SSS FUL (L18 OR L19)
L117 3003 SEA FILE=REGISTRY SUB=L21 SSS FUL L18

100.0% PROCESSED 9722 ITERATIONS 3003 ANSWERS
SEARCH TIME: 00.00.01

=> d que nos l125
L1 1 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-569873/APPS
L3 TRANSFER PLU=ON L1 1- RN : 322 TERMS
L4 322 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L3
L5 STR
L6 (402314)SEA FILE=REGISTRY SSS FUL L5
L7 STR
L8 STR
L9 33651 SEA FILE=REGISTRY SUB=L6 SSS FUL (L7 OR L8)
L18 STR

```
L19             STR
L21        9722 SEA FILE=REGISTRY SUB=L9 SSS FUL (L18 OR L19)
L22             STR
L23 (    402314)SEA FILE=REGISTRY SSS FUL L22
L24             STR
L25             STR
L26 (     33651)SEA FILE=REGISTRY SUB=L23 SSS FUL (L24 OR L25)
L27             QUE  SPE=ON  ABB=ON  PLU=ON  1-2 5/SZS
L28 (     21400)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L26 AND L27
L29             QUE  SPE=ON  ABB=ON  PLU=ON  2 6/SZS
L30 (      3263)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L26 AND L29
L31 (       113)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L26 AND NCNCNC/ESS
L32             STR
L33             STR
L34 (      7261)SEA FILE=REGISTRY SUB=L26 SSS FUL (L32 OR L33)
L35       29198 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L28 OR L30 OR L31 OR
                L34
L36        8396 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L21 AND L35
L37          88 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L4 AND L36
L53             QUE  SPE=ON  ABB=ON  PLU=ON  CHENG, W?/AU,AUTH
L54             QUE  SPE=ON  ABB=ON  PLU=ON  CO, E?/AU,AUTH
L55             QUE  SPE=ON  ABB=ON  PLU=ON  WANG-CO, E?/AU,AUTH
L56             QUE  SPE=ON  ABB=ON  PLU=ON  WANG CO, E?/AU,AUTH
L57             QUE  SPE=ON  ABB=ON  PLU=ON  WANGCO, E?/AU,AUTH
L58             QUE  SPE=ON  ABB=ON  PLU=ON  KIM, M?/AU,AUTH
L59             QUE  SPE=ON  ABB=ON  PLU=ON  KLEIN, R?/AU,AUTH
L60             QUE  SPE=ON  ABB=ON  PLU=ON  LE, D?/AU,AUTH
L61             QUE  SPE=ON  ABB=ON  PLU=ON  TSUHAKO, A?/AU,AUTH
L62             QUE  SPE=ON  ABB=ON  PLU=ON  LEW, A?/AU,AUTH
L63             QUE  SPE=ON  ABB=ON  PLU=ON  LEW-TSUHAKO, A?/AU,AUTH
L64             QUE  SPE=ON  ABB=ON  PLU=ON  LEWTSUHAKO, A?/AU,AUTH
L65             QUE  SPE=ON  ABB=ON  PLU=ON  NUSS, J?/AU,AUTH
L66             QUE  SPE=ON  ABB=ON  PLU=ON  XU, W?/AU,AUTH
L67             QUE  SPE=ON  ABB=ON  PLU=ON  BAJJALIEH, W?/AU,AUTH
L68             QUE  SPE=ON  ABB=ON  PLU=ON  BAJJALIEH, B?/AU,AUTH
L84             QUE  SPE=ON  ABB=ON  PLU=ON  AY<2004 OR PY<2004 OR PRY<20
                04 OR MY<2004 OR REVIEW/DT
L85         359 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L36
L86           1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L85 AND (L53 OR L54
                OR L55 OR L56 OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63
                OR L64 OR L65 OR L66 OR L67 OR L68)
L87           1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L1 AND L86
L88           0 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L1 NOT L86
L89           1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L86 OR L87 OR L88)
L90         358 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L85 NOT L89
L91         229 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L90 AND L84
L92             QUE  SPE=ON  ABB=ON  PLU=ON  C(1W)KIT
L93             QUE  SPE=ON  ABB=ON  PLU=ON  STEM(1W)CELL
L94           0 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L91 AND (L92 OR L93)
L95         197 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L85 (L)(THU OR PKT OR
                PAC OR DMA)/RL
L96          88 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L91 AND L95
L97          88 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L94 OR L96
L98             QUE  SPE=ON  ABB=ON  PLU=ON  "C-KIT (PROTEIN)"+PFT,OLD,NE
                W,NT/CT
L99           0 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L91 AND L98
L100         88 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L97 OR L99
L101          2 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L37
L102          1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L101 AND (L53 OR L54
                OR L55 OR L56 OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63
```

```
                OR L64 OR L65 OR L66 OR L67 OR L68)
L103          1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L89 OR L102
L104         90 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L100 OR L101)
L105         89 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L104 NOT L103
L106         88 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L105 AND L84
L107            TRANSFER  PLU=ON  L106 1- RN HIT :     471 TERMS
L108        471 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L107
L109        459 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L108 NOT ETHANEDIAMID
                E/CNS
L110        115 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L109
L111         98 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L91 AND L110
L112         86 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L106 AND L111
L113          0 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L112 AND (L53 OR L54
                OR L55 OR L56 OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63
                OR L64 OR L65 OR L66 OR L67 OR L68)
L114         86 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L112 NOT L113
L115         86 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L114 AND L84
L117       3003 SEA FILE=REGISTRY SUB=L21 SSS FUL L18
L118        183 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L117
L119          2 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L118 AND (L53 OR L54
                OR L55 OR L56 OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63
                OR L64 OR L65 OR L66 OR L67 OR L68)
L120          1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L1 AND L119
L121          0 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L1 NOT L119
L122          2 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L119 OR L120 OR
                L121)
L123        181 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L118 NOT L122
L124        117 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L123 AND L84
L125         36 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L115 AND L124
```

```
=> d ibib ed abs hitind hitstr l125 1-30
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y



L125 ANSWER 1 OF 36  HCAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2008:1106595  HCAPLUS  Full-text
DOCUMENT NUMBER:          149:307851
TITLE:                    Preparation of imidazolidin-2-imines and their analogs
                          as aspartyl protease inhibitors for treating various
                          diseases
INVENTOR(S):              Zhu, Zhaoning; McKittrick, Brian; Sun, Zhong-Yue; Ye,
                          Yuanzan C.; Voigt, Johannes H.; Strickland, Corey;
                          Smith, Elizabeth M.; Stamford, Andrew; Greenlee,
                          William J.; Mazzola, Robert D., Jr.; Caldwell, John;
                          Cumming, Jared N.; Wang, Lingyan; Wu, Yusheng;
                          Iserloh, Ulrich; Liu, Xiaoxiang; Huang, Ying; Li,
                          Guoqing; Pan, Jianping; Misiaszek, Jeffrey A.; Guo,
                          Tao; Le, Thuy X. H.; Saionz, Kurt W.; Babu, Suresh D.;
                          Hunter, Rachael C.; Morris, Michelle L.; Gu, Huizhong;
                          Qian, Gang; Tadesse, Dawit; Lai, Gaifa; Duo, Jingqi;
                          Qu, Chuanxing; Shao, Yuefei
PATENT ASSIGNEE(S):       Schering Corporation, USA; Pharmacopeia, Inc.
SOURCE:                   PCT Int. Appl., 702 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   5
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2008103351         A2    20080828    WO 2008-XA2182          20080220
     WO 2008103351         A3    20090723
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
     US 20080200445        A1    20080821    US 2007-710582          20070223 <--
     WO 2008103351         A2    20080828    WO 2008-US2182          20080220
     WO 2008103351         A3    20090723
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
```

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2007-710582 A 20070223
WO 2008-US2182 20080220
US 2003-529535P P 20031215 <--
US 2004-10772 A2 20041213
US 2005-149027 A2 20050609

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 12 Sep 2008

GI



I



II



III

AB Disclosed are compds. I [W = a bond, C(S), S(O), etc.; X = O, NR5 or CR6R7; U = a bond, S(O), SO2, C(O), etc.; R1, R2, R5 = H, alkyl, cycloalkyl, etc.; R3, R4, R6, R7 = H, alkyl, cycloalkyl, etc.; with provisos] or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof; and the pharmaceutical compns. comprising the compds. I. Over 1000 compds. I were prepared E.g., synthesis of imidazolidin-2-imine II, starting from III, was described. Compds. I were tested in various assays (data given for selected compds. I). Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting Human Immunodeficiency Virus, plasmepsin, cathepsin D, and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compds. I in combination with a cholinesterase inhibitor or a muscarinic M1 agonist or M2 antagonist. This abstract record is one of 2 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 7, 63

IT 1049645-25-1P 1049645-26-2P 1049645-27-3P 1049645-30-8P
1049645-31-9P 1049645-32-0P 1049645-33-1P 1049645-35-3P
1049645-36-4P 1049645-37-5P 1049645-38-6P 1049645-39-7P
1049645-41-1P 1049645-43-3P 1049645-44-4P 1049645-45-5P
1049645-46-6P 1049645-47-7P 1049645-48-8P 1049645-49-9P
1049645-50-2P 1049645-51-3P 1049645-53-5P 1049645-54-6P

1049645-56-8P 1049645-57-9P 1049645-58-0P 1049645-59-1P
1049645-60-4P 1049645-62-6P 1049645-63-7P 1049645-64-8P
1049645-65-9P 1049645-67-1P 1049645-69-3P 1049645-70-6P
1049645-71-7P 1049645-72-8P 1049645-73-9P 1049645-75-1P
1049645-76-2P 1049645-77-3P 1049645-79-5P 1049645-81-9P
1049645-83-1P 1049645-84-2P 1049645-85-3P 1049645-86-4P
1049645-87-5P 1049645-88-6P 1049645-90-0P 1049645-91-1P
1049645-92-2P 1049645-93-3P 1049645-94-4P 1049645-95-5P
1049645-96-6P 1049645-98-8P 1049646-00-5P 1049646-01-6P
1049646-04-9P 1049646-05-0P 1049646-06-1P 1049646-07-2P
1049646-08-3P 1049646-13-0P 1049646-14-1P 1049646-16-3P
1049646-17-4P 1049646-18-5P 1049646-19-6P 1049646-20-9P
1049646-21-0P 1049646-22-1P 1049646-23-2P 1049646-24-3P
1049646-26-5P 1049646-27-6P 1049646-28-7P 1049646-30-1P
1049646-32-3P 1049646-33-4P 1049646-34-5P 1049646-35-6P
1049646-36-7P 1049646-40-3P 1049646-41-4P 1049646-42-5P
1049646-43-6P 1049646-44-7P 1049646-45-8P 1049646-46-9P
1049646-47-0P 1049646-48-1P 1049646-49-2P 1049646-51-6P
1049646-52-7P 1049646-54-9P 1049646-55-0P 1049646-56-1P
1049646-59-4P 1049646-60-7P 1049646-61-8P 1049646-62-9P
1049646-63-0P 1049646-64-1P 1049646-65-2P 1049646-66-3P
1049646-67-4P 1049646-68-5P 1049646-69-6P 1049646-70-9P
1049646-71-0P 1049646-73-2P 1049646-74-3P 1049646-75-4P
1049646-78-7P 1049646-79-8P 1049646-80-1P 1049646-81-2P
1049646-82-3P 1049646-83-4P 1049646-84-5P 1049646-85-6P
1049646-86-7P 1049646-87-8P 1049646-88-9P 1049646-90-3P
1049646-92-5P 1049646-93-6P 1049646-94-7P 1049646-96-9P
1049646-99-2P 1049647-00-8P 1049647-01-9P 1049647-02-0P
1049647-03-1P 1049647-05-3P 1049647-06-4P 1049647-07-5P
1049647-08-6P 1049647-09-7P 1049647-10-0P 1049647-11-1P
1049647-12-2P 1049647-15-5P 1049647-16-6P 1049647-18-8P
1049647-19-9P 1049647-20-2P 1049647-22-4P 1049647-23-5P
1049647-24-6P 1049647-25-7P 1049647-27-9P 1049647-28-0P
1049647-29-1P 1049647-31-5P 1049647-32-6P 1049647-33-7P
1049647-34-8P 1049647-35-9P 1049647-36-0P 1049647-37-1P
1049647-39-3P 1049647-40-6P 1049647-42-8P 1049647-44-0P
1049647-45-1P 1049647-48-4P 1049647-49-5P 1049647-50-8P
1049647-51-9P 1049647-53-1P 1049647-55-3P 1049647-58-6P
1049647-59-7P 1049647-60-0P 1049647-61-1P 1049647-62-2P
1049647-63-3P 1049647-64-4P 1049647-66-6P 1049647-67-7P
1049647-68-8P 1049647-69-9P 1049647-70-2P 1049647-71-3P
1049647-72-4P 1049647-74-6P 1049647-75-7P 1049647-76-8P
1049647-77-9P 1049647-78-0P 1049647-80-4P 1049647-81-5P
1049647-82-6P 1049647-83-7P 1049647-85-9P 1049647-86-0P
1049647-87-1P 1049647-88-2P 1049647-92-8P 1049647-93-9P
1049647-94-0P 1049647-96-2P 1049647-97-3P 1049647-98-4P
1049648-00-1P 1049648-01-2P 1049648-02-3P 1049648-03-4P
1049648-04-5P 1049648-05-6P 1049648-06-7P 1049648-07-8P
1049648-10-3P 1049648-11-4P 1049648-12-5P 1049648-13-6P
1049648-14-7P 1049648-15-8P 1049648-16-9P 1049648-17-0P
1049648-18-1P 1049648-19-2P 1049648-20-5P 1049648-22-7P
1049648-23-8P 1049648-24-9P 1049648-25-0P 1049648-26-1P
1049648-29-4P 1049648-30-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolidin-2-imines and their analogs as aspartyl protease inhibitors for treating various diseases)

IT 1049648-31-8P 1049648-32-9P 1049648-33-0P 1049648-36-3P

1049648-38-5P 1049648-39-6P 1049648-40-9P 1049648-41-0P
1049648-43-2P 1049648-44-3P 1049648-45-4P 1049648-46-5P
1049648-47-6P 1049648-48-7P 1049648-49-8P 1049648-50-1P
1049648-53-4P 1049648-55-6P 1049648-56-7P 1049648-57-8P
1049648-58-9P 1049648-59-0P 1049648-60-3P 1049648-62-5P
1049648-64-7P 1049648-66-9P 1049648-70-5P 1049648-72-7P
1049648-80-7P 1049648-84-1P 1049648-86-3P 1049648-88-5P
1049648-90-9P 1049648-92-1P 1049648-94-3P 1049648-98-7P
1049649-00-4P 1049649-02-6P 1049649-04-8P 1049649-06-0P
1049649-08-2P 1049649-12-8P 1049649-16-2P 1049649-19-5P
1049649-21-9P 1049649-25-3P 1049649-27-5P 1049649-29-7P
1049649-31-1P 1049649-33-3P 1049649-35-5P 1049649-39-9P
1049649-41-3P 1049649-43-5P 1049649-45-7P 1049649-47-9P
1049649-49-1P 1049649-51-5P 1049649-53-7P 1049649-55-9P
1049649-58-2P 1049649-59-3P 1049649-61-7P 1049649-69-5P
1049649-73-1P 1049649-75-3P 1049649-79-7P 1049649-81-1P
1049649-83-3P 1049649-85-5P 1049649-86-6P 1049649-88-8P
1049649-90-2P 1049649-92-4P 1049649-97-9P 1049649-99-1P
1049650-01-2P 1049650-05-6P 1049650-07-8P 1049650-09-0P
1049650-11-4P 1049650-12-5P 1049650-14-7P 1049650-16-9P
1049650-19-2P 1049650-21-6P 1049650-23-8P 1049650-25-0P
1049650-29-4P 1049650-31-8P 1049650-35-2P 1049650-37-4P
1049650-39-6P 1049650-45-4P 1049650-48-7P 1049650-50-1P
1049650-52-3P 1049650-55-6P 1049650-57-8P 1049650-62-5P
1049650-66-9P 1049650-68-1P 1049650-76-1P 1049650-78-3P
1049650-80-7P 1049650-82-9P 1049650-86-3P 1049650-88-5P
1049650-90-9P 1049650-96-5P 1049651-00-4P 1049651-02-6P
1049651-05-9P 1049651-07-1P 1049651-09-3P 1049651-11-7P
1049651-13-9P 1049651-15-1P 1049651-17-3P 1049651-19-5P
1049651-21-9P 1049651-23-1P 1049651-25-3P 1049651-29-7P
1049651-31-1P 1049651-32-2P 1049651-35-5P 1049651-36-6P
1049651-38-8P 1049651-39-9P 1049651-41-3P 1049651-43-5P
1049651-45-7P 1049651-48-0P 1049651-49-1P 1049651-50-4P
1049651-52-6P 1049651-54-8P 1049651-55-9P 1049651-58-2P
1049651-59-3P 1049651-62-8P 1049651-63-9P 1049651-65-1P
1049651-67-3P 1049651-69-5P 1049651-70-8P 1049651-72-0P
1049651-78-6P 1049651-80-0P 1049651-84-4P 1049651-86-6P
1049651-88-8P 1049651-90-2P 1049651-96-8P 1049651-98-0P
1049651-99-1P 1049652-00-7P 1049652-01-8P 1049652-02-9P
1049652-03-0P 1049652-04-1P 1049652-07-4P 1049652-09-6P
1049652-12-1P 1049652-14-3P 1049652-16-5P 1049652-17-6P
1049652-19-8P 1049652-20-1P 1049652-21-2P 1049652-23-4P
1049652-24-5P 1049652-26-7P 1049652-27-8P 1049652-28-9P
1049652-30-3P 1049652-31-4P 1049652-32-5P 1049652-33-6P
1049652-36-9P 1049652-38-1P 1049652-39-2P 1049652-40-5P
1049652-41-6P 1049652-42-7P 1049652-44-9P 1049652-45-0P
1049652-46-1P 1049652-47-2P 1049652-48-3P 1049652-49-4P
1049652-51-8P 1049652-52-9P 1049652-53-0P 1049652-54-1P
1049652-58-5P 1049652-60-9P 1049652-62-1P 1049652-64-3P
1049652-66-5P 1049652-67-6P 1049652-69-8P 1049652-70-1P
1049652-71-2P 1049652-72-3P 1049652-73-4P 1049652-74-5P
1049652-75-6P 1049652-78-9P 1049652-79-0P 1049652-80-3P
1049652-82-5P 1049652-83-6P 1049652-84-7P 1049652-85-8P
1049652-87-0P 1049652-88-1P 1049652-89-2P 1049652-92-7P
1049652-93-8P 1049652-94-9P 1049652-95-0P 1049652-98-3P
1049652-99-4P 1049653-00-0P 1049653-01-1P 1049653-03-3P
1049653-04-4P 1049653-08-8P 1049653-09-9P 1049653-10-2P
1049653-11-3P 1049653-12-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)
(preparation of imidazolidin-2-imines and their analogs as aspartyl protease
inhibitors for treating various diseases)

IT 1049686-89-6P 1049686-90-9P 1049686-91-0P 1049686-92-1P
1049686-93-2P 1049686-94-3P 1049686-95-4P 1049686-96-5P
1049686-97-6P 1049686-98-7P 1049687-00-4P 1049687-01-5P
1049687-03-7P 1049687-05-9P 1049687-07-1P 1049687-08-2P
1049687-09-3P 1049687-10-6P 1049687-11-7P 1049687-12-8P
1049687-13-9P 1049687-14-0P 1049687-15-1P 1049687-16-2P
1049687-17-3P 1049687-18-4P 1049687-19-5P 1049687-20-8P
1049687-21-9P 1049687-22-0P 1049687-24-2P 1049687-25-3P
1049687-28-6P 1049687-30-0P 1049687-31-1P 1049687-32-2P
1049687-33-3P 1049687-35-5P 1049687-36-6P 1049687-37-7P
1049687-38-8P 1049687-39-9P 1049687-40-2P 1049687-41-3P
1049687-45-7P 1049687-46-8P 1049687-47-9P 1049687-50-4P
1049687-52-6P 1049687-53-7P 1049687-54-8P 1049687-55-9P
1049687-57-1P 1049687-58-2P 1049687-60-6P 1049687-61-7P
1049687-62-8P 1049687-64-0P 1049687-65-1P 1049687-66-2P
1049687-68-4P 1049687-69-5P 1049687-70-8P 1049687-71-9P
1049687-72-0P 1049687-73-1P 1049687-74-2P 1049687-76-4P
1049687-78-6P 1049687-80-0P 1049687-84-4P 1049687-86-6P
1049687-87-7P 1049687-91-3P 1049687-92-4P 1049687-93-5P
1049687-94-6P 1049687-95-7P 1049687-96-8P 1049687-97-9P
1049687-99-1P 1049688-00-7P 1049688-01-8P 1049688-02-9P
1049688-03-0P 1049688-04-1P 1049688-05-2P 1049688-06-3P
1049688-07-4P 1049688-08-5P 1049688-09-6P 1049688-10-9P
1049688-11-0P 1049688-12-1P 1049688-13-2P 1049688-14-3P
1049688-15-4P 1049688-16-5P 1049688-17-6P 1049688-18-7P
1049688-22-3P 1049688-23-4P 1049688-25-6P 1049688-26-7P
1049688-27-8P 1049688-28-9P 1049688-29-0P 1049688-30-3P
1049688-32-5P 1049688-33-6P 1049688-34-7P 1049688-35-8P
1049688-36-9P 1049688-37-0P 1049688-38-1P 1049688-40-5P
1049688-41-6P 1049688-43-8P 1049688-44-9P 1049688-46-1P
1049688-47-2P 1049688-48-3P 1049688-49-4P 1049688-50-7P
1049688-51-8P 1049688-52-9P 1049688-53-0P 1049688-55-2P
1049688-56-3P 1049688-57-4P 1049688-59-6P 1049688-61-0P
1049688-64-3P 1049688-66-5P 1049688-68-7P 1049688-74-5P
1049688-76-7P 1049688-78-9P 1049688-80-3P 1049688-82-5P
1049688-84-7P 1049688-85-8P 1049688-87-0P 1049688-89-2P
1049688-91-6P 1049688-93-8P 1049688-95-0P 1049688-97-2P
1049689-01-1P 1049689-03-3P 1049689-05-5P 1049689-07-7P
1049689-09-9P 1049689-11-3P 1049689-13-5P 1049689-15-7P
1049689-17-9P 1049689-20-4P 1049689-22-6P 1049689-24-8P
1049689-26-0P 1049689-28-2P 1049689-30-6P 1049689-32-8P
1049689-34-0P 1049689-36-2P 1049689-43-1P 1049689-45-3P
1049689-47-5P 1049689-49-7P 1049689-51-1P 1049689-53-3P
1049689-55-5P 1049689-57-7P 1049689-59-9P 1049689-61-3P
1049689-63-5P 1049689-67-9P 1049689-69-1P 1049689-73-7P
1049689-75-9P 1049689-77-1P 1049689-81-7P 1049689-87-3P
1049689-93-1P 1049689-96-4P 1049689-98-6P 1049690-00-7P
1049690-02-9P 1049690-04-1P 1049690-06-3P 1049690-08-5P
1049690-10-9P 1050246-45-1P 1050246-49-5P 1050246-52-0P
1050246-57-5P 1050246-64-4P 1050246-65-5P 1050246-66-6P
1050246-67-7P 1050246-69-9P 1050246-73-5P 1050246-75-7P
1050246-77-9P 1050246-82-6P 1050246-84-8P 1050246-86-0P
1050246-89-3P 1050246-91-7P 1050246-94-0P 1050246-96-2P
1050246-98-4P 1050247-00-1P 1050247-02-3P 1050247-04-5P
1050247-07-8P 1050247-13-6P 1050247-14-7P 1050247-18-1P
1050247-23-8P 1050247-25-0P 1050247-28-3P 1050247-31-8P

1050247-32-9P 1050247-37-4P 1050247-40-9P 1050247-41-0P
1050247-45-4P 1050247-49-8P 1050247-50-1P 1050247-58-9P
1050247-60-3P 1050247-64-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolidin-2-imines and their analogs as aspartyl protease
inhibitors for treating various diseases)

IT 1049647-76-8P 1049652-40-5P 1049686-97-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolidin-2-imines and their analogs as aspartyl protease
inhibitors for treating various diseases)

RN 1049647-76-8 HCAPLUS
CN Urea, N-[[3'-(2-amino-4,5-dihydro-1,4-dimethyl-5-oxo-1H-imidazol-4-yl)-5-chloro[1,1'-biphenyl]-2-yl]methyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)



RN 1049652-40-5 HCAPLUS
CN Urea, N-[[3'-(2-amino-4,5-dihydro-1,4-dimethyl-5-oxo-1H-imidazol-4-yl)-5-chloro[1,1'-biphenyl]-2-yl]methyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)



RN 1049686-97-6 HCAPLUS
CN Urea, N-[[3'-(2-amino-4,5-dihydro-1,4-dimethyl-5-oxo-1H-imidazol-4-yl)-5-chloro[1,1'-biphenyl]-2-yl]methyl]-N'-(2-chlorophenyl)- (CA INDEX NAME)



L125 ANSWER 2 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1042502 HCAPLUS Full-text
DOCUMENT NUMBER: 149:307845
TITLE: Preparation of imidazolidin-2-imines and their analogs as aspartyl protease inhibitors for treating various diseases
INVENTOR(S): Zhu, Zhaoning; McKittrick, Brian; Sun, Zhong-Yue; Ye, Yuanzan C.; Voigt, Johannes H.; Strickland, Corey; Smith, Elizabeth M.; Stamford, Andrew; Greenlee, William J.; Mazzola, Robert D., Jr.; Caldwell, John; Cumming, Jared N.; Wang, Lingyan; Wu, Yusheng; Iserloh, Ulrich; Liu, Xiaoxiang; Huang, Ying; Li, Guoqing; Pan, Jianping; Misiaszek, Jeffrey A.; Guo, Tao; Le, Thuy X. H.; Saionz, Kurt W.; Babu, Suresh D.; Hunter, Rachael C.; Morris, Michelle L.; Gu, Huizhong; Qian, Gang; Tadesse, Dawit; Lai, Gaifa; Duo, Jingqi; Qu, Chuanxing; Shao, Yuefei
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
SOURCE: PCT Int. Appl., 702 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008103351	A2	20080828	WO 2008-US2182	20080220
WO 2008103351	A3	20090723		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20080200445	A1	20080821	US 2007-710582	20070223 <--
AU 2008219071	A1	20080828	AU 2008-219071	20080220
CA 2678958	A1	20080828	CA 2008-2678958	20080220
WO 2008103351	A2	20080828	WO 2008-XA2182	20080220
WO 2008103351	A3	20090723		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,				

CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 2097387	A2	20090909	EP 2008-714220		20080220
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS					
KR 2009114468	A	20091103	KR 2009-719655		20080220
IN 2009CN04921	A	20091106	IN 2009-CN4921		20090821
MX 2009009063	A	20100129	MX 2009-9063		20090824
PRIORITY APPLN. INFO.:			US 2007-710582	A	20070223
			US 2003-529535P	P	20031215 <--
			US 2004-10772	A2	20041213
			US 2005-149027	A2	20050609
			WO 2008-US2182	W	20080220

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 149:307845
ED Entered STN: 29 Aug 2008
GI



I



II



III

AB Disclosed are compds. I [W = a bond, C(S), S(O), etc.; X = O, NR5 or CR6R7; U = a bond, S(O), SO2, C(O), etc.; R1, R2, R5 = H, alkyl, cycloalkyl, etc.; R3, R4, R6, R7 = H, alkyl, cycloalkyl, etc.; with provisos] or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof; and the pharmaceutical compns. comprising the compds. I. Over 1000 compds. I were prepared E.g., synthesis of imidazolidin-2-imine II, starting from III, was described. Compds. I were tested in various assays (data given for selected compds. I). Also disclosed is the method of inhibiting aspartyl protease, and

in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting Human Immunodeficiency Virus, plasmepsin, cathepsin D, and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compds. I in combination with a cholinesterase inhibitor or a muscarinic M1 agonist or M2 antagonist. This abstract record is one of 2 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 7, 63

IT 1049645-69-3P 1049645-70-6P 1049645-71-7P 1049645-72-8P
1049645-73-9P 1049645-74-0P 1049645-75-1P 1049645-76-2P
1049645-77-3P 1049645-78-4P 1049645-79-5P 1049645-80-8P
1049645-81-9P 1049645-82-0P 1049645-83-1P 1049645-84-2P
1049645-85-3P 1049645-86-4P 1049645-87-5P 1049645-88-6P
1049645-89-7P 1049645-90-0P 1049645-92-2P 1049645-93-3P
1049645-94-4P 1049645-95-5P 1049645-96-6P 1049645-98-8P
1049645-99-9P 1049646-00-5P 1049646-01-6P 1049646-02-7P
1049646-03-8P 1049646-04-9P 1049646-05-0P 1049646-06-1P
1049646-07-2P 1049646-09-4P 1049646-10-7P 1049646-11-8P
1049646-12-9P 1049646-13-0P 1049646-15-2P 1049646-16-3P
1049646-17-4P 1049646-19-6P 1049646-20-9P 1049646-21-0P
1049646-22-1P 1049646-23-2P 1049646-24-3P 1049646-25-4P
1049646-26-5P 1049646-27-6P 1049646-28-7P 1049646-29-8P
1049646-30-1P 1049646-31-2P 1049646-32-3P 1049646-33-4P
1049646-34-5P 1049646-35-6P 1049646-36-7P 1049646-37-8P
1049646-40-3P 1049646-41-4P 1049646-42-5P 1049646-43-6P
1049646-44-7P 1049646-45-8P 1049646-46-9P 1049646-47-0P
1049646-48-1P 1049646-49-2P 1049646-50-5P 1049646-51-6P
1049646-52-7P 1049646-55-0P 1049646-56-1P 1049646-57-2P
1049646-58-3P 1049646-59-4P 1049646-62-9P 1049646-64-1P
1049646-65-2P 1049646-66-3P 1049646-67-4P 1049646-68-5P
1049646-69-6P 1049646-70-9P 1049646-72-1P 1049646-73-2P
1049646-74-3P 1049646-75-4P 1049646-76-5P 1049646-77-6P
1049646-78-7P 1049646-79-8P 1049646-80-1P 1049646-81-2P
1049646-82-3P 1049646-83-4P 1049646-85-6P 1049646-86-7P
1049646-87-8P 1049646-88-9P 1049646-89-0P 1049646-90-3P
1049646-91-4P 1049646-92-5P 1049646-93-6P 1049646-94-7P
1049646-95-8P 1049646-96-9P 1049646-97-0P 1049646-98-1P
1049646-99-2P 1049647-00-8P 1049647-01-9P 1049647-02-0P
1049647-03-1P 1049647-04-2P 1049647-05-3P 1049647-07-5P
1049647-08-6P 1049647-09-7P 1049647-10-0P 1049647-11-1P
1049647-12-2P 1049647-13-3P 1049647-14-4P 1049647-15-5P
1049647-16-6P 1049647-17-7P 1049647-18-8P 1049647-19-9P
1049647-20-2P 1049647-21-3P 1049647-22-4P 1049647-23-5P
1049647-24-6P 1049647-25-7P 1049647-26-8P 1049647-27-9P
1049647-28-0P 1049647-29-1P 1049647-30-4P 1049647-31-5P
1049647-32-6P 1049647-33-7P 1049647-34-8P 1049647-37-1P
1049647-38-2P 1049647-39-3P 1049647-40-6P 1049647-41-7P
1049647-42-8P 1049647-43-9P 1049647-45-1P 1049647-46-2P
1049647-47-3P 1049647-48-4P 1049647-49-5P 1049647-50-8P
1049647-51-9P 1049647-52-0P 1049647-53-1P 1049647-54-2P
1049647-55-3P 1049647-58-6P 1049647-59-7P 1049647-60-0P
1049647-61-1P 1049647-62-2P 1049647-63-3P 1049647-64-4P
1049647-65-5P 1049647-66-6P 1049647-67-7P 1049647-68-8P
1049647-69-9P 1049647-71-3P 1049647-72-4P 1049647-73-5P
1049647-74-6P 1049647-75-7P 1049647-76-8P 1049647-77-9P
1049647-78-0P 1049647-79-1P 1049647-80-4P 1049647-81-5P
1049647-82-6P 1049647-83-7P 1049647-84-8P 1049647-85-9P
1049647-86-0P 1049647-87-1P 1049647-88-2P 1049647-89-3P

1049647-90-6P 1049647-91-7P 1049647-92-8P 1049647-93-9P
1049647-94-0P 1049647-95-1P 1049647-96-2P 1049647-97-3P
1049647-98-4P 1049647-99-5P 1049648-00-1P 1049648-01-2P
1049648-03-4P 1049648-04-5P 1049648-05-6P 1049648-06-7P
1049648-07-8P 1049648-08-9P 1049648-09-0P 1049648-10-3P
1049648-11-4P 1049648-12-5P 1049648-13-6P 1049648-14-7P
1049648-15-8P 1049648-16-9P 1049648-17-0P 1049648-18-1P
1049648-19-2P 1049648-20-5P 1049648-21-6P 1049648-22-7P
1049648-23-8P 1049648-24-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolidin-2-imines and their analogs as aspartyl protease
inhibitors for treating various diseases)

IT 1049648-25-0P 1049648-26-1P 1049648-28-3P 1049648-29-4P
1049648-30-7P 1049648-31-8P 1049648-32-9P 1049648-33-0P
1049648-34-1P 1049648-35-2P 1049648-36-3P 1049648-38-5P
1049648-40-9P 1049648-41-0P 1049648-42-1P 1049648-43-2P
1049648-44-3P 1049648-45-4P 1049648-46-5P 1049648-47-6P
1049648-48-7P 1049648-49-8P 1049648-50-1P 1049648-51-2P
1049648-53-4P 1049648-54-5P 1049648-56-7P 1049648-57-8P
1049648-58-9P 1049648-59-0P 1049648-60-3P 1049648-62-5P
1049648-64-7P 1049648-66-9P 1049648-68-1P 1049648-70-5P
1049648-72-7P 1049648-74-9P 1049648-76-1P 1049648-78-3P
1049648-82-9P 1049648-84-1P 1049648-88-5P 1049648-90-9P
1049648-92-1P 1049648-94-3P 1049648-96-5P 1049648-98-7P
1049649-00-4P 1049649-02-6P 1049649-04-8P 1049649-06-0P
1049649-08-2P 1049649-10-6P 1049649-12-8P 1049649-14-0P
1049649-16-2P 1049649-19-5P 1049649-21-9P 1049649-25-3P
1049649-27-5P 1049649-29-7P 1049649-31-1P 1049649-33-3P
1049649-35-5P 1049649-37-7P 1049649-39-9P 1049649-41-3P
1049649-43-5P 1049649-45-7P 1049649-47-9P 1049649-49-1P
1049649-51-5P 1049649-53-7P 1049649-55-9P 1049649-57-1P
1049649-58-2P 1049649-63-9P 1049649-65-1P 1049649-67-3P
1049649-69-5P 1049649-71-9P 1049649-73-1P 1049649-75-3P
1049649-77-5P 1049649-79-7P 1049649-81-1P 1049649-83-3P
1049649-85-5P 1049649-86-6P 1049649-88-8P 1049649-90-2P
1049649-92-4P 1049649-94-6P 1049649-97-9P 1049649-99-1P
1049650-01-2P 1049650-03-4P 1049650-05-6P 1049650-07-8P
1049650-09-0P 1049650-11-4P 1049650-14-7P 1049650-18-1P
1049650-19-2P 1049650-21-6P 1049650-23-8P 1049650-25-0P
1049650-27-2P 1049650-29-4P 1049650-31-8P 1049650-33-0P
1049650-35-2P 1049650-37-4P 1049650-39-6P 1049650-41-0P
1049650-43-2P 1049650-45-4P 1049650-48-7P 1049650-50-1P
1049650-52-3P 1049650-54-5P 1049650-55-6P 1049650-57-8P
1049650-59-0P 1049650-61-4P 1049650-62-5P 1049650-64-7P
1049650-66-9P 1049650-68-1P 1049650-72-7P 1049650-74-9P
1049650-76-1P 1049650-78-3P 1049650-80-7P 1049650-82-9P
1049650-84-1P 1049650-86-3P 1049650-90-9P 1049650-92-1P
1049650-94-3P 1049650-96-5P 1049650-98-7P 1049651-00-4P
1049651-02-6P 1049651-05-9P 1049651-07-1P 1049651-09-3P
1049651-11-7P 1049651-13-9P 1049651-15-1P 1049651-17-3P
1049651-19-5P 1049651-21-9P 1049651-23-1P 1049651-25-3P
1049651-27-5P 1049651-29-7P 1049651-31-1P 1049651-32-2P
1049651-34-4P 1049651-35-5P 1049651-36-6P 1049651-37-7P
1049651-39-9P 1049651-43-5P 1049651-45-7P 1049651-46-8P
1049651-48-0P 1049651-49-1P 1049651-50-4P 1049651-52-6P
1049651-53-7P 1049651-55-9P 1049651-56-0P 1049651-58-2P
1049651-59-3P 1049651-60-6P 1049651-62-8P 1049651-63-9P

1049651-65-1P 1049651-67-3P 1049651-69-5P 1049651-70-8P
1049651-72-0P 1049651-74-2P 1049651-76-4P 1049651-78-6P
1049651-80-0P 1049651-82-2P 1049651-84-4P 1049651-86-6P
1049651-88-8P 1049651-90-2P 1049651-94-6P 1049651-95-7P
1049651-96-8P 1049651-98-0P 1049651-99-1P 1049652-00-7P
1049652-01-8P 1049652-02-9P 1049652-03-0P 1049652-04-1P
1049652-05-2P 1049652-07-4P 1049652-11-0P 1049652-12-1P
1049652-14-3P 1049652-16-5P 1049652-17-6P 1049652-19-8P
1049652-20-1P 1049652-21-2P 1049652-22-3P 1049652-23-4P
1049652-24-5P 1049652-26-7P 1049652-27-8P 1049652-28-9P
1049652-30-3P 1049652-31-4P 1049652-32-5P 1049652-33-6P
1049652-36-9P 1049652-38-1P 1049652-39-2P 1049652-40-5P
1049652-41-6P 1049652-43-8P 1049652-44-9P 1049652-45-0P
1049652-46-1P 1049652-47-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolidin-2-imines and their analogs as aspartyl protease
inhibitors for treating various diseases)

IT 1049660-28-7P 1049660-29-8P 1049660-30-1P 1049660-31-2P
1049660-34-5P 1049660-35-6P 1049660-36-7P 1049660-37-8P
1049660-38-9P 1049660-39-0P 1049660-40-3P 1049660-41-4P
1049660-42-5P 1049660-43-6P 1049660-44-7P 1049660-45-8P
1049660-46-9P 1049660-47-0P 1049660-48-1P 1049660-49-2P
1049660-50-5P 1049660-51-6P 1049660-52-7P 1049660-53-8P
1049660-54-9P 1049660-55-0P 1049660-56-1P 1049660-57-2P
1049660-58-3P 1049660-59-4P 1049660-60-7P 1049660-61-8P
1049660-62-9P 1049660-63-0P 1049660-65-2P 1049660-66-3P
1049660-67-4P 1049660-68-5P 1049660-69-6P 1049660-71-0P
1049660-72-1P 1049660-74-3P 1049660-76-5P 1049660-78-7P
1049660-81-2P 1049660-83-4P 1049660-84-5P 1049660-85-6P
1049660-86-7P 1049660-87-8P 1049660-88-9P 1049660-89-0P
1049660-90-3P 1049660-91-4P 1049660-92-5P 1049660-93-6P
1049660-94-7P 1049660-95-8P 1049660-96-9P 1049660-97-0P
1049660-99-2P 1049661-00-8P 1049661-01-9P 1049661-03-1P
1049661-04-2P 1049661-05-3P 1049661-06-4P 1049661-07-5P
1049661-08-6P 1049661-09-7P 1049661-10-0P 1049661-12-2P
1049661-13-3P 1049661-14-4P 1049661-15-5P 1049661-16-6P
1049661-17-7P 1049661-19-9P 1049661-20-2P 1049661-21-3P
1049661-22-4P 1049661-23-5P 1049661-24-6P 1049661-25-7P
1049661-26-8P 1049661-27-9P 1049661-28-0P 1049661-29-1P
1049661-30-4P 1049661-32-6P 1049661-34-8P 1049661-35-9P
1049661-36-0P 1049661-37-1P 1049661-38-2P 1049661-39-3P
1049661-40-6P 1049661-41-7P 1049661-43-9P 1049661-44-0P
1049661-46-2P 1049661-47-3P 1049661-49-5P 1049661-51-9P
1049661-52-0P 1049661-53-1P 1049661-54-2P 1049661-55-3P
1049661-56-4P 1049661-57-5P 1049661-58-6P 1049661-59-7P
1049661-60-0P 1049661-61-1P 1049661-62-2P 1049661-63-3P
1049661-64-4P 1049661-65-5P 1049661-66-6P 1049661-67-7P
1049669-59-1P 1049669-60-4P 1049669-61-5P 1049669-63-7P
1049669-64-8P 1049669-65-9P 1049669-66-0P 1049669-67-1P
1049669-68-2P 1049669-69-3P 1049669-70-6P 1049669-71-7P
1049669-72-8P 1049669-73-9P 1049669-74-0P 1049669-75-1P
1049669-77-3P 1049669-78-4P 1049669-79-5P 1049669-80-8P
1049669-81-9P 1049669-82-0P 1049669-83-1P 1049669-85-3P
1049669-86-4P 1049669-87-5P 1049669-88-6P 1049669-89-7P
1049669-90-0P 1049669-91-1P 1049669-92-2P 1049669-93-3P
1049669-94-4P 1049669-95-5P 1049669-96-6P 1049669-97-7P
1049669-98-8P 1049669-99-9P 1049670-00-9P 1049670-02-1P

1049670-03-2P 1049670-04-3P 1049670-05-4P 1049670-06-5P
1049670-07-6P 1049670-08-7P 1049670-09-8P 1049670-10-1P
1049670-11-2P 1049670-12-3P 1049670-13-4P 1049670-14-5P
1049670-15-6P 1049670-16-7P 1049670-17-8P 1049670-18-9P
1049670-19-0P 1049670-20-3P 1049670-21-4P 1049670-22-5P
1049670-23-6P 1049670-24-7P 1049670-27-0P 1049670-28-1P
1049670-29-2P 1049670-30-5P 1049670-31-6P 1049670-32-7P
1049670-33-8P 1049670-34-9P 1049670-35-0P 1049670-36-1P
1049670-37-2P 1049670-38-3P 1049670-39-4P 1049670-40-7P
1049670-41-8P 1049670-42-9P 1049670-43-0P 1049670-44-1P
1049670-45-2P 1049670-47-4P 1049670-48-5P 1049670-49-6P
1049670-50-9P 1049670-51-0P 1049670-52-1P 1049670-53-2P
1049670-54-3P 1049670-55-4P 1049670-56-5P 1049670-57-6P
1049670-58-7P 1049670-59-8P 1049670-60-1P 1049670-61-2P
1049670-63-4P 1049670-64-5P 1049670-65-6P 1049670-66-7P
1049670-67-8P 1049670-68-9P 1049670-69-0P 1049670-70-3P
1049670-71-4P 1049670-72-5P 1049670-73-6P 1049670-75-8P
1049670-76-9P 1049670-77-0P 1049670-79-2P 1049670-80-5P
1049670-81-6P 1049670-82-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolidin-2-imines and their analogs as aspartyl protease
inhibitors for treating various diseases)

IT 1049686-34-1P 1049686-35-2P 1049686-36-3P 1049686-37-4P
1049686-38-5P 1049686-39-6P 1049686-40-9P 1049686-41-0P
1049686-42-1P 1049686-43-2P 1049686-44-3P 1049686-45-4P
1049686-47-6P 1049686-48-7P 1049686-49-8P 1049686-50-1P
1049686-51-2P 1049686-52-3P 1049686-53-4P 1049686-54-5P
1049686-55-6P 1049686-56-7P 1049686-57-8P 1049686-58-9P
1049686-59-0P 1049686-60-3P 1049686-61-4P 1049686-62-5P
1049686-63-6P 1049686-64-7P 1049686-65-8P 1049686-66-9P
1049686-67-0P 1049686-68-1P 1049686-69-2P 1049686-70-5P
1049686-71-6P 1049686-72-7P 1049686-73-8P 1049686-74-9P
1049686-75-0P 1049686-77-2P 1049686-78-3P 1049686-79-4P
1049686-81-8P 1049686-82-9P 1049686-83-0P 1049686-84-1P
1049686-85-2P 1049686-87-4P 1049686-88-5P 1049686-89-6P
1049686-90-9P 1049686-91-0P 1049686-92-1P 1049686-93-2P
1049686-94-3P 1049686-95-4P 1049686-96-5P 1049686-97-6P
1049686-98-7P 1049686-99-8P 1049687-00-4P 1049687-01-5P
1049687-03-7P 1049687-05-9P 1049687-07-1P 1049687-08-2P
1049687-09-3P 1049687-10-6P 1049687-11-7P 1049687-12-8P
1049687-13-9P 1049687-14-0P 1049687-15-1P 1049687-16-2P
1049687-17-3P 1049687-18-4P 1049687-19-5P 1049687-20-8P
1049687-21-9P 1049687-22-0P 1049687-23-1P 1049687-24-2P
1049687-25-3P 1049687-26-4P 1049687-27-5P 1049687-28-6P
1049687-29-7P 1049687-30-0P 1049687-31-1P 1049687-32-2P
1049687-33-3P 1049687-35-5P 1049687-36-6P 1049687-37-7P
1049687-38-8P 1049687-39-9P 1049687-40-2P 1049687-41-3P
1049687-43-5P 1049687-45-7P 1049687-46-8P 1049687-47-9P
1049687-48-0P 1049687-50-4P 1049687-51-5P 1049687-52-6P
1049687-53-7P 1049687-54-8P 1049687-55-9P 1049687-56-0P
1049687-57-1P 1049687-58-2P 1049687-60-6P 1049687-61-7P
1049687-62-8P 1049687-63-9P 1049687-64-0P 1049687-65-1P
1049687-66-2P 1049687-67-3P 1049687-68-4P 1049687-69-5P
1049687-70-8P 1049687-71-9P 1049687-72-0P 1049687-73-1P
1049687-74-2P 1049687-76-4P 1049687-78-6P 1049687-80-0P
1049687-84-4P 1049687-86-6P 1049687-87-7P 1049687-90-2P
1049687-91-3P 1049687-92-4P 1049687-93-5P 1049687-95-7P

1049687-96-8P 1049687-97-9P 1049687-99-1P 1049688-00-7P
1049688-02-9P 1049688-03-0P 1049688-04-1P 1049688-05-2P
1049688-06-3P 1049688-07-4P 1049688-08-5P 1049688-09-6P
1049688-10-9P 1049688-11-0P 1049688-12-1P 1049688-13-2P
1049688-14-3P 1049688-15-4P 1049688-16-5P 1049688-17-6P
1049688-18-7P 1049688-19-8P 1049688-20-1P 1049688-21-2P
1049688-22-3P 1049688-23-4P 1049688-24-5P 1049688-26-7P
1049688-27-8P 1049688-28-9P 1049688-29-0P 1049688-30-3P
1049688-31-4P 1049688-32-5P 1049688-33-6P 1049688-34-7P
1049688-35-8P 1049688-36-9P 1049688-37-0P 1049688-38-1P
1049688-39-2P 1049688-40-5P 1049688-41-6P 1049688-42-7P
1049688-43-8P 1049688-44-9P 1049688-45-0P 1049688-46-1P
1049688-47-2P 1049688-48-3P 1049688-49-4P 1049688-50-7P
1049688-51-8P 1049688-52-9P 1049688-53-0P 1049688-54-1P
1049688-55-2P 1049688-57-4P 1049688-59-6P 1049688-61-0P
1049688-66-5P 1049688-74-5P 1049688-76-7P 1049688-78-9P
1049688-80-3P 1049688-82-5P 1049688-84-7P 1049688-85-8P
1049688-87-0P 1049688-89-2P 1049688-91-6P 1049688-93-8P
1049688-95-0P 1049688-97-2P 1049689-01-1P 1049689-03-3P
1049689-05-5P 1049689-07-7P 1049689-09-9P 1049689-11-3P
1049689-13-5P 1049689-15-7P 1049689-17-9P 1049689-20-4P
1049689-22-6P 1049689-24-8P 1049689-26-0P 1049689-28-2P
1049689-32-8P 1049689-34-0P 1049689-36-2P 1049689-41-9P
1049689-43-1P 1049689-45-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolidin-2-imines and their analogs as aspartyl protease
inhibitors for treating various diseases)

IT 1049647-76-8P 1049652-40-5P 1049669-70-6P
1049686-97-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolidin-2-imines and their analogs as aspartyl protease
inhibitors for treating various diseases)

RN 1049647-76-8 HCAPLUS
CN Urea, N-[[3'-(2-amino-4,5-dihydro-1,4-dimethyl-5-oxo-1H-imidazol-4-yl)-5-chloro[1,1'-biphenyl]-2-yl]methyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)



RN 1049652-40-5 HCAPLUS
CN Urea, N-[[3'-(2-amino-4,5-dihydro-1,4-dimethyl-5-oxo-1H-imidazol-4-yl)-5-chloro[1,1'-biphenyl]-2-yl]methyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)



RN 1049669-70-6 HCAPLUS
CN Urea, N-[[3'-(2-amino-4,5-dihydro-1,4-dimethyl-5-oxo-1H-imidazol-4-yl)-5'-chloro[1,1'-biphenyl]-2-yl]methyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)



RN 1049686-97-6 HCAPLUS
CN Urea, N-[[3'-(2-amino-4,5-dihydro-1,4-dimethyl-5-oxo-1H-imidazol-4-yl)-5-chloro[1,1'-biphenyl]-2-yl]methyl]-N'-(2-chlorophenyl)- (CA INDEX NAME)



L125 ANSWER 3 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1011066 HCAPLUS Full-text
DOCUMENT NUMBER: 149:307842
TITLE: Preparation of imidazolidin-2-imines and their analogs as aspartyl protease inhibitors for treating various diseases
INVENTOR(S): Zhu, Zhaoning; McKittrick, Brian; Sun, Zhong-Yue; Ye, Yuanzan C.; Voigt, Johannes H.; Strickland, Corey O.; Smith, Elizabeth M.; Stamford, Andrew; Greenlee, William J.; Mazzola, Robert D.; Caldwell, John P.; Cumming, Jared N.; Wang, Lingyan; Wu, Yusheng; Iserloh, Ulrich; Liu, Xiaoxiang; Guo, Tao; Le, Thuy X. E.; Saionz, Kurt W.; Babu, Suresh D.; Hunter, Rachael C.; Morris, Michelle L.; Gu, Huizhong; Qian, Gang;

	Tadesse, Dawit; Huang, Ying; Li, Guoqing; Pan, Jianping; Misiaszek, Jeffrey A.; Lai, Gaifa; Duo, Jingqi; Qu, Chuanxing; Shao, Yuefei
PATENT ASSIGNEE(S):	Schering Corporation, USA; Pharmacopeia Drug Discovery, Inc.
SOURCE:	U.S. Pat. Appl. Publ., 1209pp., Cont.-in-part of U.S. Ser. No. 149,027. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	5
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080200445	A1	20080821	US 2007-710582	20070223 <--
US 20070072852	A1	20070329	US 2004-10772	20041213 <--
US 7592348	B2	20090922		
EP 2153832	A2	20100217	EP 2009-174520	20041213 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 101671307	A	20100317	CN 2009-10163552	20041213 <--
US 20060111370	A1	20060525	US 2005-149027	20050609 <--
US 7700603	B2	20100420		
AU 2005317204	A1	20060622	AU 2005-317204	20050609
CA 2591033	A1	20060622	CA 2005-2591033	20050609
WO 2006065277	A2	20060622	WO 2005-US20446	20050609
WO 2006065277	A3	20070125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1838304	A2	20071003	EP 2005-766007	20050609
EP 1838304	B1	20090819		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2008523059	T	20080703	JP 2007-545436	20050609
BR 2005019034	A2	20081223	BR 2005-19034	20050609
AT 439835	T	20090915	AT 2005-766007	20050609
NZ 556477	A	20090925	NZ 2005-556477	20050609
ES 2330124	T3	20091204	ES 2005-766007	20050609
ZA 2007005071	A	20081126	ZA 2007-5071	20070612
IN 2007CN02535	A	20070907	IN 2007-CN2535	20070613
KR 2007106689	A	20071105	KR 2007-713310	20070613
MX 2007007058	A	20071211	MX 2007-7058	20070613
NO 2007003616	A	20070912	NO 2007-3616	20070712
CN 101115482	A	20080130	CN 2005-80047939	20070809
AU 2008219071	A1	20080828	AU 2008-219071	20080220
CA 2678958	A1	20080828	CA 2008-2678958	20080220
WO 2008103351	A2	20080828	WO 2008-US2182	20080220

```
     WO 2008103351         A3    20090723
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
     WO 2008103351         A2    20080828    WO 2008-XA2182         20080220
     WO 2008103351         A3    20090723
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
     EP 2097387            A2    20090909    EP 2008-714220         20080220
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI,
             SK, TR, AL, BA, MK, RS
     KR 2009114468         A     20091103    KR 2009-719655         20080220
     JP 2008174570         A     20080731    JP 2008-79293          20080325 <--
     IN 2009CN04921        A     20091106    IN 2009-CN4921         20090821
     MX 2009009063         A     20100129    MX 2009-9063           20090824
PRIORITY APPLN. INFO.:                       US 2003-529535P     P  20031215 <--
                                             US 2004-10772       A2 20041213
                                             US 2005-149027      A2 20050609
                                             CN 2004-80041516    A3 20041213
                                             EP 2004-813947      A3 20041213
                                             JP 2006-544081      A3 20041213
                                             WO 2005-US20446     W  20050609
                                             US 2007-710582      A  20070223
                                             WO 2008-US2182      W  20080220
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
ED   Entered STN:  21 Aug 2008
GI
```



I



II



III

AB Disclosed are compds. I [W = a bond, C(S), S(O), etc.; X = O, NR5 or CR6R7; U = a bond, S(O), SO2, C(O), etc.; R1, R2, R5 = H, alkyl, cycloalkyl, etc.; R3, R4, R6, R7 = H, alkyl, cycloalkyl, etc.; with provisos] or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof; and the pharmaceutical compns. comprising the compds. I. Over 1000 compds. I were prepared E.g., synthesis of imidazolidin-2-imine II, starting from III, was described. Compds. I were tested in various assays (data given for selected compds. I). Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepsin, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compds. I in combination with a cholinesterase inhibitor or a muscarinic M1 agonist or M2 antagonist.

INCL 514210020; 514222200; 514229200; 514235800; 514249000; 514272000; 514313000; 514318000; 514326000; 514341000

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 7, 63

IT 1049645-69-3P 1049645-70-6P 1049645-71-7P 1049645-72-8P
1049645-73-9P 1049645-74-0P 1049645-75-1P 1049645-76-2P
1049645-77-3P 1049645-78-4P 1049645-79-5P 1049645-80-8P
1049645-81-9P 1049645-82-0P 1049645-83-1P 1049645-84-2P
1049645-85-3P 1049645-86-4P 1049645-87-5P 1049645-88-6P
1049645-89-7P 1049645-90-0P 1049645-92-2P 1049645-93-3P
1049645-94-4P 1049645-95-5P 1049645-96-6P 1049645-98-8P
1049645-99-9P 1049646-00-5P 1049646-01-6P 1049646-02-7P
1049646-03-8P 1049646-04-9P 1049646-05-0P 1049646-06-1P
1049646-07-2P 1049646-09-4P 1049646-10-7P 1049646-11-8P
1049646-12-9P 1049646-13-0P 1049646-15-2P 1049646-16-3P
1049646-17-4P 1049646-19-6P 1049646-20-9P 1049646-21-0P
1049646-22-1P 1049646-23-2P 1049646-24-3P 1049646-25-4P
1049646-26-5P 1049646-27-6P 1049646-28-7P 1049646-29-8P
1049646-30-1P 1049646-31-2P 1049646-32-3P 1049646-33-4P
1049646-34-5P 1049646-35-6P 1049646-36-7P 1049646-37-8P
1049646-40-3P 1049646-41-4P 1049646-42-5P 1049646-43-6P
1049646-44-7P 1049646-45-8P 1049646-46-9P 1049646-47-0P
1049646-48-1P 1049646-49-2P 1049646-50-5P 1049646-51-6P
1049646-52-7P 1049646-55-0P 1049646-56-1P 1049646-57-2P
1049646-58-3P 1049646-59-4P 1049646-62-9P 1049646-64-1P

1049646-65-2P 1049646-66-3P 1049646-67-4P 1049646-68-5P
1049646-69-6P 1049646-70-9P 1049646-72-1P 1049646-73-2P
1049646-74-3P 1049646-75-4P 1049646-76-5P 1049646-77-6P
1049646-78-7P 1049646-79-8P 1049646-80-1P 1049646-81-2P
1049646-82-3P 1049646-83-4P 1049646-85-6P 1049646-86-7P
1049646-87-8P 1049646-88-9P 1049646-89-0P 1049646-90-3P
1049646-91-4P 1049646-92-5P 1049646-93-6P 1049646-94-7P
1049646-95-8P 1049646-96-9P 1049646-97-0P 1049646-98-1P
1049646-99-2P 1049647-00-8P 1049647-01-9P 1049647-02-0P
1049647-03-1P 1049647-04-2P 1049647-05-3P 1049647-07-5P
1049647-08-6P 1049647-09-7P 1049647-10-0P 1049647-11-1P
1049647-12-2P 1049647-13-3P 1049647-14-4P 1049647-15-5P
1049647-16-6P 1049647-17-7P 1049647-18-8P 1049647-19-9P
1049647-20-2P 1049647-21-3P 1049647-22-4P 1049647-23-5P
1049647-24-6P 1049647-25-7P 1049647-26-8P 1049647-27-9P
1049647-28-0P 1049647-29-1P 1049647-30-4P 1049647-31-5P
1049647-32-6P 1049647-33-7P 1049647-34-8P 1049647-37-1P
1049647-38-2P 1049647-39-3P 1049647-40-6P 1049647-41-7P
1049647-42-8P 1049647-43-9P 1049647-45-1P 1049647-46-2P
1049647-47-3P 1049647-48-4P 1049647-49-5P 1049647-50-8P
1049647-51-9P 1049647-52-0P 1049647-53-1P 1049647-54-2P
1049647-55-3P 1049647-58-6P 1049647-59-7P 1049647-60-0P
1049647-61-1P 1049647-62-2P 1049647-63-3P 1049647-64-4P
1049647-65-5P 1049647-66-6P 1049647-67-7P 1049647-68-8P
1049647-69-9P 1049647-70-2P 1049647-71-3P 1049647-72-4P
1049647-73-5P 1049647-74-6P 1049647-75-7P 1049647-76-8P
1049647-77-9P 1049647-78-0P 1049647-79-1P 1049647-80-4P
1049647-81-5P 1049647-82-6P 1049647-83-7P 1049647-84-8P
1049647-85-9P 1049647-86-0P 1049647-87-1P 1049647-88-2P
1049647-89-3P 1049647-90-6P 1049647-91-7P 1049647-92-8P
1049647-93-9P 1049647-94-0P 1049647-95-1P 1049647-96-2P
1049647-97-3P 1049647-98-4P 1049647-99-5P 1049648-00-1P
1049648-01-2P 1049648-03-4P 1049648-04-5P 1049648-05-6P
1049648-06-7P 1049648-07-8P 1049648-08-9P 1049648-09-0P
1049648-10-3P 1049648-11-4P 1049648-12-5P 1049648-13-6P
1049648-14-7P 1049648-15-8P 1049648-16-9P 1049648-17-0P
1049648-18-1P 1049648-19-2P 1049648-20-5P 1049648-21-6P
1049648-22-7P 1049648-23-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolidin-2-imines and their analogs as aspartyl protease
inhibitors for treating various diseases)

IT 1049648-24-9P 1049648-25-0P 1049648-26-1P 1049648-28-3P
1049648-29-4P 1049648-30-7P 1049648-31-8P 1049648-32-9P
1049648-33-0P 1049648-34-1P 1049648-35-2P 1049648-36-3P
1049648-38-5P 1049648-40-9P 1049648-41-0P 1049648-42-1P
1049648-43-2P 1049648-44-3P 1049648-45-4P 1049648-46-5P
1049648-47-6P 1049648-48-7P 1049648-49-8P 1049648-50-1P
1049648-51-2P 1049648-53-4P 1049648-54-5P 1049648-56-7P
1049648-57-8P 1049648-58-9P 1049648-59-0P 1049648-60-3P
1049648-62-5P 1049648-64-7P 1049648-66-9P 1049648-68-1P
1049648-70-5P 1049648-72-7P 1049648-74-9P 1049648-76-1P
1049648-78-3P 1049648-82-9P 1049648-84-1P 1049648-88-5P
1049648-90-9P 1049648-92-1P 1049648-94-3P 1049648-96-5P
1049648-98-7P 1049649-00-4P 1049649-02-6P 1049649-04-8P
1049649-06-0P 1049649-08-2P 1049649-10-6P 1049649-12-8P
1049649-14-0P 1049649-16-2P 1049649-19-5P 1049649-21-9P
1049649-25-3P 1049649-27-5P 1049649-29-7P 1049649-31-1P

1049649-33-3P 1049649-35-5P 1049649-37-7P 1049649-39-9P
1049649-41-3P 1049649-43-5P 1049649-45-7P 1049649-47-9P
1049649-49-1P 1049649-51-5P 1049649-53-7P 1049649-55-9P
1049649-57-1P 1049649-58-2P 1049649-63-9P 1049649-65-1P
1049649-67-3P 1049649-69-5P 1049649-71-9P 1049649-73-1P
1049649-75-3P 1049649-77-5P 1049649-79-7P 1049649-81-1P
1049649-83-3P 1049649-85-5P 1049649-86-6P 1049649-88-8P
1049649-90-2P 1049649-92-4P 1049649-94-6P 1049649-97-9P
1049649-99-1P 1049650-01-2P 1049650-03-4P 1049650-05-6P
1049650-07-8P 1049650-09-0P 1049650-11-4P 1049650-14-7P
1049650-18-1P 1049650-19-2P 1049650-21-6P 1049650-23-8P
1049650-25-0P 1049650-27-2P 1049650-29-4P 1049650-31-8P
1049650-33-0P 1049650-35-2P 1049650-37-4P 1049650-39-6P
1049650-41-0P 1049650-43-2P 1049650-45-4P 1049650-48-7P
1049650-50-1P 1049650-52-3P 1049650-54-5P 1049650-55-6P
1049650-57-8P 1049650-59-0P 1049650-61-4P 1049650-62-5P
1049650-64-7P 1049650-66-9P 1049650-68-1P 1049650-72-7P
1049650-74-9P 1049650-76-1P 1049650-78-3P 1049650-80-7P
1049650-82-9P 1049650-84-1P 1049650-86-3P 1049650-90-9P
1049650-92-1P 1049650-94-3P 1049650-96-5P 1049650-98-7P
1049651-00-4P 1049651-02-6P 1049651-05-9P 1049651-07-1P
1049651-09-3P 1049651-11-7P 1049651-13-9P 1049651-15-1P
1049651-17-3P 1049651-19-5P 1049651-21-9P 1049651-23-1P
1049651-25-3P 1049651-27-5P 1049651-29-7P 1049651-31-1P
1049651-32-2P 1049651-34-4P 1049651-35-5P 1049651-36-6P
1049651-37-7P 1049651-39-9P 1049651-43-5P 1049651-45-7P
1049651-46-8P 1049651-48-0P 1049651-49-1P 1049651-50-4P
1049651-52-6P 1049651-53-7P 1049651-55-9P 1049651-56-0P
1049651-58-2P 1049651-59-3P 1049651-60-6P 1049651-62-8P
1049651-63-9P 1049651-65-1P 1049651-67-3P 1049651-69-5P
1049651-70-8P 1049651-72-0P 1049651-74-2P 1049651-76-4P
1049651-78-6P 1049651-80-0P 1049651-82-2P 1049651-84-4P
1049651-86-6P 1049651-88-8P 1049651-90-2P 1049651-94-6P
1049651-95-7P 1049651-96-8P 1049651-98-0P 1049651-99-1P
1049652-00-7P 1049652-01-8P 1049652-02-9P 1049652-03-0P
1049652-04-1P 1049652-05-2P 1049652-07-4P 1049652-11-0P
1049652-12-1P 1049652-14-3P 1049652-16-5P 1049652-17-6P
1049652-19-8P 1049652-20-1P 1049652-21-2P 1049652-22-3P
1049652-23-4P 1049652-24-5P 1049652-26-7P 1049652-27-8P
1049652-28-9P 1049652-30-3P 1049652-31-4P 1049652-32-5P
1049652-33-6P 1049652-36-9P 1049652-38-1P 1049652-39-2P
1049652-40-5P 1049652-41-6P 1049652-43-8P 1049652-44-9P
1049652-45-0P 1049652-46-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolidin-2-imines and their analogs as aspartyl protease inhibitors for treating various diseases)

IT 1049660-27-6P 1049660-28-7P 1049660-29-8P 1049660-30-1P
1049660-31-2P 1049660-34-5P 1049660-35-6P 1049660-36-7P
1049660-37-8P 1049660-38-9P 1049660-39-0P 1049660-40-3P
1049660-41-4P 1049660-42-5P 1049660-43-6P 1049660-44-7P
1049660-45-8P 1049660-46-9P 1049660-47-0P 1049660-48-1P
1049660-49-2P 1049660-50-5P 1049660-51-6P 1049660-52-7P
1049660-53-8P 1049660-54-9P 1049660-55-0P 1049660-56-1P
1049660-57-2P 1049660-58-3P 1049660-59-4P 1049660-60-7P
1049660-61-8P 1049660-62-9P 1049660-63-0P 1049660-65-2P
1049660-66-3P 1049660-67-4P 1049660-68-5P 1049660-69-6P
1049660-71-0P 1049660-72-1P 1049660-74-3P 1049660-76-5P

1049660-78-7P 1049660-81-2P 1049660-83-4P 1049660-84-5P
1049660-85-6P 1049660-86-7P 1049660-87-8P 1049660-88-9P
1049660-89-0P 1049660-90-3P 1049660-91-4P 1049660-92-5P
1049660-93-6P 1049660-94-7P 1049660-95-8P 1049660-96-9P
1049660-97-0P 1049660-99-2P 1049661-00-8P 1049661-01-9P
1049661-03-1P 1049661-04-2P 1049661-05-3P 1049661-06-4P
1049661-07-5P 1049661-08-6P 1049661-09-7P 1049661-10-0P
1049661-12-2P 1049661-13-3P 1049661-14-4P 1049661-15-5P
1049661-16-6P 1049661-17-7P 1049661-19-9P 1049661-20-2P
1049661-21-3P 1049661-22-4P 1049661-23-5P 1049661-24-6P
1049661-25-7P 1049661-26-8P 1049661-27-9P 1049661-28-0P
1049661-29-1P 1049661-30-4P 1049661-32-6P 1049661-34-8P
1049661-35-9P 1049661-36-0P 1049661-37-1P 1049661-38-2P
1049661-39-3P 1049661-40-6P 1049661-41-7P 1049661-43-9P
1049661-44-0P 1049661-46-2P 1049661-47-3P 1049661-49-5P
1049661-51-9P 1049661-52-0P 1049661-53-1P 1049661-54-2P
1049661-55-3P 1049661-56-4P 1049661-57-5P 1049661-58-6P
1049661-59-7P 1049661-60-0P 1049661-61-1P 1049661-62-2P
1049661-63-3P 1049661-64-4P 1049661-65-5P 1049661-66-6P
1049661-67-7P 1049669-59-1P 1049669-60-4P 1049669-61-5P
1049669-63-7P 1049669-64-8P 1049669-65-9P 1049669-66-0P
1049669-67-1P 1049669-68-2P 1049669-69-3P 1049669-70-6P
1049669-71-7P 1049669-72-8P 1049669-73-9P 1049669-74-0P
1049669-75-1P 1049669-77-3P 1049669-78-4P 1049669-79-5P
1049669-80-8P 1049669-81-9P 1049669-82-0P 1049669-83-1P
1049669-85-3P 1049669-86-4P 1049669-87-5P 1049669-88-6P
1049669-89-7P 1049669-90-0P 1049669-91-1P 1049669-92-2P
1049669-93-3P 1049669-94-4P 1049669-95-5P 1049669-96-6P
1049669-97-7P 1049669-98-8P 1049669-99-9P 1049670-00-9P
1049670-02-1P 1049670-03-2P 1049670-04-3P 1049670-05-4P
1049670-06-5P 1049670-07-6P 1049670-08-7P 1049670-09-8P
1049670-10-1P 1049670-11-2P 1049670-12-3P 1049670-13-4P
1049670-14-5P 1049670-15-6P 1049670-16-7P 1049670-17-8P
1049670-18-9P 1049670-19-0P 1049670-20-3P 1049670-21-4P
1049670-22-5P 1049670-23-6P 1049670-24-7P 1049670-27-0P
1049670-28-1P 1049670-29-2P 1049670-30-5P 1049670-31-6P
1049670-32-7P 1049670-33-8P 1049670-34-9P 1049670-35-0P
1049670-36-1P 1049670-37-2P 1049670-38-3P 1049670-39-4P
1049670-40-7P 1049670-41-8P 1049670-42-9P 1049670-43-0P
1049670-44-1P 1049670-45-2P 1049670-47-4P 1049670-48-5P
1049670-49-6P 1049670-50-9P 1049670-51-0P 1049670-52-1P
1049670-53-2P 1049670-54-3P 1049670-55-4P 1049670-56-5P
1049670-57-6P 1049670-58-7P 1049670-59-8P 1049670-60-1P
1049670-61-2P 1049670-63-4P 1049670-64-5P 1049670-65-6P
1049670-66-7P 1049670-67-8P 1049670-68-9P 1049670-69-0P
1049670-70-3P 1049670-71-4P 1049670-72-5P 1049670-73-6P
1049670-75-8P 1049670-76-9P 1049670-77-0P 1049670-79-2P
1049670-80-5P 1049670-81-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolidin-2-imines and their analogs as aspartyl protease
inhibitors for treating various diseases)

IT 1049686-33-0P 1049686-34-1P 1049686-35-2P 1049686-36-3P
1049686-37-4P 1049686-38-5P 1049686-39-6P 1049686-40-9P
1049686-41-0P 1049686-42-1P 1049686-43-2P 1049686-44-3P
1049686-45-4P 1049686-47-6P 1049686-48-7P 1049686-49-8P
1049686-50-1P 1049686-51-2P 1049686-52-3P 1049686-53-4P
1049686-54-5P 1049686-55-6P 1049686-56-7P 1049686-57-8P

1049686-58-9P 1049686-59-0P 1049686-60-3P 1049686-61-4P
1049686-62-5P 1049686-63-6P 1049686-64-7P 1049686-65-8P
1049686-66-9P 1049686-67-0P 1049686-68-1P 1049686-69-2P
1049686-70-5P 1049686-71-6P 1049686-72-7P 1049686-73-8P
1049686-74-9P 1049686-75-0P 1049686-77-2P 1049686-78-3P
1049686-79-4P 1049686-81-8P 1049686-82-9P 1049686-83-0P
1049686-84-1P 1049686-85-2P 1049686-87-4P 1049686-88-5P
1049686-89-6P 1049686-90-9P 1049686-91-0P 1049686-92-1P
1049686-93-2P 1049686-94-3P 1049686-95-4P 1049686-96-5P
1049686-97-6P 1049686-98-7P 1049686-99-8P 1049687-00-4P
1049687-01-5P 1049687-03-7P 1049687-05-9P 1049687-07-1P
1049687-08-2P 1049687-09-3P 1049687-10-6P 1049687-11-7P
1049687-12-8P 1049687-13-9P 1049687-14-0P 1049687-15-1P
1049687-16-2P 1049687-17-3P 1049687-18-4P 1049687-19-5P
1049687-20-8P 1049687-21-9P 1049687-22-0P 1049687-23-1P
1049687-24-2P 1049687-25-3P 1049687-26-4P 1049687-27-5P
1049687-28-6P 1049687-29-7P 1049687-30-0P 1049687-31-1P
1049687-32-2P 1049687-33-3P 1049687-35-5P 1049687-36-6P
1049687-37-7P 1049687-38-8P 1049687-39-9P 1049687-40-2P
1049687-41-3P 1049687-43-5P 1049687-45-7P 1049687-46-8P
1049687-47-9P 1049687-48-0P 1049687-50-4P 1049687-51-5P
1049687-52-6P 1049687-53-7P 1049687-54-8P 1049687-55-9P
1049687-56-0P 1049687-57-1P 1049687-58-2P 1049687-60-6P
1049687-61-7P 1049687-62-8P 1049687-63-9P 1049687-64-0P
1049687-65-1P 1049687-66-2P 1049687-67-3P 1049687-68-4P
1049687-69-5P 1049687-70-8P 1049687-71-9P 1049687-72-0P
1049687-73-1P 1049687-74-2P 1049687-76-4P 1049687-78-6P
1049687-80-0P 1049687-84-4P 1049687-86-6P 1049687-87-7P
1049687-90-2P 1049687-91-3P 1049687-92-4P 1049687-93-5P
1049687-95-7P 1049687-96-8P 1049687-97-9P 1049687-99-1P
1049688-00-7P 1049688-02-9P 1049688-03-0P 1049688-04-1P
1049688-05-2P 1049688-06-3P 1049688-07-4P 1049688-08-5P
1049688-09-6P 1049688-10-9P 1049688-11-0P 1049688-12-1P
1049688-13-2P 1049688-14-3P 1049688-15-4P 1049688-16-5P
1049688-17-6P 1049688-18-7P 1049688-19-8P 1049688-20-1P
1049688-21-2P 1049688-22-3P 1049688-23-4P 1049688-24-5P
1049688-26-7P 1049688-27-8P 1049688-28-9P 1049688-29-0P
1049688-30-3P 1049688-31-4P 1049688-32-5P 1049688-33-6P
1049688-34-7P 1049688-35-8P 1049688-36-9P 1049688-37-0P
1049688-38-1P 1049688-39-2P 1049688-40-5P 1049688-41-6P
1049688-42-7P 1049688-43-8P 1049688-44-9P 1049688-45-0P
1049688-46-1P 1049688-47-2P 1049688-48-3P 1049688-49-4P
1049688-50-7P 1049688-51-8P 1049688-52-9P 1049688-53-0P
1049688-54-1P 1049688-55-2P 1049688-57-4P 1049688-59-6P
1049688-61-0P 1049688-66-5P 1049688-74-5P 1049688-76-7P
1049688-78-9P 1049688-80-3P 1049688-82-5P 1049688-84-7P
1049688-85-8P 1049688-87-0P 1049688-89-2P 1049688-91-6P
1049688-93-8P 1049688-95-0P 1049688-97-2P 1049689-01-1P
1049689-03-3P 1049689-05-5P 1049689-07-7P 1049689-09-9P
1049689-11-3P 1049689-13-5P 1049689-15-7P 1049689-17-9P
1049689-20-4P 1049689-22-6P 1049689-24-8P 1049689-26-0P
1049689-28-2P 1049689-32-8P 1049689-34-0P 1049689-36-2P
1049689-41-9P 1049689-43-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolidin-2-imines and their analogs as aspartyl protease
inhibitors for treating various diseases)
IT 1049647-76-8P 1049652-40-5P 1049669-70-6P

1049686-97-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolidin-2-imines and their analogs as aspartyl protease
inhibitors for treating various diseases)

RN 1049647-76-8 HCAPLUS
CN Urea, N-[[3'-(2-amino-4,5-dihydro-1,4-dimethyl-5-oxo-1H-imidazol-4-yl)-5-chloro[1,1'-biphenyl]-2-yl]methyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)



RN 1049652-40-5 HCAPLUS
CN Urea, N-[[3'-(2-amino-4,5-dihydro-1,4-dimethyl-5-oxo-1H-imidazol-4-yl)-5-chloro[1,1'-biphenyl]-2-yl]methyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)



RN 1049669-70-6 HCAPLUS
CN Urea, N-[[3'-(2-amino-4,5-dihydro-1,4-dimethyl-5-oxo-1H-imidazol-4-yl)-5'-chloro[1,1'-biphenyl]-2-yl]methyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)



RN 1049686-97-6 HCAPLUS
CN Urea, N-[[3'-(2-amino-4,5-dihydro-1,4-dimethyl-5-oxo-1H-imidazol-4-yl)-5-chloro[1,1'-biphenyl]-2-yl]methyl]-N'-(2-chlorophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

L125 ANSWER 4 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:527397 HCAPLUS Full-text
DOCUMENT NUMBER: 143:78096
TITLE: Preparation of quinolines useful in treating LXR (liver X receptor)-mediated diseases
INVENTOR(S): Collini, Michael D.; Singhaus, Robert R.; Hu, Baihua; Jetter, James W.; Morris, Robert L.; Kaufman, David H.; Miller, Christopher P.; Ullrich, John W.; Unwalla, Rayomand J.; Wrobel, Jay E.; Quinet, Elaine; Nambi, Ponnal; Bernotas, Ronald C.; Elloso, Merle
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 169 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050131014	A1	20050616	US 2004-10236	20041210 <--
US 7576215	B2	20090818		
AU 2004298486	A1	20050630	AU 2004-298486	20041210 <--
CA 2547518	A1	20050630	CA 2004-2547518	20041210 <--
WO 2005058834	A2	20050630	WO 2004-US41399	20041210 <--
WO 2005058834	A3	20051117		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
EP 1692111	A2	20060823	EP 2004-813688	20041210 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1914173	A	20070214	CN 2004-80041595	20041210 <--
BR 2004017543	A	20070327	BR 2004-17543	20041210 <--

JP 2007516258	T	20070621	JP 2006-544016		20041210 <--
IN 2006KN01443	A	20070504	IN 2006-KN1443		20060529 <--
NO 2006002561	A	20060908	NO 2006-2561		20060602 <--
MX 2006006533	A	20060731	MX 2006-6533		20060608 <--
ZA 2006004775	A	20081126	ZA 2006-4775		20060609 <--
KR 2007001922	A	20070104	KR 2006-714042		20060712 <--
PRIORITY APPLN. INFO.:			US 2003-529009P	P	20031212 <--
			US 2004-600296P	P	20040810
			WO 2004-US41399	W	20041210

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:78096; MARPAT 143:78096
ED Entered STN: 19 Jun 2005
GI



I

AB This invention provides quinolines of formula I (R1 = H or C1-C3 alkyl; X1 = a bond or an appropriate group to link R2 which is an optionally substituted heterocycle; X2 = a bond or CH2; R3 = optionally substituted Ph, naphthyl, or heterocycle; R4, R5, and R6 = H or F, R7 = H, C1-C4 alkyl, C1-C4 perfluoroalkyl, halogen, NO2, CN, optionally substituted phenyl) that are useful in the treatment or inhibition of LXR mediated diseases (no data). The LXR mediated diseases specifically claimed are, for example, atherosclerosis, Alzheimer's disease, dementia, diabetes, multiple sclerosis, and thyroiditis. Pharmaceutical compns. containing the compds. of the invention and synthetic procedures for preparing them are also claimed.

IC ICM A61K031-4709
ICS C07D041-02
INCL 514311000; 514314000; 546153000; 546167000
CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
IT 854771-17-8P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,4-Dichlorobenzyl)Amine 854771-18-9P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2-Fluorobenzyl)Amine 854771-19-0P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,3-Difluorobenzyl)Amine 854771-20-3P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,3,6-Trichlorobenzyl)Amine 854771-21-4P, 2-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-4-Fluorophenol 854771-22-5P, 4-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-2-Ethoxyphenol 854771-23-6P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,3-Dihydro-1,4-Benzodioxin-6-ylmethyl)Amine 854771-24-7P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2-Fluoro-6-Methoxybenzyl)Amine 854771-25-8P, 3-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]Benzene-1,2-Diol 854771-26-9P, 2-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-6-Fluorophenol 854771-27-0P, 2-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-

4-yl]Phenyl]Amino]Methyl]-6-Ethoxyphenol 854771-28-1P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][(1-Methyl-1H-Indol-2-yl)Methyl]Amine 854771-29-2P, N-[4-(Benzyloxy)-3-Methoxybenzyl]-3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Aniline 854771-30-5P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][(6-Bromopyridin-3-yl)Methyl]Amine 854771-31-6P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][(2-Chloroquinolin-3-yl)Methyl]Amine 854771-32-7P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][(6-Methoxypyridin-3-yl)Methyl]Amine 854771-33-8P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][(6-Chloropyridin-3-yl)Methyl]Amine 854771-34-9P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,3,4-Trimethoxybenzyl)Amine 854771-35-0P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](1H-Indol-5-ylmethyl)Amine 854771-36-1P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](1H-Indol-6-ylmethyl)Amine 854771-37-2P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][(1-Ethyl-1H-Indol-6-yl)Methyl]Amine 854771-38-3P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][(1-Methyl-1H-Indol-5-yl)Methyl]Amine 854771-39-4P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][(1-Methyl-1H-Indol-7-yl)Methyl]Amine 854771-40-7P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](1H-Indol-7-ylmethyl)Amine 854771-41-8P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](1H-Indol-4-ylmethyl)Amine 854771-42-9P, 2-[4-[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]-2-Methylpropanoic Acid 854771-43-0P, 2-[4-[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]Propanoic Acid 854771-44-1P 854771-45-2P, 3-Benzyl-4-[3-[[5-Chloro-2-(Trifluoromethyl)Benzyl]Oxy]Phenyl]-8-(Trifluoromethyl)Quinoline 854771-46-3P, 3-Benzyl-4-[3-[[5-Fluoro-2-(Trifluoromethyl)Benzyl]Oxy]Phenyl]-8-(Trifluoromethyl)Quinoline 854771-47-4P, [4-[(1S)-1-[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Ethyl]Phenyl]Acetic Acid 854771-48-5P, [4-[(1R)-1-[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Ethyl]Phenyl]Acetic Acid 854771-49-6P, 5-[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Benzyl]Oxy]-1H-Indole-2-Carboxylic Acid 854771-50-9P, N-[3-[3-(2-Methylphenyl)-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]-N'-Phenylurea 854771-51-0P, N-(2-Chlorophenyl)-N'-[3-[3-(2-Methylphenyl)-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Urea 854771-52-1P, N-(2-Fluorophenyl)-N'-[3-[3-(2-Methylphenyl)-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Urea 854771-53-2P, N-(2-Chlorophenyl)-N'-[3-[3-(2-Trifluoromethylphenyl)-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Urea 854771-54-3P, [4-[3-(Benzylthio)Phenyl]-8-(Trifluoromethyl)Quinolin-3-yl]phenylmethanone 854771-55-4P, 3-[4-[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Phenyl]Propanoic Acid 854771-57-6P 854771-58-7P, N-[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]-N'-(2-Chlorophenyl)-N'-Cyanoguanidine 854771-59-8P, N-[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]-N'-(2-Fluorophenyl)Guanidine 854771-61-2P, 2-Chlorophenyl [3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Carbamate 854771-62-3P 854771-63-4P, [2-[4-[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Benzyl]Oxy]Phenyl]-1,3-Oxazol-4-yl]Acetic Acid 854771-64-5P, N-[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Benzyl]-N'-(2-Fluorophenyl)Urea 854771-65-6P, 4-[3-[[3-Cyano-8-(Trifluoromethyl)Quinolin-4-yl]Amino]Phenyl]-8-(Trifluoromethyl)Quinoline-3-Carbonitrile 854771-67-8P, [4-[[[3-[3-Cyano-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]Phenyl]Acetic Acid 854771-68-9P, N-(2-Chlorophenyl)-N'-[3-[3-Cyano-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Urea 854771-70-3P, [4-[[3-[3-Cyano-8-(Trifluoromethyl)Quinolin-

4-yl]Phenoxy]Methyl]Phenyl]Acetic Acid 854771-71-4P, [4-[[[[4-[[3-[3-Cyano-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]Acetyl]Oxy]Methyl]Phenyl]Acetic Acid 854771-73-6P, Ethyl 3-[[[[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Carbonyl]Amino]Benzoate 854771-74-7P, 3-[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Quinazoline-2,4(1H,3H)-Dione 854771-75-8P, 3-[[[[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Carbonyl]Amino]Benzoic Acid 854771-77-0P, [4-[[[3-[3-(Aminocarbonyl)-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]Phenyl]Acetic Acid 854771-78-1P, [4-[[3-[3-(Aminocarbonyl)-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]Acetic Acid 854771-79-2P, [4-[[[[4-[[3-[3-(Aminocarbonyl)-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]Acetyl]Oxy]Methyl]Phenyl]Acetic Acid 854771-82-7P, Ethyl 4-[3-[[[(2-Chlorophenyl)Amino]Carbonyl]Amino]Phenyl]-8-(Trifluoromethyl)Quinoline-3-Carboxylate 854771-83-8P, 4-[3-[(2-Fluorobenzyl)Oxy]Phenyl]-8-(Trifluoromethyl)Quinoline-3-Carboxylic Acid 854771-84-9P 854771-86-1P, 2-[4-[[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]-3-[4-(Carboxymethyl)Phenyl]Propanoic Acid 854771-87-2P 854771-88-3P, 2-[4-[[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]-3-(4-tert-Butylphenyl)Propanoic Acid 854771-89-4P, 2-[4-[[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]-3-(4-Nitrophenyl)Propanoic Acid 854771-90-7P, 2-[4-[[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]-3-Biphenyl-4-ylpropanoic Acid 854771-91-8P, 2-[4-[[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]-3-Phenylpropanoic Acid 854771-92-9P, 2-[4-[[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]-3,3-Diphenylpropanoic Acid 854771-94-1P, [4-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Sulfonyl]Methyl]Phenyl]Acetic Acid 854771-95-2P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,3-Dimethoxybenzyl)Amine 854771-96-3P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,5-Dichlorobenzyl)Amine 854771-97-4P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](3-Phenoxybenzyl)Amine 854771-98-5P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,5-Dimethoxybenzyl)Amine 854771-99-6P, 2-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-4-Chlorophenol 854772-00-2P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](3,4-Dimethoxybenzyl)Amine 854772-01-3P, 3-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-4-Nitrophenol 854772-02-4P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](4,5-Dimethoxy-2-Nitrobenzyl)Amine 854772-03-5P, 2-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-4-Bromophenol 854772-04-6P, 2-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-5-Methoxyphenol 854772-05-7P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][[4-(Dimethylamino)-1-Naphthyl]Methyl]Amine 854772-06-8P, 2-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-4-Methoxyphenol 854772-07-9P, 4-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]Benzene-1,2-Diol 854772-08-0P, 2-[4-[[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]Pent-4-enoic Acid 854772-09-1P, 2-[4-[[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]-4-Hexynoic Acid 854772-10-4P, 2-[4-[[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-

yl]Phenoxy]Methyl]Phenyl]-4-Heptynoic Acid 854772-11-5P 854772-12-6P,
[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2-Fluoro-3-
Methoxybenzyl)Amine 854772-13-7P,
[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][3-
(Trifluoromethyl)Benzyl]Amine 854772-14-8P,
[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](5-Fluoro-2-
Methoxybenzyl)Amine 854772-15-9P,
2-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-4-
Iodophenol 854772-16-0P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-
yl]Phenyl](3,4-Diethoxybenzyl)Amine 854772-17-1P,
N-[2-(Benzyloxy)-3-Methoxybenzyl]-3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-
4-yl]Aniline 854772-18-2P, N,N-Dibenzyl-3-[3-Benzyl-8-
(Trifluoromethyl)Quinolin-4-yl]Aniline 854772-19-3P,
[3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl]bis(3-
methylbenzyl)Amine 854772-20-6P,
[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Bis(2-Ethoxy-3-
Methoxybenzyl)Amine 854772-21-7P,
N-Benzyl-3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Aniline
854772-22-8P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](3-
Methoxybenzyl)Amine 854772-23-9P,
[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](4-
Methoxybenzyl)Amine 854772-24-0P,
[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2-Ethoxy-3-
Methoxybenzyl)Amine 854772-25-1P,
[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](3-Chloro-4-
Fluorobenzyl)Amine 854772-26-2P,
[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](3-Chloro-4-
Methoxybenzyl)Amine 854772-27-3P,
[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](3-Chloro-2-
Fluorobenzyl)Amine 854772-28-4P,
2-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-4-
(Trifluoromethoxy)Phenol 854772-29-5P,
[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][5-Chloro-2-
(Trifluoromethyl)Benzyl]Amine 854772-30-8P,
[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][5-Fluoro-2-
(Trifluoromethyl)Benzyl]Amine 854772-31-9P,
3-Benzyl-4-[3-[(2,5-Dimethylphenoxy)Methyl]Phenyl]-8-
(Trifluoromethyl)Quinoline 854772-32-0P,
3-Benzyl-4-[3-[[2-Fluoro-3-(Trifluoromethyl)Phenoxy]Methyl]Phenyl]-8-
(Trifluoromethyl)Quinoline 854772-33-1P,
3-Benzyl-4-[3-[(2,3-Dimethylphenoxy)Methyl]Phenyl]-8-
(Trifluoromethyl)Quinoline 854772-34-2P,
3-Benzyl-4-[3-[[2-Chloro-3-(Trifluoromethyl)Phenoxy]Methyl]Phenyl]-8-
(Trifluoromethyl)Quinoline 854772-35-3P,
3-Benzyl-4-[3-[(1-Methyl-1H-Pyrrol-2-yl)Methoxy]Phenyl]-8-
(Trifluoromethyl)Quinoline 854772-36-4P, Methyl
[5-[[4-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]-1-Methyl-
1H-Pyrrol-2-yl]Acetate 854772-37-5P,
[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2-
Thienylmethyl)Amine 854772-38-6P,
[2-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-3-
Thienyl]Acetic Acid 854772-39-7P,
[5-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-2-
Thienyl]Acetic Acid 854772-42-2P,
5-[4-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-
yl]Phenyl]Amino]Methyl]Benzyl]-1,3-Thiazolidine-2,4-Dione 854772-43-3P,
5-[4-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-
yl]Phenyl]Amino]Methyl]Benzyl]-2-Thioxo-1,3-Thiazolidin-4-one
854772-44-4P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][(4-
Fluorobiphenyl-3-yl)Methyl]Amine 854772-48-8P 854772-49-9P,

[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][(3-Fluoro-4'-Methoxybiphenyl-4-yl)Methyl]Amine 854772-50-2P, 3'-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-4'-Fluorobiphenyl-4-ol 854772-51-3P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](3-Methylbenzyl)Amine 854772-52-4P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,4-Dimethylbenzyl)Amine 854772-53-5P, N-[(1-Acetyl-1H-Indol-3-yl)Methyl]-3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Aniline 854772-54-6P, N,N-Bis[(1-acetyl-1H-indol-3-yl)methyl]-3-[3-benzyl-8-(trifluoromethyl)Quinolin-4-yl]Aniline 854772-55-7P, 3-Benzyl-4-[3-[(1-Methyl-1H-Indol-3-yl)Methoxy]Phenyl]-8-(Trifluoromethyl)Quinoline 854772-56-8P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][2-Fluoro-5-(1H-pyrrol-2-yl)benzyl]amine 854772-57-9P, 3-Benzyl-4-[3-[(1-Methyl-1H-Indol-7-yl)Methoxy]Phenyl]-8-(Trifluoromethyl)Quinoline 854772-59-1P, 3-Benzyl-4-(3-Phenylethynyl-Phenyl)-8-Trifluoromethyl-Quinoline 854772-60-4P, [4-[2-[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Ethyl]Phenyl]Acetic Acid 854772-62-6P, Ethyl 3-[[3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl]ethynyl]benzoate 854772-63-7P, 3-[[3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl]ethynyl]benzoic acid 854772-64-8P, Methyl 4-[[3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl]ethynyl]benzoate 854772-65-9P, 4-[[3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl]ethynyl]benzoic acid 854772-67-1P, 3-[4-[[3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl]ethynyl]phenyl]propanoic acid 854772-68-2P, Methyl 3-[4-[[3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl]ethynyl]phenyl]propanoate 854772-69-3P, [3-[[3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl]ethynyl]phenyl]acetic acid 854772-70-6P, 3-[3-[[3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl]ethynyl]phenyl]propanoic acid 854772-71-7P, Methyl 3-[3-[[3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl]ethynyl]phenyl]propanoate 854772-72-8P, 3-Benzyl-4-[3-[(2-fluorophenyl)ethynyl]phenyl]-8-(trifluoromethyl)quinoline 854772-73-9P, 3-Benzyl-4-[3-[(2-chlorophenyl)ethynyl]phenyl]-8-(trifluoromethyl)quinoline 854772-74-0P, 3-Benzyl-4-[3-[(4-bromophenyl)ethynyl]phenyl]-8-(trifluoromethyl)quinoline 854772-75-1P, 3-Benzyl-4-[3-[(2,5-dichlorophenyl)ethynyl]phenyl]-8-(trifluoromethyl)quinoline 854772-76-2P, 3-Benzyl-4-[3-[(2,4-dichlorophenyl)ethynyl]phenyl]-8-(trifluoromethyl)quinoline 854772-77-3P, 3-Benzyl-4-[3-[(3,4-dichlorophenyl)ethynyl]phenyl]-8-(trifluoromethyl)quinoline 854772-79-5P, Methyl 4-[[3-[[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Methyl]Phenoxy]Methyl]Benzoate 854772-80-8P, Ethyl [3-[[3-[[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Methyl]Phenoxy]Methyl]Phenyl]Acetate 854772-81-9P, 3-[3-[[3-[[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Methyl]Phenoxy]Methyl]Phenyl]Propanoic acid methyl ester 854772-82-0P, Methyl [3-[[3-[[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Methyl]Phenoxy]Methyl]Phenoxy]Acetate 854772-83-1P 854772-84-2P, 3-[[3-[[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Methyl]Phenoxy]Methyl]Benzoic Acid 854772-85-3P, 4-[[3-[[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Methyl]Phenoxy]Methyl]Benzoic Acid 854772-86-4P, [3-[[3-[[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Methyl]Phenoxy]Methyl]Phenyl]Acetic Acid 854772-87-5P,

3-[3-[[3-[[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Methyl]Phenoxy]Methyl]Phenyl]Propanoic Acid 854772-88-6P, [3-[[3-[[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Methyl]Phenoxy]Methyl]Phenoxy]Acetic Acid 854772-89-7P, [4-[[3-[[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Methyl]Phenoxy]Methyl]Phenoxy]Acetic Acid 854772-90-0P, 3-[3-(8-Chloro-3-Methylquinolin-4-yl)Phenoxy]-N-Ethylbenzamide 854772-92-2P, 2-[3-[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Phenyl]Propan-2-ol 854772-93-3P 854772-94-4P 854772-95-5P, 3-[[3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenyl]Amino]Benzamide 854772-96-6P, 3-[[3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenyl]Amino]-N-(2-Hydroxyethyl)Benzamide 854772-97-7P, 3-[[3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenyl]Amino]-N-Methylbenzamide 854772-98-8P, 3-[[3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenyl]Amino]-N-Ethylbenzamide 854772-99-9P, 3-[[3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenyl]Amino]-N-Cyclopropylbenzamide 854773-00-5P, 3-[[3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenyl]Amino]-N-isopropylbenzamide 854773-01-6P, 3-[[3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenyl]Amino]-N,N-Diethylbenzamide 854773-02-7P, [3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenyl][3-(Pyrrolidin-1-ylcarbonyl)Phenyl]Amine 854773-03-8P, [3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenyl][3-(Piperidin-1-ylcarbonyl)Phenyl]Amine 854773-04-9P, [3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenyl][3-(Morpholin-4-ylcarbonyl)Phenyl]Amine 854773-05-0P, 3-[3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenoxy]-5-Bromobenzonitrile 854773-06-1P, 3-Benzyl-4-[3-[3-Bromo-5-(Trifluoromethyl)Phenoxy]Phenyl]-8-Chloroquinoline 854773-07-2P, 3-[3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenoxy]-5-Fluorobenzonitrile 854773-08-3P, 3-Benzyl-4-[3-(3-Bromo-5-Chlorophenoxy)Phenyl]-8-Chloroquinoline 854773-09-4P, N-[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]-1H-Imidazole-1-Carboximidamide 854773-13-0P 854773-14-1P 854773-15-2P, N-[4-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]Benzoyl]Glycine 854773-16-3P 854773-17-4P, 3-[3-[[[3-[3-Cyano-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]Phenyl]Propanoic Acid 854773-19-6P, [4'-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-1,1'-Biphenyl-3-yl]Acetic Acid 854773-20-9P, [4'-[[[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-1,1'-Biphenyl-3-yl]Acetic Acid 854773-21-0P, 4-[4-[2-[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Ethyl]Piperidin-1-yl]Benzoic Acid 854773-22-1P, [4-[[3-(8-Chloro-3-Phenylquinolin-4-yl)Phenoxy]Methyl]Phenyl]Acetic Acid 854773-23-2P, [4-[[3-(8-Chloro-3-MethylQuinolin-4-yl)Phenoxy]Methyl]Phenyl]Acetic Acid 854773-24-3P, [4-[[3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenoxy]Methyl]Phenyl]Acetic Acid 854773-27-6P, 2-[4-[[3-(8-Chloro-3-Phenylquinolin-4-yl)Phenoxy]Methyl]Phenyl]-2-Methylpropanoic Acid 854773-28-7P, 2-[4-[[3-(3-Benzyl-8-Chloroquinolin-4-yl)Phenoxy]Methyl]Phenyl]-2-Methylpropanoic Acid 854773-29-8P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,5-Dimethylbenzyl)Amine 854773-30-1P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,3-Dimethylbenzyl)Amine 854773-31-2P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,6-Dimethylbenzyl)amine 854773-32-3P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](1H-Imidazol-2-ylmethyl)Amine 854773-33-4P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][3-[3-(Trifluoromethyl)Phenoxy]Benzyl]Amine 854773-34-5P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,6-Dimethoxybenzyl)Amine 854773-35-6P

, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][3,5-Bis(Benzyloxy)Benzyl]Amine 854773-36-7P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2-Methoxybenzyl)Amine 854773-37-8P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](4-Methylbenzyl)Amine 854773-38-9P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][(1-Oxidopyridin-4-yl)Methyl]Amine 854773-39-0P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][(4,5-Dimethyl-2-Furyl)Methyl]Amine 854773-40-3P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](1-Naphthylmethyl)Amine 854773-41-4P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](3,5-Dimethoxybenzyl)Amine 854773-42-5P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,4-Dimethoxybenzyl)Amine 854773-43-6P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2-Naphthylmethyl)Amine 854773-44-7P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][4-(Diphenylamino)Benzyl]Amine 854773-45-8P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](4-isopropylbenzyl)Amine 854773-46-9P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2-Nitrobenzyl)Amine 854773-47-0P, [3-[3-Benzyl-8-(Trifluoromethyl)quinolin-4-yl]Phenyl](3-Nitrobenzyl)Amine 854773-49-2P, 2-[4-[[3-(8-Chloro-3-Methylquinolin-4-yl)Phenoxy]Methyl]Phenyl]-2-MethylPropanoic Acid 854773-50-5P, 5-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-2-Methoxyphenol 854773-51-6P, 4-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]-2-Methoxyphenol 854773-52-7P, 2-[[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]Amino]Methyl]Benzene-1,4-Diol 854773-53-8P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2-Fluoro-5-Nitrobenzyl)Amine 854773-54-9P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](5-Bromo-2-Ethoxybenzyl)Amine 854773-55-0P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](3-Ethoxy-4-Methoxybenzyl)Amine 854773-56-1P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,5-Difluorobenzyl)Amine 854773-57-2P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](3,4-Difluorobenzyl)Amine 854773-58-3P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](5-Bromo-2-Methoxybenzyl)Amine 854773-59-4P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](5-Bromo-2-Fluorobenzyl)Amine 854773-60-7P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][2-Fluoro-3-(Trifluoromethyl)Benzyl]Amine 854773-61-8P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2-Fluoro-5-Methoxybenzyl)Amine 854773-62-9P, [3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl][2,5-bis(Trifluoromethyl)Benzyl]Amine 854773-63-0P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2-Methylbenzyl)Amine 854773-64-1P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](2,4,6-Trifluorobenzyl)Amine 854773-65-2P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](3-Fluoro-4-Methoxybenzyl)amine 854773-66-3P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](Cyclopropylmethyl)Amine 854773-67-4P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][(2-Methyl-1H-Imidazol-5-yl)Methyl]Amine 854773-68-5P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](Pyridin-3-ylmethyl)Amine 854773-69-6P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-

yl]Phenyl](Pyridin-4-ylmethyl)Amine 854773-70-9P, 1-[4-[[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Benzyl]Oxy]Phenyl]Ethane-1,2-Diol 854773-72-1P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](3-Thienylmethyl)Amine 854773-73-2P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](3-Furylmethyl)Amine 854773-75-4P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][2-(Trifluoromethoxy)Benzyl]Amine 854773-76-5P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][3-Chloro-2-Fluoro-6-(Trifluoromethyl)Benzyl]Amine 854773-77-6P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](Pyridin-2-ylmethyl)Amine 854773-78-7P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl][4-(Trifluoromethoxy)Benzyl]Amine 854773-79-8P, [3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl](4-Chloro-3-Fluorobenzyl)Amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinolines useful in treating LXR (liver X receptor)-mediated diseases)

IT 854771-64-5P, N-[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Benzyl]-N'-(2-Fluorophenyl)Urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinolines useful in treating LXR (liver X receptor)-mediated diseases)

RN 854771-64-5 HCAPLUS
CN Urea, N-[[3-[3-benzoyl-8-(trifluoromethyl)-4-quinolinyl]phenyl]methyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 124 THERE ARE 124 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 5 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:232568 HCAPLUS Full-text
DOCUMENT NUMBER: 142:291383
TITLE: Nitrosated and nitrosylated cardiovascular compounds, compositions, and methods of therapeutic use
INVENTOR(S): Garvey, David S.; Letts, Gordon L.; Worcel, Manuel
PATENT ASSIGNEE(S): Nitromed, Inc., USA
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023182	A2	20050317	WO 2004-US26910	20040820 <--
WO 2005023182	A3	20061019		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004270161	A1	20050317	AU 2004-270161	20040820 <--
AU 2004270162	A1	20050317	AU 2004-270162	20040820 <--
CA 2536967	A1	20050317	CA 2004-2536967	20040820 <--
CA 2536975	A1	20050317	CA 2004-2536975	20040820 <--
US 20050059655	A1	20050317	US 2004-921936	20040820 <--
US 7282519	B2	20071016		
WO 2005023183	A2	20050317	WO 2004-US26911	20040820 <--
WO 2005023183	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1667643	A2	20060614	EP 2004-781570	20040820 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
EP 1668008	A2	20060614	EP 2004-781571	20040820 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007504135	T	20070301	JP 2006-524730	20040820 <--
JP 2007504136	T	20070301	JP 2006-524731	20040820 <--
US 20070238740	A1	20071011	US 2006-568819	20061103 <--
PRIORITY APPLN. INFO.:			US 2003-498309P P	20030828 <--
			US 2004-535542P P	20040112
			WO 2004-US26910 W	20040820
			WO 2004-US26911 W	20040820

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 142:291383
ED Entered STN: 17 Mar 2005
AB The invention provides nitrosated and/or nitrosylated cardiovascular compds. or pharmaceutically acceptable salts thereof, and compns. comprising at least one nitrosated and/or nitrosylated cardiovascular compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides compns. and kits comprising at least one

cardiovascular compound of the invention that is optionally nitrosated and/or nitrosylated and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; and (k) treating nephropathy. The nitrosated and/or nitrosylated cardiovascular compds. are preferably nitrosated and/or nitrosylated aldosterone antagonists, nitrosated and/or nitrosylated angiotensin II antagonists, nitrosated and/or nitrosylated calcium channel blockers, nitrosated and/or nitrosylated endothelin antagonists, nitrosated and/or nitrosylated hydralazine compds., nitrosated and/or nitrosylated neutral endopeptidase inhibitors and nitrosated and/or nitrosylated renin inhibitors.

IC ICM A61K

CC 1-8 (Pharmacology)
Section cross-reference(s): 63

IT 52-01-7, Spironolactone 58-93-5, Hydrochlorothiazide 77-36-1, Chlorthalidone 86-54-4D, Hydralazine, compds. 127-07-1D, Hydroxyurea, derivs. 304-20-1, Hydralazine hydrochloride 318-98-9, Propranolol hydrochloride 396-01-0, Triamterene 497-27-8D, Furoxan, derivs. 2016-88-8, Amiloride hydrochloride 7803-49-8D, Hydroxylamine, derivs. 13115-21-4D, N-Hydroxyguanidine, derivs. 26921-17-5, Timolol maleate 56392-17-7, Metoprolol tartrate 62571-86-2, Captopril 72956-09-3, Carvedilol 76095-16-4, Enalapril maleate 76547-98-3, Lisinopril 82586-52-5, Moexipril hydrochloride 82586-55-8, Quinapril hydrochloride 86541-74-4, Benazepril hydrochloride 87679-37-6, Trandolapril 87679-71-8, Trandolaprilat 88889-14-9, Fosinopril sodium 104344-23-2, Bisoprolol fumarate 107724-20-9, Eplerenone 114798-26-4D, Losartan, nitrosated/nitrosylated derivs. 114798-27-5D, nitrosated/nitrosylated derivs. 114798-28-6D, nitrosated/nitrosylated derivs. 114798-29-7D, nitrosated/nitrosylated derivs. 124749-82-2D, nitrosated/nitrosylated derivs. 124749-84-4D, nitrosated/nitrosylated derivs. 124750-88-5D, nitrosated/nitrosylated derivs. 124750-91-0D, nitrosated/nitrosylated derivs. 124750-92-1D, nitrosated/nitrosylated derivs. 124750-93-2D, nitrosated/nitrosylated derivs. 124750-99-8, Losartan potassium 133040-01-4D, Eprosartan, nitrosated/nitrosylated derivs. 133240-46-7D, nitrosated/nitrosylated derivs. 135070-05-2D, nitrosated/nitrosylated derivs. 137862-53-4, Valsartan 137862-53-4D, Valsartan, nitrosated/nitrosylated derivs. 137882-98-5D, Abitesartan, nitrosated/nitrosylated derivs. 138402-11-6, Irbesartan 138402-11-6D, Irbesartan, nitrosated/nitrosylated derivs. 139481-59-7D, Candesartan, nitrosated/nitrosylated derivs. 139958-16-0D, nitrosated/nitrosylated derivs. 141309-82-2D, nitrosated/nitrosylated derivs. 144143-96-4, Eprosartan mesylate 144689-24-7D, Olmesartan, nitrosated/nitrosylated derivs. 144689-63-4, Olmesartan medoxomil 144701-48-4, Telmisartan 144701-48-4D, Telmisartan, nitrosated/nitrosylated derivs. 145040-37-5, Candesartan cilexetil 145160-84-5D, nitrosated/nitrosylated derivs. 145216-43-9D, Forasartan, nitrosated/nitrosylated derivs. 145733-36-4D, Tasosartan, nitrosated/nitrosylated derivs. 145781-32-4D, Zolasartan, nitrosated/nitrosylated derivs. 146623-69-0D, Saprisartan, nitrosated/nitrosylated derivs. 147403-03-0D, nitrosated/nitrosylated derivs. 148504-51-2D, Ripisartan, nitrosated/nitrosylated derivs. 148564-47-0D, Milfasartan, nitrosated/nitrosylated derivs. 149968-26-3D, Elisartan, nitrosated/nitrosylated derivs. 153235-15-5D, Fonsartan, nitrosated/nitrosylated derivs. 153806-29-2D, nitrosated/nitrosylated derivs. 154749-99-2D, nitrosated/nitrosylated derivs. 155884-08-5D, nitrosated/nitrosylated derivs. 155918-60-8D, nitrosated/nitrosylated derivs. 155918-61-9D, nitrosated/nitrosylated derivs. 156001-18-2D,

Embusartan, nitrosated/nitrosylated derivs. 158807-14-8D, nitrosated/nitrosylated derivs. 158807-15-9D, nitrosated/nitrosylated derivs. 158807-16-0D, nitrosated/nitrosylated derivs. 158807-17-1D, nitrosated/nitrosylated derivs. 158807-18-2D, nitrosated/nitrosylated derivs. 158807-19-3D, nitrosated/nitrosylated derivs. 158807-20-6D, nitrosated/nitrosylated derivs. 158872-96-9D, nitrosated/nitrosylated derivs. 158872-97-0D, nitrosated/nitrosylated derivs. 159237-67-9D, Enoltasosartan, nitrosated/nitrosylated derivs. 161946-65-2D, nitrosated/nitrosylated derivs. 161947-47-3D, nitrosated/nitrosylated derivs. 161947-48-4D, nitrosated/nitrosylated derivs. 161947-51-9D, nitrosated/nitrosylated derivs. 161947-52-0D, nitrosated/nitrosylated derivs. 161947-55-3D, nitrosated/nitrosylated derivs. 161947-56-4D, nitrosated/nitrosylated derivs. 161947-60-0D, nitrosated/nitrosylated derivs. 161947-61-1D, nitrosated/nitrosylated derivs. 161947-68-8D, nitrosated/nitrosylated derivs. 161947-69-9D, nitrosated/nitrosylated derivs. 161947-70-2D, nitrosated/nitrosylated derivs. 161947-71-3D, nitrosated/nitrosylated derivs. 161947-72-4D, nitrosated/nitrosylated derivs. 161947-74-6D, nitrosated/nitrosylated derivs. 161947-75-7D, nitrosated/nitrosylated derivs. 161947-81-5D, nitrosated/nitrosylated derivs. 161947-82-6D, nitrosated/nitrosylated derivs. 161947-83-7D, nitrosated/nitrosylated derivs. 161947-84-8D, nitrosated/nitrosylated derivs. 161947-85-9D, nitrosated/nitrosylated derivs. 161947-86-0D, nitrosated/nitrosylated derivs. 161947-87-1D, nitrosated/nitrosylated derivs. 161947-88-2D, nitrosated/nitrosylated derivs. 161947-89-3D, nitrosated/nitrosylated derivs. 161947-90-6D, nitrosated/nitrosylated derivs. 161947-91-7D, nitrosated/nitrosylated derivs. 161947-92-8D, nitrosated/nitrosylated derivs. 161947-93-9D, nitrosated/nitrosylated derivs. 161947-94-0D, nitrosated/nitrosylated derivs. 161947-95-1D, nitrosated/nitrosylated derivs. 161947-96-2D, nitrosated/nitrosylated derivs. 161947-97-3D, nitrosated/nitrosylated derivs. 161947-98-4D, nitrosated/nitrosylated derivs. 161947-99-5D, nitrosated/nitrosylated derivs. 161948-00-1D, nitrosated/nitrosylated derivs. 161948-01-2D, nitrosated/nitrosylated derivs. 161948-02-3D, nitrosated/nitrosylated derivs. 165113-01-9D, nitrosated/nitrosylated derivs. 165113-02-0D, nitrosated/nitrosylated derivs. 165113-03-1D, nitrosated/nitrosylated derivs. 165113-05-3D, nitrosated/nitrosylated derivs. 165113-06-4D, nitrosated/nitrosylated derivs. 165113-07-5D, nitrosated/nitrosylated derivs. 165113-08-6D, nitrosated/nitrosylated derivs. 165113-09-7D, nitrosated/nitrosylated derivs. 165113-10-0D, nitrosated/nitrosylated derivs. 165113-11-1D, nitrosated/nitrosylated derivs. 165113-12-2D, nitrosated/nitrosylated derivs. 165113-13-3D, nitrosated/nitrosylated derivs. 165113-14-4D, nitrosated/nitrosylated derivs. 165113-15-5D, nitrosated/nitrosylated derivs. 165113-16-6D, nitrosated/nitrosylated derivs. 165113-17-7D, nitrosated/nitrosylated derivs. 165113-18-8D, nitrosated/nitrosylated derivs. 165113-19-9D, nitrosated/nitrosylated derivs. 165113-20-2D, nitrosated/nitrosylated derivs. 165113-21-3D, nitrosated/nitrosylated derivs. 165113-22-4D, nitrosated/nitrosylated derivs. 165113-23-5D, nitrosated/nitrosylated derivs. 165113-24-6D, nitrosated/nitrosylated derivs. 165113-25-7D, nitrosated/nitrosylated derivs. 165113-26-8D, nitrosated/nitrosylated derivs. 165113-27-9D, nitrosated/nitrosylated derivs. 165113-28-0D, nitrosated/nitrosylated derivs. 165113-29-1D, nitrosated/nitrosylated derivs. 165113-30-4D, nitrosated/nitrosylated derivs. 165113-31-5D, nitrosated/nitrosylated derivs. 165113-32-6D, nitrosated/nitrosylated derivs. 165113-33-7D, nitrosated/nitrosylated derivs. 165113-34-8D, nitrosated/nitrosylated derivs. 165113-35-9D, nitrosated/nitrosylated derivs. 165113-36-0D, nitrosated/nitrosylated derivs. 165113-37-1D, nitrosated/nitrosylated derivs. 165113-38-2D, nitrosated/nitrosylated derivs. 165113-39-3D, nitrosated/nitrosylated derivs. 165113-40-6D, nitrosated/nitrosylated derivs. 165113-41-7D, nitrosated/nitrosylated derivs. 165113-42-8D,

nitrosated/nitrosylated derivs. 165113-43-9D, nitrosated/nitrosylated derivs. 165113-44-0D, nitrosated/nitrosylated derivs. 165113-45-1D, nitrosated/nitrosylated derivs. 165113-46-2D, nitrosated/nitrosylated derivs. 165113-47-3D, nitrosated/nitrosylated derivs. 165113-48-4D, nitrosated/nitrosylated derivs. 165113-49-5D, nitrosated/nitrosylated derivs. 165113-50-8D, nitrosated/nitrosylated derivs. 165113-51-9D, nitrosated/nitrosylated derivs. 165113-52-0D, nitrosated/nitrosylated derivs. 165113-53-1D, nitrosated/nitrosylated derivs. 165113-54-2D, nitrosated/nitrosylated derivs. 165113-55-3D, nitrosated/nitrosylated derivs. 165113-56-4D, nitrosated/nitrosylated derivs. 165113-57-5D, nitrosated/nitrosylated derivs. 165113-58-6D, nitrosated/nitrosylated derivs. 165113-59-7D, nitrosated/nitrosylated derivs. 165113-60-0D, nitrosated/nitrosylated derivs. 165113-61-1D, nitrosated/nitrosylated derivs. 165113-62-2D, nitrosated/nitrosylated derivs. 165113-63-3D, nitrosated/nitrosylated derivs. 165113-64-4D, nitrosated/nitrosylated derivs. 165113-65-5D, nitrosated/nitrosylated derivs. 165113-66-6D, nitrosated/nitrosylated derivs. 165113-67-7D, nitrosated/nitrosylated derivs. 165113-68-8D, nitrosated/nitrosylated derivs. 165113-69-9D, nitrosated/nitrosylated derivs. 165113-70-2D, nitrosated/nitrosylated derivs. 165113-71-3D, nitrosated/nitrosylated derivs. 165113-72-4D, nitrosated/nitrosylated derivs. 165113-73-5D, nitrosated/nitrosylated derivs. 165113-74-6D, nitrosated/nitrosylated derivs. 166813-82-7D, nitrosated/nitrosylated derivs. 166961-56-4D, nitrosated/nitrosylated derivs. 166961-58-6D, nitrosated/nitrosylated derivs. 167301-42-0D, nitrosated/nitrosylated derivs. 167371-59-7D, nitrosated/nitrosylated derivs. 168686-32-6D, nitrosated/nitrosylated derivs. 169281-89-4D, nitrosated/nitrosylated derivs. 177848-35-0D, nitrosated/nitrosylated derivs. 207400-83-7D, Glycyllosartan, nitrosated/nitrosylated derivs. 223926-77-0D, nitrosated/nitrosylated derivs. 244126-99-6D, nitrosated/nitrosylated derivs. 272438-16-1D, nitrosated/nitrosylated derivs. 272446-75-0D, nitrosated/nitrosylated derivs. 439904-54-8D, nitrosated/nitrosylated derivs. 439904-55-9D, nitrosated/nitrosylated derivs. 439904-56-0D, nitrosated/nitrosylated derivs. 439904-57-1D, nitrosated/nitrosylated derivs. 439904-58-2D, nitrosated/nitrosylated derivs. 439904-65-1D, nitrosated/nitrosylated derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrosated and nitrosylated cardiovascular compds., compns., and therapeutic use)

IT 439904-55-9D, nitrosated/nitrosylated derivs.
439904-56-0D, nitrosated/nitrosylated derivs.
439904-57-1D, nitrosated/nitrosylated derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrosated and nitrosylated cardiovascular compds., compns., and therapeutic use)

RN 439904-55-9 HCAPLUS

CN Urea, N-pentyl-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 439904-56-0 HCAPLUS
CN Urea, N-heptyl-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 439904-57-1 HCAPLUS
CN Urea, N'-(2,4-difluorophenyl)-N-heptyl-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 6 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:158627 HCAPLUS Full-text
DOCUMENT NUMBER: 142:261304
TITLE: Preparation of anthranilic acid derivatives as selective agonists of the nicotinic acid receptor HM74A
INVENTOR(S): Campbell, Mathew; Hatley, Richard Jonathan; Heer, Jag Paul; Mason, Andrew McMurtrie; Nicholson, Neville Hubert; Pinto, Ivan Leo; Rahman, Shahzad Sharooq; Smith, Ian Edward David

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016870	A1	20050224	WO 2004-GB3528	20040813 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1670749	A1	20060621	EP 2004-768088	20040813 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007502264	T	20070208	JP 2006-523062	20040813 <--
PRIORITY APPLN. INFO.:			GB 2003-19124 A	20030814 <--
			WO 2004-GB3528 W	20040813

OTHER SOURCE(S): CASREACT 142:261304; MARPAT 142:261304
ED Entered STN: 24 Feb 2005
GI



I

AB Therapeutically active anthranilic acid derivs. I [R1 = H, halo, alkyl; R2 = 5-6 membered aryl, heteroaryl, heterocyclyl, alicyclic ring; Z = (CH2)q, CH:CH, (CH2)nO, etc.; q = 1-4; n = 2-4], processes for the preparation of said compds. I, pharmaceutical formulations containing the active compds. and the use of the compds. in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial, are disclosed. Over sixty compds. I were prepared E.g., a 3-step synthesis of I [R1 = H; R2 = 3'-methoxybiphenylyl; Z = CH2O], starting from Me anthranilate, was given. The compds. I showed EC50 of 5.0 or greater and efficacy of 30% or greater in HM74A in-vitro assays.

IC ICM C07C235-38
ICS C07D307-52; C07D213-65; C07D231-12; C07D271-06; C07D333-24; A61K031-4412; A61P009-10

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1, 63

IT 69764-13-2P 178271-22-2P 195393-51-2P 217655-56-6P 233693-99-7P
233694-00-3P 340014-45-1P 697235-49-7P 782480-94-8P 845889-73-8P
845889-74-9P 845889-75-0P 845889-76-1P 845889-77-2P 845889-78-3P
845889-79-4P 845889-80-7P 845889-81-8P 845889-82-9P 845889-83-0P
845889-84-1P 845889-85-2P 845889-86-3P 845889-87-4P 845889-88-5P
845889-89-6P 845889-90-9P 845889-91-0P 845889-92-1P 845889-93-2P
845889-94-3P 845889-95-4P 845889-96-5P 845889-97-6P 845889-98-7P
845889-99-8P 845890-00-8P 845890-01-9P 845890-02-0P 845890-03-1P
845890-04-2P 845890-05-3P 845890-06-4P 845890-07-5P 845890-08-6P
845890-09-7P 845890-10-0P 845890-11-1P 845890-12-2P
845890-13-3P 845890-14-4P 845890-15-5P 845890-16-6P 845890-17-7P
845890-18-8P 845890-19-9P 845890-20-2P 845890-21-3P 845890-22-4P
845890-23-5P 845890-24-6P 845890-25-7P 845890-26-8P 845890-27-9P
845890-28-0P 845890-29-1P 845890-32-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anthranilic acid derivs. as selective agonists of the nicotinic acid receptor HM74A for treating lipid metabolic diseases)

IT 845890-09-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anthranilic acid derivs. as selective agonists of the nicotinic acid receptor HM74A for treating lipid metabolic diseases)

RN 845890-09-7 HCAPLUS

CN Benzoic acid, 2-[[2-([1,1'-biphenyl]-4-yloxy)acetyl]amino]-4-fluoro- (CA INDEX NAME)



OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 7 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:566609 HCAPLUS Full-text

DOCUMENT NUMBER: 141:123608

TITLE: Preparation of pyrrolopyridinones as mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds

INVENTOR(S): Anderson, David R.; Mahoney, Matthew W.; Phillion, Dennis P.; Rogers, Thomas E.; Meyers, Marvin J.; Poda, Gennadiy; Hegde, Shridhar G.; Singh, Megh; Reitz, David B.; Wu, Kun K.; Buchler, Ingrid P.; Xie, Jin; Vernier, William F.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 573 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058762	A1	20040715	WO 2003-US40811	20031219 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509565	A1	20040715	CA 2003-2509565	20031219 <--
WO 2004058762	A1	20040715	WO 2003-XA40811	20031219 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003297431	A1	20040722	AU 2003-297431	20031219 <--
US 20040152739	A1	20040805	US 2003-742494	20031219 <--
US 20040209897	A1	20041021	US 2003-742072	20031219 <--
EP 1572693	A1	20050914	EP 2003-814268	20031219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017430	A	20051025	BR 2003-17430	20031219 <--
CN 1747949	A	20060315	CN 2003-80109626	20031219 <--
JP 2006514043	T	20060427	JP 2004-563888	20031219 <--
ZA 2005004898	A	20061129	ZA 2005-4898	20031219 <--
MX 2005006569	A	20050922	MX 2005-6569	20050617 <--
US 20080113971	A1	20080515	US 2007-958229	20071217 <--
PRIORITY APPLN. INFO.:			US 2002-434962P P	20021220 <--
			US 2003-742494 A1	20031219 <--
			WO 2003-US40811 W	20031219 <--

OTHER SOURCE(S): MARPAT 141:123608
ED Entered STN: 15 Jul 2004
GI



I



II

AB The title compds. [I; Z1, Z3, Z4 = C, N; Z2, Z5 = C, N, S, O, and join together with Z1, Z3 and Z4 to form a ring that is selected from a pyrrole, furan, thiophene, oxazole, thiazole, triazole, and imidazole; when either Z2, or Z5 = O or S, it has no substituent group; when Z1-Z5 form an imidazole ring, Z1 = C and if Z2 and Z5 = N, one is unsubstituted and Z3 and Z4 = C, if Z3 and Z5 = N, Z5 is unsubstituted and Z2 and Z4 = C, and if Z2 and Z4 = N, Z2 is unsubstituted and Z3 and Z5 = C; when Z1-Z5 form an oxazole or thiazole ring, Z1, Z3 and Z4 = C and one of Z2 and Z5 = N that is unsubstituted; when Z1-Z5 form a triazole ring, Z2 and Z5 = N that is unsubstituted; T = C, N; p = 0-3; X = C, S; Ra = (un)substituted 5-6 membered hetero(aryl) or partially unsatd. 5-6 membered ring; R2, R5, R50-R53, R56 = absent, H, alkyl, aryl, etc.; R54, R55 = oxo, absent] which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2), were prepared Thus, reacting 2-(2-chloropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (preparation given) with 3-thiopheneboronic acid in the presence of Cs2CO3, Pd(PPh3)4 in DMF afforded 57% II.TFA. The compds. I were tested for MK-2 inhibition activity (biol. data given for over 800 compds). Methods of using compds. I for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNFα, are described, where the method involves administering to the subject an MK-2 inhibiting compound I. Therapeutic compns., pharmaceutical compns. and kits which contain the present MK-2 inhibiting compds. I are also described. [This abstract record is one of 2 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IC ICM C07D471-06

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT

724729-62-8P	724729-63-9P	724729-64-0P	724729-65-1P	724729-66-2P
724729-67-3P	724729-68-4P	724729-69-5P	724729-70-8P	724729-71-9P
724729-72-0P	724729-73-1P	724729-74-2P	724729-75-3P	724729-76-4P
724729-77-5P	724729-78-6P	724729-79-7P	724729-80-0P	724729-81-1P
724729-82-2P	724729-83-3P	724729-84-4P	724729-85-5P	724729-86-6P
724729-87-7P	724729-88-8P	724729-89-9P	724729-90-2P	724729-91-3P
724729-92-4P	724729-93-5P	724729-94-6P	724729-95-7P	724729-96-8P
724729-97-9P	724729-98-0P	724729-99-1P	724730-00-1P	724730-01-2P
724730-02-3P	724730-03-4P	724730-04-5P	724730-05-6P	724730-06-7P
724730-07-8P	724730-08-9P	724730-09-0P	724730-10-3P	724730-11-4P
724730-12-5P	724730-13-6P	724730-14-7P	724730-15-8P	724730-16-9P
724730-17-0P	724730-18-1P	724730-19-2P	724730-20-5P	724730-21-6P
724730-22-7P	724730-23-8P	724730-24-9P	724730-25-0P	724730-26-1P
724730-27-2P	724730-28-3P	724730-29-4P	724730-30-7P	724730-31-8P
724730-32-9P	724730-33-0P	724730-34-1P	724730-35-2P	724730-36-3P
724730-37-4P	724730-38-5P	724730-39-6P	724730-40-9P	724730-41-0P
724730-42-1P	724730-43-2P	724730-44-3P	724730-45-4P	724730-46-5P
724730-47-6P	724730-48-7P	724730-49-8P	724730-50-1P	724730-51-2P
724730-52-3P	724730-53-4P	724730-54-5P	724730-55-6P	724730-56-7P
724730-57-8P	724730-58-9P	724730-59-0P	724730-60-3P	
724730-61-4P	724730-62-5P	724730-63-6P	724730-64-7P	724730-65-8P
724730-66-9P	724730-67-0P	724730-68-1P	724730-69-2P	
724730-70-5P	724730-71-6P	724730-72-7P	724730-73-8P	724730-74-9P
724730-76-1P	724730-77-2P	724730-78-3P	724730-79-4P	724730-81-8P
724730-83-0P	724730-85-2P	724730-87-4P	724730-89-6P	724730-91-0P
724730-93-2P	724730-95-4P	724730-97-6P	724730-99-8P	724731-01-5P
724731-02-6P	724731-03-7P	724731-04-8P	724731-05-9P	724731-06-0P
724731-07-1P	724731-08-2P	724731-09-3P	724731-10-6P	724731-11-7P
724731-12-8P	724731-13-9P	724731-14-0P	724731-15-1P	724731-16-2P
724731-17-3P	724731-18-4P	724731-19-5P	724731-20-8P	724731-21-9P
724731-22-0P	724731-23-1P	724731-24-2P	724731-25-3P	724731-26-4P
724731-27-5P	724731-28-6P	724731-29-7P	724731-30-0P	724731-31-1P

724731-32-2P 724731-33-3P 724731-34-4P 724731-35-5P 724731-36-6P
724731-37-7P 724731-38-8P 724731-39-9P 724731-40-2P 724731-41-3P
724731-42-4P 724731-43-5P 724731-44-6P 724731-45-7P 724731-46-8P
724731-47-9P 724731-48-0P 724731-49-1P 724731-50-4P 724731-51-5P
724731-52-6P 724731-53-7P 724731-54-8P 724731-55-9P 724731-56-0P
724731-57-1P 724731-58-2P 724731-59-3P 724731-60-6P 724731-61-7P
724731-62-8P 724731-63-9P 724731-64-0P 724731-65-1P 724731-66-2P
724731-67-3P 724731-68-4P 724731-69-5P 724731-70-8P 724731-71-9P
724731-72-0P 724731-73-1P 724731-74-2P 724731-75-3P 724731-76-4P
724731-77-5P 724731-78-6P 724731-79-7P 724731-80-0P 724731-81-1P
724731-82-2P 724731-83-3P 724731-84-4P 724731-85-5P 724731-86-6P
724731-87-7P 724731-88-8P 724731-89-9P 724731-90-2P 724731-91-3P
724731-92-4P 724731-95-7P 724731-97-9P 724731-98-0P 724731-99-1P
724732-00-7P 724732-01-8P 724732-02-9P 724732-03-0P 724732-04-1P
724732-05-2P 724732-06-3P 724732-07-4P 724732-08-5P 724732-09-6P
724732-10-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolopyridinones as mitogen activated protein kinase-activated protein kinase-2 inhibiting compds. for preventing or treating a TNFα mediated diseases)

IT 724730-57-8P 724730-68-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolopyridinones as mitogen activated protein kinase-activated protein kinase-2 inhibiting compds. for preventing or treating a TNFα mediated diseases)

RN 724730-57-8 HCAPLUS
CN Acetamide, 2-[2-methoxy-4-[4-(4,5,6,7-tetrahydro-4-oxo-1H-pyrrolo[3,2-c]pyridin-2-yl)-2-pyrimidinyl]phenoxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 724730-68-1 HCAPLUS
CN Acetamide, 2-[2-ethoxy-4-[4-(4,5,6,7-tetrahydro-4-oxo-1H-pyrrolo[3,2-c]pyridin-2-yl)-2-pyrimidinyl]phenoxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L125 ANSWER 8 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:493691 HCAPLUS Full-text
DOCUMENT NUMBER: 141:54347
TITLE: A preparation of heterocyclic non-nucleoside reverse transcriptase inhibitors, useful for the treatment of HIV-1
INVENTOR(S): Simoneau, Bruno; Thavonekham, Bounkham; Landry, Serge; O'Meara, Jeffrey; Yoakim, Christiane; Faucher, Anne-Marie
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050643	A2	20040617	WO 2003-CA1870	20031201 <--
WO 2004050643	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050054639	A1	20050310	US 2003-719369	20031121 <--
US 7642277	B2	20100105		
CA 2505033	A1	20040617	CA 2003-2505033	20031201 <--
AU 2003287806	A1	20040623	AU 2003-287806	20031201 <--
EP 1569919	A2	20050907	EP 2003-779603	20031201 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016385	A	20051004	BR 2003-16385	20031201 <--
CN 1720043	A	20060111	CN 2003-80105164	20031201 <--
JP 2006514936	T	20060518	JP 2004-555920	20031201 <--
ZA 2005003960	A	20061129	ZA 2005-3960	20050517 <--
IN 2005DN02266	A	20070406	IN 2005-DN2266	20050527 <--
MX 2005005871	A	20050829	MX 2005-5871	20050602 <--
HR 2005000502	A2	20060731	HR 2005-502	20050603 <--
NO 2005002712	A	20050627	NO 2005-2712	20050606 <--
PRIORITY APPLN. INFO.:			US 2002-430796P P	20021204 <--
			WO 2003-CA1870 W	20031201 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 141:54347
ED Entered STN: 18 Jun 2004
GI



I



II

AB The invention relates to heterocyclic compds. of formula Ar1-X-W-Ar2 [wherein: Ar1 is (un)substituted 5- or 6-membered aromatic heterocycle containing N, O, or S; Ar2 is (un)substituted Ph or pyridine derivative; X is a heteroatom (O, S, S(O), or SO2, etc.), a valence bond or an optionally substituted divalent methylene, etc.; W is a divalent alkylene or (un)substituted alkyleneamido, amido, or oxy radicals, etc.], useful for the treatment of HIV-1. The invention compds. were screened in reverse transcriptase assays (enzymic assay, P24 cellular assay, and C8166 HIV-1 Luciferase assay). The compds. have inhibitory activity against Wild Type (WT) and single or double mutant strains of HIV. For instance, tetrazole derivative I (WT IC50 < 50 nM; K103N/Y181C EC50 > 100 nM) was prepared via heterocyclization of 1-naphthalenylisothiocyanate with NaN3, acetylation of the obtained tetrazolethione derivative II (R = H), and subsequent amidation of the obtained carboxylic acid II (R = CH2CO2H) by o-chloroaniline (example 1, entry 208).

IC ICM C07D257-00

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 215655-59-7P 296772-85-5P 296801-21-3P 303065-42-1P 310456-59-8P
327047-29-0P 333353-64-3P 485371-83-3P 634168-75-5P 685505-58-2P
685505-68-4P 685505-72-0P 705969-01-3P 705969-03-5P 705969-06-8P
705969-08-0P 705969-11-5P 705969-12-6P 705969-13-7P 705969-14-8P
705969-15-9P 705969-17-1P 705969-18-2P 705969-19-3P
705969-20-6P 705969-21-7P 705969-22-8P 705969-23-9P 705969-24-0P
705969-25-1P 705969-26-2P 705969-27-3P 705969-28-4P 705969-29-5P
705969-30-8P 705969-31-9P 705969-32-0P 705969-33-1P 705969-34-2P
705969-35-3P 705969-36-4P 705969-37-5P 705969-38-6P 705969-39-7P
705969-40-0P 705969-41-1P 705969-42-2P 705969-43-3P 705969-44-4P
705969-45-5P 705969-46-6P 705969-47-7P 705969-48-8P 705969-49-9P
705969-50-2P 705969-51-3P 705969-52-4P 705969-53-5P 705969-54-6P
705969-55-7P 705969-56-8P 705969-57-9P 705969-58-0P 705969-59-1P
705969-60-4P 705969-61-5P 705969-62-6P 705969-63-7P 705969-64-8P
705969-65-9P 705969-66-0P 705969-67-1P 705969-68-2P 705969-69-3P
705969-70-6P 705969-71-7P 705969-72-8P 705969-73-9P 705969-74-0P
705969-75-1P 705969-76-2P 705969-77-3P 705969-78-4P 705969-79-5P
705969-80-8P 705969-81-9P 705969-82-0P 705969-83-1P 705969-84-2P
705969-85-3P 705969-86-4P 705969-87-5P 705969-88-6P 705969-89-7P
705969-90-0P 705969-91-1P 705969-92-2P 705969-93-3P 705969-94-4P
705969-95-5P 705969-96-6P 705969-97-7P 705969-98-8P 705969-99-9P

705970-00-9P 705970-01-0P 705970-02-1P 705970-03-2P 705970-04-3P
705970-05-4P 705970-07-6P 705970-09-8P 705970-11-2P 705970-13-4P
705970-15-6P 705970-17-8P 705970-19-0P 705970-21-4P 705970-23-6P
705970-25-8P 705970-28-1P 705970-30-5P 705970-32-7P 705970-34-9P
705970-36-1P 705970-38-3P 705970-40-7P 705970-42-9P 705970-44-1P
705970-46-3P 705970-48-5P 705970-50-9P 705970-52-1P 705970-54-3P
705970-55-4P 705970-57-6P 705970-59-8P 705970-60-1P 705970-61-2P
705970-62-3P 705970-63-4P 705970-64-5P 705970-65-6P 705970-66-7P
705970-67-8P 705970-68-9P 705970-69-0P 705970-70-3P 705970-71-4P
705970-72-5P 705970-73-6P 705970-74-7P
705970-75-8P 705970-76-9P 705970-77-0P 705970-78-1P 705970-79-2P
705970-80-5P 705970-81-6P 705970-82-7P
705970-83-8P 705970-84-9P 705970-85-0P 705970-86-1P
705970-87-2P 705970-88-3P 705970-89-4P 705970-90-7P 705970-91-8P
705970-92-9P 705970-93-0P 705970-94-1P 705970-95-2P 705970-96-3P
705970-97-4P 705970-98-5P 705970-99-6P 705971-00-2P 705971-01-3P
705971-02-4P 705971-03-5P 705971-04-6P 705971-05-7P 705971-06-8P
705971-07-9P 705971-08-0P 705971-09-1P 705971-10-4P 705971-11-5P
705971-12-6P 705971-13-7P 705971-14-8P 705971-15-9P 705971-16-0P
705971-17-1P 705971-18-2P 705971-19-3P 705971-20-6P 705971-21-7P
705971-22-8P 705971-23-9P 705971-24-0P 705971-25-1P 705971-26-2P
705971-27-3P 705971-28-4P 705971-29-5P 705971-30-8P 705971-31-9P
705971-52-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic non-nucleoside reverse transcriptase inhibitors)

IT 705969-15-9P 705970-72-5P 705970-73-6P
705970-80-5P 705970-82-7P 705970-83-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic non-nucleoside reverse transcriptase inhibitors)

RN 705969-15-9 HCAPLUS
CN Acetamide, N-(2-chlorophenyl)-2-[[2-(1-naphthalenyl)phenyl]thio]- (CA INDEX NAME)



RN 705970-72-5 HCAPLUS
CN Acetamide, N-(2-chlorophenyl)-2-[[2-(1-naphthalenyl)phenyl]sulfinyl]- (CA INDEX NAME)



RN 705970-73-6 HCAPLUS
CN Acetamide, N-(2-chlorophenyl)-2-[[2-(1-naphthalenyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 705970-80-5 HCAPLUS
CN Acetamide, 2-[(2'-chloro-4'-methyl[1,1'-biphenyl]-2-yl)thio]-N-(2-chlorophenyl)- (CA INDEX NAME)



RN 705970-82-7 HCAPLUS
CN Benzoic acid, 3-chloro-4-[[2-[(2'-chloro-4'-methyl[1,1'-biphenyl]-2-yl)thio]acetyl]amino]-, methyl ester (CA INDEX NAME)



RN 705970-83-8 HCAPLUS
CN Benzoic acid, 3-chloro-4-[[2-[(2'-chloro-4'-methyl[1,1'-biphenyl]-2-yl)thio]acetyl]amino]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 9 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:390211 HCAPLUS Full-text
DOCUMENT NUMBER: 140:406638
TITLE: Preparation of arylamides as melanin concentrating hormone (MCH) receptor antagonists.
INVENTOR(S): Stenkamp, Dirk; Mueller, Stephan Georg; Roth, Gerald Juergen; Lustenberger, Philipp; Rudolf, Klaus; Lehmann-Lintz, Thorsten; Arndt, Kirsten; Lotz, Ralf R. H.; Lenter, Martin; Wieland, Heike-Andrea
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany; et al.
SOURCE: PCT Int. Appl., 276 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039764	A1	20040513	WO 2003-EP11933	20031028 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10250743	A1	20040519	DE 2002-10250743	20021031 <--
CA 2504207	A1	20040513	CA 2003-2504207	20031028 <--
AU 2003285306	A1	20040525	AU 2003-285306	20031028 <--
EP 1558567	A1	20050803	EP 2003-778292	20031028 <--
EP 1558567	B1	20090624		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR	2003015797	A	20050913	BR 2003-15797		20031028 <--
CN	1708476	A	20051214	CN 2003-80102236		20031028 <--
JP	2006504761	T	20060209	JP 2004-547576		20031028 <--
AT	434601	T	20090715	AT 2003-778292		20031028 <--
ES	2327329	T3	20091028	ES 2003-778292		20031028 <--
US	20040152742	A1	20040805	US 2003-699089		20031031 <--
US	7351719	B2	20080401			
ZA	2005001164	A	20061025	ZA 2005-1164		20050209 <--
NO	2005000745	A	20050523	NO 2005-745		20050211 <--
MX	2005002865	A	20050527	MX 2005-2865		20050315 <--
IN	2005DN01643	A	20090515	IN 2005-DN1643		20050421 <--
HR	2005000383	A2	20060831	HR 2005-383		20050429 <--
PRIORITY APPLN. INFO.:				DE 2002-10250743	A	20021031 <--
				US 2003-456482P	P	20030321 <--
				WO 2003-EP11933	W	20031028 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:406638

ED Entered STN: 13 May 2004

AB R1R2NXYZNR3COWABb [R1, R2 = H, (substituted) alkyl, cycloalkyl, heterocyclyl, Ph, pyridyl; R1R2 = alkylene optionally interrupted by CH:N, CH:CH, O, S, SO, SO2, CO, imino, etc.; R3 = H, alkyl, cycloalkyl, cycloalkylalkyl; X = alkylene optionally interrupted by CH:CH, C.tplbond.C, O, S, SO, SO2, CO, imino; W = CR6aR6bO, CR7a:CR7c, etc.; Z = bond, (fused) (alkyl-substituted) alkylene; Y, A, B = Cy; b = 0, 1; Cy = (substituted) (unsatd.) carbocyclyl, Ph, (aromatic) heterocyclyl; R6a, R6b = H, alkyl, CF3; R7a, R7c = H, F, Cl, alkyl, CF3; with provisos and specific exceptions], were prepared for treatment of obesity, diabetes, heart failure, arteriosclerosis, hypertension, arthritis, mastocytosis, depression, anxiety, etc. Thus, Me aminoacetate hydrochloride, Et3N, and N-[3-chloro-4-(2-oxoethoxy)phenyl]-2-(2,4-dichlorophenoxy)acetamide in CH2Cl2/THF were treated with NaBH(OAc)3 followed by stirring for 3 h to give 78% Me [2-[2-chloro-4-[2-(2,4-dichlorophenoxy)acetylamino]phenoxy]ethylamino]acetate. Tested title compds. bound to MCH-1 receptors with IC50 = 17-41 nM.

IC ICM C07C233-29

ICS C07C235-24; C07C237-04; C07C255-60; C07D207-08; C07D207-20; C07D209-08; C07D211-62; C07D213-30; C07D213-56; C07D295-08; C07D295-12; C07D307-42; C07D333-16; A61K031-16; A61K031-33; A61P003-00

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1

IT

742085-44-5	1026711-83-0	1064158-95-7	1064158-96-8	1064158-97-9
1064158-98-0	1064159-01-8	1064159-02-9	1064159-03-0	1064159-04-1
1064159-06-3	1064159-07-4	1064159-08-5	1064159-09-6	1064159-11-0
1064159-12-1	1064159-13-2	1064159-14-3	1064159-17-6	1064159-18-7
1064159-19-8	1064159-20-1	1064159-22-3	1064159-23-4	1064159-24-5
1064159-25-6	1064159-28-9	1064159-29-0	1064159-31-4	1064159-32-5
1064159-34-7	1064159-35-8	1064159-37-0	1064159-38-1	1064159-39-2
1064159-40-5	1064159-42-7	1064159-43-8	1064159-44-9	1064159-45-0
1064159-46-1	1064159-47-2	1064159-50-7	1064159-51-8	1064159-53-0
1064159-54-1	1064159-56-3	1064159-57-4	1064159-58-5	1064159-59-6
1064159-61-0	1064159-62-1	1064159-63-2	1064159-64-3	1064159-66-5
1064159-69-8	1064159-70-1	1064159-71-2	1064159-72-3	1064159-74-5
1064159-75-6	1064159-76-7	1064159-77-8	1064159-78-9	1064159-80-3
1064159-81-4	1064159-82-5	1064159-84-7	1064159-85-8	1064159-86-9
1064159-87-0	1064159-89-2	1064159-90-5	1064159-91-6	1064159-92-7
1064159-94-9	1064159-95-0	1064159-96-1	1064159-97-2	1064160-00-4
1064160-01-5	1064160-02-6	1064160-03-7	1064160-05-9	1064160-06-0
1064160-07-1	1064160-08-2	1064160-10-6	1064160-11-7	1064160-12-8

1064160-13-9 1064160-15-1 1064160-16-2 1064160-17-3
1064160-18-4 1064160-20-8 1064160-21-9
1064160-22-0 1064160-23-1 1064160-24-2 1064160-25-3 1064160-26-4
1064160-27-5 1064160-29-7 1064160-30-0 1064160-31-1 1064160-32-2
1064160-33-3 1064160-34-4 1064160-35-5 1064160-37-7
1064160-38-8 1064160-39-9 1064160-40-2
1064160-41-3 1064160-42-4 1064160-43-5 1064160-44-6 1064160-45-7
1064160-46-8 1064160-47-9 1064160-48-0 1064160-49-1 1064160-50-4
1064160-51-5 1064160-52-6 1064160-53-7 1064160-56-0 1064160-57-1
1064160-58-2 1064160-59-3 1064160-60-6 1064160-61-7 1064160-62-8
1064160-63-9 1064160-64-0 1064160-67-3 1064160-68-4 1064160-69-5
1064160-70-8 1064160-71-9 1064160-72-0 1064160-73-1 1064160-74-2
1064160-76-4 1064160-77-5 1064160-78-6 1064160-79-7 1064160-82-2
1064160-83-3 1064160-84-4 1064160-85-5 1064160-87-7 1064160-88-8
1064160-89-9 1064160-90-2 1064160-91-3 1064160-93-5 1064160-94-6
1064160-95-7 1064160-98-0 1064160-99-1 1064161-00-7 1064161-01-8
1064161-03-0 1064161-04-1 1064161-05-2 1064161-06-3

RL: PRPH (Prophetic)
(Preparation of arylamides as melanin concentrating hormone (MCH) receptor antagonists.)

IT 689299-35-2P 689299-36-3P 689299-37-4P 689299-38-5P 689299-39-6P
689299-40-9P 689299-41-0P 689299-42-1P 689299-43-2P
689299-44-3P 689299-45-4P 689299-46-5P 689299-47-6P 689299-48-7P
689299-49-8P 689299-50-1P 689299-51-2P 689299-52-3P 689299-53-4P
689299-54-5P 689299-55-6P 689299-56-7P
689299-57-8P 689299-58-9P 689299-59-0P 689299-60-3P
689299-61-4P 689299-62-5P 689299-63-6P 689299-64-7P 689299-65-8P
689299-66-9P 689299-67-0P 689299-68-1P 689299-69-2P 689299-70-5P
689299-71-6P 689299-72-7P 689299-73-8P 689299-74-9P 689299-75-0P
689299-76-1P 689299-77-2P 689299-78-3P 689299-79-4P 689299-80-7P
689299-81-8P 689299-82-9P 689299-83-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of arylamides as melanin concentrating hormone (MCH) receptor antagonists)

IT 689300-99-0P 689301-00-6P 689301-01-7P 689301-02-8P 689301-03-9P
689301-04-0P 689301-05-1P 689301-06-2P 689301-07-3P 689301-08-4P
689301-09-5P 689301-10-8P 689301-11-9P 689301-12-0P 689301-13-1P
689301-14-2P 689301-15-3P 689301-16-4P 689301-17-5P 689301-18-6P
689301-19-7P 689301-20-0P 689301-21-1P 689301-22-2P 689301-23-3P
689301-24-4P 689301-25-5P 689301-26-6P 689301-27-7P 689301-28-8P
689301-29-9P 689301-30-2P 689301-31-3P 689301-32-4P 689301-33-5P
689301-34-6P 689301-35-7P 689301-36-8P 689301-37-9P
689301-38-0P 689301-39-1P 689301-40-4P 689301-41-5P 689301-42-6P
689301-43-7P 689301-44-8P 689301-45-9P 689301-46-0P 689301-48-2P
689301-50-6P 689301-51-7P 689301-52-8P 689301-53-9P 689301-54-0P
689301-55-1P 689301-56-2P 689301-57-3P 689301-58-4P 689301-59-5P
689301-60-8P 689301-61-9P 689301-62-0P 689301-63-1P 689301-64-2P
689301-65-3P 689301-66-4P 689301-67-5P 689301-68-6P 689301-69-7P
689301-70-0P 689301-71-1P 689301-72-2P 689301-73-3P 689301-74-4P
689301-75-5P 689301-76-6P 689301-77-7P 689301-78-8P 689301-79-9P
689301-80-2P 689301-81-3P 689301-82-4P 689301-83-5P 689301-84-6P
689301-85-7P 689301-86-8P 689301-87-9P 689301-88-0P 689301-89-1P
689301-90-4P 689301-91-5P 689301-92-6P 689301-93-7P
689301-94-8P 689301-95-9P 689301-96-0P
689301-97-1P 689301-99-3P 689302-01-0P 689302-02-1P
689302-03-2P 689302-04-3P 689302-06-5P 689302-08-7P 689302-09-8P
689302-10-1P 689302-11-2P 689302-12-3P 689302-13-4P

689302-14-5P 689302-15-6P 689302-16-7P
689302-17-8P 689302-18-9P 689302-19-0P
689302-20-3P 689302-21-4P 689302-22-5P
689302-23-6P 689302-24-7P 689302-25-8P 689302-26-9P
689302-27-0P 689302-28-1P 689302-29-2P 689302-30-5P 689302-32-7P
689302-33-8P 689302-34-9P 689302-35-0P 689302-36-1P 689302-37-2P
689302-38-3P 689302-39-4P 689302-40-7P 689302-41-8P 689302-43-0P
689302-44-1P 689302-45-2P 689302-46-3P 689302-47-4P 689302-48-5P
689302-49-6P 689302-50-9P 689302-51-0P 689302-52-1P 689302-53-2P
689302-55-4P 689302-57-6P 689302-58-7P 689302-59-8P 689302-60-1P
689302-62-3P 689302-63-4P 689302-65-6P 689302-66-7P 689302-67-8P
689302-68-9P 689302-69-0P 689302-70-3P 689302-71-4P 689302-72-5P
689302-74-7P 689302-76-9P 689302-78-1P 689302-80-5P 689302-82-7P
689302-84-9P 689302-86-1P 689302-88-3P 689302-90-7P 689302-92-9P
689302-94-1P 689302-96-3P 689302-97-4P 689302-98-5P 689302-99-6P
689303-33-1P 689303-34-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylamides as melanin concentrating hormone (MCH) receptor antagonists)

IT 1064160-17-3 1064160-18-4 1064160-20-8
1064160-21-9 1064160-37-7 1064160-38-8
1064160-39-9 1064160-40-2
RL: PRPH (Prophetic)
(Preparation of arylamides as melanin concentrating hormone (MCH) receptor antagonists.)

RN 1064160-17-3 HCAPLUS
CN Acetamide, 2-[(3-chloro[1,1'-biphenyl]-4-yl)oxy]-N-[3-chloro-4-[2-(1-pyrrolidinyl)ethyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1064160-18-4 HCAPLUS
CN Acetamide, 2-[(3-chloro[1,1'-biphenyl]-4-yl)oxy]-N-[3-chloro-4-[2-(1-piperidinyl)ethyl]phenyl]- (CA INDEX NAME)



RN 1064160-20-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A



RN 1064160-21-9 HCAPLUS
CN Acetamide, 2-[(3-chloro[1,1'-biphenyl]-4-yl)oxy]-N-[3-chloro-4-[3-(diethylamino)propoxy]phenyl]- (CA INDEX NAME)



RN 1064160-37-7 HCAPLUS
CN Acetamide, 2-[(3-chloro[1,1'-biphenyl]-4-yl)oxy]-N-[3-chloro-4-[2-(4-hydroxy-1-piperidinyl)ethyl]phenyl]- (CA INDEX NAME)



RN 1064160-38-8 HCAPLUS
CN Acetamide, 2-[(3-chloro[1,1'-biphenyl]-4-yl)oxy]-N-[3-chloro-4-[2-(2,5-dihydro-1H-pyrrol-1-yl)ethyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1064160-39-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A



RN 1064160-40-2 HCAPLUS
CN Acetamide, N-[3-bromo-4-[2-(diethylamino)ethoxy]phenyl]-2-[(3-chloro[1,1'-biphenyl]-4-yl)oxy]- (CA INDEX NAME)



IT 689299-42-1P 689299-55-6P 689299-56-7P
689299-57-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of arylamides as melanin concentrating hormone (MCH)
receptor antagonists)

RN 689299-42-1 HCAPLUS
CN Acetamide, 2-[(3-chloro[1,1'-biphenyl]-4-yl)oxy]-N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 689299-55-6 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(dimethylamino)ethoxy]phenyl]-2-[2-chloro-4-(2-furanyl)phenoxy]- (CA INDEX NAME)



RN 689299-56-7 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(dimethylamino)ethoxy]phenyl]-2-[2-chloro-4-(2-thienyl)phenoxy]- (CA INDEX NAME)



RN 689299-57-8 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(dimethylamino)ethoxy]phenyl]-2-[2-chloro-4-(3-pyridinyl)phenoxy]- (CA INDEX NAME)



IT 689301-37-9P 689301-93-7P 689301-94-8P
689301-95-9P 689301-96-0P 689301-97-1P
689302-14-5P 689302-15-6P 689302-16-7P
689302-19-0P 689302-20-3P 689302-21-4P
689302-23-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylamides as melanin concentrating hormone (MCH) receptor antagonists)

RN 689301-37-9 HCAPLUS
CN Acetamide, 2-[(5-chloro[1,1'-biphenyl]-2-yl)oxy]-N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 689301-93-7 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]-2-[(4'-chloro-3-methyl[1,1'-biphenyl]-4-yl)oxy]- (CA INDEX NAME)



RN 689301-94-8 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]-2-[(3'-chloro-3-methyl[1,1'-biphenyl]-4-yl)oxy]- (CA INDEX NAME)



RN 689301-95-9 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]-2-[(2'-chloro-3-methyl[1,1'-biphenyl]-4-yl)oxy]- (CA INDEX NAME)



RN 689301-96-0 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]-2-[(4'-methoxy-3-methyl[1,1'-biphenyl]-4-yl)oxy]- (CA INDEX NAME)



RN 689301-97-1 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]-2-[(3,4'-dimethyl[1,1'-biphenyl]-4-yl)oxy]- (CA INDEX NAME)



RN 689302-14-5 HCAPLUS
CN Acetamide, 2-([1,1'-biphenyl]-4-yloxy)-N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 689302-15-6 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]-2-[2-chloro-4-(2-furanyl)phenoxy]- (CA INDEX NAME)



RN 689302-16-7 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]-2-[2-chloro-4-(2-thienyl)phenoxy]- (CA INDEX NAME)



RN 689302-19-0 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]-2-[(2',3-dichloro[1,1'-biphenyl]-4-yl)oxy]- (CA INDEX NAME)



RN 689302-20-3 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]-2-[(3,4'-dichloro[1,1'-biphenyl]-4-yl)oxy]- (CA INDEX NAME)



RN 689302-21-4 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]-2-[2-chloro-4-(3-pyridinyl)phenoxy]- (CA INDEX NAME)



RN 689302-23-6 HCAPLUS
CN Acetamide, N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]-2-[(3-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 10 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:220337 HCAPLUS Full-text
DOCUMENT NUMBER: 140:270878
TITLE: Kinase-modulating 6-aryl-imidazo[1,2-a]pyrazin-8-ylamines, method of their preparation, and method of their use, e.g., against cancer cells
INVENTOR(S): Desimone, Robert W.; Pippin, Douglas A.; Darrow, James W.; Mitchell, Scott A.; Currie, Kevin S.
PATENT ASSIGNEE(S): Cellular Genomics, Inc., USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022562	A1	20040318	WO 2003-US28329	20030909 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003270489	A1	20040329	AU 2003-270489	20030909 <--
US 20040067951	A1	20040408	US 2003-658121	20030909 <--
US 7312341	B2	20071225		
PRIORITY APPLN. INFO.:			US 2002-409161P P	20020909 <--
			WO 2003-US28329 W	20030909 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 140:270878
ED Entered STN: 19 Mar 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, cycloalkylmethyl, (hetero)(cyclo)alkyl, sulfonamide, alkoxy, alkoxyalkoxy, alkoxyalkyl, (di)(alkyl)amino(alkyl), (un)substituted Ph or heteroaryl; R2 = (hetero)(cyclo)alkyl, cycloalkylmethyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, (di)(alkyl)amino(alkyl), (un)substituted Ph, heteroaryl, phenoxyphenyl, phenyl- or heteroarylpiperazine; R3 = H, CO2H or esters, (hetero)(cyclo)alkyl, (un)substituted Ph, heteroaryl, phenoxyphenyl, phenyl- or heteroarylpiperazine; R4 = H, (hetero)(cyclo)alkyl, alkoxyalkyl, (un)substituted Ph, heteroaryl, phenoxyphenyl, phenyl- or heteroarylpiperazine; X = N or CH; Z1 = bond, CO, (un)substituted CH2, CH2CH2, CONH; Z2 = bond, CO, (un)substituted CH2NHCONH, NHCONHCH2, CH2, CH2CH2, CONH, NHCO, NHCONH, SO2NH, NHSO2; some substituents may be linked; with provisos] and their pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixts., are disclosed. Compds. I are of particular utility in the treatment of kinase-implicated disorders. A list of 91 invention compds. is given in examples, and the compds. are individually claimed. A general preparatory method starting from 3,5-dibromo-2-aminopyrazine is given; the steps include (among others) cyclocondensation with α-bromo aldehydes, monoaminolysis of the resultant 6,8-dibromoimidazopyrazines, Pd-catalyzed arylation of the obtained 8-amino-6-bromoimidazopyrazines, and reaction of 6-(aminophenyl)imidazolpyrazines with Ph isocyanate derivs. to form ureas. An exemplary invention compound is II. In tests against human cancer cell lines, including one over-expressing transfected human myrAKT-1 kinase gene (AKT-1 kinase), exemplified compds. I had IC50 values ≤ 25 μM.

IC ICM C07D487-04
ICS C07D519-00; A61K031-4985; A61P035-02; A61P037-00

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT 618454-80-1P, 1-(4-Chlorophenyl)-3-[3-(8-phenylaminoimidazo[1,2-a]pyrazin-6-yl)phenyl]urea 618454-86-7P, 1-(4-Chlorophenyl)-3-[3-[8-(4-chlorophenylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 618454-91-4P, 1-(4-Chlorophenyl)-3-[3-[8-(3-chlorophenylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 618455-30-4P, 4-[6-[3-[3-(4-Chlorophenyl)ureido]phenyl]imidazo[1,2-a]pyrazin-8-ylamino]benzoic acid ethyl ester 618455-54-2P, 1-[4-[8-(2-Methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-phenylurea 618455-60-0P, (2-Methoxybenzyl)[6-[3-(4-methoxybenzylamino)phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 618455-66-6P, 1-(2-Chlorophenyl)-3-[4-[8-(2-methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 618455-69-9P, 1-[4-[8-(2-Methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(2-methoxyphenyl)urea 618455-71-3P,

1-[4-[8-(2-Methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-methoxyphenyl)urea 618455-73-5P,
4-[6-[4-(Piperidine-1-carbonyl)phenyl]imidazo[1,2-a]pyrazin-8-ylamino]benzoic acid ethyl ester 618455-75-7P,
4-[6-[3-[3-(2-Methylsulfanylphenyl)ureido]phenyl]imidazo[1,2-a]pyrazin-8-ylamino]benzoic acid ethyl ester 618455-77-9P,
[4-[8-(4-Chlorophenylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]piperidin-1-ylmethanone 618455-84-8P, 1-(3-Chloro-4-fluorophenyl)-3-[3-(8-phenylaminoimidazo[1,2-a]pyrazin-6-yl)phenyl]urea 618455-86-0P,
1-[3-(8-Phenylaminoimidazo[1,2-a]pyrazin-6-yl)phenyl]-3-(3-trifluoromethylphenyl)urea 618455-88-2P,
1-(2-Chloro-5-trifluoromethylphenyl)-3-[3-(8-phenylaminoimidazo[1,2-a]pyrazin-6-yl)phenyl]urea 618455-91-7P,
1-[3-[8-(4-Chlorophenylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 618455-94-0P,
1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(3-chlorophenylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 618455-97-3P,
1-[3-[8-(3-Chlorophenylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 618455-99-5P,
1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-chlorophenylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673856-56-9P,
1-[4-[8-[(3-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(2-chlorophenyl)urea 673856-57-0P,
1-[4-[8-[(3-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-chlorophenyl)urea 673856-58-1P,
1-[4-[8-[(3-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(2-methoxyphenyl)urea 673856-59-2P,
1-[4-[8-[(3-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-chlorophenyl)urea 673856-60-5P,
1-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-chlorophenyl)urea 673856-61-6P,
1-[4-[8-[(3-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-trifluoromethylphenyl)urea 673856-62-7P,
1-[4-[8-[(3-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-trifluoromethoxyphenyl)urea 673856-63-8P,
1-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(2-methylsulfanylphenyl)urea 673856-64-9P,
1-[3-[8-[Methyl(4-methylbenzyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(2-methylsulfanylphenyl)urea 673856-65-0P,
1-(4-Chlorophenyl)-3-[3-[8-[methyl(4-methylbenzyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673856-66-1P,
1-[3-[8-[Methyl(4-methylbenzyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea 673856-67-2P, 1-(4-Chlorophenyl)-3-[3-[8-(3,4-dihydro-1H-isoquinolin-2-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673856-68-3P,
1-[3-[8-(3,4-Dihydro-1H-isoquinolin-2-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(2-methylsulfanylphenyl)urea 673856-69-4P,
1-[3-[8-(3,4-Dihydro-1H-isoquinolin-2-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea 673856-70-7P,
1-[3-[8-(3,4-Dihydro-1H-isoquinolin-2-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(2-methoxyphenyl)urea 673856-71-8P,
8-[(4-Chlorobenzyl)methylamino]-6-[3-[3-(2-trifluoromethylphenyl)ureido]phenyl]imidazo[1,2-a]pyrazine-3-carboxylic acid ethyl ester 673856-72-9P, 8-[(4-Chlorobenzyl)methylamino]-6-[3-(3-o-tolylureido)phenyl]imidazo[1,2-a]pyrazine-3-carboxylic acid ethyl ester 673856-73-0P, 8-[(4-Chlorobenzyl)methylamino]-6-[3-[3-(4-chlorophenyl)ureido]phenyl]imidazo[1,2-a]pyrazine-3-carboxylic acid ethyl ester 673856-74-1P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-[methyl(4-methylbenzyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673856-75-2P,
1-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-chloro-4-fluorophenyl)urea 673856-76-3P,

1-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]benzyl]-3-(4-chlorophenyl)urea 673856-77-4P,
1-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]benzyl]-3-(3-chloro-4-fluorophenyl)urea 673856-78-5P,
1-[3-[8-[(4-Chlorobenzyl)ethylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea 673856-79-6P, 1-[3-[8-[(4-Chlorobenzyl)ethylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-chlorophenyl)urea 673856-80-9P,
1-[3-[8-[(4-Chlorobenzyl)ethylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-chloro-4-fluorophenyl)urea 673856-81-0P,
1-[3-[8-[(4-Chlorobenzyl)propylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea 673856-82-1P, 1-[3-[8-[(4-Chlorobenzyl)propylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-chloro-4-fluorophenyl)urea 673856-83-2P, 1-[3-[8-[Butyl(4-chlorobenzyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea 673856-84-3P, 1-[3-[8-[(4-Chlorobenzyl)propylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-chlorophenyl)urea 673856-85-4P,
1-[3-[8-[(4-Chlorobenzyl)propylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 673856-86-5P,
1-[3-[8-[Butyl(4-chlorobenzyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-chlorophenyl)urea 673856-87-6P,
1-[3-[8-[Butyl(4-chlorobenzyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 673856-88-7P,
1-[3-[8-[Butyl(4-chlorobenzyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-chloro-4-fluorophenyl)urea 673856-89-8P,
1-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 673856-90-1P,
1-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea 673856-91-2P, 1-[3-[8-(Benzylmethylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-chlorophenyl)urea 673856-92-3P,
1-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-trifluoromethoxyphenyl)urea 673856-93-4P,
1-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(5-fluoro-2-trifluoromethylphenyl)urea 673856-94-5P,
1-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3,5-dichlorophenyl)urea 673856-95-6P,
1-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3,4-dichlorophenyl)urea 673856-96-7P,
1-[3-[8-[(2-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-chlorophenyl)urea 673856-97-8P,
1-[3-[8-[Methyl(pyridin-4-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 673856-98-9P,
1-(4-Chlorobenzyl)-3-[3-[8-[(4-chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673856-99-0P,
1-[3-[8-[(4-Chlorobenzyl)(2-methoxyethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-chlorophenyl)urea 673857-00-6P,
1-[3-[8-[(4-Chlorobenzyl)(2-methoxyethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 673857-01-7P,
1-[3-[8-[(4-Chlorobenzyl)(2-methoxyethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-chloro-3-fluorophenyl)urea 673857-02-8P,
1-[3-[8-[(4-Chlorobenzyl)(2-methoxyethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-(4-methylpiperazin-1-ylmethyl)phenyl]urea 673857-03-9P,
N-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]benzenesulfonamide 673857-04-0P,
N-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 673857-05-1P,
4-Chloro-N-[3-[8-[(4-chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 673857-06-2P,
2-Chloro-N-[3-[8-[(4-chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 673857-07-3P,
[4-[8-[(3-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-

yl]phenyl]piperidin-1-ylmethanone 673857-08-4P,
[4-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-
yl]phenyl]piperidin-1-ylmethanone 673857-09-5P,
3-Methoxy-N-[3-[8-(2-methoxybenzylamino)imidazo[1,2-a]pyrazin-6-
yl]phenyl]benzamide 673857-10-8P,
2-Methoxy-N-[3-[8-(2-methoxybenzylamino)imidazo[1,2-a]pyrazin-6-
yl]phenyl]benzamide 673857-11-9P,
1-[3-(8-Phenylaminoimidazo[1,2-a]pyrazin-6-yl)phenyl]-3-(4-
trifluoromethylphenyl)urea 673857-12-0P,
1-(3-Chloro-4-fluorophenyl)-3-[3-[8-[(pyridin-2-ylmethyl)amino]imidazo[1,2-
a]pyrazin-6-yl]phenyl]urea 673857-13-1P,
1-(4-Chlorophenyl)-3-[3-[8-[(pyridin-3-ylmethyl)amino]imidazo[1,2-
a]pyrazin-6-yl]phenyl]urea 673857-14-2P,
1-(3-Chloro-4-fluorophenyl)-3-[3-[8-[(pyridin-3-ylmethyl)amino]imidazo[1,2-
a]pyrazin-6-yl]phenyl]urea 673857-15-3P,
1-(4-Chlorophenyl)-3-[3-[8-[(pyridin-4-ylmethyl)amino]imidazo[1,2-
a]pyrazin-6-yl]phenyl]urea 673857-16-4P,
1-[3-[8-[(Pyridin-4-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-
trifluoromethylphenyl)urea 673857-17-5P,
1-(3-Chloro-4-fluorophenyl)-3-[3-[8-[(pyridin-4-ylmethyl)amino]imidazo[1,2-
a]pyrazin-6-yl]phenyl]urea 673857-18-6P,
1-[3-[8-(Pyridin-4-ylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-
trifluoromethylphenyl)urea 673857-19-7P 673857-20-0P,
1-(4-Chlorophenyl)-3-[3-[8-[(pyridin-2-ylmethyl)amino]imidazo[1,2-
a]pyrazin-6-yl]phenyl]urea 673857-21-1P,
1-[3-[8-[(Pyridin-2-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-
trifluoromethylphenyl)urea 673857-22-2P,
1-(2-Methoxy-6-methylphenyl)-3-[3-[8-(pyridin-4-ylamino)imidazo[1,2-
a]pyrazin-6-yl]phenyl]urea 673857-23-3P,
1-(2-Methoxy-5-methylphenyl)-3-[3-(8-phenylaminoimidazo[1,2-a]pyrazin-6-
yl)phenyl]urea 673857-24-4P, 1-[3-[8-(3-Chlorophenylamino)imidazo[1,2-
a]pyrazin-6-yl]phenyl]-3-(2-methoxy-5-methylphenyl)urea 673857-25-5P,
1-[3-[8-(2-Chlorophenylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(2-
methoxy-5-methylphenyl)urea 673857-26-6P,
1-[3-[8-(Pyridin-3-ylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-
trifluoromethylphenyl)urea 673857-27-7P,
1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(pyridin-3-ylamino)imidazo[1,2-
a]pyrazin-6-yl]phenyl]urea 673857-29-9DP,
1-[4-(8-Aminoimidazo[1,2-a]pyrazin-6-yl)phenyl]-3-phenylurea, derivs.
RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(drug candidate; preparation of arylimidazopyrazinylamines as kinase
modulators)

IT 673856-76-3P, 1-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-
a]pyrazin-6-yl]benzyl]-3-(4-chlorophenyl)urea 673856-77-4P,
1-[3-[8-[(4-Chlorobenzyl)methylamino]imidazo[1,2-a]pyrazin-6-yl]benzyl]-3-
(3-chloro-4-fluorophenyl)urea 673856-98-9P,
1-(4-Chlorobenzyl)-3-[3-[8-[(4-chlorobenzyl)methylamino]imidazo[1,2-
a]pyrazin-6-yl]phenyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(drug candidate; preparation of arylimidazopyrazinylamines as kinase
modulators)

RN 673856-76-3 HCAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[[3-[8-[[(4-
chlorophenyl)methyl]methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]methyl]-
(CA INDEX NAME)



RN 673856-77-4 HCAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[[3-[8-[[(4-chlorophenyl)methyl]methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]methyl]- (CA INDEX NAME)



RN 673856-98-9 HCAPLUS
CN Urea, N-[(4-chlorophenyl)methyl]-N'-[3-[8-[[(4-chlorophenyl)methyl]methylamino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 11 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:971891 HCAPLUS Full-text
DOCUMENT NUMBER: 140:13098
TITLE: Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
INVENTOR(S): Baraldi, Pier Giovanni; Borea, Pier Andrea
PATENT ASSIGNEE(S): King Pharmaceuticals Research & Development, Inc., USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101455	A2	20031211	WO 2003-US17313	20030530 <--
WO 2003101455	A3	20040521		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2454654	A1	20031211	CA 2003-2454654	20030530 <--
AU 2003245380	A1	20031219	AU 2003-245380	20030530 <--
US 20040039004	A1	20040226	US 2003-452788	20030530 <--
US 7064204	B2	20060620		
BR 2003004963	A	20040928	BR 2003-4963	20030530 <--
EP 1549319	A2	20050706	EP 2003-739019	20030530 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005527635	T	20050915	JP 2004-508812	20030530 <--
MX 2004000908	A	20040326	MX 2004-908	20040129 <--
ZA 2004000784	A	20050503	ZA 2004-784	20040130 <--
PRIORITY APPLN. INFO.:			US 2002-384809P P	20020530 <--
			WO 2003-US17313 W	20030530 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 140:13098
ED Entered STN: 14 Dec 2003
AB Tricyclic pyrazolotriazolopyrimidines which possess antagonistic activity for adenosine receptors may be useful for modulating biol. function in the nervous, cardiovascular, renal, respiratory and immune systems. General synthetic schemes and examples of formulations for the compds. are presented.
IC ICM A61K031-519
ICS C07D487-14; A61P025-00
CC 1-12 (Pharmacology)
Section cross-reference(s): 28, 63
IT 512845-14-6P 512845-17-9P 512845-20-4P 512845-28-2P 512845-31-7P

512845-34-0P 512846-12-7P 512846-14-9P 512846-18-3P
512846-20-7P 512846-24-1P 512846-26-3P 512846-28-5P 512846-32-1P
512846-34-3P 512846-36-5P 512846-38-7P 631842-40-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tricyclic pyrazolotriazolopyrimidines with antagonistic activity for adenosine receptors)

IT 512845-34-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tricyclic pyrazolotriazolopyrimidines with antagonistic activity for adenosine receptors)

RN 512845-34-0 HCAPLUS
CN Acetamide, 2-[4-[5-amino-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-2-yl]phenoxy]-N-(4-iodophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 12 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:757679 HCAPLUS Full-text
DOCUMENT NUMBER: 139:276825
TITLE: Preparation of 8-arylquinoline PDE4 inhibitors
INVENTOR(S): Gallant, Michel; Lacombe, Patrick; Dube, Daniel; Deschenes, Denis; MacDonald, Dwight; Dube, Laurence
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 184 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078397	A1	20030925	WO 2003-CA374	20030317 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2479069	A1	20030925	CA 2003-2479069	20030317	<--
AU 2003209896	A1	20030929	AU 2003-209896	20030317	<--
EP 1487797	A1	20041222	EP 2003-744288	20030317	<--
EP 1487797	B1	20090527			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
AT 432261	T	20090615	AT 2003-744288	20030317	<--
US 20050245513	A1	20051103	US 2004-508261	20040917	<--
US 7144896	B2	20061205			
PRIORITY APPLN. INFO.:			US 2002-365088P	P 20020318	<--
			WO 2003-CA374	W 20030317	<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 139:276825
ED Entered STN: 26 Sep 2003
GI



AB Title compds. I [wherein R1 = H, halo, or (un)substituted alkanoyl, (cyclo)alkyl, alkenyl, alkoxy, (hetero)aryl, CN, heterocycloalkyl, carbamoyl, sulfamoyl, etc.; R2 = H, halo, OH, or (un)substituted alkyl or alkoxy; R3 = absent or H, CO2H, or (un)substituted (cycloalkyl)alkyl, alkanoyl, benzoyl, carbamoyl, etc.; R4 = (un)substituted Ph, pyrazolopyrimidinyl, benzothiazolyl, quinazolinyl, or heteroaryl; R5 = absent or H; R6 = absent, H, or alkyl; R7 = absent or H; X = O, S, N, C, or CO; wherein when X = O, S, or CO, then R6 and R7 are absent and when X = N, then R7 is absent; Y = C, S, N, SO2, O, or CO; wherein when Y = S, SO2, O, or CO, then R3 and R5 are absent and when Y = N, then R5 is absent; and pharmaceutically acceptable salts thereof] were prepared as phosphodiesterase IV (PDE4) inhibitors. For example, 3-(6-isopropylquinolin-8-yl)phenol was coupled with 1-chloromethyl-4-methanesulfonylbenzene in acetone to give II. One hundred sixteen invention compds. suppressed PDE4 with IC50 values ranging from 80 μM to 0.029 μM in assays evaluating LPS- and FMLP-induced inhibition of tumor necrosis factor α (TNF-α) and leukotriene B4 (LTB4) in human whole blood. In a test measuring IgE-mediated allergic pulmonary inflammation induced by inhalation of antigen by sensitized guinea pigs, administration of I resulted in a significant reduction in the eosinophilia and the accumulation of other inflammatory leukocytes and effected less inflammatory lung damage. One hundred forty-one invention compds. also inhibited the hydrolysis of cAMP to AMP by human recombinant phosphodiesterase IVa with IC50 values ranging from 150 nM to

0.056 nM. Thus, I and their pharmaceutical compns. are useful for the treatment or prevention of a variety of allergic, inflammatory, CNS, and other conditions (no data).

IC ICM C07D215-04
ICS C07D215-12; C07D215-14; C07D401-06; C07D409-14; C07D401-12; C07D417-12; C07D409-12; C07D401-14; C07D413-12; C07D487-04; A61K031-47; A61K031-4709; A61P011-00; A61P025-00

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63

IT 605683-58-7P, 6-Isopropyl-8-[3-[[4-(methanesulfonyl)benzyl]oxy]phenyl]quinoline 605683-59-8P, 2-[[3-(6-Isopropylquinolin-8-yl)phenoxy]methyl]benzonitrile 605683-60-1P, 3-[[3-(6-Isopropylquinolin-8-yl)phenoxy]methyl]benzonitrile 605683-61-2P, 4-[[3-(6-Isopropylquinolin-8-yl)phenoxy]methyl]benzonitrile 605683-62-3P, 8-[3-[[2-(Benzenesulfonylmethyl)benzyl]oxy]phenyl]-6-isopropylquinoline 605683-63-4P, 6-Isopropyl-8-[3-(4-trifluoromethoxybenzyloxy)phenyl]quinoline 605683-64-5P, 6-Isopropyl-8-[3-[[3-(trifluoromethylsulfanyl)benzyl]oxy]phenyl]quinoline 605683-65-6P, 6-Isopropyl-8-[3-[[4-([1,2,3]thiadiazol-4-yl)benzyl]oxy]phenyl]quinoline 605683-67-8P, 4-[[3-(6-Isopropylquinolin-8-yl)phenoxy]methyl]benzoic acid 605683-68-9P, 2-[4-[[3-(6-Isopropylquinolin-8-yl)phenoxy]methyl]phenyl]propan-2-ol 605683-70-3P, 8-[3-Fluoro-5-[[4-(methanesulfonyl)benzyl]oxy]phenyl]-6-isopropylquinoline 605683-71-4P, 8-[3-(Benzyloxy)phenyl]-6-isopropylquinoline 605683-73-6P, 1-[3-(6-Isopropylquinolin-8-yl)phenoxy]-2-methyl-1-phenylpropan-2-ol 605683-74-7P, 1-[3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenoxy]-1-[4-(methanesulfonyl)phenyl]-2-methylpropan-2-ol 605683-75-8P, 8-[3-(Benzylsulfanyl)phenyl]-6-isopropylquinoline 605683-76-9P, 4-Azido-3-iodo-N-[3-[6-[(pyridin-4-yl)methyl]quinolin-8-yl]phenyl]benzamide 605683-78-1P, N-[3-[6-[(1-Oxopyridin-4-yl)methyl]quinolin-8-yl]phenyl]benzamide 605683-80-5P, Thiophene-2-sulfonic acid N-[3-[6-[(pyridin-4-yl)methyl]quinolin-8-yl]phenyl]amide 605683-81-6P, N-[3-[6-[(1-Oxopyridin-4-yl)methyl]quinolin-8-yl]phenyl]benzenesulfonamide 605683-83-8P, Benzenesulfonic acid 3-[6-(1-hydroxy-1-methylethyl)quinolin-8-yl]phenyl ester 605683-86-1P, 4-Fluoro-N-[3-(6-isopropylquinolin-8-yl)benzyl]-N-[4-(methanesulfonyl)phenyl]benzenesulfonamide 605683-87-2P, (Cyclopropylmethyl)[3-(6-isopropylquinolin-8-yl)benzyl][4-(methanesulfonyl)phenyl]amine 605683-88-3P, Propane-2-sulfonic acid N-[3-(6-isopropylquinolin-8-yl)benzyl]-N-[4-(methanesulfonyl)phenyl]amide 605683-89-4P, N-[3-(6-Cyclopropylquinolin-8-yl)benzyl]-N-[4-(methanesulfonyl)phenyl]-1-phenylmethanesulfonamide 605683-90-7P, 2-Phenylethenesulfonic acid N-[3-(6-cyclopropylquinolin-8-yl)benzyl]-N-[4-(methanesulfonyl)phenyl]amide 605683-91-8P, Thiophene-2-sulfonic acid N-[3-(6-cyclopropylquinolin-8-yl)benzyl]-N-[4-(methanesulfonyl)phenyl]amide 605683-92-9P, Butane-1-sulfonic acid N-[3-(6-cyclopropylquinolin-8-yl)benzyl]-N-[4-(methanesulfonyl)phenyl]amide 605683-93-0P, 5-Methylisoxazole-3-carboxylic acid N-[3-[6-(cyanodimethylmethyl)quinolin-8-yl]benzyl]-N-[4-(methanesulfonyl)phenyl]amide 605683-94-1P, 2-[8-[3-[[(4-Fluorobenzyl)[4-(methanesulfonyl)phenyl]amino]methyl]phenyl]quinolin-6-yl]-2-methylpropionitrile 605683-96-3P, [3-[6-(Cyanodimethylmethyl)quinolin-8-yl]benzyl][4-(methanesulfonyl)phenyl]carbamic acid isopropyl ester 605683-97-4P, [[3-[6-(Cyanodimethylmethyl)quinolin-8-yl]benzyl][4-(methanesulfonyl)phenyl]amino]acetic acid 605683-98-5P,

N-[3-[6-(Cyanodimethylmethyl)quinolin-8-yl]benzyl]-N-[4-(methanesulfonyl)phenyl]benzamide 605683-99-6P, 1-[3-[6-(Cyanodimethylmethyl)quinolin-8-yl]benzyl]-3-ethyl-1-[4-(methanesulfonyl)phenyl]urea 605684-00-2P, 1-[3-[6-(Cyanodimethylmethyl)quinolin-8-yl]benzyl]-3-isopropyl-1-[4-(methanesulfonyl)phenyl]urea 605684-01-3P, 1-[3-[6-(Cyanodimethylmethyl)quinolin-8-yl]benzyl]-1-[4-(methanesulfonyl)phenyl]-3-phenylurea 605684-02-4P, N-[1-[3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-N-[4-(methanesulfonyl)phenyl]benzamide 605684-03-5P, Cyclopropanecarboxylic acid N-[1-[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-N-[4-(methanesulfonyl)phenyl]amide 605684-04-6P, 2,2,2-Trifluoro-N-[1-[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-N-[4-(methanesulfonyl)phenyl]acetamide 605684-05-7P, 5-Methylisoxazole-3-carboxylic acid N-[1-[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-N-[4-(methanesulfonyl)phenyl]amide 605684-09-1P, N-[1-[3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-N-[4-(methanesulfonyl)phenyl]acetamide 605684-10-4P, N-[1-[3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-N-[4-(methanesulfonyl)phenyl]-2,4-difluorobenzamide 605684-11-5P, 4-(1-Hydroxy-1-methylethyl)-N-[1-[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-N-[4-(methanesulfonyl)phenyl]benzamide 605684-12-6P, N-[1-[3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-N-[4-(methanesulfonyl)phenyl]nicotinamide 605684-13-7P, 4-Fluoro-N-[1-[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-N-[4-(methanesulfonyl)phenyl]-3-trifluoromethylbenzamide 605684-14-8P, 2,4,6-Trifluoro-N-[1-[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-N-[4-(methanesulfonyl)phenyl]benzamide 605684-15-9P, 2-Chloro-N-[1-[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-N-[4-(methanesulfonyl)phenyl]-4-nitrobenzamide 605684-16-0P, 3-Isopropyl-1-[1-[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-1-[4-(methanesulfonyl)phenyl]urea 605684-18-2P, 3-(2-Chlorophenyl)-1-[1-[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-1-[4-(methanesulfonyl)phenyl]urea 605684-19-3P, 3,4-Dichloro-N-[1-[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-N-[4-(methanesulfonyl)phenyl]benzenesulfonamide 605684-20-6P, 1-[2-Fluoro-5-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]-3-isopropyl-1-[4-(methanesulfonyl)phenyl]urea 605684-21-7P, N-[2-Fluoro-5-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]-N-[4-(methanesulfonyl)phenyl]benzamide 605684-23-9P, N-[1-[2-Chloro-5-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-N-[4-(methanesulfonyl)phenyl]benzamide 605684-24-0P, 1-[2-Chloro-5-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]-3-isopropyl-1-[4-(methanesulfonyl)phenyl]urea 605684-25-1P, 4-Fluoro-3-(6-isopropylquinolin-8-yl)-N-(1-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)benzamide 605684-26-2P, 4-[[3-(6-Isopropylquinolin-8-yl)benzyl]oxy]benzonitrile 605684-27-3P, 6-Isopropyl-8-[3-[[4-(methanesulfonyl)phenoxy]methyl]phenyl]quinoline 605684-28-4P, 2-[4-[[3-(6-Isopropylquinolin-8-yl)benzyl]oxy]phenyl]propan-2-ol 605684-30-8P, 1-[5-(Methanesulfonyl)-2-[[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]oxy]phenyl]ethanol 605684-31-9P, 1-[2-Hydroxy-4-[[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]oxy]phenyl]ethanone 605684-32-0P, 1-[2-Hydroxy-4-[[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]oxy]-3-propylphenyl]ethanone 605684-36-4P,

8-[3-(2-Cyclopentylphenoxymethyl)phenyl]-6-[1-(methanesulfonyl)-1-methylethyl]quinoline 605684-37-5P,
2'-[[3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]oxy]biphenyl-2-ol 605684-38-6P,
8-[3-(2-Benzylphenoxymethyl)phenyl]-6-[1-(methanesulfonyl)-1-methylethyl]quinoline 605684-39-7P,
3-[2-[[3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]oxy]phenyl]-1-phenylpropenone 605684-40-0P,
6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-[[4-methyl-2-[(piperidin-1-yl)methyl]phenoxy]methyl]phenyl]quinoline 605684-41-1P,
8-[3-[[2-(Benzothiazol-2-yl)phenoxy]methyl]phenyl]-6-[1-(methanesulfonyl)-1-methylethyl]quinoline 605684-43-3P,
6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-[[2-(morpholin-4-yl)phenoxy]methyl]phenyl]quinoline 605684-44-4P,
6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-(2-methoxyphenoxymethyl)phenyl]quinoline 605684-45-5P,
6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-(2-trifluoromethylphenoxymethyl)phenyl]quinoline 605684-46-6P,
2-[[3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]oxy]benzonitrile 605684-47-7P,
8-[3-[(2-Allyl-6-methoxyphenoxy)methyl]phenyl]-6-[1-(methanesulfonyl)-1-methylethyl]quinoline 605684-48-8P,
8-[3-(2-Benzyloxyphenoxymethyl)phenyl]-6-[1-(methanesulfonyl)-1-methylethyl]quinoline 605684-49-9P,
[2-[[3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]oxy]phenyl](1-phenyl-1H-pyrazol-4-yl)methanone 605684-50-2P,
6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-[[2-(methanesulfonyl)phenoxy]methyl]phenyl]quinoline 605684-51-3P,
Cyclopropyl[2-[[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]oxy]phenyl]phenylmethanol 605684-52-4P,
Dicyclopropyl[2-[[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]oxy]phenyl]methanol 605684-53-5P,
1-Cyclopropyl-1-[2-[[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]oxy]phenyl]-3-phenylpropan-1-ol 605684-54-6P,
8-[3-[[(4,6-Dimethylpyrimidin-2-yl)sulfanyl]methyl]phenyl]-6-[(pyridin-4-yl)methyl]quinoline 605684-55-7P,
6-[(Pyridin-4-yl)methyl]-8-[3-[[(pyridin-4-yl)sulfanyl]methyl]phenyl]quinoline 605684-57-9P,
8-[3-(Benzenesulfonylmethyl)phenyl]-6-isopropylquinoline 605684-58-0P,
6-Isopropyl-8-[3-[[(pyridin-4-yl)sulfanyl]methyl]phenyl]quinoline 605684-59-1P, 6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-[[[5-(methylsulfanyl)-[1,3,4]thiadiazol-2-yl]sulfanyl]methyl]phenyl]quinoline 605684-60-4P, 6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-[[(2,3,5,6-tetrachloropyridin-4-yl)sulfanyl]methyl]phenyl]quinoline 605684-61-5P,
6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-[[(1,3,4-thiadiazol-2-yl)sulfanyl]methyl]phenyl]quinoline 605684-62-6P,
6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-[[(4-nitrophenyl)sulfanyl]methyl]phenyl]quinoline 605684-63-7P,
6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-[[(pyrimidin-2-yl)sulfanyl]methyl]phenyl]quinoline 605684-64-8P,
6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-[[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]methyl]phenyl]quinoline 605684-65-9P,
6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-[[(1H-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanyl]methyl]phenyl]quinoline 605684-66-0P,
6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-[[(5-phenyl-[1,3,4]oxadiazol-2-yl)sulfanyl]methyl]phenyl]quinoline 605684-67-1P,
2-[[3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]sulfanyl]nicotinic acid 605684-68-2P,
2-[[3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]sulfanyl]-4,6-dimethylnicotinonitrile 605684-69-3P,

8-[3-[[(3-Chlorophenyl)sulfanyl]methyl]phenyl]-6-[1-(methanesulfonyl)-1-methylethyl]quinoline 605684-70-6P, 6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-[[(6-nitrobenzothiazol-2-yl)sulfanyl]methyl]phenyl]quinoline 605684-71-7P, 2-[[3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]sulfanyl]benzoic acid methyl ester 605684-72-8P, 6-[1-(Methanesulfonyl)-1-methylethyl]-8-[3-[[(pyridin-4-yl)sulfanyl]methyl]phenyl]quinoline 605684-73-9P, 8-[3-[[(2,6-Dichlorophenyl)sulfanyl]methyl]phenyl]-6-[1-(methanesulfonyl)-1-methylethyl]quinoline 605684-74-0P, 8-[3-[(2-Chlorophenylsulfanyl)methyl]phenyl]-6-[1-(methanesulfonyl)-1-methylethyl]quinoline 605684-75-1P, 2-[[3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]sulfanyl]-3H-quinazolin-4-one 605684-76-2P, 4-Amino-2-[[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzyl]sulfanyl]pyrimidine-5-carboxylic acid methyl ester 605684-79-5P, N-(3,5-Dichloro-1-oxopyridin-4-yl)-3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzamide 605684-82-0P, 3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]-N-[3-(methanesulfonyl)phenyl]benzamide 605684-83-1P, 3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]-N-[4-(methanesulfonyl)phenyl]benzamide 605684-85-3P, 3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]-N-(1-oxopyridin-3-yl)benzamide 605684-86-4P, 3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]-N-(5-methylthiazol-2-yl)benzamide 605684-87-5P, 3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]-N-(quinolin-3-yl)benzamide 605684-88-6P, N-[6-(Methanesulfonyl)benzothiazol-2-yl]-3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzamide 605684-89-7P, N-(5-Cyclopropyl-[1,3,4]thiadiazol-2-yl)-3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzamide 605684-90-0P, 3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]-N-(5-trifluoromethyl-[1,3,4]thiadiazol-2-yl)benzamide 605684-91-1P, N-(Benzothiazol-2-yl)-3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzamide 605684-92-2P, 3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]-N-(4-phenylthiazol-2-yl)benzamide 605684-93-3P, 3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]-N-(pyridin-2-yl)benzamide 605684-95-5P, N-(5-Bromothiazol-2-yl)-3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzamide 605684-97-7P, 3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]-N-[4-[(1-oxopyridin-4-yl)methyl]phenyl]benzamide 605684-98-8P, 3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]-N-(1-oxopyridin-4-yl)benzamide 605685-00-5P, N-[2-Bromo-4-[(1-oxopyridin-4-yl)methyl]phenyl]-3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]benzamide 605685-02-7P, 3-[6-[1-(Methanesulfonyl)-1-methylethyl]quinolin-8-yl]-N-[6-[4-(methylsulfanyl)phenyl]pyridin-3-yl]benzamide 605685-03-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PDE4 inhibitor; preparation of 8-arylquinoline PDE4 inhibitors for treatment of a variety of allergic, inflammatory, CNS, and other conditions)

IT 605684-18-2P, 3-(2-Chlorophenyl)-1-[1-[3-[6-[1-(methanesulfonyl)-1-methylethyl]quinolin-8-yl]phenyl]ethyl]-1-[4-(methanesulfonyl)phenyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE4 inhibitor; preparation of 8-arylquinoline PDE4 inhibitors for treatment of a variety of allergic, inflammatory, CNS, and other conditions)

RN 605684-18-2 HCAPLUS

CN Urea, N'-(2-chlorophenyl)-N-[1-[3-[6-[1-methyl-1-(methylsulfonyl)ethyl]-8-quinolinyl]phenyl]ethyl]-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 13 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:757507 HCAPLUS Full-text

DOCUMENT NUMBER: 139:281235

TITLE: HMG-CoA reductase inhibitor combination with ACAT inhibitors in treating or preventing Alzheimers disease

INVENTOR(S): Cai, Tian-quan; Chao, Yu-sheng

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077896	A1	20030925	WO 2003-US7038	20030307 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2478184	A1	20030925	CA 2003-2478184		20030307 <--
AU 2003218004	A1	20030929	AU 2003-218004		20030307 <--
EP 1485077	A1	20041215	EP 2003-713983		20030307 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 20050107461	A1	20050519	US 2004-507048		20040908 <--
PRIORITY APPLN. INFO.:			US 2002-363442P	P	20020312 <--
			WO 2003-US7038	W	20030307 <--

ED Entered STN: 26 Sep 2003

GI



I

AB The instant invention provides a drug combination comprised of an HMG-CoA reductase inhibitor in combination with an ACAT inhibitor, which is useful for treating or preventing Alzheimers disease. Example HMG-CoA reductase inhibitors include the statins and an example ACAT inhibitor is I.

IC ICM A61K031-16
ICS A61K031-18; A61K031-35; A61K031-40; A61K031-405; A61K031-435

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

IT 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 93957-54-1, Fluvastatin 134523-00-5, Atorvastatin 144289-00-9 147511-69-1, Pitavastatin 147538-81-6 162320-85-6 166518-60-1 179054-18-3 182255-50-1 287714-41-4, Rosuvastatin 332342-32-2 332342-33-3 332342-34-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMG-CoA reductase inhibitor combination with ACAT inhibitors in treating or preventing Alzheimers disease)

IT 179054-18-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMG-CoA reductase inhibitor combination with ACAT inhibitors in treating or preventing Alzheimers disease)

RN 179054-18-3 HCAPLUS

CN Urea, N-(phenylmethyl)-N-[[3-(1H-pyrazol-3-yl)phenyl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 14 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:559037 HCAPLUS Full-text
DOCUMENT NUMBER: 139:117338
TITLE: Preparation of biaryl compounds and their use as inhibitors for formation and secretion of amyloid β proteins, and activators for secretion of soluble amyloid precursor protein α
INVENTOR(S): Uchikawa, Osamu; Aso, Kazuyoshi; Miyamoto, Masaomi; Takahashi, Hideki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003206280	A	20030722	JP 2001-401232	20011228 <--
PRIORITY APPLN. INFO.:			JP 2001-401232	20011228 <--

OTHER SOURCE(S): MARPAT 139:117338
ED Entered STN: 22 Jul 2003
AB (R2Z)NR3C6H4BXYR1 [the benzene ring may be further substituted; B = (un)substituted benzene ring, (un)substituted pyridine ring; X = CONR4, SO2NR4, CH2NR4, NH, O, CO2, CH:CH, bond, etc.; n = 0-2; Y = C1-12 spacer, bond; XY or XR1 ma be bonded to form ring; Z = CONH, CSNH, CO, SO2, bond; R1 = (un)substituted amino, (un)substituted heterocyclyl; R2-R4 = H, (un)substituted hydrocarbyl, (un)substituted heterocyclyl; R2R3 may be bonded to form ring] or their salts, useful for treatment of nerve disorders, such as Alzheimer's disease, etc., are prepared Thus, treatment of 506 mg 4-H2NO2SC6H4CH2CH2NHCH2-3-C6H4C6H4-3-CONHCH2CH2R (R = pyrrolidin-1-yl) with PhCH2CH2NCO gave 169 mg of the corresponding urethane derivative, which at 1 μM completely inhibited formation and secretion of amyloid β protein (1-40) and (1-42), and significantly increased secretion of soluble amyloid precursor protein α in human neuroblastoma IMR-32 cell.
IC ICM C07D213-81
ICS A61K031-40; A61K031-4439; A61K031-4453; A61K031-455; A61K031-5377; A61K031-551; A61P025-00; A61P025-14; A61P025-18; A61P025-28; A61P043-00; C07D213-82; C07D295-08; C07D295-12; C07D295-14; C07D401-06; C07D401-12
CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 25, 63
IT 386290-84-2P 386290-86-4P 386290-88-6P 386297-57-0P 564477-29-8P
564477-30-1P 564477-31-2P 564477-32-3P 564477-33-4P 564477-34-5P
564477-35-6P 564477-36-7P 564477-37-8P 564477-38-9P

564477-39-0P 564477-40-3P 564477-41-4P 564477-42-5P
564477-43-6P 564477-44-7P 564477-45-8P 564477-46-9P 564477-48-1P
564477-49-2P 564477-50-5P 564477-51-6P 564477-52-7P 564477-53-8P
564477-54-9P 564477-55-0P 564477-56-1P 564477-57-2P 564477-58-3P
564477-59-4P 564477-60-7P 564477-61-8P 564477-62-9P 564477-63-0P
564477-64-1P 564477-65-2P 564477-66-3P 564477-67-4P 564477-68-5P
564477-69-6P 564477-70-9P 564477-71-0P 564477-72-1P 564477-73-2P
564477-74-3P 564477-75-4P 564477-76-5P 564477-77-6P 564477-86-7P
564477-87-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl compds. as Aβ protein formation inhibitors and sAPP secretion activators for treatment of nerve disorders)

IT 564477-39-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl compds. as Aβ protein formation inhibitors and sAPP secretion activators for treatment of nerve disorders)

RN 564477-39-0 HCAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, 3'-[[[[(4-bromophenyl)amino]carbonyl][2-(4-hydroxyphenyl)ethyl]amino]methyl]-N-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L125 ANSWER 15 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:334893 HCAPLUS Full-text
DOCUMENT NUMBER: 138:353744
TITLE: Preparation of substituted aromatic amide MCH antagonists for the treatment of obesity
INVENTOR(S): Palani, Anandan; Shapiro, Sherry A.; McBriar, Mark D.; Su, Jing
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035055	A1	20030501	WO 2002-US33869	20021023 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2464130	A1	20030501	CA 2002-2464130	20021023 <--
AU 2002337956	A1	20030506	AU 2002-337956	20021023 <--
AU 2002337956	B2	20060223		
US 20030144261	A1	20030731	US 2002-278468	20021023 <--
US 7045636	B2	20060516		
EP 1443922	A1	20040811	EP 2002-773861	20021023 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
HU 2004001656	A2	20041228	HU 2004-1656	20021023 <--
CN 1575169	A	20050202	CN 2002-821069	20021023 <--
CN 100548291	C	20091014		
JP 2005507918	T	20050324	JP 2003-537622	20021023 <--
ZA 2004003087	A	20050422	ZA 2004-3087	20040422 <--
MX 2004003858	A	20040708	MX 2004-3858	20040423 <--
PRIORITY APPLN. INFO.:			US 2001-343065P P	20011025 <--
			WO 2002-US33869 W	20021023 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 138:353744
ED Entered STN: 02 May 2003
GI



I



II

AB Title compds. I [X = bond, C, CH, alkylene, etc.; Y = bond, C, CH, alkylene, etc.; R1 = (hetero)aryl; R2 = H, alkyl, aryl, aralkyl; R3 = H, alkyl, aryl, aralkyl; R4 = alkylene-amine, amino-alkylene, etc.; R5-6 = H, (cyclo)alkyl] are prepared For instance, 3,5-dichloroaniline was acylated with bromoacetyl bromide and the product coupled to the biaryl derived from 4-bromobenzyl amine and 3-cyanophenylboronic acid to give an amine intermediate. This intermediate was acylated with 3-chloropropionic acid (CH2Cl2, EDCI) and subsequently treated with pyrrolidine (K2CO3, NaI, 80°) to give II. II had Ki = 21 nM for the melanin-concentrating hormone (MCH) receptor. I are useful for the treatment of obesity, metabolic disorders, eating disorders such as hyperphagia and diabetes.

IC ICM A61K031-277
ICS A61K031-4453; A61K031-4015; A61K031-40; C07D295-14; C07D295-12; C07D207-12; C07D205-04; C07K005-06; C07K005-02; C07C255-60

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1

IT 518306-57-5P 518306-58-6P 518306-59-7P 518306-60-0P 518306-61-1P
518306-62-2P 518306-63-3P 518306-64-4P 518306-65-5P 518306-66-6P
518306-67-7P 518306-68-8P 518306-69-9P 518306-70-2P 518306-71-3P
518306-72-4P 518306-73-5P 518306-74-6P 518306-75-7P 518306-76-8P
518306-77-9P 518306-78-0P 518306-79-1P 518306-80-4P
518306-81-5P 518306-82-6P 518306-83-7P 518306-84-8P 518306-85-9P
518306-86-0P 518306-87-1P 518306-88-2P 518306-89-3P 518306-90-6P
518306-91-7P 518306-92-8P 518306-93-9P 518306-94-0P 518306-95-1P
518306-96-2P 518306-97-3P 518306-98-4P 518306-99-5P 518307-00-1P
518307-01-2P 518307-02-3P 518307-03-4P 518307-04-5P 518307-05-6P
518307-06-7P 518307-07-8P 518307-08-9P 518307-09-0P 518307-12-5P
518307-14-7P 518307-16-9P 518307-17-0P 518307-19-2P 518307-20-5P
518307-21-6P 518307-22-7P 518307-23-8P 518307-24-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted aromatic amide MCH antagonists for treatment of obesity)

IT 518306-80-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted aromatic amide MCH antagonists for treatment of obesity)

RN 518306-80-4 HCAPLUS

CN Glycinamide, N,N-dimethylglycyl-N2-(3'-cyano[1,1'-biphenyl]-4-yl)-N-(3,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 16 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:221693 HCAPLUS Full-text
DOCUMENT NUMBER: 138:238197
TITLE: Preparation of furo- and thienopyrimidines as TIE-2 and/or VEGFR-2 kinase inhibitors useful against hyperproliferative diseases
INVENTOR(S): Adams, Jerry Leroy; Bryan, Deborah Lynne; Feng, Yanhong; Matsunaga, Shinichiro; Maeda, Yutaka; Miyazaki, Yasushi; Nakano, Masato; Rocher, Jean-Philippe; Sato, Hideyuki; Semones, Marcus; Silva, Domingos J.; Tang, Jun
PATENT ASSIGNEE(S): Glaxosmithkline K.K., Japan; Smithkline Beecham Corporation
SOURCE: PCT Int. Appl., 265 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022852	A2	20030320	WO 2002-US28650	20020910 <--
WO 2003022852	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002333524	A1	20030324	AU 2002-333524	20020910 <--
EP 1425284	A2	20040609	EP 2002-798181	20020910 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, SK				
JP 2005508904	T	20050407	JP 2003-526926	20020910 <--
US 20050004142	A1	20050106	US 2004-489052	20040309 <--
US 7427623	B2	20080923		
US 20080287466	A1	20081120	US 2008-169800	20080709 <--
PRIORITY APPLN. INFO.:			US 2001-318766P P	20010911 <--
			WO 2002-US28650 W	20020910 <--
			US 2004-489052 A3	20040309

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 138:238197
ED Entered STN: 21 Mar 2003
GI



I

AB Furo- and thienopyrimidine derivs. (shown as I; variables defined below; e.g. 4-Amino-3-(4-methoxyphenyl)-2-[3-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine), which are useful as TIE-2 (tyrosine kinase containing immunoglobin and EGF homol. domains) and/or VEGFR-2 kinase inhibitors against hyperproliferative diseases are described herein. Enzyme inhibitions by .apprx.60 examples of I are included as ranges; also, 4-amino-3-[4-[[2-fluoro-5-(trifluoromethyl)phenyl]aminocarbonylamino]phenyl]thieno[2,3-d]pyrimidine exhibited IC50 = 0.0018 μM in the TIE-2 fluorescence polarization kinase activity assay. For I: X is O or S; A is H, halo, C1-C6 alkyl, aryl, heteroaryl, aryl or heteroaryl substituted with ≥1 R3, heterocyclyl, -RR3, -C(O)OR4, -C(O)NR5R6, -C(O)R4; D is H, halo, C1-C6 alkyl, aryl, heteroaryl, aryl or heteroaryl substituted with ≥1 R3, heterocyclyl, -RR3, -C(O)OR4, -C(O)NR5R6, or -C(O)R4. R is C1-C6 alkylene, C3-C7 cycloalkylene, C1-C6 alkenylene, or C1-C6 alkynylene; R1 is H, C1-C6 alkyl, C1-C6 alkoxy, -SR4, -S(O)2R4, -NR7R7, -NR'N R'''R'''', -N(H)RR3, -C(O)OR7, or -C(O)NR7R7. R2 is H, -OH, -NR7R7 or :NH; R3 is halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C7 cycloalkoxy, C1-C6 haloalkoxy, aryl, aralkyl, aryloxy, heteroaryl, heterocyclyl, -CN, -NHC(O)R4, -N(R8)HC(O)R4, -NHC(S)R4, -NR5R6, -RNR5R6, -SR4, -S(O)2R4, -RC(O)OR4, -C(O)OR4, -C(O)R4, -C(O)NR5R6, -NHS(O)2R4, -N(S(O)2R4)S(O)2R4, -S(O)2NR5R6, or -NHC(:NH)R4. R4 is H, C1-C6 alkyl, aryl, heteroaryl, heterocyclyl, -RR3, -NR'''R'''', or - NR'NR'''R''''; R5 is H, C1-C6 alkyl, C3-C7 cycloalkyl, cyanoalkyl, -R'R'', aryl, aralkyl, heteroaryl, -NHC(O)OR''', -R'NHC(O)OR''', -R'NHC(O)NR'''R'''', or -R'C(O)OR'''. R6 is H, C1-C6 alkyl, C3-C7 cycloalkyl, cyanoalkyl, -R'R'', aryl, aralkyl, heteroaryl, -C(O)OR''', or -R'C(O)NR'''R'''; R7 is H, C1-C6 alkyl, aryl, or -C(O)OR'''; R8 is C1-C3 alkyl; R' is C1-C3 alkylene; R'' is heteroalkyl or NRR'''R''''; R''' is H, C1-C6 alkyl, aryl, aralkyl, heteroaryl, or C3-C7 cycloalkyl; R'''' is H, C1-C6 alkyl, aryl, heteroaryl, or C3-C7 cycloalkyl. Although the methods of preparation are not claimed, several example prepns. of I are included and characterization data is given for .apprx.480 examples of I.

IC ICM C07D491-04
ICS C07D495-04; C07D519-00; A61K031-505; A61P035-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT 5207-52-3P, 4-Amino-5,6-diphenylfuro[2,3-d]pyrimidine 87499-62-5P, 4-Amino-5,6-bis(3,4-O-methylidenedioxyphenyl)furo[2,3-d]pyrimidine 141764-53-6P, 3,4-Dihydro-5-(4-nitrophenyl)-4-oxofuro[2,3-d]pyrimidine 296793-25-4P, 4-Amino-6-(3-furanyl)-5-(2-furanyl)furo[2,3-d]pyrimidine 339590-38-4P, 4-Amino-5,6-bis(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-18-1P, 4-Amino-5-(4-methoxyphenyl)-6-[3-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine 501693-21-6P, 4-Amino-5-[4-(dimethylamino)phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-23-8P, 4-Amino-5-[4-[(3-chlorophenyl)sulfonylamino]phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-25-0P, 4-Amino-5-[4-[[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-26-1P, 4-Amino-5-[4-(2,3-difluorophenyl)phenyl]-6-(3-sulfamoylphenyl)furo[2,3-d]pyrimidine 501693-31-8P, 4-Amino-5-[4-(3-biphenylyl)phenyl]-6-(3-sulfamoylphenyl)furo[2,3-d]pyrimidine 501693-34-1P, 4-Amino-5-(4-biphenylyl)-6-[4-fluoro-3-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine 501693-42-1P, 4-Amino-6-(3-cyanophenyl)-5-[4-[[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]furo[2,3-d]pyrimidine 501693-53-4P, 4-Amino-5,6-dibutylfuro[2,3-d]pyrimidine 501693-54-5P, 4-Amino-5,6-bis(4-methylphenyl)furo[2,3-d]pyrimidine 501693-56-7P, 4-Amino-6-(4-methylphenyl)-5-(4-trifluoromethylphenyl)furo[2,3-d]pyrimidine 501693-58-9P, 4-Amino-5-(4-methylphenyl)-6-(4-

trifluoromethylphenyl)furo[2,3-d]pyrimidine 501693-61-4P, 4-Amino-6-(2-benzothienyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-63-6P, 4-Amino-6-(4-biphenylyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-65-8P, 4-Amino-6-(2-chlorophenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-66-9P, 4-Amino-6-(2-methoxyphenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-68-1P, 4-Amino-5-(4-methoxyphenyl)-6-(1-naphthyl)furo[2,3-d]pyrimidine 501693-70-5P, 4-Amino-5-(4-methoxyphenyl)-6-(2-naphthyl)furo[2,3-d]pyrimidine 501693-72-7P, 4-Amino-5-(4-methoxyphenyl)-6-(4-trifluoromethyloxyphenyl)furo[2,3-d]pyrimidine 501693-74-9P, 4-Amino-6-(3-methoxyphenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-77-2P, 5-(3-Acetamidophenyl)-4-amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-79-4P, 4-Amino-5-(3,4-dimethoxyphenyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-81-8P, 4-Amino-6-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)furo[2,3-d]pyrimidine 501693-82-9P, 4-Amino-5-(4-isopropylphenyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-84-1P, 4-Amino-5-(4-butylphenyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-85-2P, 4-Amino-6-(4-methoxyphenyl)-5-(3-methoxyphenyl)furo[2,3-d]pyrimidine 501693-87-4P, 4-Amino-5-(4-biphenylyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-88-5P, 4-Amino-6-(4-methoxyphenyl)-5-(2-methoxyphenyl)furo[2,3-d]pyrimidine 501693-90-9P, 4-Amino-6-(4-methoxyphenyl)-5-[4-(methylthio)phenyl]furo[2,3-d]pyrimidine 501693-92-1P, 4-Amino-6-(4-methoxyphenyl)-5-(1-naphthyl)furo[2,3-d]pyrimidine 501693-93-2P, 4-Amino-6-(4-methoxyphenyl)-5-(2-naphthyl)furo[2,3-d]pyrimidine 501693-94-3P, 4-Amino-6-(4-methoxyphenyl)-5-[4-(trifluoromethyloxy)phenyl]furo[2,3-d]pyrimidine 501693-95-4P, 4-Amino-5-(2,5-dimethoxyphenyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501693-96-5P, 4-Amino-6-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]furo[2,3-d]pyrimidine 501693-97-6P, 4-Amino-6-(4-methoxyphenyl)-5-[4-(phenyloxy)phenyl]furo[2,3-d]pyrimidine 501693-98-7P, 4-Amino-6-(4-methoxyphenyl)-5-(3-pyridyl)furo[2,3-d]pyrimidine 501693-99-8P, 4-Amino-5-(4-cyanophenyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-00-4P, 4-Amino-6-(4-methoxyphenyl)-5-(4-tert-butylphenyl)furo[2,3-d]pyrimidine 501694-01-5P, 4-Amino-6-(4-methoxyphenyl)-5-(3-fluoro-4-phenylphenyl)furo[2,3-d]pyrimidine 501694-02-6P, 4-Amino-5-(4-benzyloxy-3-fluorophenyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-03-7P, 4-Amino-5-[4-(ethylthio)phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-04-8P, 4-Amino-5-(3-chloro-4-fluorophenyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-05-9P, 4-Amino-6-(3,4-dichlorophenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-06-0P, 4-Amino-6-(4-methoxyphenyl)-5-(2-phenylethyn-1-yl)furo[2,3-d]pyrimidine 501694-07-1P, 4-Amino-5-(4-methoxyphenyl)-6-(2-methylphenyl)furo[2,3-d]pyrimidine 501694-08-2P, 4-Amino-6-(2-fluorophenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-09-3P, 4-Amino-6-(3-acetamidophenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-10-6P, 4-Amino-5-(4-methoxyphenyl)-6-(3-pyridyl)furo[2,3-d]pyrimidine 501694-11-7P, 4-Amino-5-(2-butylethyn-1-yl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-12-8P, 4-Amino-5-[2-(3-methylbutyl)ethyn-1-yl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-13-9P, 4-Amino-5-[2-(tert-butyl)ethyn-1-yl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-14-0P, 4-Amino-5-[4-(hydroxymethyl)phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-15-1P, 4-Amino-5-(4-biphenylyl)-6-(2-methoxyphenyl)furo[2,3-d]pyrimidine 501694-16-2P, 4-Amino-6-(2-methoxyphenyl)-5-[4-(methylthio)phenyl]furo[2,3-d]pyrimidine

501694-17-3P, 4-Amino-5-(4-methoxyphenyl)-6-(2-phenylethyn-1-yl)furo[2,3-d]pyrimidine 501694-18-4P, 4-Amino-6-(2-butylethyn-1-yl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-19-5P, 4-Amino-6-(2-biphenylyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-20-8P, 4-Amino-6-(3-biphenylyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-21-9P, 4-Amino-6-[4-(2-carboxyethyl)phenyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-22-0P, 4-Amino-5-(4-methoxyphenyl)-6-[4-(methylsulfonyl)phenyl]furo[2,3-d]pyrimidine 501694-23-1P, 4-Amino-6-(4-carboxyphenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-24-2P, 4-Amino-5-(4-methoxyphenyl)-6-[(4-chlorophenyl)-hydroxymethyl]furo[2,3-d]pyrimidine 501694-25-3P, 4-Amino-5-(4-isopropylphenyl)-6-(2-methoxyphenyl)furo[2,3-d]pyrimidine 501694-26-4P, 4-Amino-5-[4-(cyclopentyloxy)phenyl]-6-(2-methoxyphenyl)furo[2,3-d]pyrimidine 501694-27-5P, 4-Amino-5-[4-(isopropyloxy)phenyl]-6-(2-methoxyphenyl)furo[2,3-d]pyrimidine 501694-28-6P, 4-Benzyloxycarbonylamino-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-29-7P, 4-Amino-5-(4-methoxyphenyl)-6-(2-phenylethen-1-yl)furo[2,3-d]pyrimidine 501694-30-0P, 4-Amino-5-(4-methoxyphenyl)-6-(2-phenylethyl)furo[2,3-d]pyrimidine 501694-31-1P, 4-Amino-5-(4-methoxyphenyl)-6-[4-(morpholinocarbonyl)phenyl]furo[2,3-d]pyrimidine 501694-32-2P, 4-Amino-5-(4-methoxyphenyl)-6-[4-(methylcarbamoyl)phenyl]furo[2,3-d]pyrimidine 501694-33-3P, 4-Amino-5-(4-methoxyphenyl)-6-[4-[[2-(4-imidazolyl)ethyl]carbamoyl]phenyl]furo[2,3-d]pyrimidine 501694-34-4P, 5,6-Bis(4-methoxyphenyl)-3,4-dihydro-4-imino-3-methylfuro[2,3-d]pyrimidine 501694-35-5P, 5,6-Bis(4-methoxyphenyl)-4-(methylamino)furo[2,3-d]pyrimidine 501694-36-6P, 4-Amino-5-(4-methoxyphenyl)-6-[4-[(2-dimethylaminoethyl)carbamoyl]phenyl]furo[2,3-d]pyrimidine 501694-37-7P, 4-Amino-6-(1-hexen-1-yl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-38-8P, 4-Amino-6-hexyl-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-39-9P, 4-Amino-5-(2,4-dimethoxyphenyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-40-2P, 4-Amino-5-(4-methoxyphenyl)-6-(2-methoxypyridin-5-yl)furo[2,3-d]pyrimidine 501694-41-3P, 4-Amino-6-[4-(dimethylamino)phenyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-42-4P, 4-Amino-6-(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-43-5P, 4-Amino-6-(4-methoxyphenyl)-5-(2-methoxypyridin-5-yl)furo[2,3-d]pyrimidine 501694-44-6P, 4-Amino-6-[(3-chlorophenyl)oxymethyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-45-7P, 4-Amino-6-[(4-fluorophenyl)oxymethyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-46-8P, 4-Amino-5-(4-methoxyphenyl)-6-[(hydroxy)(phenyl)methyl]furo[2,3-d]pyrimidine 501694-47-9P, 4-Amino-6-(3-carbamoylphenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-48-0P, 4-Amino-6-[3-(dimethylcarbamoyl)phenyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-49-1P, 4-Amino-6-(1-methylindol-5-yl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-50-4P, 4-Amino-6-[2-(hydroxymethyl)phenyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-51-5P, 4-Amino-6-(3-aminophenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-52-6P, 4-Amino-6-carboxy-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-53-7P, 4-Amino-6-(2-carboxyphenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-54-8P, 4-Amino-6-(3-methoxycarbonylphenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-55-9P, 4-Amino-6-(4-methoxyphenyl)-5-(1-methylindol-5-yl)furo[2,3-d]pyrimidine 501694-56-0P, 4-Amino-6-(3-carboxyphenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-57-1P, 4-Amino-5-(4-methoxyphenyl)-6-[3-[[2-(4-imidazolyl)ethyl]carbamoyl]phenyl]furo[2,3-d]pyrimidine 501694-58-2P, 4-Amino-5-(4-methoxyphenyl)-6-[3-[(4-methylpiperazin-1-yl)carbonyl]phenyl]furo[2,3-d]pyrimidine 501694-59-3P,

4-Amino-5-(4-methoxyphenyl)-6-[3-[(2-dimethylaminoethyl)carbamoyl]phenyl]furo[2,3-d]pyrimidine 501694-60-6P, 4-Amino-6-[(2-cyanophenyl)oxymethyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-61-7P, 4-Amino-6-[(2-fluorophenyl)oxymethyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-62-8P, 4-Amino-5-(4-methoxyphenyl)-6-[3-[(4-pyridyl)carbamoyl]phenyl]furo[2,3-d]pyrimidine 501694-63-9P, 4-Amino-6-(2-carbamoylphenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-64-0P, 4-Amino-6-(4-carboxy-2-methoxyphenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-65-1P, 4-Amino-5-(4-methoxyphenyl)-6-[3-[(3-pyridyl)carbamoyl]phenyl]furo[2,3-d]pyrimidine 501694-66-2P, 6-[(3-Acetamidophenyl)oxymethyl]-4-amino-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-67-3P, 4-Amino-6-[(3-cyanophenyl)oxymethyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-68-4P, 4-Amino-6-[3-methoxycarbonyl-4-(methylamino)phenyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-69-5P, 4-Amino-5-(4-methoxyphenyl)-6-(4-methylamino-3-carboxyphenyl)furo[2,3-d]pyrimidine hydrochloride 501694-70-8P, 4-Amino-6-(4-methoxyphenyl)-5-[4-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine 501694-71-9P, 4-Amino-5-(4-methoxyphenyl)-6-[(3-methylindazol-5-yl)carbamoyl]furo[2,3-d]pyrimidine 501694-72-0P, 4-Amino-6-[[1,2-bis(ethoxycarbonyl)hydrazino]methyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-73-1P, 4-Amino-5-[4-(diethylamino)phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-74-2P, 4-Amino-5-(4-methoxyphenyl)-6-(phenylcarbamoyl)furo[2,3-d]pyrimidine 501694-75-3P, 4-Amino-6-[[5-amino-3-methylindazol-1-yl]carbonyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-76-4P, 4-Amino-5-(4-methoxyphenyl)-6-(1-pyrrolidinocarbonyl)furo[2,3-d]pyrimidine 501694-77-5P, 4-Amino-5-(4-methoxyphenyl)-6-[dicyclohexylcarbamoyl]furo[2,3-d]pyrimidine 501694-78-6P, 4-Amino-5-(4-methoxyphenyl)-6-(isopropylcarbamoyl)furo[2,3-d]pyrimidine 501694-79-7P, 4-Amino-5-(4-methoxyphenyl)-6-[(2-dimethylaminoethyl)carbamoyl]furo[2,3-d]pyrimidine 501694-80-0P, 4-Amino-6-(4-methoxyphenyl)-5-[4-(1-pyrrolidino)phenyl]furo[2,3-d]pyrimidine 501694-81-1P, 4-Amino-6-(5-indolyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-82-2P, 4-Amino-5-(4-methoxyphenyl)-6-[[2-(phenylamino)ethyl]oxycarbonyl]furo[2,3-d]pyrimidine 501694-83-3P, 4-Amino-6-[(3-hydroxypiperazin-1-yl)carbonyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-84-4P, 4-Amino-5-(4-methoxyphenyl)-6-[(2-cyanoethyl)(phenyl)carbamoyl]furo[2,3-d]pyrimidine 501694-85-5P, 4-Amino-5-(4-biphenylyl)-6-(3-carbamoylphenyl)furo[2,3-d]pyrimidine 501694-86-6P, 6-(3-Acetamidophenyl)-4-amino-5-(4-biphenylyl)furo[2,3-d]pyrimidine 501694-87-7P, 4-Amino-5-(4-methoxyphenyl)-6-[[(methoxycarbonyl)methyl](phenyl)carbamoyl]furo[2,3-d]pyrimidine 501694-88-8P, 4-Amino-6-(3-carbamoyl-4-chlorophenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-89-9P, 4-Amino-6-(3-aminophenyl)-5-(4-biphenylyl)furo[2,3-d]pyrimidine 501694-90-2P, 4-Amino-6-[3-(aminomethyl)phenyl]-5-(4-biphenylyl)furo[2,3-d]pyrimidine 501694-91-3P, 4-Amino-5-(4-biphenylyl)-6-[4-(dimethylamino)phenyl]furo[2,3-d]pyrimidine 501694-92-4P, 4-Amino-6-[[2-(tert-butoxycarbonylamino)ethyl](phenyl)carbamoyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-93-5P, 4-Amino-5-(4-methoxyphenyl)-6-[(carboxymethyl)(phenyl)carbamoyl]furo[2,3-d]pyrimidine 501694-94-6P, 4-Amino-6-carbamoyl-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-95-7P, 4-Amino-5-(4-methoxyphenyl)-6-[3-[(2-morpholinoethyl)sulfonylamino]phenyl]furo[2,3-d]pyrimidine 501694-96-8P, 4-Amino-5-(4-methoxyphenyl)-6-(2-methylbenzothiazol-5-yl)furo[2,3-

d]pyrimidine 501694-97-9P, 4-Amino-6-(6-indolyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-98-0P, 4-Amino-6-(3-carbamoyl-4-fluorophenyl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501694-99-1P, 4-Amino-5-(4-biphenylyl)-6-(3-carbamoyl-4-fluorophenyl)furo[2,3-d]pyrimidine 501695-00-7P, 4-Amino-6-[(4-hydroxypiperazin-1-yl)carbonyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-01-8P, 4-Amino-6-[4-amino-3-(methylcarbamoyl)phenyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-02-9P, 4-Amino-6-[(carbamoylmethyl)(phenyl)carbamoyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-03-0P, 4-Amino-6-[[2-(aminocarbonylamino)ethyl](phenyl)carbamoyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-04-1P, 4-Amino-6-(2-amino-1,3,4-oxadiazol-5-yl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-05-2P, 4-Amino-6-[4-(ethoxycarbonyl)thiazol-2-yl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-06-3P, 4-Amino-6-[4-(4-fluorophenyl)-5-methylthiazol-2-yl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-07-4P, 4-Amino-6-(5-indolyl)-5-[4-(3-pyridyl)phenyl]furo[2,3-d]pyrimidine 501695-08-5P, 4-Amino-6-(2-imidazolin-2-yl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-09-6P, 4-Amino-6-[2-(phenylamino)-1,3,4-oxadiazol-5-yl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-10-9P, 4-Amino-6-(8H-indeno[1,2-d]thiazol-2-yl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-11-0P, 4-Amino-5-(4-methoxyphenyl)-6-(4-methylthiazol-2-yl)furo[2,3-d]pyrimidine 501695-12-1P, 4-Amino-6-[3-[[2-(dimethylamino)ethyl]aminocarbonylamino]phenyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-13-2P, 4-Amino-5-(4-biphenylyl)-6-[3-[[[[2-(dimethylamino)ethyl]amino]carbonyl]amino]phenyl]furo[2,3-d]pyrimidine 501695-14-3P, 4-Amino-5-(4-biphenylyl)-6-[3-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine 501695-15-4P, 4-Amino-5-(4-methoxyphenyl)-6-[4-(methylcarbamoyl)thiazol-2-yl]furo[2,3-d]pyrimidine 501695-16-5P, 4-Amino-5-[4-(3-fluorophenyl)phenyl]-6-[3-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine 501695-17-6P, 4-Amino-5-(4-methoxyphenyl)-6-[4-(phenylcarbamoyl)thiazol-2-yl]furo[2,3-d]pyrimidine 501695-18-7P, 4-Amino-6-(1-benzyl-4,5-dihydro-1H-imidazol-2-yl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-19-8P, 4-Amino-5-(4-methoxyphenyl)-6-(3-sulfamoylphenyl)furo[2,3-d]pyrimidine 501695-20-1P, 4-Amino-5-(4-biphenylyl)-6-(3-sulfamoylphenyl)furo[2,3-d]pyrimidine 501695-21-2P, 4-Amino-5-(4-methoxyphenyl)-6-(1,3,4-oxadiazol-2-yl)furo[2,3-d]pyrimidine 501695-22-3P, 4-Amino-5-(4-methoxyphenyl)-6-(5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazol-3-yl)furo[2,3-d]pyrimidine 501695-23-4P, 4-Amino-6-(4-carboxythiazol-2-yl)-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-24-5P, 4-Amino-6-[3-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine 501695-25-6P, 4-Amino-5-(4-methoxyphenyl)-6-[(2-phenylethyl)carbamoyl]furo[2,3-d]pyrimidine 501695-26-7P, 4-Amino-6-[(3-fluorophenyl)carbamoyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-27-8P, 4-Amino-6-[(4-chlorophenyl)carbamoyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-28-9P, 4-Amino-5-(4-methoxyphenyl)-6-[(4-methoxyphenyl)carbamoyl]furo[2,3-d]pyrimidine 501695-29-0P, 4-Amino-6-[(2-benzimidazolyl)carbamoyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-30-3P, 4-Amino-5-[4-(2,3-difluorophenyl)phenyl]-6-[4-fluoro-3-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine 501695-31-4P, 4-Amino-6-[(2-hydroxyphenyl)carbamoyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-32-5P, 4-Amino-6-[4-fluoro-3-(methylsulfonylamino)phenyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-33-6P, 4-Amino-6-[(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)carbonyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-34-7P, 4-Amino-6-[(2-carbamoylphenyl)carbamoyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-35-8P, 4-Amino-6-[4-fluoro-3-

(methylsulfonylamino)phenyl]-5-[4-(3-thienyl)phenyl]furo[2,3-d]pyrimidine 501695-36-9P, 4-Amino-6-[3-(aminocarbonylamino)phenyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-37-0P, 4-Amino-6-[3-(aminocarbonylamino)phenyl]-5-(4-biphenylyl)furo[2,3-d]pyrimidine 501695-38-1P, 4-Amino-6-[(3-cyanophenyl)carbamoyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-39-2P, 4-Amino-5-(4-methoxyphenyl)-6-[(3-pyridyl)carbamoyl]furo[2,3-d]pyrimidine 501695-40-5P 501695-41-6P, 4-Amino-6-[(3,5-dimethoxyphenyl)carbamoyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-42-7P, 4-Amino-5-(4-biphenylyl)-6-[4-methoxy-3-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine 501695-43-8P , 4-Amino-5-(4-biphenylyl)-6-[3-[[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]furo[2,3-d]pyrimidine 501695-44-9P, 4-Amino-5-(4-biphenylyl)-6-[4-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine 501695-45-0P, 4-Amino-5-(4-biphenylyl)-6-[4-(aminocarbonylamino)phenyl]furo[2,3-d]pyrimidine 501695-46-1P, 4-Amino-5-(4-biphenylyl)-6-[3-[(4-pyridylcarbonyl)amino]phenyl]furo[2,3-d]pyrimidine 501695-47-2P, 4-Amino-5-(4-methoxyphenyl)-6-[4-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine 501695-48-3P, 4-Amino-6-[4-(aminocarbonylamino)phenyl]-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-49-4P, 4-Amino-6-(5-benzotriazolyl)-5-(4-biphenylyl)furo[2,3-d]pyrimidine 501695-50-7P, 4-Amino-5-(4-biphenylyl)-6-[3-(p-toluenesulfonylamino)phenyl]furo[2,3-d]pyrimidine 501695-51-8P, 4-Amino-6-(5-benzimidazolyl)-5-(4-biphenylyl)furo[2,3-d]pyrimidine 501695-52-9P, 4-Amino-5-(4-biphenylyl)-6-(4-sulfamoylphenyl)furo[2,3-d]pyrimidine 501695-53-0P, 4-Amino-5-(4-biphenylyl)-6-[3-(methylsulfonyl)phenyl]furo[2,3-d]pyrimidine 501695-54-1P, 4-Amino-6-[4-fluoro-3-(methylsulfonylamino)phenyl]-5-[4-(2-pyridyl)phenyl]furo[2,3-d]pyrimidine 501695-55-2P, 4-Amino-5-(4-biphenylyl)-6-[4-[(dimethylamino)sulfonylamino]phenyl]furo[2,3-d]pyrimidine 501695-56-3P, 4-Amino-5-(4-biphenylyl)-6-[4-[(1-iminoethyl)amino]phenyl]furo[2,3-d]pyrimidine 501695-57-4P, 4-Amino-5-[4-(4-tert-butylphenyl)phenyl]-6-(3-sulfamoylphenyl)furo[2,3-d]pyrimidine 501695-58-5P, 4-Amino-5-(4-biphenylyl)-6-[3-[(dimethylamino)sulfonylamino]phenyl]furo[2,3-d]pyrimidine 501695-59-6P, 4-Amino-5-[4-(2-pyridyl)phenyl]-6-(3-sulfamoylphenyl)furo[2,3-d]pyrimidine 501695-60-9P, 4-Amino-5-[4-(3-pyridyl)phenyl]-6-(3-sulfamoylphenyl)furo[2,3-d]pyrimidine 501695-61-0P, 4-Amino-5-(4-biphenylyl)-6-(4-cyanophenyl)furo[2,3-d]pyrimidine 501695-62-1P, 4-Amino-5-(4-biphenylyl)-6-[4-(tetrazol-5-yl)phenyl]furo[2,3-d]pyrimidine hydrochloride 501695-63-2P, 4-Amino-5-(4-biphenylyl)-6-[3-(tetrazol-5-yl)phenyl]furo[2,3-d]pyrimidine 501695-64-3P, 4-Amino-5-[4-(1-naphthyl)phenyl]-6-(3-sulfamoylphenyl)furo[2,3-d]pyrimidine 501695-65-4P, 4-Amino-5-[4-[4-(ethylsulfonyl)phenyl]phenyl]-6-(3-sulfamoylphenyl)furo[2,3-d]pyrimidine 501695-66-5P, 4-Amino-5,6-bis(4-methoxyphenyl)-2-(ethoxycarbonyl)furo[2,3-d]pyrimidine 501695-67-6P, 4-Amino-5-[4-[4,6-bis(trifluoromethyl)phenyl]phenyl]-6-(3-sulfamoylphenyl)furo[2,3-d]pyrimidine 501695-68-7P, 4-Amino-5-[4-(2-fluorobiphenyl-4-yl)phenyl]-6-(3-sulfamoylphenyl)furo[2,3-d]pyrimidine 501695-69-8P, 4-Amino-5,6-bis(4-methoxyphenyl)-2-carbamoylfuro[2,3-d]pyrimidine 501695-70-1P, 4-Amino-5-[4-[[[(4-chlorophenyl)amino]carbonyl]amino]phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-71-2P, 4-Amino-5-(4-methoxyphenyl)-6-[4-(tetrazol-5-yl)phenyl]furo[2,3-d]pyrimidine hydrochloride 501695-72-3P, 4-Amino-5-(4-methoxyphenyl)-6-[3-(tetrazol-5-yl)phenyl]furo[2,3-d]pyrimidine hydrochloride 501695-73-4P,

4-Amino-5-[4-[(3-fluorobenzoyl)amino]phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-74-5P, 4-Amino-5-[4-[(2-fluorobenzoyl)amino]phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-75-6P, 4-Amino-5,6-bis(4-methoxyphenyl)-2-methylfuro[2,3-d]pyrimidine 501695-76-7P, 4-Amino-5-[4-[[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-2-(methylamino)furo[2,3-d]pyrimidine 501695-77-8P, 4-Amino-5-[4-[(2-naphthylsulfonyl)amino]phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-78-9P, 4-Amino-5-[4-(3-acetamidophenyl)phenyl]-6-(3-sulfamoylphenyl)furo[2,3-d]pyrimidine 501695-79-0P, 4-Amino-5-[4-(aminocarbonylamino)phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-80-3P, 4-Amino-6-(4-methoxyphenyl)-5-[4-(phenylaminocarbonylamino)phenyl]furo[2,3-d]pyrimidine 501695-81-4P, 4-Amino-5-[4-(cyclohexylaminocarbonylamino)phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-82-5P, 4-Amino-5-[4-(butylaminocarbonylamino)phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-83-6P, 4-Amino-5-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]aminocarbonylamino]methyl]phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-84-7P, 4-Amino-5-[3-[[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-85-8P, 4-Amino-5-[4-(aminomethyl)phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-86-9P, 4-Amino-5-(3-aminophenyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine 501695-87-0P, 4-Amino-5-[4-[[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-6-(3-sulfamoylphenyl)furo[2,3-d]pyrimidine 501695-88-1P, 4-Amino-6-(4-cyanophenyl)-5-[4-[[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]furo[2,3-d]pyrimidine 501695-89-2P, 4-Amino-5-[4-[(phenylaminothiocarbonyl)amino)phenyl]furo[2,3-d]pyrimidine 501695-90-5P, 5-(4-Nitrophenyl)-4-(phenylamino)furo[2,3-d]pyrimidine 501695-91-6P, 4-(Methylamino)-5-(4-nitrophenyl)furo[2,3-d]pyrimidine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of furo- and thienopyrimidines as TIE-2 and/or VEGFR-2 kinase inhibitors useful against hyperproliferative diseases)

IT 501695-83-6P, 4-Amino-5-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]aminocarbonylamino]methyl]phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of furo- and thienopyrimidines as TIE-2 and/or VEGFR-2 kinase inhibitors useful against hyperproliferative diseases)

RN 501695-83-6 HCAPLUS

CN Urea, N-[[4-[4-amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl]methyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 17 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:196948 HCAPLUS Full-text
DOCUMENT NUMBER: 138:221357
TITLE: Preparation of 2'-aminomethylbiphenyl-2-carboxamides as Kv1.5 potassium channel blockers
INVENTOR(S): Brendel, Joachim; Schmidt, Wolfgang; Below, Peter
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: U.S., 65 pp., Cont.-in-part of U.S. Ser. No. 675,674.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6531495	B1	20030311	US 2000-698078	20001030 <--
DE 19947457	A1	20010405	DE 1999-19947457	19991002 <--
US 20030171351	A1	20030911	US 2002-252385	20020924 <--
US 6686395	B2	20040203		
US 20040102513	A1	20040527	US 2003-691624	20031024 <--
US 7514582	B2	20090407		
US 20090192096	A1	20090730	US 2009-419069	20090406 <--

PRIORITY APPLN. INFO.:
DE 1999-19947457 A 19991002 <--
US 2000-675674 A2 20000929 <--
US 2000-698078 A3 20001030 <--
US 2002-252385 A3 20020924 <--
US 2003-691624 A1 20031024 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 138:221357
ED Entered STN: 12 Mar 2003
GI



I

AB Title compds. [I; R1 = CO2R9, SO2R10, COR11, CONR12R13, CSNR12R13; R9, R10, R11, R12 = CmH2mR14; m = 0-4; R14 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; m ≠ 0 if R14 = (cyclo)alkoxy, SO2Me, or OPh; R2 and R13 = independently H, alkyl, or CF3; R3 = CnH2nR16 or CHR18R19; n = 0-4; n ≠ 0 if R16 = OR17, SO2Me; R17 = H, (cyclo)alkyl, (un)substituted Ph, or pyridyl, R16 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; R18 = H or CpH2pR16; p = 0-3; R19 = CO2H, CONH2, CH2OH, etc.; R4 = H, alkyl, or CF3; or NR3R4 = heterocyclyl; R5, R6, R7, R8 = independently H, halo, CF3, NO2, cyano, etc.; R30 and R31 = independently H or alkyl; CR30R31 = cyclopropyl; and pharmaceutically acceptable salts thereof] were prepared Thus, 2'-aminomethylbiphenyl-2-(N-phenethyl)carboxamide (preparation given) and NaHCO3 in dioxane and H2O were treated dropwise with 4-trifluoromethylbenzyl-N-succinimide carbonate (preparation given) in dioxane followed by 12 h stirring at room temperature to give 2'-(4-trifluoromethylbenzyloxycarbonylaminomethyl)-biphenyl-2-(N-phenethyl)carboxamide. Tested I inhibited Kv1.5 potassium flow with IC50 = 0.2 μM - 11.3 μM. Thus, I are especially suitable as antiarrhythmic active agents, in particular for the treatment and prophylaxis of atrial arrhythmia, e.g. atrial fibrillation (AF) or atrial flutter (no data).

IC ICM A61K031-44
ICS C07D213-55; C07D213-56

INCL 514357000; 546264000; 546265000; 546266000; 546267000

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 34

IT 332378-34-4P 332378-35-5P 332378-36-6P 332378-37-7P 332378-38-8P
332378-40-2P 332378-41-3P 332378-42-4P 332378-43-5P 332378-44-6P
332378-45-7P 332378-46-8P 332378-47-9P 332378-48-0P 332378-49-1P
332378-50-4P 332378-51-5P 332378-52-6P 332378-53-7P 332378-54-8P
332378-55-9P 332378-56-0P 332378-57-1P 332378-58-2P 332378-59-3P
332378-60-6P 332378-61-7P 332378-62-8P 332378-63-9P 332378-64-0P
332378-65-1P 332378-66-2P 332378-67-3P 332378-68-4P 332378-69-5P
332378-70-8P 332378-71-9P 332378-72-0P 332378-73-1P 332378-74-2P
332378-75-3P 332378-76-4P 332378-77-5P 332378-78-6P 332378-79-7P
332378-80-0P 332378-81-1P 332378-82-2P 498577-29-0P 498577-30-3P
498577-31-4P 498577-32-5P 498577-33-6P 498577-34-7P 498577-35-8P
498577-36-9P 498577-37-0P 498577-38-1P 498577-39-2P 498577-40-5P
498577-41-6P 498577-42-7P 498577-43-8P 498577-44-9P 498577-45-0P
498577-46-1P 498577-48-3P 498577-49-4P 498577-50-7P 498577-51-8P
498577-52-9P 498577-53-0P 498577-54-1P 498577-55-2P 498577-56-3P
498577-57-4P 498577-58-5P 498577-59-6P 498577-60-9P 498577-61-0P
498577-62-1P 498577-63-2P 498577-64-3P 498577-65-4P 498577-66-5P
498577-67-6P 498577-68-7P 498577-69-8P 498577-70-1P 498577-71-2P
498577-72-3P 498577-73-4P 498577-74-5P 498577-75-6P 498577-76-7P
498577-77-8P 498577-78-9P 498577-79-0P 498577-80-3P 498577-81-4P
498577-82-5P 498577-83-6P 498577-84-7P 498577-85-8P 498577-86-9P
498577-87-0P 498577-88-1P 498577-89-2P 498577-90-5P 498577-91-6P

498577-92-7P 498577-93-8P 498577-94-9P 498577-95-0P 498577-96-1P
498577-97-2P 498577-98-3P 498577-99-4P 498578-00-0P 498578-01-1P
498578-02-2P 498578-03-3P 498578-04-4P 498578-05-5P
498578-06-6P 498578-07-7P 498578-08-8P
498578-09-9P 498578-10-2P 498578-11-3P
498578-12-4P 498578-13-5P 498578-14-6P
498578-15-7P 498578-16-8P 498578-17-9P
498578-18-0P 498578-19-1P 498578-20-4P
498578-21-5P 498578-22-6P 498578-23-7P 498578-24-8P
498578-25-9P 498578-26-0P 498578-27-1P 498578-28-2P 498578-29-3P
498578-30-6P 498578-31-7P 498578-32-8P 498578-33-9P 498578-34-0P
498578-35-1P 498578-36-2P 498578-37-3P 498578-38-4P 498578-39-5P
498578-40-8P 498578-41-9P 498578-42-0P 498578-44-2P 498578-45-3P
498578-46-4P 498578-47-5P 498578-48-6P 498578-49-7P 498578-52-2P
498578-53-3P 498578-55-5P 498578-57-7P 498578-58-8P 498578-59-9P
498578-60-2P 498578-62-4P 498578-63-5P 498578-65-7P 498578-66-8P
498578-68-0P 498578-70-4P 498578-71-5P 498578-72-6P 498578-74-8P
498578-76-0P 498578-77-1P 498578-80-6P 498578-81-7P 498578-82-8P
498578-83-9P 498578-84-0P 498578-85-1P 498578-87-3P 498578-89-5P
498578-92-0P 498578-95-3P 498578-96-4P 498578-98-6P 498578-99-7P
498579-00-3P 498579-01-4P 498579-04-7P 498579-07-0P 498579-09-2P
498579-13-8P 498579-15-0P 498579-18-3P 498579-21-8P 498579-43-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiarrhythmic; preparation of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)

IT 498578-05-5P 498578-07-7P 498578-08-8P
498578-09-9P 498578-10-2P 498578-11-3P
498578-12-4P 498578-13-5P 498578-14-6P
498578-15-7P 498578-16-8P 498578-17-9P
498578-18-0P 498578-19-1P 498578-21-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiarrhythmic; preparation of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)

RN 498578-05-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 498578-07-7 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(2-pyridinylmethyl)-2'-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-08-8 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-2'-[[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-09-9 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 498578-10-2 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(4-chlorophenyl)amino]carbonyl]amino]methyl]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 498578-11-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-[(3,4,5-trimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 498578-12-4 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-methoxyphenyl)ethyl]-2'-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-13-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-14-6 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-15-7 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(4-chlorophenyl)amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 498578-16-8 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-17-9 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 498578-18-0 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'-[[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-19-1 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-(2-phenoxyethyl)- (CA INDEX NAME)



RN 498578-21-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2'-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 18 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:193044 HCAPLUS Full-text
DOCUMENT NUMBER: 138:187521
TITLE: Preparation of 2'-aminomethylbiphenyl-2-carboxamides as Kv1.5 potassium channel blockers.
INVENTOR(S): Brendel, Joachim; Schmidt, Wolfgang; Below, Peter
PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025189	A1	20010412	WO 2000-EP9151	20000919 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19947457	A1	20010405	DE 1999-19947457	19991002 <--
CA 2385859	A1	20010412	CA 2000-2385859	20000919 <--
CA 2385859	C	20091124		
BR 2000014465	A	20020611	BR 2000-14465	20000919 <--
EP 1222163	A1	20020717	EP 2000-967703	20000919 <--
EP 1222163	B1	20060712		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511363	T	20030325	JP 2001-528137	20000919 <--
HU 2002003505	A2	20030328	HU 2002-3505	20000919 <--
HU 2002003505	A3	20040128		
EE 200200160	A	20030415	EE 2002-160	20000919 <--
EE 5000	B1	20080415		

AU 766365	B2	20031016	AU 2000-77778		20000919	<--
NZ 518065	A	20040827	NZ 2000-518065		20000919	<--
RU 2252214	C2	20050520	RU 2002-111561		20000919	<--
IL 148870	A	20070515	IL 2000-148870		20000919	<--
SK 286756	B6	20090507	SK 2002-438		20000919	<--
MX 2002002691	A	20020730	MX 2002-2691		20020313	<--
NO 2002001398	A	20020531	NO 2002-1398		20020320	<--
NO 327709	B1	20090914				
HR 2002000264	A2	20040229	HR 2002-264		20020328	<--
HK 1048986	A1	20050729	HK 2003-101193		20030218	<--
PRIORITY APPLN. INFO.:			DE 1999-19947457	A	19991002	<--
			WO 2000-EP9151	W	20000919	<--

OTHER SOURCE(S): MARPAT 138:187521
ED Entered STN: 12 Mar 2003
GI



I

AB Title compds. [I; R1 = CO2R9, SO2R10, COR11, CONR12R13, CSNR12R13; R9, R10, R11, R12 = CmH2mR14; m = 0-4; R14 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; m ≠ 0 if R14 = (cyclo)alkoxy, SO2Me, or OPh; R2 and R13 = independently H, alkyl, or CF3; R3 = CnH2nR16 or CHR18R19; n = 0-4; n ≠ 0 if R16 = OR17, SO2Me; R17 = H, (cyclo)alkyl, (un)substituted Ph, or pyridyl, R16 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; R18 = H or CpH2pR16; p = 0-3; R19 = CO2H, CONH2, CH2OH, etc.; R4 = H, alkyl, or CF3; or NR3R4 = heterocyclyl; R5, R6, R7, R8 = independently H, halo, CF3, NO2, cyano, etc.; R30 and R31 = independently H or alkyl; CR30R31 = cyclopropyl; and pharmaceutically acceptable salts thereof] were prepared Thus, 2'-aminomethylbiphenyl-2-(N-phenethyl)carboxamide (preparation given) and NaHCO3 in dioxane and H2O were treated dropwise with 4-trifluoromethylbenzyl-N-succinimide carbonate (preparation given) in dioxane followed by 12 h stirring at room temperature to give 2'-(4-trifluoromethylbenzyloxycarbonylaminomethyl)-biphenyl-2-(N-phenethyl)carboxamide. Tested I inhibited Kv1.5 potassium flow with IC50 = 0.2 μM - 11.3 μM. Thus, I are especially suitable as antiarrhythmic active agents, in particular for the treatment and prophylaxis of atrial arrhythmia, e.g. atrial fibrillation (AF) or atrial flutter (no data).

IC ICM C07C271-22
ICS C07D213-40; C07C311-19; C07C311-06; C07C311-13; C07C233-11; C07C233-87; C07C235-38; C07C275-28; C07C275-24; C07C335-16; C07C335-12; C07D233-54; A61K031-165; A61P009-06

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 34

IT 332378-34-4P 332378-35-5P 332378-36-6P 332378-37-7P 332378-38-8P 332378-40-2P 332378-41-3P 332378-42-4P 332378-43-5P 332378-44-6P

332378-45-7P 332378-46-8P 332378-47-9P 332378-48-0P 332378-49-1P
332378-50-4P 332378-51-5P 332378-52-6P 332378-53-7P 332378-54-8P
332378-55-9P 332378-56-0P 332378-57-1P 332378-58-2P 332378-59-3P
332378-60-6P 332378-61-7P 332378-62-8P 332378-63-9P 332378-64-0P
332378-65-1P 332378-66-2P 332378-67-3P 332378-68-4P 332378-69-5P
332378-70-8P 332378-71-9P 332378-72-0P 332378-73-1P 332378-74-2P
332378-75-3P 332378-76-4P 332378-77-5P 332378-78-6P 332378-79-7P
332378-80-0P 332378-81-1P 332378-82-2P 498577-29-0P 498577-30-3P
498577-31-4P 498577-32-5P 498577-33-6P 498577-34-7P 498577-35-8P
498577-36-9P 498577-37-0P 498577-38-1P 498577-39-2P 498577-40-5P
498577-41-6P 498577-42-7P 498577-43-8P 498577-44-9P 498577-45-0P
498577-46-1P 498577-48-3P 498577-49-4P 498577-50-7P 498577-51-8P
498577-52-9P 498577-53-0P 498577-54-1P 498577-55-2P 498577-56-3P
498577-57-4P 498577-58-5P 498577-59-6P 498577-60-9P 498577-61-0P
498577-62-1P 498577-63-2P 498577-64-3P 498577-65-4P 498577-66-5P
498577-67-6P 498577-68-7P 498577-69-8P 498577-70-1P 498577-71-2P
498577-72-3P 498577-73-4P 498577-74-5P 498577-75-6P 498577-76-7P
498577-77-8P 498577-78-9P 498577-79-0P 498577-80-3P 498577-81-4P
498577-82-5P 498577-83-6P 498577-84-7P 498577-85-8P 498577-86-9P
498577-87-0P 498577-88-1P 498577-89-2P 498577-90-5P 498577-91-6P
498577-92-7P 498577-93-8P 498577-94-9P 498577-95-0P 498577-96-1P
498577-97-2P 498577-98-3P 498577-99-4P 498578-00-0P 498578-01-1P
498578-02-2P 498578-03-3P 498578-04-4P 498578-05-5P
498578-06-6P 498578-07-7P 498578-08-8P
498578-09-9P 498578-10-2P 498578-11-3P
498578-12-4P 498578-13-5P 498578-14-6P
498578-15-7P 498578-16-8P 498578-17-9P
498578-18-0P 498578-19-1P 498578-20-4P
498578-21-5P 498578-22-6P 498578-23-7P 498578-24-8P
498578-25-9P 498578-26-0P 498578-27-1P 498578-28-2P 498578-29-3P
498578-30-6P 498578-31-7P 498578-32-8P 498578-33-9P 498578-34-0P
498578-35-1P 498578-36-2P 498578-37-3P 498578-38-4P 498578-39-5P
498578-40-8P 498578-41-9P 498578-42-0P 498578-44-2P 498578-45-3P
498578-46-4P 498578-47-5P 498578-48-6P 498578-49-7P 498578-52-2P
498578-53-3P 498578-55-5P 498578-57-7P 498578-58-8P 498578-59-9P
498578-60-2P 498578-62-4P 498578-63-5P 498578-65-7P 498578-66-8P
498578-68-0P 498578-70-4P 498578-71-5P 498578-72-6P 498578-74-8P
498578-76-0P 498578-77-1P 498578-80-6P 498578-81-7P 498578-82-8P
498578-83-9P 498578-84-0P 498578-85-1P 498578-87-3P 498578-89-5P
498578-92-0P 498578-95-3P 498578-96-4P 498578-98-6P 498578-99-7P
498579-00-3P 498579-01-4P 498579-04-7P 498579-07-0P 498579-09-2P
498579-13-8P 498579-15-0P 498579-18-3P 498579-21-8P 498579-43-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiarrhythmic; preparation of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)

IT 498578-05-5P 498578-07-7P 498578-08-8P
498578-09-9P 498578-10-2P 498578-11-3P
498578-12-4P 498578-13-5P 498578-14-6P
498578-15-7P 498578-16-8P 498578-17-9P
498578-18-0P 498578-19-1P 498578-21-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiarrhythmic; preparation of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)

RN 498578-05-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (CA

INDEX NAME)



RN 498578-07-7 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(2-pyridinylmethyl)-2'-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-08-8 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-2'-[[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-09-9 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 498578-10-2 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(4-chlorophenyl)amino]carbonyl]amino]methyl]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 498578-11-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-[(3,4,5-trimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 498578-12-4 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-methoxyphenyl)ethyl]-2'-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-13-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-14-6 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-15-7 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(4-chlorophenyl)amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 498578-16-8 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-17-9 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 498578-18-0 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'-[[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-19-1 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-(2-phenoxyethyl)- (CA INDEX NAME)



RN 498578-21-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2'-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 19 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:151162 HCAPLUS Full-text
DOCUMENT NUMBER: 138:321211
TITLE: Design, Synthesis, and Biological Evaluation of C9- and C2-Substituted Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as New A2A and A3 Adenosine Receptor Antagonists
AUTHOR(S): Baraldi, Pier Giovanni; Fruttarolo, Francesca; Tabrizi, Mojgan Aghazadeh; Preti, Delia; Romagnoli, Romeo; El-Kashef, Hussein; Moorman, Allan; Varani, Katia; Gessi, Stefania; Merighi, Stefania; Borea, Pier Andrea
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche and Dipartimento di Medicina Clinica e Sperimentale-Sezione di Farmacologia, Universita di Ferrara, Ferrara, 44100, Italy
SOURCE: Journal of Medicinal Chemistry (2003), 46(7), 1229-1241
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:321211
ED Entered STN: 28 Feb 2003
GI



I

AB Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines such as I are prepared as selective adenosine A2a and A3 receptor antagonists. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines substituted at the 9-position retain receptor affinity but lose selectivity for the adenosine A2a and A3 receptors over other adenosine receptors. Replacement of the furan moiety present in the pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidine with a Ph or a substituted aromatic ring abolishes affinity at all the adenosine receptor subtypes, demonstrating that the furanyl ring is a necessary structural element to guarantee interaction with the adenosine receptor surface; replacement of the furan ring with an ortho-ethoxy-substituted aromatic ring did not enhance affinity. Introduction of a N-methylpiperazinomethyl or morpholinomethyl function at the 5' position of the furanyl ring of I or introduction of a methylsulfanyl moiety at the 9-position of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines yields inhibitors with improved water solubilities but reduced affinities for adenosine A2a and A3 receptors.

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT 512845-17-9P 512845-20-4P 512845-23-7P 512845-31-7P
512845-34-0P 512846-12-7P 512846-14-9P 512846-18-3P
512846-20-7P 512846-22-9P 512846-24-1P 512846-26-3P 512846-28-5P
512846-32-1P 512846-34-3P 512846-36-5P 512846-38-7P 512846-40-1P
512846-46-7P 512846-48-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and structure-activity relationships of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potential selective adenosine A2a and A3 receptor antagonists)

IT 512845-34-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and structure-activity relationships of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potential selective adenosine A2a and A3 receptor antagonists)

RN 512845-34-0 HCAPLUS
CN Acetamide, 2-[4-[5-amino-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-2-yl]phenoxy]-N-(4-iodophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 46 THERE ARE 46 CAPLUS RECORDS THAT CITE THIS RECORD (47 CITINGS)
REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 20 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:133223 HCAPLUS Full-text
DOCUMENT NUMBER: 138:169972
TITLE: Preparation of substituted N-naphthyl-N'-phenylureas and N-substituted naphthylacetamides as vanilloid receptor 1 (VR1) antagonists
INVENTOR(S): Yura, Takeshi; Mogi, Munet; Ikegami, Yuka; Masuda, Tsutoma; Kokubo, Toshio; Urbahns, Klaus; Lowinger, Timothy B.; Yoshida, Nagahiro; Freitag, Joachim; Meier, Heinrich; Wittka-Nopper, Reilinde; Marumo, Makiko; Shiroo, Masahiro; Tajimi, Masaomi; Takeshita, Keisuke; Moriwaki, Toshuda; Tsukimi, Yasuhiro
PATENT ASSIGNEE(S): Bayer AG, Germany
SOURCE: PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003014064	A1	20030220	WO 2002-EP8493	20020731 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2003055209	A	20030226	JP 2001-232503	20010731	<--
CA 2455754	A1	20030220	CA 2002-2455754	20020731	<--
AU 2002325381	A1	20030224	AU 2002-325381	20020731	<--
EP 1414788	A1	20040506	EP 2002-758413	20020731	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 2005501873	T	20050120	JP 2003-524319	20020731	<--
US 20040259875	A1	20041223	US 2004-485481	20040726	<--

PRIORITY APPLN. INFO.:

JP 2001-232503	A	20010731	<--
JP 2001-392310	A	20011225	<--
WO 2002-EP8493	W	20020731	<--

OTHER SOURCE(S): MARPAT 138:169972
ED Entered STN: 21 Feb 2003
GI



I

AB The title compds. R7Q(Y)C(O)NXR6 [X = (un)substituted Ph, cycloalkyl optionally fused by benzene, thienyl, quinolyl, etc.; Q = CH, N; R6, R7 = H, Me; Y = substituted 1-naphthyl] or their salts which have vanilloid receptor 1 (VR1) antagonistic activity, and therefore are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders, were prepared Thus, reacting 8-amino-5,7-dichloro-2-naphthol (preparation given) with 3-chlorophenyl isocyanate in 1,4-dioxane afforded 39% I which showed IC50 of ≤ 10 nM for VR1.

IC ICM C07C235-38
ICS C07C275-32; C07C275-34; C07C275-36; C07C275-38; C07C275-40; C07C275-42; C07C311-08; C07C311-47; C07C323-44; C07D209-88; C07D215-38; C07D235-10; C07D239-69; C07D261-14; C07D261-16; C07D263-10; C07D285-06; C07D295-135; C07D307-88

CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1

IT 199584-96-8P 199929-52-7P 391937-38-5P 497148-29-5P 497148-30-8P
497148-31-9P 497148-32-0P 497148-33-1P 497148-34-2P 497148-35-3P
497148-36-4P 497148-37-5P 497148-38-6P 497148-39-7P 497148-40-0P

497148-41-1P 497148-42-2P 497148-43-3P 497148-44-4P 497148-45-5P
497148-46-6P 497148-47-7P 497148-48-8P 497148-49-9P 497148-50-2P
497148-51-3P 497148-52-4P 497148-53-5P 497148-54-6P 497148-55-7P
497148-56-8P 497148-57-9P 497148-58-0P 497148-59-1P 497148-60-4P
497148-61-5P 497148-62-6P 497148-63-7P 497148-64-8P 497148-65-9P
497148-66-0P 497148-67-1P 497148-68-2P 497148-69-3P 497148-70-6P
497148-71-7P 497148-72-8P 497148-73-9P 497148-74-0P 497148-75-1P
497148-76-2P 497148-79-5P 497148-82-0P 497148-84-2P 497148-85-3P
497148-86-4P 497148-87-5P 497148-88-6P 497148-90-0P 497148-91-1P
497148-92-2P 497148-93-3P 497148-94-4P 497148-95-5P 497148-96-6P
497148-97-7P 497148-98-8P 497149-00-5P 497149-01-6P 497149-02-7P
497149-04-9P 497149-05-0P 497149-06-1P 497149-07-2P 497149-08-3P
497149-09-4P 497149-11-8P 497149-12-9P 497149-14-1P 497149-15-2P
497149-16-3P 497149-17-4P 497149-18-5P 497149-19-6P 497149-20-9P
497149-21-0P 497149-22-1P 497149-24-3P 497149-25-4P 497149-26-5P
497149-27-6P 497149-28-7P 497149-29-8P 497149-30-1P 497149-31-2P
497149-32-3P 497149-33-4P 497149-34-5P 497149-35-6P 497149-36-7P
497149-37-8P 497149-38-9P 497149-39-0P 497149-40-3P 497149-41-4P
497149-42-5P 497149-43-6P 497149-44-7P 497149-45-8P 497149-46-9P
497149-47-0P 497149-48-1P 497149-49-2P 497149-50-5P 497149-51-6P
497149-52-7P 497149-53-8P 497149-54-9P 497149-55-0P 497149-56-1P
497149-57-2P 497149-58-3P 497149-59-4P 497149-60-7P 497149-61-8P
497149-62-9P 497149-63-0P 497149-64-1P 497149-66-3P 497149-67-4P
497149-68-5P 497149-69-6P 497149-70-9P 497149-71-0P 497149-72-1P
497149-73-2P 497149-74-3P 497149-75-4P 497149-76-5P 497149-77-6P
497149-78-7P 497149-79-8P 497149-80-1P 497149-81-2P 497149-82-3P
497149-83-4P 497149-84-5P 497149-85-6P 497149-86-7P 497149-87-8P
497149-88-9P 497149-89-0P 497149-90-3P 497149-91-4P 497149-92-5P
497149-93-6P 497149-94-7P 497149-95-8P 497149-96-9P 497149-97-0P
497149-98-1P 497149-99-2P 497150-00-2P 497150-01-3P 497150-02-4P
497150-03-5P 497150-04-6P 497150-05-7P 497150-06-8P 497150-07-9P
497150-08-0P 497150-09-1P 497150-10-4P 497150-11-5P 497150-12-6P
497150-13-7P 497150-14-8P 497150-15-9P 497150-16-0P
497150-17-1P 497150-18-2P 497150-19-3P 497150-20-6P 497150-21-7P
497150-22-8P 497150-23-9P 497150-24-0P 497150-25-1P 497150-26-2P
497150-27-3P 497150-28-4P 497150-29-5P 497150-30-8P 497150-31-9P
497150-34-2P 497150-35-3P 497150-36-4P 497150-38-6P 497150-40-0P
497150-42-2P 497150-43-3P 497150-44-4P 497150-45-5P 497150-46-6P
497150-47-7P 497150-48-8P 497150-49-9P 497150-50-2P 497150-52-4P
497150-54-6P 497150-55-7P 497150-56-8P 497150-57-9P 497150-58-0P
497150-59-1P 497150-60-4P 497150-61-5P 497150-62-6P 497150-63-7P
497150-64-8P 497150-65-9P 497150-66-0P 497150-67-1P 497150-68-2P
497150-69-3P 497150-70-6P 497150-71-7P 497150-72-8P 497150-73-9P
497150-74-0P 497150-75-1P 497150-76-2P 497150-77-3P 497150-78-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted N-naphthyl-N'-phenylureas and N-substituted naphthylacetamides as vanilloid receptor 1 (VR1) antagonists)

IT 497150-14-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted N-naphthyl-N'-phenylureas and N-substituted naphthylacetamides as vanilloid receptor 1 (VR1) antagonists)

RN 497150-14-8 HCAPLUS

CN Urea, N-(2-chloro-7-hydroxy-1-naphthalenyl)-N'-[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 31 THERE ARE 31 CAPLUS RECORDS THAT CITE THIS RECORD (32 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 21 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:5963 HCAPLUS Full-text
DOCUMENT NUMBER: 138:73267
TITLE: Preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor inhibitors
INVENTOR(S): Vidal Juan, Bernat; Esteve Trias, Cristina; Segarra Matamoros, Victor; Ravina Rubira, Enrique; Fernandez Gonzalez, Franco; Loza Garcia, Maria Isabel; Sanz Carreras, Ferran
PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain
SOURCE: PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000694	A1	20030103	WO 2002-EP6727	20020618 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2193839	A1	20031101	ES 2001-1452	20010622 <--
ES 2193839	B1	20050216		
AU 2002350425	A1	20030108	AU 2002-350425	20020618 <--
EP 1409489	A1	20040421	EP 2002-780834	20020618 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534828	T	20041118	JP 2003-507097	20020618 <--

US 20050070558 A1 20050331 US 2004-481728 20041019 <--
PRIORITY APPLN. INFO.: ES 2001-1452 A 20010622 <--
WO 2002-EP6727 W 20020618 <--
OTHER SOURCE(S): MARPAT 138:73267
ED Entered STN: 05 Jan 2003
GI



I

AB The title compds. [I; R1, R2 = H, (CH2)nR7, (un)substituted alkyl (wherein n = 0-4; R7 = cycloalkyl, (un)substituted Ph, 3-7 membered (non)aromatic ring containing 1-4 heteroatoms and which is optionally fused to (hetero)aromatic ring); R3 = H, halo, NO2, etc.; R4, R5 = H, halo, alkyl, etc.; L1 = a direct bond, O, S, etc.; R6 = CONR10R11, SO2NR10R11, ON:CR12R13, aryl, etc.; R10, R11 = H, alkyl, cycloalkyl, etc.; R12, R13 = defined as R10 and R11, except that either or both of R12 and R13 can be an amino, alkylamino or dialkylamino] which have therapeutic potential as A2 adenosine receptor inhibitors (biol. data given), were prepared and formulated. Thus, coupling {4-[2-(5-nitro-2,6-dioxo-1,3-dipropyl-1,2,3,6-tetrahydropyrimidin-4- yl)vinyl]phenoxy}acetic acid (preparation given) with aniline (yield 42%) followed by reductive cyclization of the resulting intermediate mediated by triethylphosphite (46%) afforded I [R1, R2 = Pr; R3-R5 = H; L1 = OCH2; R6 = CONHPh].

IC ICM C07D487-04
ICS C07D519-00; A61K031-505; A61P011-06; A61P011-08; A61P037-08; A61P001-12; A61P025-16; A61P003-10; A61P037-00; A61P007-06; A61P043-00; A61P017-06; A61P017-00
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT

480991-19-3P	480991-20-6P	480991-21-7P	480991-22-8P	
480991-23-9P	480991-24-0P	480991-25-1P		
480991-26-2P	480991-27-3P	480991-28-4P	480991-29-5P	480991-30-8P
480991-31-9P	480991-32-0P	480991-33-1P	480991-34-2P	480991-35-3P
480991-36-4P	480991-37-5P	480991-38-6P	480991-39-7P	480991-40-0P
480991-41-1P	480991-42-2P	480991-43-3P	480991-44-4P	480991-45-5P
480991-46-6P	480991-47-7P	480991-48-8P	480991-49-9P	480991-51-3P
480991-52-4P	480991-53-5P	480991-54-6P	480991-55-7P	480991-56-8P
480991-57-9P	480991-58-0P	480991-59-1P	480991-62-6P	
480991-64-8P	480991-65-9P	480991-66-0P	480991-67-1P	480991-69-3P
480991-70-6P	480991-71-7P	480991-72-8P	480991-73-9P	
480991-74-0P	480991-75-1P	480991-76-2P	480991-77-3P	
480991-78-4P	480991-79-5P	480991-80-8P	480991-81-9P	480991-82-0P
480991-83-1P	480991-84-2P	480991-85-3P	480991-86-4P	480991-87-5P
480991-88-6P	480991-89-7P	480991-90-0P	480991-91-1P	480991-92-2P
480991-93-3P	480991-94-4P	480991-95-5P	480991-96-6P	480991-97-7P
480991-98-8P	480991-99-9P	480992-00-5P	480992-01-6P	480992-02-7P
480992-03-8P	480992-04-9P	480992-05-0P	480992-06-1P	480992-07-2P
480992-08-3P	480992-09-4P	480992-10-7P	480992-11-8P	
480992-12-9P	480992-13-0P	480992-14-1P	480992-15-2P	480992-16-3P
480992-17-4P	480992-18-5P	480992-19-6P	480992-20-9P	480992-21-0P
480992-22-1P	480992-23-2P	480992-24-3P		
480992-25-4P	480992-26-5P	480992-27-6P		

480992-28-7P 480992-29-8P 480992-30-1P 480992-31-2P 480992-32-3P
480992-33-4P 480992-34-5P 480992-35-6P 480992-36-7P 480992-37-8P
480992-38-9P 480992-39-0P 480992-40-3P 480992-41-4P
480992-42-5P 480992-43-6P 480992-44-7P
480992-45-8P 480992-46-9P 480992-47-0P 480992-48-1P
480992-49-2P 480992-50-5P 480992-51-6P
480992-52-7P 480992-53-8P 480992-54-9P 480992-55-0P
480992-56-1P 480992-57-2P 480992-58-3P
480992-59-4P 480992-60-7P 480992-61-8P
480992-62-9P 480992-63-0P 480992-64-1P 480992-65-2P
480992-66-3P 480992-67-4P 480992-68-5P
480992-69-6P 480992-70-9P 480992-71-0P 480992-72-1P
480992-73-2P 480992-74-3P 480992-75-4P 480992-76-5P
480992-77-6P 480992-78-7P 480992-79-8P 480992-80-1P
480992-81-2P 480992-82-3P 480992-83-4P 480992-84-5P
480992-85-6P 480992-86-7P 480992-87-8P 480992-88-9P 480992-89-0P
480992-90-3P 480992-91-4P 480992-92-5P 480992-93-6P
480992-94-7P 480992-95-8P 480992-96-9P 480992-97-0P
480992-98-1P 480992-99-2P 480993-00-8P
480993-01-9P 480993-02-0P 480993-03-1P
480993-04-2P 480993-05-3P 480993-06-4P 480993-07-5P
480993-08-6P 480993-09-7P 480993-10-0P 480993-11-1P
480993-12-2P 480993-13-3P 480993-14-4P 480993-15-5P 480993-16-6P
480993-17-7P 480993-18-8P 480993-19-9P 480993-20-2P 480993-21-3P
480993-22-4P 480993-23-5P 480993-24-6P 480993-25-7P 480993-26-8P
480993-27-9P 480993-29-1P 480993-30-4P 480993-31-5P 480993-32-6P
480993-33-7P 480993-34-8P 480993-35-9P 480993-36-0P 480993-37-1P
480993-38-2P 480993-39-3P 480993-40-6P 480993-41-7P 480993-42-8P
480993-43-9P 480993-44-0P 480993-45-1P 480993-46-2P 480993-47-3P
480993-48-4P 480993-49-5P 480993-50-8P 480993-51-9P 480993-52-0P
480993-53-1P 480993-54-2P 480993-55-3P 480993-56-4P 480993-57-5P
480993-58-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor inhibitors)

IT 480993-59-7P 480993-60-0P 480993-61-1P 480993-62-2P 480993-63-3P
480993-64-4P 480993-65-5P 480993-66-6P 480993-67-7P 480993-68-8P
480993-69-9P 480993-70-2P 480993-71-3P
480993-72-4P 480993-73-5P 480993-74-6P 480993-75-7P 480993-76-8P
480993-77-9P 480993-78-0P 480993-79-1P 480993-80-4P 480993-81-5P
480993-82-6P 480993-83-7P 480993-84-8P 480993-85-9P
480993-86-0P 480993-87-1P 480993-88-2P 480993-89-3P 480993-90-6P
480993-91-7P 480993-92-8P 480993-93-9P 480993-94-0P 480993-95-1P
480993-96-2P 480993-97-3P 480993-98-4P 480993-99-5P 480994-00-1P
480994-01-2P 480994-02-3P 480994-03-4P 480994-04-5P 480994-05-6P
480994-06-7P 480994-07-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor inhibitors)

IT 480991-21-7P 480991-23-9P 480991-24-0P
480991-59-1P 480991-73-9P 480991-75-1P
480992-08-3P 480992-23-2P 480992-25-4P
480992-27-6P 480992-41-4P 480992-42-5P
480992-44-7P 480992-45-8P 480992-49-2P
480992-50-5P 480992-55-0P 480992-56-1P
480992-58-3P 480992-59-4P 480992-60-7P

480992-61-8P 480992-66-3P 480992-68-5P
480992-73-2P 480992-77-6P 480992-82-3P
480992-90-3P 480992-93-6P 480992-94-7P
480992-98-1P 480992-99-2P 480993-03-1P
480993-04-2P 480993-08-6P 480993-69-9P
480993-70-2P 480993-82-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor inhibitors)

RN 480991-21-7 HCAPLUS
CN Acetamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480991-23-9 HCAPLUS
CN Acetamide, N-(4-chlorophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480991-24-0 HCAPLUS
CN Acetamide, 2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 480991-59-1 HCAPLUS
CN Acetamide, N-(4-iodophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480991-73-9 HCAPLUS
CN Acetamide, N-(4-bromophenyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480991-75-1 HCAPLUS
CN Acetamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-08-3 HCAPLUS
CN Acetamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-23-2 HCAPLUS
CN Acetamide, N-(4-iodophenyl)-2-[4-(2,3,4,5-tetrahydro-1-methyl-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-25-4 HCAPLUS
CN Acetamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-27-6 HCAPLUS
CN Acetamide, N-(4-bromophenyl)-2-[4-(2,3,4,5-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-41-4 HCAPLUS
CN Acetamide, N-(4-bromophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-42-5 HCAPLUS
CN Acetamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-44-7 HCAPLUS
CN Acetamide, N-(4-fluorophenyl)-2-[4-[2,3,4,5-tetrahydro-1,3-bis(2-methoxyethyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]- (CA INDEX NAME)



RN 480992-45-8 HCAPLUS
CN Acetamide, N-(4-bromophenyl)-2-[4-[2,3,4,5-tetrahydro-1,3-bis(2-methoxyethyl)-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]- (CA INDEX NAME)



RN 480992-49-2 HCAPLUS
CN Acetamide, 2-[4-[1,3-bis(cyclopropylmethyl)-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 480992-50-5 HCAPLUS
CN Acetamide, 2-[4-[1,3-bis(cyclopropylmethyl)-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl]phenoxy]-N-(4-bromophenyl)- (CA INDEX NAME)



RN 480992-55-0 HCAPLUS
CN Acetamide, 2-[4-(7-bromo-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 480992-56-1 HCAPLUS
CN Acetamide, 2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 480992-58-3 HCAPLUS
CN Acetamide, N-(4-bromophenyl)-2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-59-4 HCAPLUS
CN Acetamide, N-(2-chlorophenyl)-2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-60-7 HCAPLUS
CN Acetamide, N-(4-chlorophenyl)-2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-61-8 HCAPLUS
CN Acetamide, 2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-(2-fluorophenyl)- (CA INDEX NAME)



RN 480992-66-3 HCAPLUS
CN Acetamide, 2-[4-(7-chloro-2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-(3-fluorophenyl)- (CA INDEX NAME)



RN 480992-68-5 HCAPLUS
CN Acetamide, N-(4-fluorophenyl)-2-[3-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-73-2 HCAPLUS
CN Acetamide, N-(4-bromophenyl)-2-[3-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-77-6 HCAPLUS
CN Acetamide, N-(4-fluorophenyl)-2-[2-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-82-3 HCAPLUS
CN Acetamide, N-(4-bromophenyl)-2-[2-methoxy-4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-90-3 HCAPLUS
CN Propanamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-93-6 HCAPLUS
CN Propanamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-94-7 HCAPLUS
CN Propanamide, N-(4-bromophenyl)-2-[4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-98-1 HCAPLUS
CN Butanamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480992-99-2 HCAPLUS
CN Butanamide, N-(4-bromophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480993-03-1 HCAPLUS
CN Propanamide, N-(4-fluorophenyl)-2-methyl-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480993-04-2 HCAPLUS
CN Propanamide, N-(4-bromophenyl)-2-methyl-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480993-08-6 HCAPLUS

CN Benzeneacetamide, N-(4-fluorophenyl)-α-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480993-69-9 HCAPLUS

CN Acetamide, N-(4-fluorophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480993-70-2 HCAPLUS

CN Acetamide, N-(4-bromophenyl)-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-3-propyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (CA INDEX NAME)



RN 480993-82-6 HCAPLUS
CN Carbamic acid, (4-fluorophenyl)-, [4-(2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 22 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:555466 HCAPLUS Full-text
DOCUMENT NUMBER: 137:125096
TITLE: Preparation of phenyl derivatives containing inhibitors of coagulation factor for prophylaxis and/or therapy of thromboembolic disorders
INVENTOR(S): Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Cezanne, Bertram; Gleitz, Johannes; Barnes, Christopher
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057236	A1	20020725	WO 2001-EP14296	20011205 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10102322	A1	20020725	DE 2001-10102322	20010119 <--
CA 2434937	A1	20020725	CA 2001-2434937	20011205 <--
AU 2002227993	A1	20020730	AU 2002-227993	20011205 <--
AU 2002227993	B2	20070809		
EP 1351938	A1	20031015	EP 2001-989580	20011205 <--
EP 1351938	B1	20070411		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

BR 2001016804	A	20040217	BR 2001-16804		20011205 <--
CN 1518541	A	20040804	CN 2001-823061		20011205 <--
JP 2004535362	T	20041125	JP 2002-557917		20011205 <--
JP 4180375	B2	20081112			
HU 2005000110	A2	20050628	HU 2005-110		20011205 <--
AT 359271	T	20070515	AT 2001-989580		20011205 <--
ES 2284718	T3	20071116	ES 2001-989580		20011205 <--
MX 2003006483	A	20030922	MX 2003-6483		20030718 <--
IN 2003KN01033	A	20060602	IN 2003-KN1033		20030813 <--
ZA 2003006419	A	20041118	ZA 2003-6419		20030818 <--
US 20040087582	A1	20040506	US 2003-466680		20031218 <--
US 7273867	B2	20070925			
PRIORITY APPLN. INFO.:			DE 2001-10102322	A	20010119 <--
			WO 2001-EP14296	W	20011205 <--

OTHER SOURCE(S): MARPAT 137:125096

ED Entered STN: 26 Jul 2002

AB Novel compds. of the formula R1R2C6H3-W-X-Y-T in which W, X, Y, T, R1 and R2 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders. Thus, 3-(5-methyl-1,2,4-oxadiazol-3-yl)phenol wa reacted with Et 2-bromovalerate, sodium hydroxide, thionyl chloride, 4-morpholin-4-ylaniline, followed a hydrogenation in acetic acid to give 2-(3-amidinophenoxy)-N-(4-morpholin-4-ylphenyl)valeramide acetate, showing IC50=3x10-7 M and IC50=4.9x10-7 M.

IC ICM C07D211-76
ICS C07D211-74; C07D265-32; C07D241-08; C07D401-04; C07D263-22; C07D237-14; C07D223-10; A61K031-535; A61K031-50; A61K031-4412; A61K031-421

CC 27-19 (Heterocyclic Compounds (One Hetero Atom))

IT

444001-94-9P	444001-95-0P	444001-96-1P	444001-97-2P	444001-98-3P
444001-99-4P	444002-00-0P	444002-01-1P	444002-02-2P	444002-03-3P
444002-04-4P	444002-05-5P	444002-06-6P	444002-07-7P	444002-08-8P
444002-09-9P	444002-10-2P	444002-11-3P	444002-12-4P	444002-13-5P
444002-14-6P	444002-15-7P	444002-16-8P	444002-17-9P	444002-18-0P
444002-20-4P	444002-21-5P	444002-22-6P		
444002-23-7P	444002-24-8P	444002-25-9P	444002-26-0P	444002-27-1P
444002-28-2P	444002-29-3P	444002-30-6P	444002-31-7P	444002-32-8P
444002-33-9P	444002-35-1P	444002-36-2P	444002-37-3P	444002-38-4P
444002-39-5P	444002-40-8P	444002-41-9P	444002-42-0P	444002-43-1P
444002-44-2P	444002-46-4P	444002-47-5P	444002-48-6P	444002-49-7P
444002-50-0P	444002-51-1P	444002-52-2P	444003-03-6P	444003-05-8P
444003-07-0P	444003-08-1P	444003-09-2P	444003-10-5P	444003-11-6P
444003-12-7P	444003-13-8P	444003-14-9P	444003-15-0P	444003-16-1P
444003-17-2P	444003-18-3P	444003-19-4P	444003-20-7P	444003-21-8P
444003-22-9P	444003-23-0P	444003-24-1P	444003-25-2P	444003-26-3P
444003-27-4P	444003-28-5P	444003-29-6P	444003-30-9P	444003-31-0P
444003-33-2P	444003-34-3P	444003-35-4P	444003-36-5P	444003-37-6P
444003-38-7P	444003-39-8P	444003-40-1P	444003-41-2P	444003-42-3P
444003-43-4P	444003-44-5P	444003-45-6P	444003-46-7P	444003-47-8P
444003-48-9P	444003-50-3P	444003-52-5P	444003-54-7P	444003-56-9P
444003-57-0P	444003-59-2P	444003-61-6P	444003-62-7P	444003-63-8P
444003-64-9P	444003-66-1P	444003-68-3P	444003-70-7P	444003-72-9P
444003-74-1P	444003-75-2P	444003-76-3P	444003-77-4P	444003-78-5P
444003-79-6P	444003-80-9P	444003-82-1P	444003-83-2P	444003-84-3P
444003-85-4P	444003-86-5P	444003-87-6P	444003-88-7P	444003-89-8P
444003-90-1P	444003-91-2P	444003-93-4P	444003-94-5P	444003-95-6P
444003-96-7P	444003-97-8P	444003-98-9P	444003-99-0P	444004-00-6P
444004-01-7P	444004-02-8P	444004-03-9P	444004-04-0P	444004-05-1P
444004-06-2P	444004-07-3P	444004-08-4P	444004-09-5P	444004-10-8P
444004-11-9P	444004-12-0P	444004-13-1P	444004-14-2P	444004-15-3P

444004-16-4P 444004-17-5P 444004-18-6P 444004-19-7P 444004-20-0P
444004-21-1P 444004-22-2P 444004-23-3P 444004-24-4P 444004-25-5P
444004-27-7P 444004-29-9P 444004-31-3P 444004-33-5P 444004-34-6P
444004-35-7P 444004-36-8P 444004-37-9P 444004-38-0P 444004-39-1P
444004-40-4P 444004-41-5P 444004-42-6P 444004-43-7P 444004-44-8P
444021-44-7P 444021-46-9P 444021-50-5P 444021-51-6P 444021-53-8P
444021-54-9P 444021-57-2P 444021-59-4P 444021-61-8P 444021-63-0P
444021-65-2P
RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of Ph derivs. containing inhibitors of coagulation factor for prophylaxis and/or therapy of thromboembolic disorders)

IT 444002-21-5P 444002-22-6P
RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of Ph derivs. containing inhibitors of coagulation factor for prophylaxis and/or therapy of thromboembolic disorders)

RN 444002-21-5 HCAPLUS
CN Pentanamide, N-[4-(2,5-dioxo-1-pyrrolidinyl)-3-(trifluoromethyl)phenyl]-2-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenoxy]- (CA INDEX NAME)



RN 444002-22-6 HCAPLUS
CN Pentanamide, N-[3-chloro-4-(2,5-dioxo-1-pyrrolidinyl)phenyl]-2-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 23 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:539647 HCAPLUS Full-text
DOCUMENT NUMBER: 137:109128
TITLE: Preparation of biaryl compounds for treatment of hyperlipidemia and arteriosclerosis
INVENTOR(S): Kori, Masakuni; Ishikawa, Eiichiro; Nakata, Mikiyo; Kobayashi, Makoto
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 470 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055484	A1	20020718	WO 2002-JP73	20020110 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002226675	A1	20020724	AU 2002-226675	20020110 <--
JP 2003055326	A	20030226	JP 2002-4422	20020111 <--
PRIORITY APPLN. INFO.:			JP 2001-5823 A	20010112 <--
			JP 2001-174901 A	20010608 <--
			WO 2002-JP73 W	20020110 <--

OTHER SOURCE(S): MARPAT 137:109128
ED Entered STN: 19 Jul 2002
GI



I

AB The title compds. I [rings A and B each represents an optionally substituted five- or six-membered aromatic ring; R1 and R2 each represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; X1, X2, X3, and X4 each represents a bond or an optionally substituted divalent hydrocarbon group; Y represents NR3CO, CONR3, NR3SO2, SO2NR3, NR3CH2 (R3 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group), etc.; Z represents CONH, CSNH, CO, or SO2; and Ar represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group] are prepared I increase the amount of low-d. lipoprotein (LDL) receptors. The LDL receptor gene transcription promoting activities of compds. of this invention were demonstrated. Processes for preparing I are disclosed.
IC ICM C07C233-78
ICS C07C233-80; C07C271-08; C07C271-40; C07C275-28; C07C311-01; C07C311-15; C07C311-30; C07C335-16; C07D213-40; C07D213-56; C07D213-75; C07D213-81; C07D213-82; C07D307-52; C07D333-20; C07D401-12; C07D405-12; C07D409-12; A61K031-17
CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 27, 28
IT 443340-73-6P 443340-76-9P 443340-77-0P
443342-38-9P 443342-45-8P 443343-42-8P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or

reagent); USES (Uses)
(preparation of biaryl compds. for treatment of hyperlipidemia and arteriosclerosis)

IT 443340-69-0P 443340-70-3P 443340-71-4P 443340-74-7P 443340-75-8P
443340-78-1P 443340-79-2P 443340-80-5P
443340-81-6P 443340-82-7P 443340-83-8P
443340-84-9P 443340-85-0P 443340-86-1P
443340-87-2P 443340-88-3P 443340-89-4P
443340-90-7P 443340-91-8P 443340-92-9P
443340-93-0P 443340-94-1P 443340-95-2P 443340-96-3P
443340-97-4P 443340-98-5P 443340-99-6P 443341-00-2P
443341-01-3P 443341-02-4P 443341-03-5P 443341-04-6P 443341-05-7P
443341-06-8P 443341-07-9P 443341-08-0P 443341-09-1P
443341-10-4P 443341-11-5P 443341-12-6P 443341-13-7P 443341-14-8P
443341-15-9P 443341-16-0P 443341-17-1P 443341-18-2P 443341-19-3P
443341-20-6P 443341-21-7P 443341-22-8P 443341-23-9P 443341-24-0P
443341-25-1P 443341-26-2P 443341-27-3P
443341-28-4P 443341-29-5P 443341-30-8P
443341-31-9P 443341-32-0P 443341-33-1P
443341-34-2P 443341-35-3P 443341-36-4P
443341-38-6P 443341-40-0P 443341-41-1P
443341-42-2P 443341-43-3P 443341-44-4P
443341-45-5P 443341-46-6P 443341-47-7P
443341-48-8P 443341-49-9P 443341-50-2P
443341-51-3P 443341-52-4P 443341-53-5P
443341-54-6P 443341-55-7P 443341-56-8P
443341-57-9P 443341-58-0P 443341-59-1P
443341-60-4P 443341-61-5P 443341-62-6P
443341-63-7P 443341-64-8P 443341-65-9P
443341-66-0P 443341-67-1P 443341-68-2P
443341-69-3P 443341-70-6P 443341-71-7P 443341-72-8P
443341-73-9P 443341-74-0P 443341-75-1P 443341-76-2P
443341-77-3P 443341-78-4P 443341-79-5P
443341-80-8P 443341-81-9P 443341-82-0P 443341-83-1P 443341-84-2P
443341-85-3P 443341-86-4P 443341-87-5P 443341-88-6P 443341-89-7P
443341-90-0P 443341-91-1P 443341-92-2P 443341-93-3P 443341-94-4P
443341-95-5P 443341-96-6P 443341-97-7P 443341-98-8P 443341-99-9P
443342-00-5P 443342-01-6P 443342-02-7P 443342-03-8P 443342-04-9P
443342-05-0P 443342-06-1P 443342-07-2P 443342-08-3P 443342-09-4P
443342-10-7P 443342-11-8P 443342-12-9P 443342-13-0P 443342-14-1P
443342-15-2P 443342-16-3P 443342-17-4P 443342-18-5P 443342-19-6P
443342-20-9P 443342-21-0P 443342-22-1P 443342-23-2P 443342-24-3P
443342-25-4P 443342-26-5P 443342-27-6P 443342-28-7P 443342-29-8P
443342-30-1P 443342-31-2P 443342-32-3P 443342-33-4P 443342-34-5P
443342-35-6P 443342-36-7P 443342-37-8P 443342-39-0P 443342-40-3P
443342-41-4P 443342-42-5P 443342-43-6P 443342-44-7P 443342-46-9P
443342-47-0P 443342-48-1P 443342-49-2P 443342-50-5P 443342-51-6P
443342-52-7P 443342-53-8P 443342-54-9P 443342-55-0P 443342-56-1P
443342-57-2P 443342-58-3P 443342-59-4P
443342-60-7P 443342-61-8P 443342-62-9P 443342-63-0P
443342-64-1P 443342-65-2P 443342-66-3P
443342-67-4P 443342-68-5P 443342-69-6P 443342-70-9P 443342-71-0P
443342-72-1P 443342-73-2P 443342-74-3P 443342-75-4P 443342-76-5P
443342-77-6P 443342-78-7P 443342-79-8P 443342-80-1P 443342-81-2P
443342-82-3P 443342-83-4P 443342-84-5P 443342-85-6P 443342-86-7P
443342-87-8P 443342-88-9P 443342-89-0P 443342-90-3P 443342-91-4P
443342-92-5P 443342-93-6P 443342-94-7P 443342-95-8P 443342-96-9P
443342-97-0P 443342-98-1P 443342-99-2P 443343-00-8P 443343-01-9P
443343-02-0P 443343-03-1P 443343-04-2P 443343-05-3P 443343-06-4P
443343-07-5P 443343-08-6P 443343-09-7P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl compds. for treatment of hyperlipidemia and arteriosclerosis)

IT 1762-34-1P 1762-46-5P 6311-35-9P, 6-Bromonicotinic acid 29886-62-2P, 4-(2-Thienyl)benzoic acid 31181-90-5P 33024-60-1P 35461-98-4P 65586-64-3P 70000-61-2P 70917-02-1P 75601-33-1P 105501-69-7P 122306-01-8P 130497-31-3P 131818-17-2P 153171-22-3P 171663-13-1P 312922-67-1P 328125-41-3P 443343-62-2P 443343-63-3P 443343-64-4P 443343-65-5P 443343-66-6P 443343-67-7P 443343-68-8P 443343-69-9P 443343-70-2P 443343-71-3P 443343-72-4P 443343-73-5P 443343-74-6P 443343-75-7P 443343-76-8P 443343-77-9P 443343-78-0P 443343-79-1P 443343-80-4P 443343-81-5P 443343-82-6P 443343-83-7P 443343-84-8P 443343-85-9P 443343-86-0P 443343-87-1P 443343-88-2P 443343-89-3P 443343-90-6P 443343-91-7P 443343-92-8P 443343-93-9P 443343-94-0P 443343-95-1P 443343-96-2P 443343-97-3P 443343-98-4P 443343-99-5P 443344-00-1P 443344-01-2P 443344-02-3P 443344-03-4P 443344-04-5P 443344-05-6P 443344-06-7P 443344-07-8P 443344-08-9P 443344-09-0P 443344-11-4P 443344-13-6P 443344-15-8P 443344-16-9P 443344-17-0P 443344-18-1P 443344-19-2P 443344-20-5P 443344-21-6P 443344-23-8P 443344-26-1P 443344-28-3P 443344-30-7P 443344-32-9P 443344-33-0P 443344-34-1P 443344-35-2P 443344-36-3P 443344-37-4P 443344-38-5P 443344-39-6P 443344-40-9P 443344-41-0P 443344-42-1P 443344-43-2P 443344-44-3P 443344-45-4P 443344-46-5P 443344-47-6P 443344-48-7P 443344-49-8P 443344-50-1P 443344-51-2P 443344-52-3P 443344-53-4P 443344-54-5P 443344-55-6P 443344-56-7P 443344-57-8P 443344-58-9P 443344-59-0P 443344-60-3P 443344-61-4P 443344-62-5P 443344-63-6P 443344-64-7P 443344-65-8P 443344-66-9P 443344-67-0P 443344-68-1P 443344-69-2P 443344-70-5P 443344-71-6P 443344-72-7P 443344-73-8P 443344-74-9P 443344-76-1P 443344-77-2P 443344-79-4P 443344-80-7P 443344-81-8P 443344-82-9P 443344-83-0P 443344-84-1P 443344-85-2P 443344-86-3P 443344-87-4P 443344-88-5P 443344-89-6P 443344-90-9P 443344-91-0P 443344-92-1P 443344-93-2P 443344-94-3P 443344-95-4P 443344-96-5P 443344-97-6P 443344-98-7P 443344-99-8P 443345-00-4P 443345-01-5P 443345-02-6P 443345-03-7P 443345-04-8P 443345-05-9P 443345-06-0P 443345-07-1P 443345-08-2P 443345-09-3P 443345-10-6P 443345-11-7P 443345-12-8P 443345-13-9P 443345-14-0P 443345-15-1P 443345-16-2P 443345-17-3P 443345-18-4P 443345-19-5P 443345-20-8P 443345-21-9P 443345-22-0P 443345-23-1P 443345-24-2P 443345-25-3P 443345-26-4P 443345-27-5P 443345-28-6P 443345-29-7P 443345-30-0P 443345-31-1P 443345-32-2P 443345-33-3P 443345-34-4P 443345-35-5P 443345-36-6P 443345-37-7P 443345-38-8P 443345-39-9P 443345-40-2P 443345-41-3P 443345-42-4P 443345-43-5P 443345-44-6P 443345-45-7P 443345-46-8P 443345-47-9P 443345-48-0P 443345-49-1P 443345-50-4P 443345-51-5P 443345-52-6P 443345-53-7P 443345-54-8P 443345-55-9P 443345-56-0P 443345-57-1P 443345-58-2P 443345-59-3P 443345-60-6P 443345-61-7P 443345-62-8P 443345-63-9P 443345-64-0P 443345-65-1P 443345-66-2P 443345-67-3P 443345-68-4P 443345-69-5P 443345-70-8P 443345-71-9P 443345-72-0P 443345-73-1P 443345-74-2P 443345-75-3P

443345-76-4P 443345-77-5P 443345-78-6P 443345-79-7P 443345-80-0P
443345-81-1P 443345-82-2P 443345-83-3P 443345-86-6P 443345-87-7P
443345-88-8P 443345-89-9P 443345-93-5P 443345-96-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of biaryl compds. for treatment of hyperlipidemia and arteriosclerosis)

IT 443340-76-9P 443340-77-0P 443343-42-8P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of biaryl compds. for treatment of hyperlipidemia and arteriosclerosis)

RN 443340-76-9 HCAPLUS
CN Carbamic acid, [[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443340-77-0 HCAPLUS
CN Urea, N-[[4'-(aminomethyl)[1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443343-42-8 HCAPLUS
CN Cyclohexanecarboxamide, N-[6-[4-[[[[(4-bromophenyl)amino]carbonyl](3-pyridinylmethyl)amino]methyl]phenyl]-3-pyridinyl]- (CA INDEX NAME)



IT 443340-78-1P 443340-79-2P 443340-80-5P
443340-81-6P 443340-82-7P 443340-83-8P
443340-84-9P 443340-85-0P 443340-86-1P
443340-87-2P 443340-88-3P 443340-89-4P
443340-90-7P 443340-91-8P 443340-97-4P
443341-06-8P 443341-26-2P 443341-27-3P
443341-28-4P 443341-29-5P 443341-30-8P
443341-31-9P 443341-32-0P 443341-33-1P
443341-34-2P 443341-35-3P 443341-36-4P
443341-40-0P 443341-42-2P 443341-44-4P
443341-45-5P 443341-47-7P 443341-48-8P
443341-49-9P 443341-51-3P 443341-53-5P
443341-55-7P 443341-57-9P 443341-59-1P
443341-61-5P 443341-63-7P 443341-65-9P
443341-68-2P 443341-69-3P 443341-72-8P
443341-73-9P 443341-78-4P 443341-79-5P
443342-57-2P 443342-58-3P 443342-59-4P
443342-60-7P 443342-63-0P 443342-64-1P
443342-65-2P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl compds. for treatment of hyperlipidemia and arteriosclerosis)

RN 443340-78-1 HCAPLUS

CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 443340-79-2 HCAPLUS

CN Urea, N-[[4'-[(cyclopentylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-80-5 HCAPLUS
CN Urea, N-[[4'-[(cycloheptylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-81-6 HCAPLUS
CN Urea, N-[[4'-[(cyclooctylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-82-7 HCAPLUS
CN Urea, N-[[4'-[[(cyclohexylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-

N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-83-8 HCAPLUS

CN Urea, N-[[4'-[[(1-methylethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-84-9 HCAPLUS

CN Urea, N-[[4'-[(nonylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-85-0 HCAPLUS
CN Urea, N-[[4'-[[bis(3-phenylpropyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-86-1 HCAPLUS
CN Urea, N-[[4'-[[(phenylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 443340-87-2 HCAPLUS
CN Urea, N-[[4'-[[[(4-fluorophenyl)methyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-88-3 HCAPLUS
CN Urea, N-(3-pyridinylmethyl)-N-[[4'-[[(3-pyridinylmethyl)amino]methyl][1,1'-

biphenyl]-4-yl]methyl]-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 443340-89-4 HCAPLUS

CN Urea, N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-N-[[4'-[[[4-(trifluoromethyl)phenyl]methyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



●2 HCl

PAGE 1-B

RN 443340-90-7 HCAPLUS

CN Urea, N-[[4'-[[[(4-methoxyphenyl)methyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



●2 HCl

PAGE 1-B

—OMe

RN 443340-91-8 HCAPLUS
CN Urea, N-[[4'-[[bis(cyclohexylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-97-4 HCAPLUS
CN Urea, N'-[3,5-bis(trifluoromethyl)phenyl]-N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 443341-06-8 HCAPLUS
CN Urea, N'-(4-chlorophenyl)-N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 443341-26-2 HCAPLUS
CN Benzamide, N-[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 443341-27-3 HCAPLUS
CN Cyclohexanecarboxamide, N-[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 443341-28-4 HCAPLUS
CN Benzenesulfonamide, N-[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 443341-29-5 HCAPLUS
CN Benzamide, N-[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 443341-30-8 HCAPLUS
CN Benzamide, 4-nitro-N-[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 443341-31-9 HCAPLUS
CN Benzamide, 4-fluoro-N-[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 443341-32-0 HCAPLUS
CN Benzamide, 4-methoxy-N-[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 443341-33-1 HCAPLUS
CN Benzamide, 4-methyl-N-[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 443341-34-2 HCAPLUS
CN Benzamide, 4-cyano-N-[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 443341-35-3 HCAPLUS
CN Hexanamide, N-[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 443341-36-4 HCAPLUS
CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(phenylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 443341-40-0 HCAPLUS

CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(2-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443341-42-2 HCAPLUS

CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(4-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443341-44-4 HCAPLUS

CN Urea, N'-(4-chlorophenyl)-N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(4-pyridinylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443341-45-5 HCAPLUS
CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-2-pyridinyl-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443341-47-7 HCAPLUS
CN Urea, N'-(4-chlorophenyl)-N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-2-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 443341-48-8 HCAPLUS
CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-[(2-methyl-3-pyridinyl)methyl]-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443341-49-9 HCAPLUS
CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-[(6-methyl-3-pyridinyl)methyl]-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 443341-51-3 HCAPLUS
CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-phenyl-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 443341-53-5 HCAPLUS
CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(4-methoxyphenyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 443341-55-7 HCAPLUS
CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 443341-57-9 HCAPLUS
CN Urea, N-cyclohexyl-N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 443341-59-1 HCAPLUS
CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(cyclohexylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 443341-61-5 HCAPLUS
CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(2-thienylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 443341-63-7 HCAPLUS
CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(2-furanylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 443341-65-9 HCAPLUS
CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(2-phenylethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 443341-68-2 HCAPLUS
CN Urea, N-[[3'-(aminomethyl)[1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 443341-69-3 HCAPLUS
CN Urea, N-[[3'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 443341-72-8 HCAPLUS
CN Urea, N-[[3'-(aminomethyl)[1,1'-biphenyl]-3-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 443341-73-9 HCAPLUS
CN Urea, N-[[3'-[(cyclohexylamino)methyl][1,1'-biphenyl]-3-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 443341-78-4 HCAPLUS
CN Urea, N-[[4'-(cyclohexylamino)[1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 443341-79-5 HCAPLUS
CN Urea, N-[(4'-amino[1,1'-biphenyl]-4-yl)methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 443342-57-2 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-cyclohexyl-4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 443342-58-3 HCAPLUS
CN Urea, N-[[4'-(1-piperidinylcarbonyl)[1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 443342-59-4 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[(4-fluorophenyl)methyl]-4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 443342-60-7 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(4-methoxyphenyl)-4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 443342-63-0 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-cyclohexyl-4'-[[2-pyridinyl[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 443342-64-1 HCAPLUS
CN [1,1'-Biphenyl]-4-acetamide, N-cyclohexyl-4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 443342-65-2 HCAPLUS
CN [1,1'-Biphenyl]-4-acetamide, N-(4-methoxyphenyl)-4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



IT 443343-94-0P 443343-95-1P 443344-03-4P
443344-04-5P 443344-06-7P 443344-35-2P
443344-36-3P 443344-37-4P 443344-38-5P
443344-39-6P 443344-40-9P 443344-41-0P
443344-42-1P 443344-43-2P 443344-44-3P
443344-45-4P 443344-46-5P 443344-47-6P
443344-48-7P 443344-49-8P 443344-50-1P
443344-51-2P 443344-52-3P 443344-62-5P
443344-63-6P 443344-72-7P 443344-73-8P
443344-76-1P 443344-97-6P 443344-99-8P
443345-01-5P 443345-03-7P 443345-04-8P
443345-06-0P 443345-07-1P 443345-08-2P
443345-10-6P 443345-12-8P 443345-14-0P
443345-16-2P 443345-18-4P 443345-20-8P
443345-22-0P 443345-24-2P 443345-27-5P
443345-29-7P 443345-30-0P 443345-33-3P
443345-34-4P 443345-39-9P 443345-40-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of biaryl compds. for treatment of hyperlipidemia and arteriosclerosis)

RN 443343-94-0 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-, ethyl ester (CA INDEX NAME)



RN 443343-95-1 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 443344-03-4 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[2-pyridinyl[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-

, ethyl ester (CA INDEX NAME)



RN 443344-04-5 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[2-pyridinyl[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 443344-06-7 HCAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 443344-35-2 HCAPLUS
CN Urea, N-[[4'-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 443344-36-3 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-37-4 HCAPLUS
CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 443344-38-5 HCAPLUS
CN Urea, N-[[4'-[(cyclopentylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 443344-39-6 HCAPLUS
CN Carbamic acid, cycloheptyl[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-40-9 HCAPLUS
CN Carbamic acid, cyclooctyl[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-41-0 HCAPLUS
CN Carbamic acid, (cyclohexylmethyl)[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-42-1 HCAPLUS
CN Carbamic acid, (1-methylethyl)[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-43-2 HCAPLUS
CN Carbamic acid, nonyl[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-44-3 HCAPLUS
CN Urea, N-[[4'-[[bis(3-phenylpropyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 443344-45-4 HCAPLUS
CN Carbamic acid, [(4-fluorophenyl)methyl][[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-46-5 HCAPLUS
CN Carbamic acid, (3-pyridinylmethyl)[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-47-6 HCAPLUS
CN Carbamic acid, [[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl][[4-(trifluoromethyl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-48-7 HCAPLUS
CN Carbamic acid, [(4-methoxyphenyl)methyl][[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-49-8 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[(3-pyridinylmethyl)[[[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-

yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-50-1 HCAPLUS
CN Urea, N-[[4'-[[bis(cyclohexylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 443344-51-2 HCAPLUS
CN Carbamic acid, (cyclohexylmethyl)[[4'-[[(3-pyridinylmethyl)[[[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-52-3 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[(3-pyridinylmethyl)[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-62-5 HCAPLUS
CN Carbamic acid, [[4'-[[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl](3-pyridinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-63-6 HCAPLUS
CN Carbamic acid, [[4'-[[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl](3-pyridinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]cyclohexyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-72-7 HCAPLUS
CN Carbamic acid, [[4'-[[[[(4-chlorophenyl)amino]carbonyl](3-pyridinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-73-8 HCAPLUS
CN Carbamic acid, [[4'-[[[[(4-chlorophenyl)amino]carbonyl](3-pyridinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]cyclohexyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-76-1 HCAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-, ethyl ester (CA INDEX NAME)



RN 443344-97-6 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[(phenylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-99-8 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[(2-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-01-5 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[(4-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-03-7 HCAPLUS
CN Carbamic acid, [[4'-[[[[(4-chlorophenyl)amino]carbonyl](4-pyridinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]cyclohexyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-04-8 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[2-pyridinyl[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-06-0 HCAPLUS
CN Carbamic acid, [[4'-[[[[(4-chlorophenyl)amino]carbonyl]-2-pyridinylamino]methyl][1,1'-biphenyl]-4-yl]methyl]cyclohexyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-07-1 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[[(2-methyl-3-pyridinyl)methyl][[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-08-2 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[[(6-methyl-3-pyridinyl)methyl][[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-10-6 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[phenyl[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-12-8 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[(4-methoxyphenyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-14-0 HCAPLUS
CN Carbamic acid, [[4'-[[butyl[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]cyclohexyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-16-2 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[cyclohexyl[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-18-4 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[(cyclohexylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-20-8 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[(2-thienylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-22-0 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[(2-furanylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-24-2 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[(2-phenylethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-27-5 HCAPLUS
CN Carbamic acid, cyclohexyl[[3'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-29-7 HCAPLUS
CN Carbamic acid, [[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-30-0 HCAPLUS
CN Carbamic acid, cyclohexyl[[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-33-3 HCAPLUS
CN Carbamic acid, [[3'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-34-4 HCAPLUS
CN Carbamic acid, cyclohexyl[[3'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-39-9 HCAPLUS
CN Carbamic acid, cyclohexyl[4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-40-2 HCAPLUS
CN Carbamic acid, [4'-[[(3-pyridinylmethyl)[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 24 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:533181 HCAPLUS Full-text
DOCUMENT NUMBER: 137:88464
TITLE: Urea derivatives as angiotensin II receptor antagonists and acyl Co A cholesterol acyltransferase inhibitors for treatment of hypertension and hyperlipidemia
INVENTOR(S): Namiki, Takayuki; Kishii, Kaneichi; Mitani, Masaki; Tamai, Masashi; Hiyama, Naoki; Kimura, Makoto; Ichinomiya, Satoshi
PATENT ASSIGNEE(S): Pola Chemical Industries, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002201127	A	20020716	JP 2000-402702	20001228 <--
PRIORITY APPLN. INFO.:			JP 2000-402702	20001228 <--

OTHER SOURCE(S): MARPAT 137:88464
ED Entered STN: 17 Jul 2002

GI



I

AB Urea derivs. (I; R1 = C5-7; R2 = (substituted)aromatic hydrocarbon radical or cycloalkyl; R3 = tetrazolyl, -NHSO2CF3; Z = single bond or -SO2NH-) are claimed as angiotensin II receptor antagonists and acyl Co A cholesterol acyltransferase inhibitors for treatment of hypertension, hyperlipidemia, and arteriosclerosis. Examples of I granules were formulated.

IC ICM A61K031-41
ICS A61P003-06; A61P009-10; A61P009-12; C07D257-04

CC 1-10 (Pharmacology)
Section cross-reference(s): 28, 63

IT 439904-54-8P 439904-55-9P 439904-56-0P
439904-57-1P 439904-58-2P 439904-60-6P
439904-65-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(urea derivs. as angiotensin II receptor antagonists and acyl Co A cholesterol acyltransferase inhibitors for treatment of hypertension and hyperlipidemia)

IT 439904-67-3P 439904-68-4P 439904-69-5P 439904-72-0P
439904-73-1P 439904-74-2P 439904-85-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(urea derivs. as angiotensin II receptor antagonists and acyl Co A cholesterol acyltransferase inhibitors for treatment of hypertension and hyperlipidemia)

IT 439904-55-9P 439904-56-0P 439904-57-1P
439904-60-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(urea derivs. as angiotensin II receptor antagonists and acyl Co A cholesterol acyltransferase inhibitors for treatment of hypertension and hyperlipidemia)

RN 439904-55-9 HCAPLUS

CN Urea, N-pentyl-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 439904-56-0 HCAPLUS
CN Urea, N-heptyl-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 439904-57-1 HCAPLUS
CN Urea, N'-(2,4-difluorophenyl)-N-heptyl-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 439904-60-6 HCAPLUS
CN Methanesulfonamide, 1,1,1-trifluoro-N-[4'-[[pentyl[[(2,4,6-trifluorophenyl)amino]carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]- (CA INDEX NAME)



IT 439904-68-4P 439904-74-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(urea derivs. as angiotensin II receptor antagonists and acyl Co A cholesterol acyltransferase inhibitors for treatment of hypertension and hyperlipidemia)

RN 439904-68-4 HCAPLUS
CN Urea, N-pentyl-N'-(2,4,6-trifluorophenyl)-N-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 439904-74-2 HCAPLUS
CN Urea, N-[(2'-nitro[1,1'-biphenyl]-4-yl)methyl]-N-pentyl-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L125 ANSWER 25 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:504751 HCAPLUS Full-text
DOCUMENT NUMBER: 137:78959
TITLE: Preparation of biphenyl derivatives as acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors
INVENTOR(S): Namiki, Takayuki; Kishii, Kenichi; Mitani, Masaki; Tamai, Masashi; Hiyama, Naoki; Kimura, Makoto; Ichinomiya, Satoshi
PATENT ASSIGNEE(S): Pola Chemical Industries, Inc., Japan
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051799	A1	20020704	WO 2001-JP10626	20011205 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2434228	A1	20020704	CA 2001-2434228	20011205 <--
CA 2434228	C	20090804		
AU 2002221055	A1	20020708	AU 2002-221055	20011205 <--
EP 1354871	A1	20031022	EP 2001-272246	20011205 <--
EP 1354871	B1	20080220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 4035444	B2	20080123	JP 2002-552896	20011205 <--
AT 386716	T	20080315	AT 2001-272246	20011205 <--
US 20040048909	A1	20040311	US 2003-451408	20030623 <--
US 7531576	B2	20090512		
PRIORITY APPLN. INFO.:			JP 2000-394372 A	20001226 <--
			WO 2001-JP10626 W	20011205 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 137:78959
ED Entered STN: 05 Jul 2002
GI



I

AB Biphenyl derivs. represented by the general formula (I) or salts thereof [wherein R1 is C5-7 alkyl; R2 is optionally substituted aromatic hydrocarbyl or cycloalkyl; R3 is tetrazolyl, NHCOCF3, NHSO2CF3, or SO2NHCONHR4 (wherein R4 is optionally substituted aromatic hydrocarbyl); and Z is a single bond, C1-4 alkylene, or SO2NH] are prepared Also disclosed are ACAT inhibitors or medicines containing the same as the active ingredient. The derivs. I and the salts have excellent ACAT inhibiting activity and are useful as preventive and/or therapeutic drugs for diseases due to the rise in ACAT activity, in particular hypercholesterolemia and atherosclerosis. Thus, a suspension of N-(chloroacetyl)-2,6-diisopropylaniline 196.3, N-pentyl-N-[[2'-[N-(triphenylmethyl)-1H-tetrazol-5-yl]-1,1'-biphenyl-4- yl]methyl]amine 430.0 mg , KI 70, and 0.6 g Et3N in 3 mL DMF was heated at .apprx.80° with stirring for 3 h to give 33% N-[[[(2,6-diisopropylphenyl)amino]carbonyl]methyl]-N-pentyl-N-[[2'-[N- (triphenylmethyl)-1H-tetrazol-5-yl]-1,1'-biphenyl-4-yl]methyl]amine which (278.3 mg) was dissolved in 10 mL THF, treated with 3.0 mL 10% aqueous HCl, and stirred at room temperature for 19 h to give N-[[[(2,6-diisopropylphenyl)amino]carbonyl]methyl]-N-pentyl-N-[[2'-(1H- tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]amine (II) hydrochloride. The free amine II showed pIC50 of 6.57 against ACAT.

IC ICM C07C275-30
ICS C07C311-09; C07C311-60; C07D257-04; A61K031-41; A61K031-17; A61K031-18; A61K031-54; A61K031-166; A61K031-167; A61P043-00;

A61P003-06; A61P009-10
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 7, 25
IT 439904-53-7P 439904-54-8P 439904-55-9P
439904-56-0P 439904-57-1P 439904-58-2P
439904-59-3P 439904-60-6P 439904-61-7P
439904-62-8P 439904-63-9P 439904-64-0P 439904-65-1P 439904-81-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biphenyl derivs. as acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors for prevention and/or treatment of hypercholesterolemia and atherosclerosis)
IT 141872-29-9P 142777-65-9P 439904-66-2P 439904-67-3P
439904-68-4P 439904-69-5P 439904-70-8P
439904-71-9P 439904-72-0P 439904-73-1P 439904-74-2P
439904-75-3P 439904-76-4P 439904-77-5P
439904-78-6P 439904-79-7P 439904-80-0P 439904-82-2P
439904-84-4P 439904-85-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of biphenyl derivs. as acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors for prevention and/or treatment of hypercholesterolemia and atherosclerosis)
IT 439904-55-9P 439904-56-0P 439904-57-1P
439904-59-3P 439904-60-6P 439904-61-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biphenyl derivs. as acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors for prevention and/or treatment of hypercholesterolemia and atherosclerosis)
RN 439904-55-9 HCAPLUS
CN Urea, N-pentyl-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 439904-56-0 HCAPLUS
CN Urea, N-heptyl-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 439904-57-1 HCAPLUS
CN Urea, N'-(2,4-difluorophenyl)-N-heptyl-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 439904-59-3 HCAPLUS
CN Acetamide, 2,2,2-trifluoro-N-[4'-[[pentyl[[(2,4,6-trifluorophenyl)amino]carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]- (CA INDEX NAME)



RN 439904-60-6 HCAPLUS
CN Methanesulfonamide, 1,1,1-trifluoro-N-[4'-[[pentyl[[(2,4,6-trifluorophenyl)amino]carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]- (CA INDEX NAME)



RN 439904-61-7 HCAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]-4'-[[heptyl[[(2,4,6-trifluorophenyl)amino]carbonyl]amino]methyl]- (CA INDEX NAME)



IT 439904-68-4P 439904-70-8P 439904-71-9P
439904-74-2P 439904-75-3P 439904-77-5P
439904-78-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of biphenyl derivs. as acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors for prevention and/or treatment of hypercholesterolemia and atherosclerosis)
RN 439904-68-4 HCAPLUS
CN Urea, N-pentyl-N'-(2,4,6-trifluorophenyl)-N-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 439904-70-8 HCAPLUS
CN Urea, N-heptyl-N'-(2,4,6-trifluorophenyl)-N-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 439904-71-9 HCAPLUS
CN Urea, N'-(2,4-difluorophenyl)-N-heptyl-N-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 439904-74-2 HCAPLUS
CN Urea, N-[(2'-nitro[1,1'-biphenyl]-4-yl)methyl]-N-pentyl-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 439904-75-3 HCAPLUS
CN Urea, N-[(2'-amino[1,1'-biphenyl]-4-yl)methyl]-N-pentyl-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 439904-77-5 HCAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(1,1-dimethylethyl)-4'-[[heptyl[[(2,4,6-trifluorophenyl)amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 439904-78-6 HCAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[heptyl[[(2,4,6-trifluorophenyl)amino]carbonyl]amino]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 26 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:10426 HCAPLUS Full-text
DOCUMENT NUMBER: 136:85822
TITLE: Preparation of biphenylcarboxamide compounds as GPR14 antagonists or somatostatin receptor regulators
INVENTOR(S): Tarui, Naoki; Santo, Takashi; Watanabe, Hiroyuki; Aso, Kazuyoshi; Miwa, Tetsuo; Takekawa, Shiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 274 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000606	A1	20020103	WO 2001-JP5541	20010628 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001066346	A	20020108	AU 2001-66346	20010628 <--
JP 2002080439	A	20020319	JP 2001-196645	20010628 <--
EP 1295867	A1	20030326	EP 2001-943851	20010628 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040106792	A1	20040603	US 2002-312015	20021220 <--
US 7091247	B2	20060815		

PRIORITY APPLN. INFO.: JP 2000-200118 A 20000628 <--
WO 2001-JP5541 W 20010628 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 136:85822
ED Entered STN: 04 Jan 2002

GI



I

AB The title compds. (I) or salts thereof [wherein R1 represents hydrogen or (un)substituted hydrocarbyl; X represents a spacer having a 1 to 12 atom linear chain moiety; A represents (un)substituted amino or N-heterocyclyl; R2 represents (un)substituted hydrocarbyl or amino; and R3 represents (un)substituted hydrocarbyl; ring B and C represent an optionally further substituted benzene ring], which have an antagonism against urotensin II receptor GPR14 (orphan receptor), are prepared These compds. are also somatostatin, in particular somatostatin 5 receptor-function regulators such as somatostatin receptor agonists and antagonists and are useful for the prevention and treatment of hypertension, arteriosclerosis, cardiac hypertrophy, myocardial infarction, diabetes, obesity, diabetes complications, central diseases, digestive tract diseases, glaucoma, acromegaly, or tumor. Thus, 3'-[[2-[4- (aminosulfonyl)phenyl]ethyl]aminomethyl]-N-[2-(1-pyrrolidinyl)ethyl]-1,1'- biphenyl-3-carboxamide was condensed with trans-cinnamic acid using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1-hydroxybenzoriazole in CH2Cl2 and DMF at room temperature for 18 h to give 3'-[[N-[2-[4-(aminosulfonyl)phenyl]ethyl]-N-[(E)-3-phenyl-2-propenoyl]amino]methyl]-N-[2-(1-pyrrolidinyl)ethyl]-1,1'-biphenyl-3-carboxamide (II). N-(2-aminoethyl)-3'-[[N-[4-(aminosulfonyl)benzoyl]-N-(1-naphthylmethyl)amino]methyl]-1,1'-biphenyl-2-carboxamide trifluoroacetate and N-(2-aminoethyl)-3'-[[N-[4-[[[amino(imino)methyl]amino]methyl]benzoyl]- N-(1-naphthylmethyl)amino]methyl]-1,1'-biphenyl-2-carboxamide trifluoroacetate showed IC50 of 3 and 6 nM for inhibiting the binding of [125I]-somatostatin to CHO cell line expressing human somatostatin 5 receptor. A capsule and a tablet formulation containing II were prepared

IC ICM C07C233-69
ICS C07C233-78; C07C233-79; C07C311-46; C07C321-14; C07D295-12; C07D209-18; C07D405-12; C07D211-26; C07D213-40; C07D207-27; C07D401-12; C07D307-54; C07D333-20; C07D257-04; C07D409-12; C07D209-42; C07D213-56; C07D213-70; C07D401-14

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 386295-63-2P 386295-65-4P 386295-67-6P 386295-69-8P 386295-71-2P
386295-73-4P 386295-75-6P 386295-77-8P 386295-79-0P 386295-81-4P
386295-83-6P 386295-85-8P 386295-87-0P 386295-89-2P 386295-91-6P
386295-93-8P 386295-95-0P 386295-97-2P 386295-99-4P 386296-01-1P
386296-03-3P 386296-05-5P 386296-07-7P 386296-09-9P 386296-11-3P
386296-13-5P 386296-15-7P 386296-17-9P 386296-19-1P 386296-21-5P
386296-23-7P 386296-25-9P 386296-27-1P 386296-29-3P 386296-31-7P
386296-33-9P 386296-35-1P 386296-37-3P 386296-39-5P 386296-41-9P
386296-43-1P 386296-45-3P 386296-47-5P 386296-49-7P 386296-51-1P
386296-53-3P 386296-55-5P 386296-57-7P

386296-59-9P 386296-61-3P 386296-63-5P 386296-65-7P
386296-67-9P 386296-69-1P 386296-71-5P 386296-73-7P 386296-75-9P
386296-77-1P 386296-79-3P 386296-81-7P 386296-83-9P 386296-85-1P
386296-87-3P 386296-89-5P 386296-91-9P 386296-93-1P 386296-95-3P
386296-97-5P 386296-99-7P 386297-01-4P 386297-03-6P 386297-05-8P
386297-07-0P 386297-09-2P 386297-11-6P 386297-13-8P 386297-15-0P
386297-16-1P 386297-17-2P 386297-19-4P 386297-21-8P 386297-23-0P
386297-25-2P 386297-27-4P 386297-29-6P 386297-32-1P 386297-34-3P
386297-36-5P 386297-38-7P 386297-40-1P 386297-42-3P 386297-44-5P
386297-46-7P 386297-48-9P 386297-50-3P 386297-52-5P 386297-54-7P
386297-69-4P 386298-30-2P 386298-33-5P 386298-36-8P 386298-40-4P
386298-44-8P 387871-93-4P 387871-95-6P 387871-97-8P 387871-99-0P
387872-01-7P 387872-03-9P 387872-05-1P 387872-07-3P 387872-14-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biphenylcarboxamide compds. as GPR14 antagonists or somatostatin receptor regulators for therapeutic agents)

IT 386296-53-3P 386296-57-7P 386296-61-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biphenylcarboxamide compds. as GPR14 antagonists or somatostatin receptor regulators for therapeutic agents)

RN 386296-53-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(2-aminoethyl)-3'-[[[2-(4-hydroxyphenyl)ethyl][[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 386296-52-2
CMF C32 H31 F3 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 386296-57-7 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(6-aminohexyl)-3'-[[[2-(4-hydroxyphenyl)ethyl][[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 386296-56-6
CMF C36 H39 F3 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 386296-61-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[[4-(aminomethyl)cyclohexyl]methyl]-3'-[[[2-(4-hydroxyphenyl)ethyl][[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 386296-60-2
CMF C38 H41 F3 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 27 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:526050 HCAPLUS Full-text
DOCUMENT NUMBER: 135:107149
TITLE: Synthesis, antibacterial activity and RNA polymerase inhibition of phenylamidine derivs.
INVENTOR(S): Li, Leping; Chen, Xiaoqui; Fan, Pingchen; Mihalic, Jeffrey Thomas; Cutler, Serena
PATENT ASSIGNEE(S): Tularik Inc., USA
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051456	A2	20010719	WO 2001-US1219	20010112 <--
WO 2001051456	A3	20011220		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2397575	A1	20010719	CA 2001-2397575	20010112 <--
US 20020045749	A1	20020418	US 2001-759633	20010112 <--
US 6780858	B2	20040824		
EP 1246795	A2	20021009	EP 2001-914329	20010112 <--
EP 1246795	B1	20071031		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519676	T	20030624	JP 2001-551838	20010112 <--
AT 376996	T	20071115	AT 2001-914329	20010112 <--
ES 2293980	T3	20080401	ES 2001-914329	20010112 <--
US 20040235911	A1	20041125	US 2004-877408	20040625 <--
US 7053234	B2	20060530		
US 20060270651	A1	20061130	US 2006-344111	20060201 <--
US 7148259	B1	20061212		

PRIORITY APPLN. INFO.:	US 2000-175892P	P	20000113 <--
	US 2001-759633	A1	20010112 <--
	WO 2001-US1219	W	20010112 <--
	US 2004-877408	A3	20040625

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 135:107149
ED Entered STN: 20 Jul 2001
GI



I

AB Synthesis of hydroxyamidines, e.g. (I) and related compds. are disclosed which are suitable as antibacterial agents by their inhibition of RNA polymerase. Antibacterial activity against S. aureus and E. coli are given.

IC ICM C07C259-18
ICS C07C311-37; C07C317-32; C07D295-14; C07D205-04; C07D207-09; C07D207-14; C07D207-12; C07D211-58; C07D307-22; C07D211-70; C07C323-42; C07D333-60; C07D213-53; C07D209-18; C07D307-54; C07D333-38; C07D215-54; C07D317-46; C07D307-85

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1

IT 288246-39-9P 350486-51-0P 350486-53-2P 350486-55-4P 350486-57-6P
350486-58-7P 350486-60-1P 350486-62-3P 350486-64-5P 350486-66-7P
350486-68-9P 350486-70-3P 350486-74-7P 350486-76-9P 350486-88-3P
350486-90-7P 350486-92-9P 350486-94-1P 350486-95-2P 350486-96-3P
350486-97-4P 350486-98-5P 350486-99-6P 350487-00-2P 350487-01-3P
350487-02-4P 350487-03-5P 350487-04-6P 350487-06-8P 350487-08-0P
350487-09-1P 350487-10-4P 350487-11-5P 350487-12-6P 350487-13-7P

350487-14-8P 350487-15-9P 350487-16-0P 350487-17-1P 350487-18-2P
350487-19-3P 350487-20-6P 350487-21-7P 350487-22-8P 350487-23-9P
350487-24-0P 350487-25-1P 350487-26-2P 350487-27-3P 350487-28-4P
350487-29-5P 350487-30-8P 350487-31-9P 350487-32-0P 350487-33-1P
350487-34-2P 350487-35-3P 350487-36-4P 350487-37-5P 350487-38-6P
350487-39-7P 350487-41-1P 350487-42-2P 350487-43-3P 350487-44-4P
350487-45-5P 350487-47-7P 350487-48-8P 350487-49-9P 350487-50-2P
350487-51-3P 350487-52-4P 350487-53-5P 350487-54-6P 350487-55-7P
350487-56-8P 350487-57-9P 350487-58-0P 350487-59-1P 350487-60-4P
350487-61-5P 350487-63-7P 350487-64-8P 350487-65-9P 350487-66-0P
350487-67-1P 350487-68-2P 350487-69-3P 350487-70-6P 350487-71-7P
350487-73-9P 350487-75-1P 350487-77-3P 350487-79-5P 350487-82-0P
350487-84-2P 350487-86-4P 350487-88-6P 350487-91-1P 350487-93-3P
350487-95-5P 350487-96-6P 350487-97-7P 350487-98-8P 350487-99-9P
350488-01-6P 350488-02-7P 350488-04-9P 350488-05-0P 350488-06-1P
350488-07-2P 350488-08-3P 350488-09-4P 350488-10-7P 350488-11-8P
350488-12-9P 350488-13-0P 350488-14-1P 350488-15-2P 350488-16-3P
350488-19-6P 350488-20-9P 350488-21-0P 350488-22-1P
350488-23-2P 350488-24-3P 350488-25-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis, antibacterial activity and RNA polymerase inhibition of phenyl- and heterocyclylhydroxyamidine derivs.)

IT 350488-22-1P 350488-23-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis, antibacterial activity and RNA polymerase inhibition of phenyl- and heterocyclylhydroxyamidine derivs.)

RN 350488-22-1 HCAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-pyrrol-1-yl)-5-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 350488-23-2 HCAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(1H-pyrrol-1-yl)-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 28 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:289940 HCAPLUS Full-text
DOCUMENT NUMBER: 134:305303
TITLE: Tyrosine phosphatase inhibitors as antiallergic drugs
INVENTOR(S): Sato, Masakazu; Kobayashi, Yuiko; Hamaguchi, Takuya
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001114678	A	20010424	JP 1999-297001	19991019 <--

PRIORITY APPLN. INFO.: JP 1999-297001 19991019 <--
OTHER SOURCE(S): MARPAT 134:305303
ED Entered STN: 24 Apr 2001
GI



I

AB Tyrosine phosphatase inhibitors (I; R1 = Ph, halogen-substituted Ph, C1-5 alkyl and alkoxy, naphthyl, C1-10 alkyl, C3-8 cycloalkyl, etc.; R2 = Ph, halogen, C1-5 alkyl and alkoxy, naphthyl; R3 = H, benzyl) are claimed as antiallergic drugs by inhibiting CD45 antigen-activated T cells and mast cells. I were prepared, and their tyrosine phosphatase inhibiting activities were tested.
IC ICM A61K031-167
ICS A61K031-16; A61P037-02; A61P037-08; A61P043-00
CC 1-7 (Pharmacology)
Section cross-reference(s): 25
IT 125983-66-6P 125983-69-9P 328127-18-0P 335318-66-6P 335318-68-8P

335318-70-2P 335318-72-4P 335318-74-6P 335318-77-9P 335318-80-4P
335318-82-6P 335318-84-8P 335318-86-0P 335318-88-2P 335318-91-7P
335318-93-9P 335318-95-1P 335318-97-3P 335318-99-5P
335319-01-2P 335319-03-4P 335319-05-6P 335319-07-8P
335319-09-0P 335319-11-4P 335319-13-6P 335319-15-8P
335319-17-0P 335319-19-2P 335319-21-6P 335319-23-8P
335319-25-0P 335319-27-2P 335319-29-4P 335319-31-8P 335319-33-0P
335319-35-2P 335319-37-4P 335319-39-6P 335319-41-0P 335319-43-2P
335319-45-4P 335319-47-6P 335319-49-8P 335319-51-2P 335319-53-4P
335319-55-6P 335319-57-8P 335319-59-0P 335319-61-4P 335319-63-6P
335319-64-7P 335319-65-8P 335319-66-9P 335319-67-0P 335319-68-1P
335319-69-2P 335319-70-5P 335319-71-6P 335319-72-7P 335319-73-8P
335319-74-9P 335319-75-0P 335319-76-1P 335319-77-2P 335319-78-3P
335319-79-4P 335319-80-7P 335319-81-8P 335319-82-9P 335319-83-0P
335319-84-1P 335319-85-2P 335319-86-3P 335319-87-4P 335319-88-5P
335319-89-6P 335319-90-9P 335319-91-0P 335319-92-1P 335319-93-2P
335319-94-3P 335319-95-4P 335319-96-5P 335319-97-6P 335319-98-7P
335319-99-8P 335320-00-8P 335320-01-9P 335320-02-0P 335320-04-2P
335320-06-4P 335320-07-5P 335320-08-6P 335320-09-7P 335320-10-0P
335320-11-1P 335320-12-2P 335320-13-3P 335320-14-4P 335320-15-5P
335320-16-6P 335320-17-7P 335320-18-8P 335320-19-9P 335320-20-2P
335320-21-3P 335320-22-4P 335320-23-5P 335320-24-6P 335320-26-8P
335320-27-9P 335320-28-0P 335320-29-1P 335320-30-4P 335320-31-5P
335320-32-6P 335320-33-7P 335320-34-8P 335320-35-9P 335320-36-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tyrosine phosphatase inhibitors as antiallergic drugs)

IT 335318-99-5P 335319-07-8P 335319-17-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tyrosine phosphatase inhibitors as antiallergic drugs)

RN 335318-99-5 HCAPLUS
CN Acetamide, 2-([1,1'-biphenyl]-2-ylamino)-N-(3-chlorophenyl)-2-thioxo- (CA INDEX NAME)



RN 335319-07-8 HCAPLUS
CN Acetamide, 2-([1,1'-biphenyl]-2-ylamino)-N-(4-chlorophenyl)-2-thioxo- (CA INDEX NAME)



RN 335319-17-0 HCAPLUS
CN Acetamide, 2-([1,1'-biphenyl]-2-ylamino)-N-(3,4-dichlorophenyl)-2-thioxo- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L125 ANSWER 29 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:247177 HCAPLUS Full-text
DOCUMENT NUMBER: 134:275767
TITLE: Synergistic anti-hypercholesterolemic drug combination using an HMG-CoA reductase inhibitor with an ACAT inhibitor
INVENTOR(S): Chao, Yu-Sheng
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001022962	A1	20010405	WO 2000-US26414	20000926 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-157184P P 19990930 <--
ED Entered STN: 06 Apr 2001
AB The invention provides a drug combination comprised of an HMG-CoA reductase inhibitor with an ACAT inhibitor in synergistic therapeutically effective amts., which is useful for reducing cholesterol synthesis, lowering plasma LDL cholesterol levels and lowering plasma triglyceride levels. Profound synergy can be achieved only when the ACAT inhibitor is administered in low dosage amts., above which the beneficial synergistic effects diminish and disappear.
IC ICM A61K031-435
ICS A61K031-405; A61K031-40; A61K031-35; A61K031-18; A61K031-16
CC 1-10 (Pharmacology)
IT 75225-51-3 75225-51-3D, esters 75330-75-5 79902-63-9 81093-37-0 81093-37-0D, esters 85956-22-5 93957-54-1 93957-54-1D, esters 93957-56-3 121009-77-6 121009-77-6D, esters 125995-03-1 134523-00-5 134523-00-5D, esters 141750-63-2 144289-00-9 145599-86-6, Cerivastatin 145599-86-6D, esters 147098-20-2

147098-20-2D, esters 147526-32-7 147526-32-7D, esters 147538-81-6
158878-47-8 162320-85-6 166518-60-1 179054-18-3
182255-50-1 332342-31-1 332342-32-2 332342-33-3 332342-34-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMG-CoA reductase inhibitor-ACAT inhibitor synergistic hypocholesterolemic drug combination)

IT 179054-18-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMG-CoA reductase inhibitor-ACAT inhibitor synergistic hypocholesterolemic drug combination)

RN 179054-18-3 HCAPLUS
CN Urea, N-(phenylmethyl)-N-[[3-(1H-pyrazol-3-yl)phenyl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 30 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:861682 HCAPLUS Full-text
DOCUMENT NUMBER: 134:29253
TITLE: Preparation of substituted 8-phenylxanthines as antagonists of A2B adenosine receptors
INVENTOR(S): Linden, Joel M.; Jocobson, Kenneth A.; Kim, Yong-Chul
PATENT ASSIGNEE(S): University of Virginia Patent Foundation, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000073307	A2	20001207	WO 2000-US15233	20000601 <--
WO 2000073307	A3	20010531		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6545002	B1	20030408	US 2000-505504	20000217 <--
CA 2370598	A1	20001207	CA 2000-2370598	20000601 <--

EP 1192158 A2 20020403 EP 2000-938072 20000601 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.: US 1999-136898P P 19990601 <--
US 1999-136900P P 19990601 <--
US 1999-505504 A 19990601 <--
US 1999-151875P P 19990831 <--
US 2000-505504 A 20000217 <--
WO 2000-US15233 W 20000601 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 134:29253
ED Entered STN: 08 Dec 2000
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R, R1 = H, alkyl, alkenyl, etc.; Z = phenylene, cyclohexylene, cyclopentylene; X = alkylene, alkenylene, alkynylene, etc.; R2 = H, alkyl, alkenyl, etc.; R8 = H, cycloalkyl, aralkyl, etc.; R9 = cycloalkyl, aryl, alkyl, etc.] which are selective antagonists of A2B adenosine receptors (ARs), were prepared (general procedures for their preparation were given). Thus, hydrolysis of the ester II with 1N NaOH afforded the title compound III which showed Ki of 3.34 ± 0.51 nM against hA2B receptor binding.
IC ICM C07D473-00
CC 26-9 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1
IT 106465-54-7P 249892-27-1P 249892-29-3P 249892-30-6P 249892-31-7P
249892-32-8P 249892-33-9P 249892-34-0P 249892-35-1P 249892-38-4P
249892-39-5P 249892-40-8P 249892-41-9P 249892-42-0P 249892-43-1P
249892-44-2P 249892-46-4P 249892-47-5P 249892-48-6P 249892-49-7P
249926-37-2P 264622-43-7P 264622-45-9P 264622-46-0P 264622-47-1P
264622-48-2P 264622-49-3P 264622-50-6P 264622-51-7P 264622-52-8P
264622-53-9P 264622-55-1P 264622-56-2P 264622-57-3P 264622-58-4P
264622-59-5P 264622-60-8P 264622-61-9P
264622-62-0P 264622-63-1P 264622-64-2P
264622-65-3P 264622-66-4P 264622-67-5P 264622-68-6P 264622-69-7P
312311-56-1P 312311-57-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 8-phenylxanthines as antagonists of A2B adenosine receptors)
IT 264622-60-8P 264622-61-9P 264622-62-0P
264622-63-1P 264622-64-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 8-phenylxanthines as antagonists of A2B adenosine receptors)
RN 264622-60-8 HCAPLUS
CN Acetamide, 2-[4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 264622-61-9 HCAPLUS
CN Acetamide, N-(4-fluorophenyl)-2-[4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]- (CA INDEX NAME)



RN 264622-62-0 HCAPLUS
CN Acetamide, N-(4-chlorophenyl)-2-[4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]- (CA INDEX NAME)



RN 264622-63-1 HCAPLUS
CN Acetamide, N-(4-bromophenyl)-2-[4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]- (CA INDEX NAME)



RN 264622-64-2 HCAPLUS

CN Acetamide, N-(4-iodophenyl)-2-[4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib ed abs hitind hitstr l125 31-36
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L125 ANSWER 31 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:314682 HCAPLUS Full-text
DOCUMENT NUMBER: 132:334449
TITLE: Preparation of N-[4-(5-oxazolyl)phenyl] amides as novel inhibitors of IMPDH enzyme
INVENTOR(S): Gu, Henry H.; Dhar, T. G. Murali; Iwanowicz, Edwin
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000026197	A1	20000511	WO 1999-US24889	19991022 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2348267	A1	20000511	CA 1999-2348267	19991022 <--
EP 1127054	A1	20010829	EP 1999-960145	19991022 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002528533	T	20020903	JP 2000-579586	19991022 <--
US 6624184	B1	20030923	US 1999-427953	19991027 <--
US 20040082562	A1	20040429	US 2003-465425	20030619 <--
US 7053111	B2	20060530		

US 20060122245	A1	20060608	US 2003-465427		20030619 <--
US 7205324	B2	20070417			
US 20040102497	A1	20040527	US 2003-717287		20031119 <--
US 7060720	B2	20060613			
PRIORITY APPLN. INFO.:			US 1998-106180P	P	19981029 <--
			WO 1999-US24889	W	19991022 <--
			US 1999-427953	A3	19991027 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 132:334449
ED Entered STN: 15 May 2000
GI



II

AB The title compds. ZJKLX [I; Z = (un)substituted monocyclic or bicyclic ring system containing up to 4 heteroatoms selected from N, O, and S; J = NR7, CO; K = NR7, CO, CHR9; L = a single bond, CO, CR10R11, etc.; X = alkyl, alkenyl, cycloalkylalkyl, etc.; R7 = H, alkyl, alkenyl, etc.; R9 = H, alkyl, alkenyl, etc.; R10, R11 = H, F, Cl, etc.], useful in treating or preventing IMPDH associated disorders, such as transplant rejection and autoimmune disease, were prepared E.g., a multi-step synthesis of glycinamide II was given. Compds. I are effective at 0.1-500 mg/kg/day.

IC ICM C07D263-34
ICS C07D413-10; A61K031-42

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT 267405-35-6P 267405-36-7P 267405-37-8P 267405-39-0P
267405-40-3P 267405-41-4P 267405-42-5P 267405-43-6P 267405-44-7P
267405-45-8P 267405-46-9P 267405-47-0P 267405-48-1P 267405-49-2P
267405-50-5P 267405-51-6P 267405-52-7P 267405-53-8P 267405-54-9P
267405-55-0P 267405-56-1P 267405-57-2P 267405-58-3P 267405-59-4P
267405-60-7P 267405-61-8P 267405-62-9P 267405-63-0P 267405-64-1P
267405-65-2P 267405-66-3P 267405-67-4P 267405-68-5P 267405-69-6P
267405-70-9P 267405-71-0P 267405-72-1P 267405-73-2P 267405-74-3P
267405-75-4P 267405-76-5P 267405-77-6P 267405-78-7P 267405-79-8P
267405-80-1P 267405-81-2P 267405-82-3P 267405-83-4P 267405-84-5P
267405-85-6P 267405-86-7P 267405-87-8P 267405-88-9P 267405-90-3P
267405-91-4P 267405-92-5P 267405-93-6P 267405-94-7P 267405-95-8P
267405-96-9P 267405-97-0P 267405-98-1P 267405-99-2P 267406-00-8P
267406-01-9P 267406-02-0P 267406-03-1P 267406-04-2P 267406-05-3P
267406-06-4P 267406-07-5P 267406-08-6P 267406-09-7P 267406-10-0P
267406-11-1P 267406-12-2P 267406-13-3P 267406-14-4P 267406-15-5P
267406-16-6P 267406-17-7P 267406-18-8P 267406-19-9P 267406-20-2P
267406-21-3P 267406-22-4P 267406-23-5P 267406-24-6P 267406-25-7P
267406-26-8P 267406-27-9P 267406-28-0P 267406-29-1P 267406-30-4P
267406-31-5P 267406-32-6P 267406-33-7P 267406-34-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-[4-(5-oxazolyl)phenyl] amides as novel inhibitors of IMPDH
enzyme)
IT 267405-35-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[4-(5-oxazolyl)phenyl] amides as novel inhibitors of IMPDH
enzyme)
RN 267405-35-6 HCAPLUS
CN Acetamide, N-(4-fluorophenyl)-2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 32 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:277959 HCAPLUS Full-text
DOCUMENT NUMBER: 132:321662
TITLE: Preparation of aromatic amine derivatives and agents containing the same
INVENTOR(S): Oi, Satoru; Suzuki, Nobuhiro; Aso, Kazuyoshi; Banno, Yoshihiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 309 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023420	A1	20000427	WO 1999-JP5755	19991019 <--

W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR,

LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2348159	A1	20000427	CA 1999-2348159		19991019 <--
AU 9961246	A	20000508	AU 1999-61246		19991019 <--
JP 2000191615	A	20000711	JP 1999-297129		19991019 <--
EP 1123918	A1	20010816	EP 1999-947962		19991019 <--
EP 1123918	B1	20050309			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
AT 290524	T	20050315	AT 1999-947962		19991019 <--
US 7160887	B1	20070109	US 2001-807081		20010406 <--
PRIORITY APPLN. INFO.:			JP 1998-298940	A	19981020 <--
			WO 1999-JP5755	W	19991019 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 132:321662
ED Entered STN: 28 Apr 2000
GI



I



II

AB Title compds. [I; wherein A is an optionally substituted aromatic ring; B is an optionally substituted cyclic hydrocarbon oxy group; Z is an optionally substituted cyclic hydrocarbon group; R1 is hydrogen, optionally substituted hydrocarbyl, an optionally substituted heterocyclic group, or acyl; R2 is optionally substituted amino; D is a free valency or a divalent group; E is CO, CON(Ra), COO, N(Ra)CON(Rb), N(Ra)SO2, N(Ra), O, S, SO, SO2; G is a free valency or a divalent group; L is a free valency, an optionally substituted divalent hydrocarbon group which may be interrupted by O or S, or the like; X is oxygen, optionally oxidized sulfur, optionally substituted nitrogen, or an optionally substituted divalent hydrocarbon group; Y is two hydrogen atoms, oxygen, or sulfur; and the dotted line indicates that R2 and an atom on ring B may together form a ring] and salts are prepared and tested as somatostatin

receptor regulators. Thus, the title compound II was prepared in treatment or prevention of diabetes and obesity.

IC ICM C07C231-12
ICS C07C233-01; C07C235-00; C07C237-00; C07C311-00; C07C317-44; C07C323-50; C07D207-26; C07D209-16; C07D211-62; C07D211-96; C07D213-40; C07D213-74; C07D217-22; C07D217-24; C07D235-26; C07D277-30; C07D285-12; C07D295-10; C07D295-18

CC 23-4 (Aliphatic Compounds)
Section cross-reference(s): 1, 63

IT 5181-11-3P 10314-98-4P 14062-25-0P 18699-02-0P 28387-66-8P
36925-05-0P 55311-42-7P 56205-90-4P 82340-96-3P 94838-55-8P
109138-28-5P 129150-68-1P 158985-25-2P 198904-53-9P 216064-48-1P
221040-07-9P 263893-82-9P 264915-70-0P 266368-57-4P 266368-58-5P
266368-59-6P 266368-60-9P 266368-61-0P 266368-62-1P 266368-63-2P
266368-64-3P 266368-65-4P 266368-66-5P 266368-67-6P 266368-68-7P
266368-69-8P 266368-70-1P 266368-71-2P 266368-72-3P 266368-73-4P
266368-74-5P 266368-75-6P 266368-76-7P 266368-77-8P 266368-78-9P
266368-79-0P 266368-80-3P 266368-81-4P 266368-82-5P 266368-83-6P
266368-84-7P 266368-85-8P 266368-86-9P 266368-87-0P 266368-88-1P
266368-89-2P 266368-90-5P 266368-91-6P 266368-92-7P 266368-93-8P
266368-94-9P 266368-95-0P 266368-96-1P 266368-97-2P 266368-98-3P
266368-99-4P 266369-00-0P 266369-01-1P 266369-02-2P 266369-03-3P
266369-04-4P 266369-05-5P 266369-06-6P 266369-07-7P 266369-08-8P
266369-09-9P 266369-10-2P 266369-11-3P 266369-12-4P 266369-13-5P
266369-14-6P 266369-15-7P 266369-16-8P 266369-17-9P 266369-18-0P
266369-19-1P 266369-20-4P 266369-21-5P 266369-22-6P 266369-23-7P
266369-24-8P 266369-25-9P 266369-26-0P 266369-27-1P 266369-28-2P
266369-29-3P 266369-30-6P 266369-31-7P 266369-32-8P 266369-33-9P
266369-34-0P 266369-35-1P 266369-36-2P 266369-37-3P 266369-38-4P
266369-39-5P 266369-40-8P 266369-41-9P 266369-42-0P 266369-43-1P
266369-44-2P 266369-45-3P 266369-46-4P 266369-47-5P 266369-48-6P
266369-49-7P 266369-50-0P 266369-51-1P 266369-52-2P 266369-53-3P
266369-54-4P 266369-55-5P 266369-56-6P 266369-57-7P 266369-58-8P
266369-59-9P 266369-60-2P 266369-61-3P 266369-62-4P 266369-63-5P
266369-64-6P 266369-65-7P 266369-66-8P 266369-67-9P 266369-68-0P
266369-69-1P 266369-70-4P 266369-71-5P 266369-72-6P 266369-73-7P
266369-74-8P 266369-75-9P 266369-76-0P 266369-77-1P 266369-78-2P
266369-79-3P 266369-80-6P 266369-82-8P 266369-83-9P 266369-84-0P
266369-85-1P 266369-86-2P 266369-87-3P 266369-88-4P 266369-89-5P
266369-90-8P 266369-91-9P 266369-92-0P 266369-93-1P 266369-94-2P
266369-95-3P 266369-96-4P 266369-97-5P 266369-98-6P 266369-99-7P
266370-00-7P 266370-01-8P 266370-02-9P 266370-03-0P 266370-04-1P
266370-05-2P 266370-06-3P 266370-07-4P 266370-08-5P 266370-09-6P
266370-10-9P 266370-11-0P 266370-12-1P 266370-13-2P 266370-14-3P
266370-15-4P 266370-16-5P 266370-17-6P 266370-18-7P 266370-19-8P
266370-20-1P 266370-21-2P 266370-22-3P 266370-23-4P 266370-24-5P
266370-25-6P 266370-26-7P 266370-27-8P 266370-28-9P 266370-29-0P
266370-30-3P 266370-31-4P 266370-32-5P 266370-33-6P 266370-34-7P
266370-35-8P 266370-36-9P 266370-37-0P 266370-38-1P
266370-39-2P 266370-40-5P 266370-41-6P 266370-42-7P 266370-43-8P
266370-44-9P 266370-45-0P 266370-46-1P 266370-47-2P 266370-48-3P
266370-49-4P 266370-50-7P 266370-57-4P 266370-64-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aromatic amine derivs. and agents containing the same as somatostatin receptor regulators)

IT 266364-65-2P 266364-67-4P 266364-69-6P 266364-75-4P 266364-83-4P
266364-89-0P 266365-79-1P 266365-89-3P 266365-95-1P 266366-01-2P
266366-07-8P 266366-13-6P 266366-25-0P 266366-31-8P 266366-61-4P
266366-63-6P 266366-65-8P 266366-67-0P 266366-69-2P 266366-71-6P

266366-73-8P 266366-75-0P 266366-77-2P 266366-79-4P 266366-81-8P
266366-83-0P 266366-85-2P 266366-87-4P 266366-89-6P 266366-91-0P
266366-93-2P 266366-95-4P 266366-97-6P 266366-99-8P 266367-01-5P
266367-03-7P 266367-05-9P 266367-07-1P 266367-09-3P 266367-11-7P
266367-13-9P 266367-15-1P 266367-17-3P 266367-19-5P 266367-21-9P
266367-23-1P 266367-25-3P 266367-27-5P 266367-29-7P 266367-31-1P
266367-33-3P 266367-35-5P 266367-37-7P 266367-39-9P 266367-41-3P
266367-43-5P 266367-45-7P 266367-47-9P 266367-49-1P 266367-51-5P
266367-53-7P 266367-55-9P 266367-57-1P 266367-59-3P 266367-61-7P
266367-63-9P 266367-65-1P 266367-67-3P 266367-69-5P 266367-71-9P
266367-73-1P 266367-75-3P 266367-77-5P 266367-79-7P 266367-81-1P
266367-83-3P 266367-85-5P 266367-87-7P 266367-89-9P 266367-91-3P
266367-93-5P 266367-95-7P 266367-96-8P 266367-97-9P 266367-98-0P
266367-99-1P 266368-00-7P 266368-01-8P 266368-02-9P 266368-03-0P
266368-04-1P 266368-05-2P 266368-06-3P 266368-07-4P 266368-08-5P
266368-09-6P 266368-10-9P 266368-11-0P 266368-12-1P 266368-13-2P
266368-14-3P 266368-15-4P 266368-16-5P 266368-17-6P 266368-18-7P
266368-19-8P 266368-20-1P 266368-21-2P 266368-22-3P 266368-23-4P
266368-24-5P 266368-25-6P 266368-26-7P 266368-27-8P 266368-28-9P
266368-29-0P 266368-30-3P 266368-31-4P 266368-32-5P 266368-33-6P
266368-34-7P 266368-35-8P 266368-36-9P 266368-37-0P 266368-38-1P
266368-39-2P 266368-40-5P 266368-41-6P 266368-42-7P 266368-43-8P
266368-44-9P 266368-45-0P 266368-46-1P 266368-47-2P 266368-48-3P
266368-49-4P 266368-50-7P 266368-51-8P 266368-52-9P
266368-53-0P 266368-54-1P 266368-55-2P 266368-56-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic amine derivs. and agents containing the same as somatostatin receptor regulators)

IT 266370-36-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aromatic amine derivs. and agents containing the same as somatostatin receptor regulators)

RN 266370-36-9 HCAPLUS

CN Carbamic acid, [[3-[2-[[([1,1'-biphenyl]-4-yloxy)acetyl][4-[[(2-fluorophenyl)methyl]amino]-4-oxobutyl]amino]-5-chlorophenoxy]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 266368-53-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic amine derivs. and agents containing the same as somatostatin receptor regulators)
RN 266368-53-0 HCAPLUS
CN Butanamide, 4-[[2-[3-(aminomethyl)phenoxy]-4-chlorophenyl][2-([1,1'-biphenyl]-4-yloxy)acetyl]amino]-N-[(2-fluorophenyl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 33 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:193988 HCAPLUS Full-text
DOCUMENT NUMBER: 130:237569
TITLE: Preparation of N-phenylalkylurea and phenylalkylcarbamate derivatives as peroxisome proliferator-activated receptor controllers
INVENTOR(S): Tajima, Hisao; Nakayama, Yoshisuke; Fukushima, Daikichi
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912534	A1	19990318	WO 1998-JP3930	19980902 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9889966	A	19990329	AU 1998-89966	19980902 <--
PRIORITY APPLN. INFO.:			JP 1997-245101 A	19970910 <--
			WO 1998-JP3930 W	19980902 <--

OTHER SOURCE(S): MARPAT 130:237569
ED Entered STN: 25 Mar 1999
GI



AB Claimed are peroxisome proliferator-activated receptor (PPAR) controllers containing as the active ingredient compds. represented by general formula [I; A = single bond, C1-7 alkylene, C2-6 alkenylene; when A = single bond, then R1 = C1-14 alkyl, C2-6 alkenyl or alkynyl, (un)substituted C3-14 mono- or polycyclic (un)saturated carbocyclic ring, 4- to 7-membered ring monocyclic heterocyclic ring; when A = C1-7 alkylene or C2-6 alkenylene, R1 = halo, OH, C1-4 alkoxy, PhO, C1-4 alkylthio, NH2, C1-4 alkyl-carbonyloxy, C1-4 alkoxy-carbonyloxy, (un)substituted C3-14 mono- or polycyclic (un)saturated carbocyclic ring, 4- to 7-membered ring monocyclic heterocyclic ring; X1 = O, S; X2 = NR2, O; wherein R2 = H, (un)substituted C1-4 alkyl, C2-6 alkenyl, or alkynyl; R3 = CO2H, C1-4 alkoxycarbonyl, carboxyphenyl, C1-4 alkoxy-Ph, 1H-tetrazol-5-ylphenyl; E = Q or substituted alkyl, or E and R2 of NR2 are joined together to form an optionally benzene-fused and substituted monocyclic 4- to 7-membered saturated heterocyclic ring containing 1-2 N, one N and one O, or a total of three N and O atoms; ring G = benzene ring, 4- to 7-membered ring monocyclic unsatd. heterocyclic ring containing one N or O; R21 = H, C1-4 alkyl, alkoxy, or alkylthio, OH, hydroxy-C1-4 alkyl, halo, etc.; m4 = 1-3; m = 0, 1-4; n1 =1-4], salts of the same, or hydrates of both. The compds. exhibit

control effects against PPAR and are therefore useful as antihyperglycemic drugs, antihyperlipidemic drugs, HDL-cholesterol-increasing agents, LDL cholesterol- and/or VLDL cholesterol-lowering agents, risk factor decreasing agents for diabetes and syndrome X, or preventive and/or therapeutic agents for metabolic diseases such as diabetes, obesity, syndrome X, hypercholesterolemia and hyperlipo-proteinemia, hyperlipemia, arteriosclerosis, circulatory diseases, polyphagy, and ischemic heart diseases. Thus, the title compound (II).Na at 100 mg/kg/day p.o. for 14 consecutive days lowered the blood lipid (free fatty acid) from 797±201 mg/dL (control) to 575±113 mg/dL and the blood triglyceride level from 79±28 mg/dL (control) to 51±34 mg/dL in mice. A tablet and an ampule formulation containing II were described.

IC ICM A61K031-17
ICS A61K031-41; C07D257-04

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 158695-45-5 160837-87-6 160837-92-3 160837-98-9
160838-00-6 160838-06-2 160838-10-8 160838-11-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of N-phenylalkylurea and phenylalkylcarbamate derivs. as peroxisome proliferator-activated receptor controllers for treatment of diseases)

IT 160837-98-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of N-phenylalkylurea and phenylalkylcarbamate derivs. as peroxisome proliferator-activated receptor controllers for treatment of diseases)

RN 160837-98-9 HCAPLUS

CN Urea, N'-(2-bromophenyl)-N-butyl-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, sodium salt (1:1) (CA INDEX NAME)







OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 34 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1996:476652 HCAPLUS Full-text
DOCUMENT NUMBER: 125:142578
ORIGINAL REFERENCE NO.: 125:26685a,26688a
TITLE: Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists.
INVENTOR(S): Oku, Teruo; Kayakiri, Hiroshi; Satoh, Shigeki; Abe, Yoshito; Sawada, Yuki; Inoue, Takayuki; Tanaka, Hirokazu
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 263 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 9613485	A1	19960509	WO 1995-JP2192		19951025	<--
W: AU, CA, CN, HU, JP, KR, MX, RU, US						
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE						
CA 2203659	A1	19960509	CA 1995-2203659		19951025	<--
AU 9537536	A	19960523	AU 1995-37536		19951025	<--
AU 705883	B2	19990603				
EP 807105	A1	19971119	EP 1995-935563		19951025	<--
EP 807105	B1	20040616				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE						
CN 1168667	A	19971224	CN 1995-196602		19951025	<--
JP 10507764	T	19980728	JP 1996-514166		19951025	<--
JP 3697486	B2	20050921				
AT 269310	T	20040715	AT 1995-935563		19951025	<--
ES 2218554	T3	20041116	ES 1995-935563		19951025	<--
US 5994368	A	19991130	US 1997-809416		19970425	<--
PRIORITY APPLN. INFO.:			GB 1994-21684	A	19941027	<--
			GB 1995-12339	A	19950616	<--
			WO 1995-JP2192	W	19951025	<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 125:142578
ED Entered STN: 13 Aug 1996
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to title compds. I [Z = group Q1 or Q2; X1 = N or CR1; X2 = N or CR9; X3 = N or CR2; R1 = alkyl; R2 = H, (un)substituted alkyl, alkoxy, halo, aryl, amino, etc.; R3 = H, alkyl, alkoxy, halo; R4 = alkyl, alkoxy, halo; R5 = OH, nitro, (un)substituted alkoxy, substituted piperazinyl, NR6R7; R6 = H, alkyl; R7 = H, alkoxycarbonyl, (un)substituted aroyl, carbamoyl, -(AA)COQR8, -(AA)R10; R8 = (un)substituted arylthio, aryloxy, arylamino, heterocyclylthio, heterocyclylamino, etc.; R9 = H, alkyl; R10 = H, acylbiphenyl; A = alkylene; (AA) = amino acid; Y = O, NR11; R11 = H, N-protective group], and pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compns., and therapeutic use in the prevention and/or the treatment of bradykinin-mediated diseases. Such diseases include allergy, inflammation, autoimmune disease, shock, and pain. For instance, amidation of 8-[3-(N-glycyl-N-methylamino)-2,6-

dichlorobenzyloxy]-2- methylquinoline with (E)-3-[6-(ethoxycarbonyl)-3-pyridyl]acrylic acid [prepns. given] using EDC and HOBt in DMF gave title compound II. The similarly prepared title compound III.HCl gave 100% inhibition of [3H]-bradykinin binding to rat ileum receptors in vitro at 10-6 M.

IC ICM C07D215-16
ICS A61K031-47; C07D471-02; A61K031-395; C07D215-26; C07D471-04
ICI C07D471-04, C07D221-00; C07D471-04, C07D221-00, C07D277-00; C07D471-04, C07D221-00, C07D241-00
CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 28
IT 179623-46-2P 179623-47-3P 179623-48-4P 179623-49-5P 179623-50-8P
179623-51-9P 179623-52-0P 179623-53-1P 179623-54-2P 179623-55-3P
179623-56-4P 179623-57-5P 179623-58-6P 179623-59-7P 179623-60-0P
179623-61-1P 179623-62-2P 179623-63-3P 179623-64-4P 179623-65-5P
179623-66-6P 179623-67-7P 179623-68-8P 179623-69-9P 179623-70-2P
179623-71-3P 179623-72-4P 179623-73-5P 179623-74-6P 179623-75-7P
179623-76-8P 179623-77-9P 179623-78-0P 179623-79-1P 179623-80-4P
179623-81-5P 179623-82-6P 179623-83-7P 179623-84-8P 179623-85-9P
179623-86-0P 179623-87-1P 179623-88-2P 179623-89-3P 179623-90-6P
179623-91-7P 179623-92-8P 179623-93-9P 179623-94-0P 179623-95-1P
179623-96-2P 179623-97-3P 179623-98-4P 179623-99-5P 179624-00-1P
179624-01-2P 179624-02-3P 179624-03-4P 179624-04-5P 179624-05-6P
179624-06-7P 179624-07-8P 179624-08-9P 179624-09-0P 179624-10-3P
179624-11-4P 179624-12-5P 179624-13-6P 179624-14-7P 179624-15-8P
179624-16-9P 179624-17-0P 179624-18-1P 179624-19-2P 179624-20-5P
179624-21-6P 179624-22-7P 179624-23-8P 179624-24-9P 179624-25-0P
179624-26-1P 179624-27-2P 179624-28-3P 179624-29-4P 179624-30-7P
179624-31-8P 179624-32-9P 179624-33-0P 179624-34-1P 179624-35-2P
179624-36-3P 179624-37-4P 179624-38-5P 179624-39-6P 179624-40-9P
179624-41-0P 179624-42-1P 179624-43-2P 179624-44-3P 179624-45-4P
179624-46-5P 179624-47-6P 179624-48-7P 179624-49-8P 179624-50-1P
179624-51-2P 179624-52-3P 179624-53-4P 179624-54-5P 179624-55-6P
179624-56-7P 179624-57-8P 179624-58-9P 179624-59-0P 179624-60-3P
179624-61-4P 179624-62-5P 179624-63-6P 179624-64-7P 179624-65-8P
179624-66-9P 179624-67-0P 179624-68-1P 179624-69-2P 179624-70-5P
179624-71-6P 179624-72-7P 179624-73-8P 179624-74-9P 179624-75-0P
179624-76-1P 179624-77-2P 179624-78-3P 179624-79-4P 179624-80-7P
179624-81-8P 179624-82-9P 179624-83-0P 179624-84-1P 179624-85-2P
179624-86-3P 179624-87-4P 179624-88-5P 179624-89-6P 179624-90-9P
179624-91-0P 179624-92-1P 179624-93-2P 179624-94-3P 179624-95-4P
179624-96-5P 179624-97-6P 179624-98-7P 179624-99-8P 179625-00-4P
179625-01-5P 179625-02-6P 179625-03-7P 179625-04-8P 179625-05-9P
179625-06-0P 179625-07-1P 179625-08-2P 179625-09-3P 179625-10-6P
179625-11-7P 179625-12-8P 179625-13-9P 179625-14-0P
179625-15-1P 179625-16-2P 179625-17-3P 179625-18-4P 179625-19-5P
179625-20-8P 179625-21-9P 179625-22-0P 179625-23-1P 179625-24-2P
179625-25-3P 179625-26-4P 179625-27-5P 179625-28-6P 179625-29-7P
179625-30-0P 179626-51-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridopyrimidones, quinolines, and fused N-heterocycles as bradykinin antagonists)
IT 179625-12-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridopyrimidones, quinolines, and fused N-heterocycles as bradykinin antagonists)

RN 179625-12-8 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-[[2-[[2,4-dichloro-3-[[(2-methyl-8-quinolinyl)oxy]methyl]phenyl]methylamino]-2-oxoethyl]amino]-N,N-dimethyl- (CA INDEX NAME)



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 35 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1996:455768 HCAPLUS Full-text
DOCUMENT NUMBER: 125:114322
ORIGINAL REFERENCE NO.: 125:21442h,21443a
TITLE: Preparation of urea derivatives as cholesterol acyltransferase inhibitors
INVENTOR(S): Terasawa, Takeshi; Tanaka, Akira; Chiba, Toshiyuki; Takasugi, Hisashi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 228 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 9610559	A1	19960411	WO 1995-JP1982		19950929	<--
W: AU, CA, CN, HU, JP, KR, MX, RU, US						
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE						
IN 1995MA01229	A	20050225	IN 1995-MA1229		19950922	<--
CA 2200981	A1	19960411	CA 1995-2200981		19950929	<--
AU 9535779	A	19960426	AU 1995-35779		19950929	<--
EP 784612	A1	19970723	EP 1995-932934		19950929	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE						
JP 10510512	T	19981013	JP 1995-511616		19950929	<--
ZA 9508365	A	19960508	ZA 1995-8365		19951004	<--
PRIORITY APPLN. INFO.:			GB 1994-19970	A	19941004	<--
			GB 1995-6720	A	19950331	<--
			GB 1995-14021	A	19950710	<--
			WO 1995-JP1982	W	19950929	<--

OTHER SOURCE(S): MARPAT 125:114322

ED Entered STN: 02 Aug 1996

AB R4YC6H4(CH2)nNR2CONHR3 [R2 = (ar)alkyl, heterocyclyl(alkyl), alkoxyalkyl, etc.; R3,R4 = (un)substituted aryl, heterocyclyl; Y = bond, alkylene, O, CO, CONH, etc.; n = 0 or 1] were prepare Thus, 1-cycloheptyl-1-(4-phenoxyphenylmethyl)-3-(2,4,6-trifluorophenyl)urea had IC50 of 1.1x10-8M against cholesterol acyltransferase in vitro.

IC ICM C07C275-28
ICS C07D213-75; C07D257-04; C07D231-12; C07D401-12; A61K031-17; A61K031-44; A61K031-41; C07D213-40; C07D307-38; C07D277-28; C07D233-54; C07C311-21; C07D333-20

CC 25-21 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1

IT 179053-26-0P 179053-27-1P 179053-28-2P 179053-29-3P 179053-30-6P
179053-31-7P 179053-32-8P 179053-33-9P 179053-34-0P 179053-35-1P
179053-36-2P 179053-37-3P 179053-38-4P 179053-39-5P 179053-40-8P
179053-41-9P 179053-42-0P 179053-43-1P 179053-44-2P 179053-45-3P
179053-46-4P 179053-47-5P 179053-48-6P 179053-49-7P 179053-50-0P
179053-51-1P 179053-52-2P 179053-53-3P 179053-54-4P 179053-55-5P
179053-56-6P 179053-57-7P 179053-58-8P 179053-59-9P 179053-60-2P
179053-61-3P 179053-62-4P 179053-63-5P 179053-64-6P 179053-65-7P
179053-66-8P 179053-67-9P 179053-68-0P 179053-69-1P 179053-70-4P
179053-71-5P 179053-72-6P 179053-73-7P 179053-74-8P 179053-75-9P
179053-76-0P 179053-77-1P 179053-78-2P
179053-79-3P 179053-80-6P 179053-81-7P 179053-82-8P
179053-83-9P 179053-84-0P 179053-85-1P
179053-86-2P 179053-87-3P 179053-88-4P 179053-89-5P
179053-90-8P 179053-91-9P 179053-92-0P 179053-93-1P
179053-94-2P 179053-95-3P 179053-96-4P 179053-97-5P 179053-98-6P
179053-99-7P 179054-00-3P 179054-01-4P 179054-02-5P
179054-03-6P 179054-04-7P 179054-05-8P 179054-06-9P 179054-07-0P
179054-08-1P 179054-09-2P 179054-10-5P 179054-11-6P 179054-12-7P
179054-13-8P 179054-14-9P 179054-15-0P 179054-16-1P 179054-17-2P
179054-18-3P 179054-19-4P 179054-20-7P 179054-21-8P
179054-22-9P 179054-23-0P 179054-24-1P 179054-25-2P 179054-26-3P
179054-27-4P 179054-28-5P 179054-29-6P 179054-30-9P 179054-31-0P
179054-32-1P 179054-33-2P 179054-34-3P 179054-35-4P 179054-36-5P
179054-37-6P 179054-38-7P 179054-39-8P 179054-40-1P 179054-41-2P
179054-42-3P 179054-43-4P 179054-44-5P 179054-45-6P 179054-46-7P
179054-47-8P 179054-48-9P 179054-49-0P 179054-50-3P 179054-51-4P
179054-52-5P 179054-53-6P 179054-54-7P 179054-55-8P
179054-56-9P 179054-57-0P 179054-58-1P 179054-59-2P 179054-60-5P
179054-61-6P 179054-62-7P 179054-63-8P 179054-64-9P 179054-65-0P
179054-66-1P 179054-67-2P 179054-68-3P 179054-69-4P 179054-70-7P
179054-71-8P 179054-72-9P 179054-73-0P 179054-74-1P 179054-75-2P
179054-76-3P 179054-77-4P 179054-78-5P 179054-79-6P 179054-80-9P
179054-81-0P 179054-82-1P 179054-83-2P 179054-84-3P
179054-85-4P 179054-86-5P 179054-87-6P 179054-88-7P
179054-89-8P 179054-90-1P 179054-91-2P 179054-92-3P 179054-93-4P
179054-94-5P 179054-95-6P 179054-96-7P 179054-97-8P 179054-98-9P
179054-99-0P 179055-00-6P 179055-01-7P 179055-02-8P 179055-03-9P
179055-04-0P 179055-05-1P 179055-06-2P 179055-07-3P 179055-08-4P
179055-09-5P 179055-10-8P 179055-11-9P 179055-12-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of urea derivs. as cholesterol acyltransferase inhibitors)

IT 179053-78-2P 179053-79-3P 179053-82-8P
179053-84-0P 179053-85-1P 179053-86-2P
179053-91-9P 179053-99-7P 179054-18-3P
179054-54-7P 179054-85-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of urea derivs. as cholesterol acyltransferase inhibitors)

RN 179053-78-2 HCAPLUS
CN Urea, N-([1,1'-biphenyl]-3-ylmethyl)-N-cycloheptyl-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 179053-79-3 HCAPLUS
CN Urea, N-([1,1'-biphenyl]-2-ylmethyl)-N-cycloheptyl-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 179053-82-8 HCAPLUS
CN Urea, N-cycloheptyl-N-[[4-(2-pyridinyl)phenyl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 179053-84-0 HCAPLUS
CN Urea, N-cycloheptyl-N-[[4-(1H-pyrrol-1-yl)phenyl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 179053-85-1 HCAPLUS
CN Urea, N-cycloheptyl-N-[[4-(3-thienyl)phenyl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 179053-86-2 HCAPLUS
CN Urea, N-cycloheptyl-N-[[4-(2-thienyl)phenyl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 179053-91-9 HCAPLUS
CN Urea, N-cycloheptyl-N'-(2,4,6-trifluorophenyl)-N-[[3-[1-(triphenylmethyl)-1H-pyrazol-3-yl]phenyl]methyl]- (CA INDEX NAME)



RN 179053-99-7 HCAPLUS
CN Urea, N-cycloheptyl-N-[[3-(1H-pyrazol-3-yl)phenyl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 179054-18-3 HCAPLUS
CN Urea, N-(phenylmethyl)-N-[[3-(1H-pyrazol-3-yl)phenyl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 179054-54-7 HCAPLUS
CN Urea, N-[[4-(dimethylamino)phenyl]methyl]-N-[[3-(1H-pyrazol-3-yl)phenyl]methyl]-N'-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



RN 179054-85-4 HCAPLUS
CN Urea, N-[(4-fluorophenyl)methyl]-N'-(2,4,6-trifluorophenyl)-N-[[3-[1-(triphenylmethyl)-1H-pyrazol-3-yl]phenyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L125 ANSWER 36 OF 36 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1995:346786 HCAPLUS Full-text
DOCUMENT NUMBER: 122:133193
ORIGINAL REFERENCE NO.: 122:24843a,24846a
TITLE: Preparation of N-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]urea derivatives as angiotensin II antagonists
INVENTOR(S): Mori, Tetsuya; Matsui, Toshiaki; Kawamura, Masanori
PATENT ASSIGNEE(S): Ono Pharmaceutical Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 44 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06211814	A	19940802	JP 1993-22099	19930114 <--
JP 3116256	B2	20001211		
PRIORITY APPLN. INFO.:			JP 1993-22099	19930114 <--

OTHER SOURCE(S): MARPAT 122:133193
ED Entered STN: 11 Feb 1995
GI For diagram(s), see printed CA Issue.
AB The title compds. [I; T = O, S; ring A = benzene ring, 4- to 7-membered ring monocyclic unsatd. heterocycle containing 1 S or 1 N atom.; R1 = C1-8 alkyl; R2 = H, C1-4 alkyl,alkoxy, alkylthio, or hydroxyalkyl, halo, trihalomethyl, trihalomethyloxy, NO2, Ph, OCH2Ph, DR4, etc. (wherein D = single bond, C1-4 alkylene or alkyleneoxy, R4 = CO2R5, CH(OH)CO2R5, C(O)CO2R5, COCH2OH; R5 = H, C1-4 alkyl, CH2CONR6R7; R6, R7 = H, C1-4 alkyl); R3 = H, C1-4 alkyl, C2-6 alkenyl, CO2H, C1-4 alkoxycarbonyl, CONR12R13 (wherein R12, R13 = H, C1-3 alkyl or N R12R13 = 4- to 7-membered ring saturated monocyclic heterocyclyl containing 1 or 2 N atoms or 1 N and 1 O atom); Z = 1H-tetrazol-5-yl; m = 1-3;

provided that when m = 3, all 3 R2 = DR4 and all 3 R4 = CO2R5], useful for the treatment of hypertension, are prepared Thus, 77 μL Et3N and 105 mg Et 2-isocyanatobenzoate were added to a suspension of N-butyl-N-[[2'-[1-(2-cyanoethyl)tetrazol-5-yl]-1,1'- biphenyl-4-yl]methyl]amine hydrochloride in THF and the resulting mixture was stirred at room temperature for 1 h to give intermediate (II; R = CH2CH2CN). The latter compound was stirred with DBU in THF at room temperature for 5 h to give title compound II (R = H) which (109 mg) was dissolved in 1,4-dioxane-H2O (2:1), treated with 0.22 mL 1 N aqueous NaOH, and lyophilized to give 260 mg title compound Na salt II (R = Na) (III). A tablet formulation containing III was described.

IC ICM C07D257-04
ICS C07D401-12; C07D409-12

ICA A61K031-41; A61K031-44

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 160837-82-1P 160837-83-2P 160837-84-3P 160837-85-4P 160837-86-5P
160837-87-6P 160837-88-7P 160837-89-8P 160837-90-1P
160837-91-2P 160837-92-3P 160837-93-4P 160837-94-5P
160837-95-6P 160837-96-7P 160837-97-8P 160837-98-9P
160837-99-0P 160838-00-6P 160838-01-7P 160838-02-8P
160838-03-9P 160838-04-0P 160838-05-1P
160838-06-2P 160838-07-3P 160838-08-4P 160838-09-5P 160838-10-8P
160838-11-9P 160838-12-0P 160838-13-1P 160838-14-2P
160838-15-3P 160838-16-4P 160838-17-5P 160838-18-6P
160838-19-7P 160838-20-0P 160838-21-1P
160838-22-2P 160838-23-3P 160838-24-4P 160838-25-5P
160838-26-6P 160838-27-7P 160838-28-8P 160838-29-9P 160838-30-2P
160838-31-3P 160838-32-4P 160838-33-5P 160838-34-6P 160838-35-7P
160838-36-8P 160838-37-9P 160838-38-0P 160838-39-1P 160838-40-4P
160838-41-5P 160838-42-6P 161002-44-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[[(1H-tetrazolyl)biphenylyl]methyl]-N-(Ph or heterocyclyl)urea derivs. as angiotensin II antagonists)

IT 160837-91-2P 160837-98-9P 160838-03-9P
160838-05-1P 160838-14-2P 160838-19-7P
160838-20-0P 160838-21-1P 160838-25-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[[(1H-tetrazolyl)biphenylyl]methyl]-N-(Ph or heterocyclyl)urea derivs. as angiotensin II antagonists)

RN 160837-91-2 HCAPLUS

CN Urea, N-butyl-N'-(2,4-difluorophenyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, sodium salt (1:1) (CA INDEX NAME)



RN 160837-98-9 HCAPLUS
CN Urea, N'-(2-bromophenyl)-N-butyl-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, sodium salt (1:1) (CA INDEX NAME)



RN 160838-03-9 HCAPLUS
CN Urea, N-butyl-N'-(3,4-difluorophenyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, sodium salt (1:1) (CA INDEX NAME)



RN 160838-05-1 HCAPLUS
CN Urea, N-butyl-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-N'-[2-(trifluoromethyl)phenyl]-, sodium salt (1:1) (CA INDEX NAME)



RN 160838-14-2 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[butyl[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]carbonyl]amino]-, sodium salt (1:2) (CA INDEX NAME)



RN 160838-19-7 HCAPLUS
CN Benzoic acid, 2-[[[butyl[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]carbonyl]amino]-3,5-dichloro-, ethyl ester, sodium salt (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 160838-20-0 HCAPLUS
CN Benzoic acid, 2-[[[butyl[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-

yl]methyl]amino]carbonyl]amino]-3,5-dichloro-, sodium salt (1:2) (CA INDEX NAME)



RN 160838-21-1 HCAPLUS
CN Benzoic acid, 2-[[[butyl[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]carbonyl]amino]-4-fluoro-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 160838-25-5 HCAPLUS
CN Benzoic acid, 2-[[[butyl[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]carbonyl]amino]-5-chloro-, sodium salt (1:2) (CA INDEX NAME)







OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

```
=> d que nos l126
L5                STR
L6   (    402314)SEA FILE=REGISTRY SSS FUL L5
L7                STR
L8                STR
L9         33651 SEA FILE=REGISTRY SUB=L6 SSS FUL (L7 OR L8)
L18               STR
L19               STR
L21         9722 SEA FILE=REGISTRY SUB=L9 SSS FUL (L18 OR L19)
L117        3003 SEA FILE=REGISTRY SUB=L21 SSS FUL L18
L126           0 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L117 AND (MEDLINE OR
                 EMBASE OR BIOSIS)/LC
```

```
=> d que nos l122
L1             1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-569873/APPS
L5               STR
L6  (     402314)SEA FILE=REGISTRY SSS FUL L5
L7               STR
L8               STR
L9         33651 SEA FILE=REGISTRY SUB=L6 SSS FUL (L7 OR L8)
L18              STR
L19              STR
L21         9722 SEA FILE=REGISTRY SUB=L9 SSS FUL (L18 OR L19)
L53              QUE  SPE=ON  ABB=ON  PLU=ON  CHENG, W?/AU,AUTH
L54              QUE  SPE=ON  ABB=ON  PLU=ON  CO, E?/AU,AUTH
L55              QUE  SPE=ON  ABB=ON  PLU=ON  WANG-CO, E?/AU,AUTH
L56              QUE  SPE=ON  ABB=ON  PLU=ON  WANG CO, E?/AU,AUTH
L57              QUE  SPE=ON  ABB=ON  PLU=ON  WANGCO, E?/AU,AUTH
L58              QUE  SPE=ON  ABB=ON  PLU=ON  KIM, M?/AU,AUTH
L59              QUE  SPE=ON  ABB=ON  PLU=ON  KLEIN, R?/AU,AUTH
L60              QUE  SPE=ON  ABB=ON  PLU=ON  LE, D?/AU,AUTH
L61              QUE  SPE=ON  ABB=ON  PLU=ON  TSUHAKO, A?/AU,AUTH
L62              QUE  SPE=ON  ABB=ON  PLU=ON  LEW, A?/AU,AUTH
L63              QUE  SPE=ON  ABB=ON  PLU=ON  LEW-TSUHAKO, A?/AU,AUTH
L64              QUE  SPE=ON  ABB=ON  PLU=ON  LEWTSUHAKO, A?/AU,AUTH
L65              QUE  SPE=ON  ABB=ON  PLU=ON  NUSS, J?/AU,AUTH
L66              QUE  SPE=ON  ABB=ON  PLU=ON  XU, W?/AU,AUTH
L67              QUE  SPE=ON  ABB=ON  PLU=ON  BAJJALIEH, W?/AU,AUTH
L68              QUE  SPE=ON  ABB=ON  PLU=ON  BAJJALIEH, B?/AU,AUTH
L117        3003 SEA FILE=REGISTRY SUB=L21 SSS FUL L18
L118         183 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L117
L119           2 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L118 AND (L53 OR L54
                 OR L55 OR L56 OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63
                 OR L64 OR L65 OR L66 OR L67 OR L68)
L120           1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L1 AND L119
L121           0 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L1 NOT L119
L122           2 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L119 OR L120 OR
                 L121)
```

```
=> d ibib ed abs hitind hitstr l122 1-2
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y



L122 ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2005:216619  HCAPLUS  Full-text
DOCUMENT NUMBER:          142:297864
TITLE:                    Preparation of aniline derivatives and related
                          compounds as c-kit modulators
INVENTOR(S):              Cheng, Wei; Co, Erick Wang;
                          Kim, Moon Hwan; Klein, Rhett Ronald;
                          Le Donna, T.; Lew, Amy; Nuss,
                          John M.; Xu, Wei; Bajjalieh,
                          William
PATENT ASSIGNEE(S):       Exelixis, Inc., USA
SOURCE:                   PCT Int. Appl., 169 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2005020921         A2    20050310    WO 2004-US28001         20040827
     WO 2005020921         A3    20051006
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004268621         A1    20050310    AU 2004-268621          20040827
     CA 2536954            A1    20050310    CA 2004-2536954         20040827
     EP 1663204            A2    20060607    EP 2004-782473          20040827
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
     JP 2007504160          T    20070301    JP 2006-524905          20040827
     US 20080096892        A1    20080424    US 2007-569873          20070904 <--
PRIORITY APPLN. INFO.:                       US 2003-499224P     P   20030829
                                             WO 2004-US28001     W   20040827
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S):          CASREACT 142:297864; MARPAT 142:297864
ED   Entered STN:  11 Mar 2005
GI
```



I

II

AB Compds. I [wherein ring A is a five- to fourteen-membered heteroaryl; R1, R2 and R3 are H, halo, trihalomethyl, cyano, nitro, etc.; L1 is a single bond, (un)substituted alkylene, O, CH2O, etc.; ring B is five- to ten-membered aryl or heterocyclyl; ring C is five- to ten-membered (hetero)aryl; L2 is alkylene, alkylidene, alkylidyne, etc.; with some limitations and exclusions, and pharmaceutically acceptable salts, hydrates or prodrugs thereof], as exemplified by carbonyl compds. of anilines, were prepared as c-Kit kinase modulators. For example, 3-aminophenoxyacetic acid, which was obtained from the corresponding nitro compound in 76% yield via catalytic hydrogenation, was treated with HC(OEt)3 and NaN3 in AcOH followed by NaNO2/HCl to give a tetrazole in 61% yield. This acid was coupled with 5-amino-2-chlorobenzotrifluoride in the presence of HATU to afford acetamide II in 46% yield, which showed inhibition against c-Kit kinase with a IC50 of < 50 nM. Therefore, I and pharmaceutical compns. thereof are useful for modulating c-Kit kinase activity and for treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities.

IC ICM A61K

CC 25-4 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63

IT 332176-73-5P 332176-74-6P 337354-96-8P 337496-38-5P
337496-40-9P 460318-24-5P 483337-15-1P 483337-16-2P 483337-17-3P
483337-18-4P 483337-19-5P 483337-20-8P 483337-21-9P 483337-22-0P
483337-23-1P 483337-24-2P 483337-25-3P 483337-26-4P 483337-27-5P
483337-28-6P 483337-29-7P 483337-30-0P 483337-32-2P
483337-34-4P 483337-36-6P 483337-37-7P
483337-38-8P 483337-39-9P 483337-40-2P
483337-41-3P 483337-42-4P 483337-43-5P 483337-44-6P
483337-45-7P 483978-03-6P 490020-25-2P 494197-69-2P
494197-70-5P 505052-18-6P 506433-09-6P
552825-29-3P 847606-67-1P 847606-71-7P
847606-73-9P 847606-74-0P 847606-76-2P
847606-77-3P 847606-78-4P 847606-81-9P
847606-84-2P 847606-87-5P 847606-88-6P
847606-90-0P 847606-92-2P 847606-93-3P
847606-95-5P 847607-05-0P 847607-13-0P
847607-14-1P 847607-15-2P 847607-16-3P
847607-17-4P 847607-18-5P 847607-19-6P
847607-20-9P 847607-21-0P 847607-22-1P
847607-23-2P 847607-24-3P 847607-25-4P
847607-26-5P 847607-27-6P 847607-28-7P
847607-29-8P 847607-30-1P 847607-31-2P 847607-32-3P
847607-33-4P 847607-34-5P 847607-35-6P 847607-36-7P
847607-37-8P 847607-38-9P 847607-39-0P
847607-40-3P 847607-41-4P 847607-42-5P 847607-43-6P 847607-44-7P
847607-45-8P 847607-46-9P 847607-47-0P

847607-48-1P 847607-49-2P 847607-50-5P 847607-51-6P
847607-52-7P 847607-53-8P 847607-54-9P 847607-55-0P
847607-56-1P 847607-57-2P 847607-58-3P
847607-59-4P 847607-60-7P 847607-61-8P
847607-63-0P 847607-64-1P 847607-66-3P 847607-67-4P
847607-68-5P 847607-69-6P 847607-70-9P
847607-71-0P 847607-72-1P 847607-73-2P
847607-74-3P 847607-75-4P 847607-76-5P
847607-77-6P 847607-78-7P 847607-79-8P
847607-80-1P 847607-81-2P 847607-82-3P
847607-83-4P 847607-84-5P 847607-86-7P
847607-87-8P 847607-88-9P 847607-89-0P
847607-90-3P 847607-91-4P 847607-92-5P
847607-93-6P 847607-94-7P 847607-95-8P
847607-96-9P 847607-97-0P 847607-98-1P
847607-99-2P 847608-00-8P 847608-01-9P
847608-02-0P 847608-03-1P 847608-04-2P
847608-05-3P 847608-06-4P 847608-07-5P
847608-08-6P 847608-09-7P 847608-10-0P
847608-11-1P 847608-12-2P 847608-13-3P
847608-14-4P 847608-15-5P 847608-16-6P
847608-17-7P 847608-18-8P 847608-19-9P
847608-20-2P 847608-21-3P 847608-23-5P
847608-24-6P 847608-25-7P 847608-26-8P
847608-27-9P 847608-29-1P 847608-30-4P
847608-31-5P 847608-32-6P 847608-33-7P
847608-35-9P 847608-37-1P 847608-39-3P
847608-42-8P 847608-44-0P 847608-46-2P
847608-48-4P 847608-50-8P 847608-51-9P
847608-53-1P 847608-55-3P 847608-57-5P
847608-58-6P 847608-59-7P 847609-60-0P
847608-61-1P 847608-62-2P 847608-63-3P
847608-64-4P 847608-65-5P 847608-66-6P
847608-67-7P 847608-68-8P 847608-69-9P
847608-70-2P 847608-71-3P 847608-72-4P
847608-73-5P 847608-74-6P 847608-75-7P
847608-77-9P 847608-79-1P 847608-80-4P
847608-81-5P 847608-82-6P 847608-83-7P
847608-84-8P 847608-85-9P 847608-86-0P
847608-87-1P 847608-88-2P 847608-89-3P
847608-90-6P 847608-91-7P 847608-93-9P
847608-94-0P 847608-95-1P 847608-96-2P
847608-98-4P 847609-00-1P 847609-02-3P
847609-04-5P 847609-06-7P 847609-08-9P
847609-10-3P 847609-12-5P 847609-14-7P
847609-16-9P 847609-18-1P 847609-20-5P
847609-22-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(modulator; preparation of anilines and related compds. as C-kit modulators)

IT 847609-24-9P 847609-26-1P 847609-28-3P
847609-30-7P 847609-32-9P 847609-33-0P
847609-34-1P 847609-35-2P 847609-36-3P
847609-39-6P 847609-41-0P 847609-43-2P
847609-46-5P 847609-48-7P 847609-50-1P
847609-52-3P 847609-54-5P 847609-56-7P
847609-57-8P 847609-58-9P 847609-59-0P
847609-60-3P 847609-61-4P 847609-62-5P 847609-63-6P

847609-65-8P 847609-67-0P 847609-69-2P
847609-71-6P 847609-73-8P 847609-75-0P
847609-77-2P 847609-79-4P 847609-81-8P
847609-86-3P 847609-93-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(modulator; preparation of anilines and related compds. as C-kit modulators)

IT 351-33-7P 6274-24-4P, 3-Aminophenoxyacetic acid 14213-10-6P
14213-12-8P 85553-54-4P 90084-67-6P 125620-16-8P 198084-13-8P, 4-(5-Pyrimidinyl)benzyl alcohol 229643-02-1P 352347-24-1P
462067-31-8P 578748-03-5P 832739-85-2P 847606-68-2P 847606-69-3P
847606-70-6P 847606-72-8P 847606-75-1P 847606-79-5P
847606-82-0P 847606-83-1P 847606-85-3P 847606-86-4P 847606-89-7P
847606-91-1P 847606-94-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of anilines and related compds. as C-kit modulators)

IT 332176-74-6P 483337-32-2P 483337-34-4P
483337-36-6P 483337-37-7P 483337-38-8P
483337-39-9P 483337-40-2P 483337-41-3P
483978-03-6P 505052-18-6P 506433-09-6P
552825-29-3P 847606-67-1P 847606-71-7P
847606-73-9P 847606-74-0P 847606-76-2P
847606-77-3P 847606-78-4P 847606-81-9P
847606-84-2P 847606-87-5P 847606-88-6P
847606-90-0P 847606-92-2P 847606-93-3P
847606-95-5P 847607-05-0P 847607-13-0P
847607-14-1P 847607-15-2P 847607-17-4P
847607-18-5P 847607-19-6P 847607-20-9P
847607-21-0P 847607-22-1P 847607-25-4P
847607-26-5P 847607-27-6P 847607-28-7P
847607-29-8P 847607-37-8P 847607-38-9P
847607-47-0P 847607-48-1P 847607-51-6P
847607-56-1P 847607-57-2P 847607-58-3P
847607-61-8P 847607-63-0P 847607-68-5P
847607-69-6P 847607-70-9P 847607-71-0P
847607-73-2P 847607-74-3P 847607-76-5P
847607-77-6P 847607-78-7P 847607-79-8P
847607-80-1P 847607-81-2P 847607-82-3P
847607-86-7P 847607-87-8P 847607-88-9P
847607-89-0P 847607-92-5P 847607-93-6P
847607-94-7P 847607-95-8P 847607-96-9P
847607-97-0P 847607-98-1P 847607-99-2P
847608-00-8P 847608-01-9P 847608-02-0P
847608-03-1P 847608-04-2P 847608-05-3P
847608-06-4P 847608-07-5P 847608-08-6P
847608-09-7P 847608-10-0P 847608-12-2P
847608-13-3P 847608-14-4P 847608-15-5P
847608-16-6P 847608-17-7P 847608-18-8P
847608-19-9P 847608-20-2P 847608-21-3P
847608-23-5P 847608-24-6P 847608-25-7P
847608-26-8P 847608-27-9P 847608-29-1P
847608-30-4P 847608-31-5P 847608-32-6P
847608-33-7P 847608-35-9P 847608-37-1P
847608-39-3P 847608-42-8P 847608-44-0P
847608-46-2P 847608-48-4P 847608-50-8P
847608-51-9P 847608-53-1P 847608-55-3P
847608-58-6P 847608-59-7P 847608-60-0P

847608-61-1P 847608-62-2P 847608-63-3P
847608-64-4P 847608-65-5P 847608-66-6P
847608-67-7P 847608-68-8P 847608-69-9P
847608-70-2P 847608-71-3P 847608-73-5P
847608-74-6P 847608-75-7P 847608-77-9P
847608-79-1P 847608-80-4P 847608-81-5P
847608-82-6P 847608-83-7P 847608-84-8P
847608-85-9P 847608-86-0P 847608-87-1P
847608-88-2P 847608-89-3P 847608-90-6P
847608-91-7P 847608-93-9P 847608-94-0P
847608-95-1P 847608-96-2P 847608-98-4P
847609-00-1P 847609-04-5P 847609-06-7P
847609-08-9P 847609-10-3P 847609-12-5P
847609-14-7P 847609-16-9P 847609-18-1P
847609-20-5P 847609-28-3P 847609-30-7P
847609-32-9P 847609-35-2P 847609-36-3P
847609-39-6P 847609-41-0P 847609-43-2P
847609-46-5P 847609-48-7P 847609-50-1P
847609-52-3P 847609-54-5P 847609-56-7P
847609-57-8P 847609-58-9P 847609-59-0P
847609-60-3P 847609-63-6P 847609-65-8P
847609-67-0P 847609-73-8P 847609-75-0P
847609-79-4P 847609-81-8P 847609-86-3P
847609-93-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(modulator; preparation of anilines and related compds. as C-kit modulators)

RN 332176-74-6 HCAPLUS

CN Acetamide, N-(5-chloro-2-methoxyphenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 483337-32-2 HCAPLUS

CN Acetamide, N-(2-chlorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 483337-34-4 HCAPLUS

CN Acetamide, N-(2,3-dichlorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 483337-36-6 HCAPLUS
CN Acetamide, N-(3-chloro-2-methylphenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 483337-37-7 HCAPLUS
CN Acetamide, N-(4-bromophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 483337-38-8 HCAPLUS
CN Acetamide, N-(2-fluorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 483337-39-9 HCAPLUS
CN Acetamide, N-(4-fluorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 483337-40-2 HCAPLUS
CN Acetamide, 2-[3-(1H-tetrazol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 483337-41-3 HCAPLUS
CN Acetamide, 2-[3-(1H-tetrazol-1-yl)phenoxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 483978-03-6 HCAPLUS
CN Acetamide, N-(3-fluorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 505052-18-6 HCAPLUS
CN Acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 506433-09-6 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 552825-29-3 HCAPLUS
CN Acetamide, N-(4-chlorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847606-67-1 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-1,2,3-triazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847606-71-7 HCAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)



RN 847606-73-9 HCAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)



RN 847606-74-0 HCAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(5-methyl-1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847606-76-2 HCAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]thio]- (CA INDEX NAME)



RN 847606-77-3 HCAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(5-pyrimidinyl)phenoxy]- (CA INDEX NAME)



RN 847606-78-4 HCAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(4H-1,2,4-triazol-4-yl)phenoxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 847606-81-9 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(1H-tetrazol-1-yl)phenyl]methyl]- (CA INDEX NAME)



RN 847606-84-2 HCAPLUS
CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847606-87-5 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-quinoxalinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847606-88-6 HCAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-3-piperidinyl- (CA INDEX NAME)



RN 847606-90-0 HCAPLUS
CN Benzamide, N-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]-3-(1H-tetrazol-1-yl)- (CA INDEX NAME)



RN 847606-92-2 HCAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-[3-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)



RN 847606-93-3 HCAPLUS
CN Carbamic acid, [3-(trifluoromethyl)phenyl]-, [3-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847606-95-5 HCAPLUS
CN Acetamide, N-(4-chloro-3-methylphenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-05-0 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4H-1,2,4-triazol-4-yl)phenoxy]- (CA INDEX NAME)



RN 847607-13-0 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2H-tetrazol-5-yl)phenoxy]- (CA INDEX NAME)



RN 847607-14-1 HCAPLUS
CN Acetamide, N-(4-chloro-2-fluorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-15-2 HCAPLUS
CN Acetamide, N-(4-bromo-3-methylphenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-17-4 HCAPLUS
CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-18-5 HCAPLUS
CN Acetamide, N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-19-6 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-20-9 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-methyl-5-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-21-0 HCAPLUS
CN Acetamide, N-(4-chlorophenyl)-N-methyl-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-22-1 HCAPLUS
CN Acetamide, N-[4-chloro-2-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-25-4 HCAPLUS
CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-26-5 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2-methyl-2H-tetrazol-5-yl)phenoxy]- (CA INDEX NAME)



RN 847607-27-6 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2,4-dichloro-5-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-28-7 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-29-8 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[3-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-2-oxoethoxy]phenyl]-, methyl ester (CA INDEX NAME)



RN 847607-37-8 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4-pyridinyl)phenoxy]- (CA INDEX NAME)



RN 847607-38-9 HCAPLUS
CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)



RN 847607-47-0 HCAPLUS
CN Benzamide, 5-chloro-2-[[2-[3-(1H-tetrazol-1-yl)phenoxy]acetyl]amino]- (CA INDEX NAME)



RN 847607-48-1 HCAPLUS
CN Acetamide, N-(5-chloro-2,4-dimethoxyphenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-51-6 HCAPLUS
CN Acetamide, N-[2-methoxy-5-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-56-1 HCAPLUS
CN 1H-Pyrrole-1-carboxylic acid, 2-[3-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-2-oxoethoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847607-57-2 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-pyrrol-2-

yl)phenoxy]- (CA INDEX NAME)



RN 847607-58-3 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(5-pyrimidinyl)phenoxy]- (CA INDEX NAME)



RN 847607-61-8 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3-pyridinyl)phenoxy]- (CA INDEX NAME)



RN 847607-63-0 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3-furanyl)phenoxy]- (CA INDEX NAME)



RN 847607-68-5 HCAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3,5-dimethyl-4-isoxazolyl)phenoxy]- (CA INDEX NAME)



RN 847607-69-6 HCAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(7-quinolinyl)phenoxy]- (CA INDEX NAME)



RN 847607-70-9 HCAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2-furanyl)phenoxy]- (CA INDEX NAME)



RN 847607-71-0 HCAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4-dibenzofuranyl)phenoxy]- (CA INDEX NAME)



RN 847607-73-2 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-N-methyl-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-74-3 HCAPLUS
CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)



RN 847607-76-5 HCAPLUS
CN Hydrazinecarboxamide, N-[2-fluoro-5-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)



RN 847607-77-6 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(3-pyridinyl)phenoxy]- (CA INDEX NAME)



RN 847607-78-7 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847607-79-8 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847607-80-1 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847607-81-2 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847607-82-3 HCAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[4-(5-pyrimidinyl)phenoxy]- (CA INDEX NAME)



RN 847607-86-7 HCAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-methyl-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-87-8 HCAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-1,2,3-triazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-88-9 HCAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-fluoro-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-89-0 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-fluoro-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-92-5 HCAPLUS
CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[4-(3-pyridinyl)phenoxy]- (CA INDEX NAME)



RN 847607-93-6 HCAPLUS
CN Acetamide, 2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenoxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847607-94-7 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenoxy]- (CA INDEX NAME)



RN 847607-95-8 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(4-pyridinyl)phenoxy]- (CA INDEX NAME)



RN 847607-96-9 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-methoxy-4-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)



RN 847607-97-0 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[4-methoxy-3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)



RN 847607-98-1 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[4-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)



RN 847607-99-2 HCAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2,3,5,6-tetrafluoro-4-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)



RN 847608-00-8 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(1H-tetrazol-1-yl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-01-9 HCAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)



RN 847608-02-0 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-03-1 HCAPLUS
CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847608-04-2 HCAPLUS
CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847608-05-3 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2,4-dimethoxy-5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-06-4 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(2-methoxy-5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-07-5 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-08-6 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2-methoxy-5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-09-7 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-10-0 HCAPLUS
CN 1H-Indole-1-carboxylic acid, 2-[4-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-2-oxoethoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847608-12-2 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(2H-tetrazol-5-yl)phenyl]amino]- (CA INDEX NAME)



RN 847608-13-3 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2,6-difluoro-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847608-14-4 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-15-5 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-16-6 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(4-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-17-7 HCAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)



RN 847608-18-8 HCAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(3-pyridinyl)phenyl]- (CA INDEX NAME)



RN 847608-19-9 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-20-2 HCAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(4-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-21-3 HCAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-23-5 HCAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-24-6 HCAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)



RN 847608-25-7 HCAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)



RN 847608-26-8 HCAPLUS
CN Urea, N-(5-chloro-2,4-dimethoxyphenyl)-N'-[[4-(5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-27-9 HCAPLUS
CN Urea, N-(5-chloro-2,4-dimethoxyphenyl)-N'-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-29-1 HCAPLUS
CN Carbamic acid, (5-chloro-2,4-dimethoxyphenyl)-, [4-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-30-4 HCAPLUS
CN Carbamic acid, (5-chloro-2,4-dimethoxyphenyl)-, [4-(3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-31-5 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, 1-[4-(3-pyridinyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)



RN 847608-32-6 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, 1-[4-(5-pyrimidinyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)



RN 847608-33-7 HCAPLUS
CN Urea, N-(5-chloro-2,4-dimethoxyphenyl)-N'-[[3-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-35-9 HCAPLUS
CN Urea, N-(5-chloro-2,4-dimethoxyphenyl)-N'-[[3-(5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-37-1 HCAPLUS
CN Carbamic acid, (5-chloro-2,4-dimethoxyphenyl)-, [3-(3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-39-3 HCAPLUS
CN Carbamic acid, (5-chloro-2,4-dimethoxyphenyl)-, [3-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-42-8 HCAPLUS
CN Urea, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-44-0 HCAPLUS
CN Urea, N-[[3-(6-amino-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-46-2 HCAPLUS
CN Urea, N-[[4-(6-amino-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-48-4 HCAPLUS
CN Urea, N-[[3-(2-amino-5-pyrimidinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-50-8 HCAPLUS
CN Urea, N-[[4-(2-amino-5-pyrimidinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-51-9 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[1-[4-(3-pyridinyl)phenyl]ethyl]- (CA INDEX NAME)



RN 847608-53-1 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[1-[4-(5-pyrimidinyl)phenyl]ethyl]- (CA INDEX NAME)



RN 847608-55-3 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-indol-2-yl)phenoxy]- (CA INDEX NAME)



RN 847608-58-6 HCAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(4-pyridinyl)phenyl]- (CA INDEX NAME)



RN 847608-59-7 HCAPLUS
CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4-pyridinyl)phenyl]- (CA INDEX NAME)



RN 847608-60-0 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-61-1 HCAPLUS
CN 2-Pyrazinecarboxylic acid, 3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-, methyl ester (CA INDEX NAME)



RN 847608-62-2 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-quinoxalinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-63-3 HCAPLUS
CN Urea, N-[[3-(2-amino-5-methyl-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-64-4 HCAPLUS
CN 2-Pyrazinecarboxylic acid, 3-amino-6-[4-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-, methyl ester (CA INDEX NAME)



RN 847608-65-5 HCAPLUS
CN Carbamic acid, (3-chloro-4-methoxyphenyl)-, [3-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-66-6 HCAPLUS
CN Urea, N-(3-chloro-4-methoxyphenyl)-N'-[[3-(1H-tetrazol-1-yl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-67-7 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(2,5-dihydro-5-oxo-1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847608-68-8 HCAPLUS
CN Urea, N-[[3-(2-amino-5-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-69-9 HCAPLUS
CN Urea, N-[[4-(2-amino-5-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-70-2 HCAPLUS
CN Urea, N-[[3-(6-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-71-3 HCAPLUS
CN Urea, N-[[4-(6-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-

(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-73-5 HCAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 847608-74-6 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-fluoro-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-75-7 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(2-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-77-9 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-fluoro-3-

pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-79-1 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-80-4 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-methyl-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-81-5 HCAPLUS
CN Urea, N-[[4-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-82-6 HCAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-methyl-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-83-7 HCAPLUS

CN Urea, N-[[4-(2-amino-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-84-8 HCAPLUS

CN Urea, N-[[3-(2-amino-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-85-9 HCAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(6-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-86-0 HCAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,

[3-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-87-1 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(2-amino-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-88-2 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, (3-pyrazinylphenyl)methyl ester (9CI) (CA INDEX NAME)



RN 847608-89-3 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-[6-(hydroxymethyl)-3-pyridinyl]phenyl]methyl]- (CA INDEX NAME)



RN 847608-90-6 HCAPLUS
CN Urea, N-[[3-(6-acetyl-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-

(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-91-7 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-cyano-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-93-9 HCAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847608-94-0 HCAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 847608-95-1 HCAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[4-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 847608-96-2 HCAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 847608-98-4 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-00-1 HCAPLUS
CN Urea, N-[[3-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847609-04-5 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-benzimidazol-2-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-06-7 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(6-amino-2-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-08-9 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-[5-(methylthio)-3-pyridinyl]phenyl]methyl]- (CA INDEX NAME)



RN 847609-10-3 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(6-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-12-5 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-14-7 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(2-amino-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-16-9 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, (4-pyrazinylphenyl)methyl ester (9CI) (CA INDEX NAME)



RN 847609-18-1 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 847609-20-5 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(6-amino-2-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-28-3 HCAPLUS
CN Carbamic acid, (5-chloro-2-methoxyphenyl)-, [3-(3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-30-7 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-32-9 HCAPLUS
CN Carbamic acid, (5-chloro-2-methoxyphenyl)-, [3-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-35-2 HCAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847609-36-3 HCAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[4-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847609-39-6 HCAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-3-piperidinyl- (CA INDEX NAME)



RN 847609-41-0 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847609-43-2 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[3-amino-6-[4-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847609-46-5 HCAPLUS
CN Urea, N-[[3-[5-amino-6-(1-piperazinylcarbonyl)-2-pyrazinyl]phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847609-48-7 HCAPLUS
CN Urea, N-[[4-[5-amino-6-(1-piperazinylcarbonyl)-2-pyrazinyl]phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847609-50-1 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(1H-pyrazol-4-yl)phenyl]methyl]- (CA INDEX NAME)



RN 847609-52-3 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(1H-pyrazol-4-yl)phenyl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 847609-54-5 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-[2-(1-piperazinyl)-5-pyrimidinyl]phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-56-7 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-[2-(1-piperazinyl)-5-pyrimidinyl]phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-57-8 HCAPLUS
CN Urea, N-[[3-(2-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847609-58-9 HCAPLUS
CN Urea, N-[[4-(2-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847609-59-0 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(2-fluoro-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847609-60-3 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2-fluoro-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847609-63-6 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-[5-(methylthio)-2-pyridinyl]phenyl]methyl]- (CA INDEX NAME)



RN 847609-65-8 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(2,6-dimethyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-67-0 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(5-methoxy-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-73-8 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(4-isoquinolinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847609-75-0 HCAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(4-isoquinolinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847609-79-4 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-pyrazol-4-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-81-8 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(1H-pyrazol-4-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 847609-86-3 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2,5-dihydro-5-oxo-1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847609-93-2 HCAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(4-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



IT 847606-70-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of anilines and related compds. as C-kit modulators)
RN 847606-70-6 HCAPLUS
CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-[4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl]phenoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L122 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:892800 HCAPLUS Full-text
DOCUMENT NUMBER: 139:395950
TITLE: Preparation of substituted pyrazines as protein kinase modulators
INVENTOR(S): Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepp, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Thimothy Patrick;

Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 468 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093297	A2	20031113	WO 2003-US13869	20030502
WO 2003093297	A3	20040701		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2484209	A1	20031113	CA 2003-2484209	20030502
AU 2003234464	A1	20031117	AU 2003-234464	20030502
AU 2003234464	B2	20090604		
EP 1501514	A2	20050202	EP 2003-728690	20030502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005530760	T	20051013	JP 2004-501436	20030502
US 20060211709	A1	20060921	US 2005-513081	20050727

PRIORITY APPLN. INFO.: US 2002-377933P P 20020503
WO 2003-US13869 W 20030502
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 139:395950
ED Entered STN: 14 Nov 2003
GI



I

AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH; A = CO, CS, C(:NR6), R7 (when A = R7, E does not exist); R6 = H, NO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NNR2R3, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heteroalicyclyl; W = 6-10 membered arylene, 5-10 membered heteroarylene; X = a bond, (un)substituted alkylene, O(CH2)2-3O, etc.; Y = H, alkyl, aryl, etc.; with provisos] for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that

inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 67% 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.

IC ICM C07K

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT

625466-66-2P	625466-67-3P	625466-68-4P	625466-69-5P	625466-70-8P
625466-71-9P	625466-72-0P	625466-73-1P	625466-74-2P	625466-75-3P
625466-76-4P	625466-77-5P	625466-78-6P	625466-79-7P	625466-80-0P
625466-81-1P	625466-82-2P	625466-83-3P	625466-84-4P	625466-85-5P
625466-86-6P	625466-87-7P	625466-88-8P	625466-89-9P	625466-90-2P
625466-91-3P	625466-92-4P	625466-93-5P	625466-94-6P	625466-95-7P
625466-96-8P	625466-97-9P	625466-98-0P	625466-99-1P	625467-00-7P
625467-01-8P	625467-02-9P	625467-03-0P	625467-04-1P	625467-05-2P
625467-06-3P	625467-07-4P	625467-08-5P	625467-09-6P	625467-10-9P
625467-11-0P	625467-12-1P	625467-13-2P	625467-14-3P	625467-15-4P
625467-16-5P	625467-17-6P	625467-18-7P	625467-19-8P	625467-20-1P
625467-21-2P	625467-22-3P	625467-23-4P	625467-24-5P	625467-25-6P
625467-26-7P	625467-27-8P	625467-28-9P	625467-29-0P	625467-30-3P
625467-31-4P	625467-32-5P	625467-33-6P	625467-34-7P	625467-35-8P
625467-36-9P	625467-37-0P	625467-38-1P	625467-39-2P	625467-40-5P
625467-41-6P	625467-42-7P	625467-43-8P	625467-44-9P	625467-45-0P
625467-46-1P	625467-47-2P	625467-48-3P	625467-49-4P	625467-50-7P
625467-51-8P	625467-52-9P	625467-53-0P	625467-54-1P	625467-55-2P
625467-56-3P	625467-57-4P	625467-58-5P	625467-59-6P	625467-60-9P
625467-61-0P	625467-62-1P	625467-63-2P	625467-64-3P	625467-65-4P
625467-66-5P	625467-67-6P	625467-68-7P	625467-69-8P	625467-70-1P
625467-71-2P	625467-72-3P	625467-73-4P	625467-74-5P	625467-75-6P
625467-76-7P	625467-77-8P	625467-78-9P	625467-79-0P	625467-80-3P
625467-81-4P	625467-82-5P	625467-83-6P	625467-84-7P	625467-85-8P
625467-86-9P	625467-87-0P	625467-88-1P	625467-89-2P	625467-90-5P
625467-91-6P	625467-92-7P	625467-93-8P	625467-94-9P	625467-95-0P
625467-96-1P	625467-97-2P	625467-98-3P	625467-99-4P	625468-00-0P
625468-01-1P	625468-02-2P	625468-03-3P	625468-04-4P	625468-05-5P
625468-06-6P	625468-07-7P	625468-08-8P	625468-09-9P	625468-10-2P
625468-11-3P	625468-12-4P	625468-13-5P	625468-14-6P	625468-15-7P
625468-16-8P	625468-17-9P	625468-18-0P	625468-19-1P	625468-20-4P
625468-21-5P	625468-22-6P	625468-23-7P	625468-24-8P	625468-25-9P
625468-26-0P	625468-27-1P	625468-28-2P	625468-29-3P	625468-30-6P
625468-31-7P	625468-32-8P	625468-33-9P	625468-34-0P	
625468-35-1P	625468-36-2P	625468-37-3P	625468-38-4P	
625468-39-5P	625468-40-8P	625468-41-9P	625468-42-0P	625468-43-1P
625468-44-2P	625468-45-3P	625468-46-4P	625468-47-5P	625468-48-6P
625468-49-7P	625468-50-0P	625468-51-1P	625468-52-2P	
625468-53-3P	625468-54-4P	625468-55-5P	625468-56-6P	
625468-57-7P	625468-58-8P	625468-59-9P	625468-60-2P	
625468-61-3P	625468-62-4P	625468-63-5P		
625468-64-6P	625468-65-7P	625468-66-8P	625468-67-9P	625468-68-0P
625468-69-1P	625468-70-4P	625468-71-5P	625468-72-6P	
625468-73-7P	625468-74-8P	625468-75-9P	625468-76-0P	625468-77-1P
625468-78-2P	625468-79-3P	625468-80-6P	625468-81-7P	625468-82-8P

625468-83-9P 625468-84-0P 625468-85-1P 625468-86-2P 625468-87-3P
625468-88-4P 625468-89-5P 625468-90-8P 625468-91-9P 625468-92-0P
625468-93-1P 625468-94-2P 625468-95-3P 625468-96-4P
625468-97-5P 625468-98-6P 625468-99-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of protein kinase modulators)

IT 625468-35-1P 625468-49-7P 625468-54-4P
625468-61-3P 625468-62-4P 625469-71-5P
625468-97-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of protein kinase modulators)

RN 625468-35-1 HCAPLUS
CN Urea, N-[[3-[5-amino-6-[2-(3R)-3-piperidinylacetyl]-2-pyrazinyl]phenyl]methyl]-N'-(4-bromophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-49-7 HCAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[[(4-bromo-2-fluorophenyl)amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-54-4 HCAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-61-3 HCAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[[(3-bromo-5-methylphenyl)amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-62-4 HCAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[[(2-bromophenyl)amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-71-5 HCAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]- (CA INDEX

NAME)

Absolute stereochemistry.



RN 625468-97-5 HCAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[[(4-fluorophenyl)amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

=> file stnguide
FILE 'STNGUIDE' ENTERED AT 10:44:58 ON 21 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 16, 2010 (20100416/UP).

```
=> d his ful

     (FILE 'HOME' ENTERED AT 09:27:32 ON 21 APR 2010)

     FILE 'STNGUIDE' ENTERED AT 09:27:35 ON 21 APR 2010
                D SAVED

     FILE 'ZCAPLUS' ENTERED AT 09:28:22 ON 21 APR 2010
                E US2007-569873/APPS

     FILE 'HCAPLUS' ENTERED AT 09:28:40 ON 21 APR 2010
L1             1 SEA SPE=ON  ABB=ON  PLU=ON  US2007-569873/APPS

     FILE 'WPIX' ENTERED AT 09:28:57 ON 21 APR 2010
L2             1 SEA SPE=ON  ABB=ON  PLU=ON  US2007-569873/APPS

     FILE 'REGISTRY' ENTERED AT 09:29:18 ON 21 APR 2010

     FILE 'HCAPLUS' ENTERED AT 09:29:22 ON 21 APR 2010
L3               TRA PLU=ON  L1 1- RN :     322 TERMS

     FILE 'REGISTRY' ENTERED AT 09:29:22 ON 21 APR 2010
L4           322 SEA SPE=ON  ABB=ON  PLU=ON  L3
                 ACT BIA873RSET1/A
                ---------
L5               STR
L6   (    402314)SEA SSS FUL L5
L7               STR
L8               STR
L9          33651 SEA SUB=L6 SSS FUL (L7 OR L8)
                ---------
                 D QUE
                 ACT BIA873RSET2/A
                ---------
L10              STR
L11  (    402314)SEA SSS FUL L10
L12              STR
L13              STR
L14  (     33651)SEA SUB=L11 SSS FUL (L12 OR L13)
L15              STR
L16              STR
L17         7261 SEA SUB=L14 SSS FUL (L15 OR L16)
                ---------
                 D QUE
                 D QUE L9

     FILE 'LREGISTRY' ENTERED AT 09:30:46 ON 21 APR 2010
L18              STR L7
L19              STR L18

     FILE 'REGISTRY' ENTERED AT 09:34:37 ON 21 APR 2010
L20            50 SEA SUB=L9 SSS SAM (L18 OR L19)

     FILE 'STNGUIDE' ENTERED AT 09:35:21 ON 21 APR 2010
                D QUE STAT

     FILE 'REGISTRY' ENTERED AT 09:39:51 ON 21 APR 2010
L21          9722 SEA SUB=L9 SSS FUL (L18 OR L19)
                 SAVE TEMP L21 BIA873RSET1B/A
```

```
                ACT BIA873CROSS/A
               ---------
L22             STR
L23 (    402314)SEA SSS FUL L22
L24             STR
L25             STR
L26 (     33651)SEA SUB=L23 SSS FUL (L24 OR L25)
L27             QUE SPE=ON  ABB=ON  PLU=ON  1-2 5/SZS
L28 (     21400)SEA SPE=ON  ABB=ON  PLU=ON  L26 AND L27
L29             QUE SPE=ON  ABB=ON  PLU=ON  2 6/SZS
L30 (      3263)SEA SPE=ON  ABB=ON  PLU=ON  L26 AND L29
L31 (       113)SEA SPE=ON  ABB=ON  PLU=ON  L26 AND NCNCNC/ESS
L32             STR
L33             STR
L34 (      7261)SEA SUB=L26 SSS FUL (L32 OR L33)
L35       29198 SEA SPE=ON  ABB=ON  PLU=ON  L28 OR L30 OR L31 OR L34
               ---------
L36        8396 SEA SPE=ON  ABB=ON  PLU=ON  L21 AND L35
                SAVE TEMP L36 BIS873CROSSB/A
L37          88 SEA SPE=ON  ABB=ON  PLU=ON  L4 AND L36

     FILE 'STNGUIDE' ENTERED AT 09:42:47 ON 21 APR 2010
                D SAVED

     FILE 'HCAPLUS' ENTERED AT 09:43:18 ON 21 APR 2010
                ACT BIA873INV/A
               ---------
L38 (         1)SEA SPE=ON  ABB=ON  PLU=ON  US2007-569873/APPS
L39             STR
L40 (    402314)SEA SSS FUL L39
L41             STR
L42             STR
L43 (     33651)SEA SUB=L40 SSS FUL (L41 OR L42)
L44             QUE SPE=ON  ABB=ON  PLU=ON  1-2 5/SZS
L45 (     21400)SEA SPE=ON  ABB=ON  PLU=ON  L43 AND L44
L46             QUE SPE=ON  ABB=ON  PLU=ON  2 6/SZS
L47 (      3263)SEA SPE=ON  ABB=ON  PLU=ON  L43 AND L46
L48 (       113)SEA SPE=ON  ABB=ON  PLU=ON  L43 AND NCNCNC/ESS
L49             STR
L50             STR
L51 (      7261)SEA SUB=L43 SSS FUL (L49 OR L50)
L52 (     29198)SEA SPE=ON  ABB=ON  PLU=ON  L45 OR L47 OR L48 OR L51
L53             QUE SPE=ON  ABB=ON  PLU=ON  CHENG, W?/AU,AUTH
L54             QUE SPE=ON  ABB=ON  PLU=ON  CO, E?/AU,AUTH
L55             QUE SPE=ON  ABB=ON  PLU=ON  WANG-CO, E?/AU,AUTH
L56             QUE SPE=ON  ABB=ON  PLU=ON  WANG CO, E?/AU,AUTH
L57             QUE SPE=ON  ABB=ON  PLU=ON  WANGCO, E?/AU,AUTH
L58             QUE SPE=ON  ABB=ON  PLU=ON  KIM, M?/AU,AUTH
L59             QUE SPE=ON  ABB=ON  PLU=ON  KLEIN, R?/AU,AUTH
L60             QUE SPE=ON  ABB=ON  PLU=ON  LE, D?/AU,AUTH
L61             QUE SPE=ON  ABB=ON  PLU=ON  TSUHAKO, A?/AU,AUTH
L62             QUE SPE=ON  ABB=ON  PLU=ON  LEW, A?/AU,AUTH
L63             QUE SPE=ON  ABB=ON  PLU=ON  LEW-TSUHAKO, A?/AU,AUTH
L64             QUE SPE=ON  ABB=ON  PLU=ON  LEWTSUHAKO, A?/AU,AUTH
L65             QUE SPE=ON  ABB=ON  PLU=ON  NUSS, J?/AU,AUTH
L66             QUE SPE=ON  ABB=ON  PLU=ON  XU, W?/AU,AUTH
L67             QUE SPE=ON  ABB=ON  PLU=ON  BAJJALIEH, W?/AU,AUTH
L68             QUE SPE=ON  ABB=ON  PLU=ON  BAJJALIEH, B?/AU,AUTH
L69 (      2007)SEA SPE=ON  ABB=ON  PLU=ON  L52
L70 (         3)SEA SPE=ON  ABB=ON  PLU=ON  L69 AND (L53 OR L54 OR L55 OR L56
```

```
               OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63 OR L64 OR L65
               OR L66 OR L67 OR L68)
L71 (          1)SEA SPE=ON  ABB=ON  PLU=ON  L38 AND L70
L72 (          0)SEA SPE=ON  ABB=ON  PLU=ON  L38 NOT L70
L73 (          3)SEA SPE=ON  ABB=ON  PLU=ON  (L70 OR L71 OR L72)
L74 (          1)SEA SPE=ON  ABB=ON  PLU=ON  L52 AND (MEDLINE OR BIOSIS OR
               EMBASE)/LC
L75 (          0)SEA SPE=ON  ABB=ON  PLU=ON  L74
L76 (         12)SEA SPE=ON  ABB=ON  PLU=ON  L74
L77 (          0)SEA SPE=ON  ABB=ON  PLU=ON  L74
L78 (         12)SEA SPE=ON  ABB=ON  PLU=ON  L74
L79 (          0)SEA SPE=ON  ABB=ON  PLU=ON  L75 AND (L53 OR L54 OR L55 OR L56
               OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63 OR L64 OR L65
               OR L66 OR L67 OR L68)
L80 (          0)SEA SPE=ON  ABB=ON  PLU=ON  L76 AND (L53 OR L54 OR L55 OR L56
               OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63 OR L64 OR L65
               OR L66 OR L67 OR L68)
L81 (          0)SEA SPE=ON  ABB=ON  PLU=ON  L77 AND (L53 OR L54 OR L55 OR L56
               OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63 OR L64 OR L65
               OR L66 OR L67 OR L68)
L82 (          0)SEA SPE=ON  ABB=ON  PLU=ON  L78 AND (L53 OR L54 OR L55 OR L56
               OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63 OR L64 OR L65
               OR L66 OR L67 OR L68)
L83            3 DUP REM L73 L82 (0 DUPLICATES REMOVED)
                ---------

     FILE 'STNGUIDE' ENTERED AT 09:43:30 ON 21 APR 2010

     FILE 'ZCAPLUS' ENTERED AT 09:44:13 ON 21 APR 2010
L84              QUE SPE=ON  ABB=ON  PLU=ON  AY<2004 OR PY<2004 OR PRY<2004 OR
                 MY<2004 OR REVIEW/DT

     FILE 'STNGUIDE' ENTERED AT 09:44:55 ON 21 APR 2010

     FILE 'STNGUIDE' ENTERED AT 10:01:14 ON 21 APR 2010

     FILE 'HCAPLUS' ENTERED AT 10:01:38 ON 21 APR 2010
L85            359 SEA SPE=ON  ABB=ON  PLU=ON  L36
L86              1 SEA SPE=ON  ABB=ON  PLU=ON  L85 AND (L53 OR L54 OR L55 OR L56
                 OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63 OR L64 OR L65
                 OR L66 OR L67 OR L68)
L87              1 SEA SPE=ON  ABB=ON  PLU=ON  L1 AND L86
                   D BIB
L88              0 SEA SPE=ON  ABB=ON  PLU=ON  L1 NOT L86
L89              1 SEA SPE=ON  ABB=ON  PLU=ON  (L86 OR L87 OR L88)
L90            358 SEA SPE=ON  ABB=ON  PLU=ON  L85 NOT L89
L91            229 SEA SPE=ON  ABB=ON  PLU=ON  L90 AND L84

     FILE 'STNGUIDE' ENTERED AT 10:03:12 ON 21 APR 2010

     FILE 'ZCAPLUS' ENTERED AT 10:03:50 ON 21 APR 2010
L92              QUE SPE=ON  ABB=ON  PLU=ON  C(1W)KIT
L93              QUE SPE=ON  ABB=ON  PLU=ON  STEM(1W)CELL

     FILE 'HCAPLUS' ENTERED AT 10:04:28 ON 21 APR 2010
L94              0 SEA SPE=ON  ABB=ON  PLU=ON  L91 AND (L92 OR L93)
L95            197 SEA SPE=ON  ABB=ON  PLU=ON  L85 (L)(THU OR PKT OR PAC OR
                   DMA)/RL
L96             88 SEA SPE=ON  ABB=ON  PLU=ON  L91 AND L95
L97             88 SEA SPE=ON  ABB=ON  PLU=ON  L94 OR L96
```

```
     FILE 'STNGUIDE' ENTERED AT 10:06:22 ON 21 APR 2010

     FILE 'ZCAPLUS' ENTERED AT 10:06:28 ON 21 APR 2010
                E C-KIT PROTEIN/CT
                E C-KIT /CT
L98             QUE SPE=ON  ABB=ON  PLU=ON  "C-KIT (PROTEIN)"+PFT,OLD,NEW,NT/CT


     FILE 'HCAPLUS' ENTERED AT 10:07:22 ON 21 APR 2010
L99           0 SEA SPE=ON  ABB=ON  PLU=ON  L91 AND L98
L100         88 SEA SPE=ON  ABB=ON  PLU=ON  L97 OR L99
L101          2 SEA SPE=ON  ABB=ON  PLU=ON  L37
L102          1 SEA SPE=ON  ABB=ON  PLU=ON  L101 AND (L53 OR L54 OR L55 OR L56
                OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63 OR L64 OR L65
                OR L66 OR L67 OR L68)
L103          1 SEA SPE=ON  ABB=ON  PLU=ON  L89 OR L102
L104         90 SEA SPE=ON  ABB=ON  PLU=ON  (L100 OR L101)
L105         89 SEA SPE=ON  ABB=ON  PLU=ON  L104 NOT L103
L106         88 SEA SPE=ON  ABB=ON  PLU=ON  L105 AND L84

     FILE 'STNGUIDE' ENTERED AT 10:09:21 ON 21 APR 2010

     FILE 'REGISTRY' ENTERED AT 10:09:53 ON 21 APR 2010

     FILE 'HCAPLUS' ENTERED AT 10:10:01 ON 21 APR 2010
L107            TRA PLU=ON  L106 1- RN HIT :     471 TERMS

     FILE 'REGISTRY' ENTERED AT 10:10:16 ON 21 APR 2010
L108        471 SEA SPE=ON  ABB=ON  PLU=ON  L107
L109        459 SEA SPE=ON  ABB=ON  PLU=ON  L108 NOT ETHANEDIAMIDE/CNS

     FILE 'HCAPLUS' ENTERED AT 10:12:09 ON 21 APR 2010
L110        115 SEA SPE=ON  ABB=ON  PLU=ON  L109
L111         98 SEA SPE=ON  ABB=ON  PLU=ON  L91 AND L110
L112         86 SEA SPE=ON  ABB=ON  PLU=ON  L106 AND L111
L113          0 SEA SPE=ON  ABB=ON  PLU=ON  L112 AND (L53 OR L54 OR L55 OR L56
                OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63 OR L64 OR L65
                OR L66 OR L67 OR L68)
L114         86 SEA SPE=ON  ABB=ON  PLU=ON  L112 NOT L113
L115         86 SEA SPE=ON  ABB=ON  PLU=ON  L114 AND L84
                SAVE TEMP L103 BIA873INVB/A
                SAVE TEMP L115 BIA873MAINB2/A

     FILE 'STNGUIDE' ENTERED AT 10:14:08 ON 21 APR 2010
                D SAVED
                D QUE STAT L9
                D QUE STAT L21
                D QUE STAT L36
                D QUE NOS L115

     FILE 'HCAPLUS' ENTERED AT 10:17:06 ON 21 APR 2010
                D IBIB ED ABS HITIND HITSTR 1-30

     FILE 'STNGUIDE' ENTERED AT 10:17:43 ON 21 APR 2010

     FILE 'HCAPLUS' ENTERED AT 10:22:04 ON 21 APR 2010
                D IBIB ED ABS HITIND HITSTR 31-60

     FILE 'STNGUIDE' ENTERED AT 10:22:43 ON 21 APR 2010
```

```
     FILE 'LREGISTRY' ENTERED AT 10:24:36 ON 21 APR 2010

     FILE 'REGISTRY' ENTERED AT 10:26:34 ON 21 APR 2010
L116          50 SEA SUB=L21 SSS SAM L18
L117        3003 SEA SUB=L21 SSS FUL L18
                 SAVE TEMP L117 BIA873RSET2B/A

     FILE 'HCAPLUS' ENTERED AT 10:28:30 ON 21 APR 2010
L118         183 SEA SPE=ON  ABB=ON  PLU=ON  L117
L119           2 SEA SPE=ON  ABB=ON  PLU=ON  L118 AND (L53 OR L54 OR L55 OR L56
                 OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63 OR L64 OR L65
                 OR L66 OR L67 OR L68)
L120           1 SEA SPE=ON  ABB=ON  PLU=ON  L1 AND L119
                 D BIB
L121           0 SEA SPE=ON  ABB=ON  PLU=ON  L1 NOT L119
L122           2 SEA SPE=ON  ABB=ON  PLU=ON  (L119 OR L120 OR L121)
L123         181 SEA SPE=ON  ABB=ON  PLU=ON  L118 NOT L122
L124         117 SEA SPE=ON  ABB=ON  PLU=ON  L123 AND L84
L125          36 SEA SPE=ON  ABB=ON  PLU=ON  L115 AND L124

     FILE 'STNGUIDE' ENTERED AT 10:30:40 ON 21 APR 2010

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:30:44 ON 21 APR 2010

     FILE 'REGISTRY' ENTERED AT 10:30:58 ON 21 APR 2010
L126           0 SEA SPE=ON  ABB=ON  PLU=ON  L117 AND (MEDLINE OR EMBASE OR
                 BIOSIS)/LC

     FILE 'HCAPLUS' ENTERED AT 10:31:19 ON 21 APR 2010
                 SAVE TEMP L122 BIA873INVB/A
                 SAVE TEMP L125 BIA873MAINB2/A

     FILE 'STNGUIDE' ENTERED AT 10:31:53 ON 21 APR 2010
                 D SAVED
                 D QUE STAT L9
                 D QUE STAT L21
                 D QUE STAT L36
                 D QUE STAT L117
                 D QUE NOS L125

     FILE 'HCAPLUS' ENTERED AT 10:34:11 ON 21 APR 2010
                 D IBIB ED ABS HITIND HITSTR L125 1-30

     FILE 'STNGUIDE' ENTERED AT 10:34:52 ON 21 APR 2010

     FILE 'HCAPLUS' ENTERED AT 10:41:42 ON 21 APR 2010
                 D IBIB ED ABS HITIND HITSTR L125 31-36

     FILE 'STNGUIDE' ENTERED AT 10:41:49 ON 21 APR 2010
                 D QUE NOS L126
                 D QUE NOS L122

     FILE 'HCAPLUS' ENTERED AT 10:44:40 ON 21 APR 2010
                 D IBIB ED ABS HITIND HITSTR L122 1-2

     FILE 'STNGUIDE' ENTERED AT 10:44:48 ON 21 APR 2010

     FILE 'STNGUIDE' ENTERED AT 10:44:58 ON 21 APR 2010
```

FILE HOME

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 16, 2010 (20100416/UP).

FILE ZCAPLUS

FILE COVERS 1907 - 21 Apr 2010 VOL 152 ISS 17
FILE LAST UPDATED: 20 Apr 2010 (20100420/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE HCAPLUS

FILE COVERS 1907 - 21 Apr 2010 VOL 152 ISS 17
FILE LAST UPDATED: 20 Apr 2010 (20100420/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE WPIX
FILE LAST UPDATED: 14 APR 2010 <20100414/UP>
MOST RECENT UPDATE: 201024 <201024/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.5 million chemical structures in DCR <<<

>>> IPC, ECLA, US National Classifications and Japanese F-Terms
and FI-Terms have been updated with reclassifications to
end of December 2009.
No update date (UP) has been created for the reclassified
documents, but they can be identified by
specific update codes (see HELP CLA for details) <<<

>>> FOR THE LATEST DERWENT WORLD PATENTS INDEX (DWPI)
STN USER DOCUMENTATION, PLEASE VISIT:
http://www.stn-international.com/stn_dwpi.html <<<

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

>>> For changes in DWPI see HELP CHANGE - last updated April 6, 2010 <<<

>>> New display format ALLSTR available - see NEWS <<<

>>> US National Patent Classification thesaurus added - see NEWS <<<

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 APR 2010 HIGHEST RN 1219791-89-5
DICTIONARY FILE UPDATES: 20 APR 2010 HIGHEST RN 1219791-89-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE LREGISTRY
LREGISTRY IS A STATIC LEARNING FILE

CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE MEDLINE
FILE LAST UPDATED: 20 Apr 2010 (20100420/UP). FILE COVERS 1947 TO DATE.

MEDLINE and LMEDLINE have been updated with the 2010 Medical Subject
Headings (MeSH) vocabulary and tree numbers from the U.S. National Libra
of Medicine (NLM). Additional information is available at

http://www.nlm.nih.gov/pubs/techbull/nd09/nd09_medline_data_changes_2010.

The Medline file has been reloaded effective January 24, 2010. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

FILE BIOSIS
FILE COVERS 1926 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 15 April 2010 (20100415/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

FILE EMBASE
FILE COVERAGE: EMBASE-originated material 1974 to 20 Apr 2010 (20100420/E
Unique MEDLINE content 1948 to present

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

For further assistance, please contact your local helpdesk.

=>